ידיעות כלליות - נבו - המאגר המשפטי - 05-06-2008... · web viewc07d 189429...

3/2008ח'/התשס"ח

רשומותISRAEL STATE RECORDS

June 5, 2008 התשס"ח ב' בסיון

והמדגמים הפטנטים יומןPATENTS AND DESIGNS JOURNAL

PATENTSעמודפטנטיםPage

891Applications filedשהוגשו בקשות985Applications acceptedשקובלו בקשות1221Patents grantedשניתנו פטנטים1221Patents renewedשחודשו פטנטים1223Patents not in forceפקעו שתוקפם פטנטים1224Patents extensionsפטנטים הארכת1225Noticesהודעותרשומים בפרטים שינויים

1236בפנקס Changes in particulars entered

in register1237Corrigendaטעויות תיקוני1238Country codesלמדינות קודים

iIndices of applications acceptedשקובלו לבקשות מפתחות

DESIGNSמדגמים1240Designs registeredשנרשמו מדגמים1250Designs renewedשחודשו מדגמים1251Designs voidשבוטלו מדגמים

כלליות ידיעות

אל: לשלוח יש ומדגמים פטנטים מכתבים, מסמכים, וכו' בענייני, ירושלים4 והמדגמים, רח' הסדנא הפטנטים רשם

חול בימי לציבור פתוחה והיא , תלפיות, ירושלים4 ברח' הסדנא נמצאת הפטנטים לשכת.12:30 ו- 8:30 השעות בין מועד או שבת ערבי שאינם כל בעד שקלים2.50 של במחיר ושרטוטים פירוטים של תצלומים מספקת הפטנטים לשכתממנו. חלק או עמוד

מס' הדואר בבנק הלשכה לחשבון תשלום ידי על ורק אך מתקבלות הפטנטים ללשכת אגרות האגרה שעבורה לפעולה הבקשה עם יחד ללשכה הדואר בנק קבלת להציג . יש0-24145-2

שולמה.

GENERAL INFORMATION

Letters, documents, etc. concerning Patents and Designs should be addressed to:The Commissioner of Patents and Designs, 4 Hasadnah St., Jerusalem

The Patent Office is located at 4 Hasadnah St., Talpiot, Jerusalem and is open to the public on weekdays, except on Fridays or on the eves of holydays, from 08:30 to 12:30 hrs.

The Patent Office supplies photocopies of specifications and drawings at the rate of NIS 2.50 per page or part thereof.

Fees to the Patent Office can be accepted only by payment to the Postal Bank Account of the Office, No. 0-24145-2. The receipt of the Postal Bank must be presented to the office together with the application for the action for which the fee has been paid.

שמורה אלה בתקצירים היוצרים זכותמת להעתיק ישראל, אין למדינתקצירים

הפטנטים. לשכת ברשות אלא אלה

Copyright by the State of Israel. No Extracts may be published except with the permission of the Patent Office.

.Price per single issue (incl. VAT) : NIS 96.₪ 96מ.ע.מ.( )כולל בודדת חוברת מחיר: לכל

:Annual subscription (incl. VAT).₪ 1,152מ.ע.מ.( )כולל לשנה חתימה דמיNIS 1,152.

אצל: להשיג אפשר ב' הממשלה, רחוב פרסומי של ההפצה שרות, הקריה, תל-אביב.29מס'

Available at the Distribution Service of Government Publications, 29 B-Street, Hakirya, Tel-Aviv.

NOTICE UNDER SECTION 16 OF THE הפטנטים לחוק16 סעיף לפי הודעה

June 5, 2008 –התשס"ח ב' בסיון 890

1967PATENTS LAW, 5727-1967- תשכ"ז

חדשות בקשות רשימת להלןשנקבעו הדרישות אחר הממלאות

הפטנטים, )א( לתקנות32 בתקנה:1968תשכ"ח–

In the following there are listed newApplications complying with theProvisions of rule 32(a) of the PatentRegulations, 5728-1968

לפי מובאים הבקשות פרטיזה: סדר

Particulars of the applications aregiven in the following order:

הגשתה ותאריך – הבקשה מספרשל הראשונים הסמנים וארבעה

הבינלאומי הסיווג

Number and date of application And the first four symbols of theInternational Classification

ע"י שהוצע )כפי האמצאה שםהמבקש(

Title of invention(as proposed by applicant)

Applicantהמבקש– האיגוד קדימה: מדינת דין

ומספר תאריך החוץ בקשת

Priority right: Convention country – Number and date of Foreign application

International Application Numberבינלאומית בקשה מספר

International Publication Numberבינלאומי מס' פרסום

A61K18158025/10/2005

קיבתי מעכב פוליפפטיד של אנטיגן מערכיבהם והשימוש

GASTRIC INHIBITORY POLYPEPTIDE (GIP) ANTIGEN ARRAYS AND USES THEREOF

June 5, 2008891 –התשס"ח ב' בסיון

CYTOS BIOTECHNOLOGY AG25/10/2004

60/621465US

PCT/EP/2005/055529WO/2006/045796

A61K18159330/08/2005

בלוטת הורמון של המרה במעכבי שימושהתריס

USE OF THYROID HORMONE CONVERSION INHIBITORSTRUSTEES OF BOSTON UNIVERSITY

01/09/2004

60/606481US

PCT/US/2005/030919WO/2006/028835

F01D18184420/09/2005

ע"י המונעים במנועים מניפה למארז מחזקגז טורבינת

FAN CASE REINFORCEMENT IN A GAS TURBINE JET ENGINEJAMES L. CARDARELLA JR.

23/09/2004

10/947923US

PCT/US/2005/033564WO/2006/137875

H04J18293702/05/2007

רצויות לא תופעות של קיזוז טכנולוגיתאופטית תקשורת רשת בקווי

TECHNIQUE FOR COMPENSATING UNDESIRED EFFECTS IN OPTICAL LINKS OF AN OPTICAL COMMUNICATION NETWORK

.ECI TELECOM LTDבע"מ אי. סי. איי. טלקום

F41A18379610/06/2007


A PROTECTIVE BODY ARMOURלגוף שיריון מגןHAIM GOLDENBLUMגולדנבלום חיים

H04B18453411/07/2007

קו דרך בטוחה נתונים למסירת שיטהאופטי תקשורת

METHOD FOR SECURING TRANSMISSION OF DATA ALONG AN OPTICAL COMMUNICATION LINE


F42D18474719/07/2007

A METHOD AND DEVICE FORירי כדורי לספירת ומתקן שיטהCOUNTING WEAPON BULLETS

UZI EZRA HAVOSHAחבושה עזרא עוזי

A47F18478923/07/2007

ROTATING SUSPENSION LUGמסתובב מיתלה

RAFAEL ADVANCED DEFENSEבע"מ מתקדמות לחימה מערכות רפאלSYSTEMS LTD.


H04L18479423/07/2007

TRANSFERRING DIGITAL DATAדיגיטלי מידע העברתNDS LIMITED

H04L18482325/07/2007

A METHOD FOR ESTABLISHING A אלחוטיתMESH רשת להקמת שיטהMESH WIRELESS NETWORK


C08B18484427/01/2006

? כחומרים – ציקלודקסטרין של נגזרותאנטיבקטריאלים

-?CYCLODEXTRIN DERIVATIVES AS ANTIBACTERIAL AGENTSPINNACLE PHARMACEUTICALS, INC.

28/01/2005

60/647841US

PCT/US/2006/002801WO/2006/083678

C07D18503416/02/2006

להכנתן, –דיארילפירול, שיטה5, 1 תולדותבטיפולים ויישומן

1,5-DIARYLPYRROLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICSSANOFI-AVENTIS

17/02/20050501660FR

PCT/FR/2006/000356WO/2006/087476


C07C18511423/03/2006

לטיפולD ויטמין של בתרכובות שימושהרחם רירית במחלת

USE OF VITAMIN D COMPOUNDS TO TREAT ENDOMETRIOSISBIOXELL SPA

23/03/2003

0505954.8GB

31/03/2005

60/667367US

PCT/EP/2006/060983WO/2006/100285

C07D18516517/02/2006

להכנת פיראזול של בתולדה שימושלמניעתן או כליה במחלות לטיפול תרופות

USE OF A PYRAZOLE DERIVATIVE FOR PREPARING MEDICINES USEFUL FOR PREVENTING OR TREATING RENAL DISEASESSANOFI-AVENTIS

23/02/20050501919FR

12/05/20050504798FR

PCT/FR/2006/000369WO/2006/090047

A61K18522313/02/2006

COMPOUNDS AND USES THEREOFעבורן ושימושים תרכובותCOMBINATORX, INC.

14/02/2005

60/652624US

PCT/US/2006/005006WO/2006/088786

C07D18522713/02/2006


C10 ב מותמרים טקסנים תכשיריאסטר ציקלופרופיל

C10 CYCLOPROPYL ESTER SUBSTITUTED TAXANE COMPOSITIONSFLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC.

14/02/2005

60/652834US

PCT/US/2006/004914WO/2006/088767

C07D18524221/03/2006

3 בעמדות מותמרות פירולידין של נגזרותדם לחץ ביתר לטיפול4ו–

3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSIONNOVARTIS AG

23/03/2005

0505969.6GB

PCT/EP/2006/002578WO/2006/100036

C08B18524820/02/2006

היילורוניק חומצת של אמיד תולדותבאוסטאוארטרוזיס

AMIDE DERIVATIVES OF HYALURONIC ACID IN OSTEOARTHROSISFIDIA FARMACEUTICI S.P.A.

02/03/2005PD2005A000056IT

PCT/EP/2006/001644WO/2006/092233

A61K18526515/02/2006

וניתנות תרסיס בצורת פורמולציותבנזודיאצפין של ננוחלקיקים של להזרקה

AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINEELAN PHARMA INTERNATIONAL LTD.

15/02/2005

60/653034US

PCT/US/2006/005224WO/2006/088894


G01T18553226/02/2006

APPARATUS AND METHOD FORקרינה לגילוי ושיטה מערכתDETECTION OF RADIATIONADVANCED FUEL RESEARCH, INC.

28/02/2005

60/656980US

PCT/US/2006/006914WO/2007/075181

G01S18569302/08/2006

רדאר עבור יעיל אוטומטי לפוקוס שיטה שני בעלת אוניה בדגם בחלל נישא פתחיםזהים גופים

EFFICIENT AUTOFOCUS METHOD FOR SWATH SAR

RAYTHEON COMPANY10/08/2005

11/200836US

PCT/US/2006/030025WO/2007/075198

C07D18605005/04/2006

חדישות, תכשירים איזואינדול ניגזרות אותן, הכנתן, ושימושים המכילים

כמעכבי שלהן, בפרט פרמצבטייםHSP90 מלווה חלבון של פעילויות

NOVEL ISOINDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PREPARATION THEREOF AND PHARMACEUTICAL USES THEREOF IN PARTICULAR AS INHIBITORS OF CHAPERONE PROTEIN HSP90 ACTIVITIESAVENTIS PHARMA S.A.

08/04/20050503511FR

PCT/FR/2006/000750WO/2006/108948

E21B18621324/04/2006


TREATMENT OF GAS FROM AN INפנימי המרה מתהליך בגז טיפולSITU CONVERSION PROCESSSHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.

22/04/2005

60/674081US

PCT/US/2006/015286WO/2006/116207

A61L18624104/04/2006

MEDICAL SCAFFOLD, METHODS OFרפואיים בפיגומים ושימוש לייצור שיטותFABRICATION AND USING THEREOF

TECHNION RESEARCH ANDבע"מ ופתוח למחקר הטכניון מוסדDEVELOPMENT FOUNDATION LTD.

04/04/2005

60/667666US

PCT/IL/2006/000421WO/2006/106506

C07C18645803/04/2006

COQ10ב– שימוש ידי על עור העשרתשחרור כמערכת

SKIN ENRICHMENT USING COQ10 AS THE DELIVERY SYSTEMZYMES, LLC

01/04/2005

60/667380US

05/04/2005

60/668273US

PCT/US/2006/012215WO/2006/107825


C07D18653812/04/2006

PHARMACEUTICAL COMPOSITIONSרופלומילסט המכילים רוקחות תכשיריCONTAINING ROFLUMILASTNYCOMED GMBH

19/04/2005

05103147.4EP

PCT/EP/2006/061557WO/2006/111495

C07D18664107/04/2006

סלקטיבים כלוריד תעלות במאפנני שימוש באלכוהול לרעה בשימוש לטיפול

ממריצים ובחומרים

USE OF SELECTIVE CHLORIDE CHANNEL MODULATORS TO TREAT ALCOHOL AND/OR STIMULANT SUBSTANCE ABUSEHYTHIAM, INC.

21/04/2005

11/111435US

PCT/US/2006/013155WO/2006/115743

C07J18665617/04/2006

מניעת של למשטר ממושך אסטרוגן מינוןילודה

EXTENDED ESTROGEN DOSING CONTRACEPTIVE REGIMENWARNER CHILCOTT COMPANY, INC

22/04/2005

11/112290US

PCT/US/2006/014367WO/2006/115871

C07C18666213/04/2006

תרכובות באמצעות בסרטן משולב טיפולשל

ביס)תיאוהידרזיד(אמיד

COMBINATION CANCER THERAPY WITH

BIS(THIOHYDRAZIDE) AMIDE COMPOUNDSSYNTA PHARMACEUTICALS CORP.

15/04/2005

60/672139US

PCT/US/2006/014531


WO/2006/113695

C07D18673109/05/2006

פרוטאין–קינאז מערכת לוויסת שיטהעקה על–ידי המופעל

METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEMINTERMUNE, INC.

10/05/2005

60/679471US

01/11/2005

60/732230US

PCT/US/2006/017988WO/2006/122154

C07D18680408/05/2006

של ותולדותPDE4 מעכב של שלובטטראהידרוביופטארין

A COMBINATION OF A PDE4 INHIBITOR AND A TETRAHYDROBIOPTERIN DERIVATIVENYCOMED GMBH

11/05/2005

05103938.6EP

PCT/EP/2006/062117WO/2006/120176

C07C18687127/09/2005

EXTERNAL PREPARATION FOR SKINהעור על לשימוש חיצוני תכשיר


COSMO OIL CO., LTD28/04/2005

2005-131171JP

PCT/JP/2005/017681WO/2006/117885

A61K18696328/04/2006

METHODS AND COMPOSITIONS FORבכאב לטיפול ותרכובות שיטותTREATING PAINTHERAQUEST BIOSCIENCES LLC

28/04/2005

60/675442US

PCT/US/2006/016078WO/2006/116626

A61K18697304/05/2006

COMPOSITIONS AND METHODS FORבגידולים לטיפול ושיטות הרכביםTREATMENT FOR NEOPLASMSCOMBINATORX, INC.

05/05/2005

60/678078US

PCT/US/2006/017686WO/2006/122007

C07F18698528/04/2006

כתוצר פוספטי אוקסיכלוריד של ייצור DMFו– פוספטי מפנטאכלוריד לוואי

כלורינציה תגובת עבור ושימושווילסמייר– לריאגנט הפיכתו באמצעות

HAACK

GENERATION OF PHOSPHORUS OXYCHLORIDE AS BY-PRODUCT FROM PHOSPHORUS PENTACHLORIDE AND DMF AND ITS USE FOR CHLORINATION REACTION BY CONVERTING INTO VILSMEIER-HAACK REAGENTPHARMED MEDICARE PRIVATE LIMITED,

04/05/2005

545/MUM/2005IN

PCT/IN/2006/000151WO/2007/017891


A61K18709218/05/2006

לא תרופות של סינרגיסטיים שילובים של ליגנדים עם דלקתיות אנטי סטרואידיות

– דלתא2 – אלפא

SYNERGISTIC COMBINATIONS OF NON - STEROIDAL ANTIINFLAMMATORY DRUGS WITH ALPHA - 2 - DELTA LIGANDSPFIZER LIMITED

20/05/2005

60/683391US

PCT/IB/2006/001655WO/2006/123247

A61K18712803/05/2006

STABLE NANOPARTICLEיציבות ננו–חלקיקיות פורמולציותFORMULATIONSSANOFI-AVENTIS U.S. LLC

05/05/2005

60/678086US

PCT/US/2006/017059WO/2007/086911

A61K18714205/05/2006

וחומר סולודקסיד עם משולבת תרפייה כיליה במחלת בטיפול דם לחץ להורדתמסכרת הנובעת

COMBINATION THERAPY WITH SULODEXIDE AND A BLOOD PRESSURE REDUCING AGENT IN THE TREATMENT OF DIABETIC NEPHROPATHYKERYX BIOPHARMACEUTICALS, INC.

05/05/2005

60/679096US


14/11/2005

60/736973US

PCT/US/2006/017403WO/2006/121853

G10L18716705/04/2006

AUDIO CODEC POST-FILTER שמעCODEC מסנןMICROSOFT CORPORATION

31/05/2005

11/142603US

PCT/US/2006/012641WO/2006/130226

A61K18720731/05/2006

ומעכב סינתאז סקאלן מעכב של צירופיםHMA–COAלטיפול רדוקטאז

בהיפרליפידמיה

COMBINATIONS OF A SQUALENE SYNTHASE INHIBITOR AND A HMG-COA REDUCTASE INHIBITOR FOR TREATING HYPERLIPIDEMIATAKEDA PHARMACEUTICAL COMPANY LIMITED

01/06/2005

60/685871US

20/10/2005

60/728329US

PCT/JP/2006/311362WO/2006/129859

A61K18723628/07/2005

חומצה הפרשת לעיכוב ושיטות תכשיריםבקיבה

COMPOSITIONS AND METHODS FOR INHIBITING GASTRIC ACID SECRETION


.VECTA LTDבר-פלד דר' אסנת אצל בע"מ וקטה11/05/2005

60/679664US

PCT/IB/2005/002223WO/2006/120500

C07D18723810/05/2006

של במחלות לטיפול ושיטות תכשיריםהאפידרמיס של יתר התחלקות

COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE EPIDERMAL DISEASES

DERMIPSOR LTDבע"מ דרמיפסור10/05/2005

60/679556US

PCT/IL/2006/000553WO/2006/120682

C07C18727426/04/2006

דוקוסאהקסאנויקים גליצרידים של שימושגידולים של במחלות הטיפול עבור

USE OF DOCOSAHEXAENOIC GLYCERIDES FOR THE TREATMENT OF TUMORAL DISEASESPROYECTO EMPRESARIAL BRUDY, S.L.

12/05/2005

P-200501141ES

PCT/EP/2006/061833WO/2006/120120

A61K18727508/05/2006

VASOACTIVE KIT ANDושימושיו ומרכיב ואזואקטיבית ערכהCOMPOSITION AND USES THEREOF

FOAMIX LTDבע"מ פואמיקס09/05/2005

11/124676US

PCT/IB/2006/003525WO/2007/023396

C07H18727609/05/2006


SACCHARIDE FOAMABLEמוקצף במרקם סכרידCOMPOSITION


60/679020US

21/03/2006

60/784793US

PCT/IB/2006/003628WO/2007/039825

A61K18727709/05/2006

שלו רפואי והרכב מוקצף נשיאה אמצעיFOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITION THEREOF


60/679020US

21/03/2006

60/784793US

PCT/IB/2006/003519WO/2007/054818

A61K18733912/06/2006

להקטנת רוקחיות פורמולציותסם–סם אינטראקציות

PHARMACEUTICAL FORMULATIONS FOR MINIMIZING DRUG-DRUG INTERACTIONSBAXTER INTERNATIONAL INC.

14/06/2005

60/690322US

12/06/2006

11/423491US

PCT/US/2006/022715WO/2006/138202

A61K18748613/06/2006

DOSAGE REGIMEN FOR PRASUGRELלפראסוגרל מינון משטרELI LILLY AND COMPANY


17/06/2005

60/691740US

PCT/US/2006/023006WO/2006/138317

C07H18750813/05/2006

דיאריל של תרכובת המכיל משולב טיפול מעכבי או קינאזP13, AKTו– אוריאהMTORבסרטן )ראפמיצינים( לטיפול

COMBINATION THERAPY COMPRISING A DIARYL UREA COMPOUND AND A P13, AKT KINASE OR MTOR INHIBITORS (RAPAMYCINS) FOR CANCER TREATMENTBAYER HEALTHCARE AG

27/05/2005

05011477.6EP

PCT/EP/2006/004524WO/2006/125540

A61K18751222/06/2000

במצבי בטיפול (–רבוקסטיןS,Sב–) שימושואי–התאפקות כאב

USE OF (S,S)-REBOXETINE IN THE TREATMENT OF PAIN CONDITIONS AND INCONTINENCEPHARMACIA & UPJOHN COMPANY LLC

01/07/1999

60/141968US

16/07/1999

60/144131US

06/10/1999

60/158256US

13/12/1999

60/170381US

PCT/US/2000/017256WO/2001/001973

A61K18751322/06/2000

במצבי בטיפול (–רבוקסטיןS,Sב–) שימושואי–התאפקות כאב

USE OF (S,S)-REBOXETINE IN THE TREATMENT OF PAIN CONDITIONS AND INCONTINENCE


PHARMACIA & UPJOHN COMPANY LLC

01/07/1999

60/141968US

16/07/1999

60/144131US

06/10/1999

60/158256US

13/12/1999

60/170381US

PCT/US/2000/017256WO/2001/001973

C07D18755216/11/2005

PHARMACEUTICAL COMPOSITIONSנביבולול המכילים רוקחות תכשיריCONTAINING NEBIVOLOLMYLAN LABORATORIES, INC.

31/05/2005

11/141235US

10/11/2005

11/272562US

15/11/2005

11/273992US

PCT/US/2005/041275WO/2006/130174

G06Q18761408/06/2006

MEDICAL GUIDE SYSTEMרפואית הדרכה מערכתIBM CORPORATION

08/06/2005

2005-168921JP

PCT/JP/2006/311533WO/2006/132320

C07C18775902/06/2006

USES OF PROSTACYCLIN ANALOGSפרוסטציקלין של באנלוגים שימושיםTHE REGENTS OF THE UNIVERSITY OF COLORADO,


02/06/2005

60/687016US

PCT/US/2006/021666WO/2006/130879

A61K18814616/06/2006

SRC מעכבי ידיד על עצמות הרס מניעתקינאז

INHIBITION OF OSTEOLYTIC LESIONS BY SRC KINASE INHIBITORSTHE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

17/06/2005

60/691933US

PCT/US/2006/023529WO/2006/138590

C07J18823727/06/2006

בתסמינים לטיפול ושיטות תכשיריםלמחזור הקשורים

COMPOSITIONS AND METHODS FOR TREATMENT OF CYCLE-RELATED SYMPTOMSWYETH

28/06/2005

60/695077US

PCT/US/2006/025449WO/2007/002862

C07D18858329/06/2006

יסוד שילוב המכילה רוקחית מינון צורות ושל ניסולדיפין ו/או ניפדיפין של פעיל

אנגיוטנסין של אנטגוניסט

PHARMACEUTICAL DOSAGE FORM CONTAINING AN ACTIVE PRINCIPLE COMBINATION OF NIFEDIPINE AND/OR NISOLDIPINE AND OF AN ANGIOTENSIN II ANTAGONISTBAYER HEALTHCARE AG

06/07/2005

102005031577.1DE

PCT/EP/2006/006293WO/2007/003330


A61K18858406/07/2006

ציקלאז גווינילאט במשפעלי שימוש מזילוח הנגרם בנזק לטיפול מסיסים

נשנה

USE OF SOLUBLE GUANYLATE CYCLASE ACTIATORS FOR TREATING REPERFUSION DAMAGEBAYER HEALTHCARE AG

06/07/2005

102005031576.3DE

PCT/EP/2006/006600WO/2007/025595

A01N18860206/07/2006

NON-FLAMMABLE INSECTICIDEושימושיו דליק לא מדביר–חרקים הרכבCOMPOSITION AND USES THEREOF


60/696878US

PCT/IB/2006/004026WO/2007/085899

A61K18863307/07/2006

OXCARBAZEPINE FORMULATIONאוקסקארבזפין של רוקחי תכשירTARO PHARMACEUTICALS U.S.A. INC.

08/07/2005

60/697840US

PCT/US/2006/026311WO/2007/008576

C07D18903721/03/1996

מותמרים –כלורוקוינזולינים4-ALKOXY-SUBSTITUTED 4 באלקוקסי

CHLOROQUINAZOLINES

PFIZER PRODUCTS, INC.30/03/1995413300US

06/06/1995PCT/IB95/00436WO


C12N18906703/08/2006

אימונוגלובולינים לייצור ושיטות תכשיריםCOMPOSITIONS AND METHODS FOR PRODUCTION OF IMMUNOGLOBULINSFRAUNHOFER USA, INC.

03/08/2005

60/705653US

PCT/US/2006/030545WO/2007/117264

H04N18907025/06/2003

עמית מידע החלפת עבור רדיו רשת בקרלקוח ציוד על לעמית

RADIO NETWORK CONTROLLER PEER-TO-PEER EXCHANGE OF USER EQUIPMENT MEASUREMENTS INFORMATIONINTERDIGITAL TECHNOLOGY CORPORATION

27/06/2002

60/392122US

PCT/US/2003/019958WO/2004/004306

H04B18907102/02/2001


הבא בערוץ רבים משתמשים בגילוי תמיכהמלוויין

SUPPORT OF MULTIUSER DETECTION IN THE DOWNLINKINTERDIGITAL TECHNOLOGY CORPORATION

04/02/2000

60/180402US

PCT/US/2001/003380WO/2001/058041

H04Q18907205/04/2001

עבור זמני ביצוע לתיאום בסיס תחנתאל–חוטיות תקשורת מערכות

BASE STATION SYNCHRONIZATION FOR WIRELESS COMMUNICATION SYSTEMSINTERDIGITAL TECHNOLOGY CORPORATION

07/04/2000

60/195543US

04/08/2000

60/223405US

PCT/US/2001/010983WO/2001/080461

H04L18910622/05/2003

INFORMATION PROCESSINGמידע לעיבוד מערכתSYSTEMMATSUSHITA ELECTRIC INDUSTRIAL CO., LTD.

23/05/2002

2002-148705JP

PCT/JP/2003/006387WO/2003/101048


A61K18910715/12/2004

של מוצקת מינון צורת להכנת שיטהדסמופרסין

METHOD FOR PREPARING SOLID DOSAGE FORM OF DESMOPRESSINFERRING B.V.

29/12/2003

03029897.0EP

C07K18913201/09/1997

של יתר בגדילת לטיפול רוקחות תכשירי בלוטת ובסרטן הערמונית בלוטת

הערמונית

PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PROSTATE HYPERTROPHY AND PROSTATE CANCERZENTARIS GmbH

12/09/1996

60/025990US

10/04/1997

60/043228US

PCT/EP/1997/004740WO/1998/010781

C07K18913622/08/1997

דמויי אינסולינוטרופיים פפטידים אנלוגים אותם המכילים גלוקגון, תכשירים

בהם ושימושים

GLUCAGON-LIKE INSULINOTROPIC PEPTIDE ANALOGS, COMPOSITIONS COMPRISING THEM AND USES THEREOFNOVO NORDISK A/S


30/08/19960931/96DK

08/11/19961259/96DK

20/12/19961470/96DK

PCT/DK/1997/000340WO/1998/008871

C07D18917208/08/2006

רוקחות ותכשירי צרקוספוראמיד תולדותאותן המכילים

CERCOSPORAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAMEDAIICHI SANKYO COMPANY, LIMITED

09/08/2005

2005-230558JP

28/12/2005

2005-379060JP

PCT/JP/2006/315621WO/2007/018193

H01L18917307/08/2006

( תלתIC) משולב מעגל ליצירת שיטהבה המייוצר משולב ומעגל מימד

METHOD FOR PRODUCING A 3-DIMENSIONAL INTEGRATED CIRCUIT (IC) AND AN IC PRODUCED THEREBYZIPTRONIX, INC.

11/08/2005

11/201321US

PCT/US/2006/030703WO/2007/021639


G11B18917508/08/2006

מותנית גישה בעלי תוכנים לעיבוד שיטהמשתמש יחידת ידי על

METHOD FOR PROCESSING CONDITIONAL ACCESS CONTENTS BY A USER UNITNAGRAVISION S.A.

09/08/2005

05107322.9EP

PCT/EP/2006/065132WO/2007/017499

C12P18917708/08/2006

ותכשירי צרקוספוראמיד להכנת תהליךצרקוספוראמיד המכילים רוקחות

PROCESS FOR PRODUCING CARCOSPORAMIDE AND PHARMACEUTICAL COMPOSITIONS CONTAINING CERCOSPORAMIDEDAIICHI SANKYO COMPANY, LIMITED

09/08/2005

2005-230624JP

PCT/JP/2006/315622WO/2007/018194

C07D18917811/08/2006

המכילים רוקחות ותכשירי תיאזוליל תולדותאותן

THIAZOLYL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAMEVERTEX PHARMACEUTICALS INCORPORATED

11/08/2005

60/707380US

02/11/2005

60/732476US

PCT/US/2006/031457WO/2007/021982


A61F18917926/07/2006

סטומה תאי המכיל רוקחות תכשיראדיפוזית מרקמה המופקים

A PHARMACEUTICAL COMPOSITION CONTAINING ADIPOSE TISSUE-DERIVED STROMAL CELLSBOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE

01/08/2005

11/194270US

PCT/US/2006/028886WO/2007/016112

C07D18918116/08/2005

–אמינו–תיאנו4 חומצה של חדשים אמידים[C–3,2–פירידינ]קרבוקסילית7–

NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-

CARBOXYLIC ACID AMIDESF. HOFFMANN-LA ROCHE AG

PCT/EP/2005/054022WO/2007/019884

C07D18918329/08/2006

NOVEL INDOLE COMPOUNDSחדשות אינדול תרכובותLABORATOIRES FOURNIER S.A.

30/08/20050508858FR

PCT/FR/2006/050818WO/2007/026097


G01N18918519/08/2005

שלו ותולדות אנדופלסמין במקטע שימוש ו/או הגס המעי של לאדנומה ביולוגי כסמן

בחינה ומערכת לזיהוי קרצינומה; שיטה

USE OF AN ENDOPLASMIN FRAGMENT AND DERIVATIVES THEREOF AS A BIOMARKER FOR COLORECTAL ADENOMA AND/OR CARCINOMA; METHOD FOR DETECTION AND TEST SYSTEMINDIVUMED GMBH

PCT/EP/2005/009005WO/2007/019875

C07D18918621/08/2006

-HSD1PYRAZOLONE DERIVATIVES AS 11 –בטא11 כמעכבי פירזולון תולדותBETA HSD1 INHIBITORSF. HOFFMANN-LA ROCHE AG

31/08/2005

05107970.5EP

PCT/EP/2006/065471WO/2007/025880

C08G18918725/08/2006

A252–Kשל פולימר של קונג'וגאטיםשלהם ותולדות

POLYMER CONJUGATES OF K-252A AND DERIVATIVES THEREOFCREABILIS THERAPEUTICS S.P.A.

25/08/2005

60/710890US

27/09/2005

60/720454US

07/06/2006

60/811469US

PCT/EP/2006/008374WO/2007/022999


C07D18918812/09/2006

פנילאמידין תולדות של מזיקים קוטלבתיאזולילוקסי מותמרות

PESTICIDE THIAZOLYLOXY SUBSTITUTED PHENYLAMIDINE DERIVATIVESBAYER CROPSCIENCE AG

13/09/2005

05356155.1EP

PCT/EP/2006/066273WO/2007/031513

C07D18918931/08/2006

כמאפננים ושימושן פירולופירידין תולדותPPAR לרצפטור

PYRROLOPYRIDINE DERIVATIVES AND USE OF SAME AS PPAR RECEPTOR MODULATORSLABORATOIRES FOURNIER S.A.

01/09/2005

60/713459US

14/10/20050510482FR

PCT/FR/2006/050827WO/2007/026104

A61P18919028/02/2000

פלואורינציה שעברו טריאזולים של שימוש הפרעות או רגשיות והפרעות בכאב לטיפול

קשב

USE OF FLUORINATED TRIAZOLES FOR TREATING PAIN AND AFFECTIVE OR ATTENTION DISORDERSNOVARTIS AG


01/03/1999

09/259911US

01/03/1999

09/259910US

PCT/EP/2000/001626WO/2000/051577

C07D18919109/08/2006

המשמשות פיפרידין נגזרות, תיאזוליל רצפטור3H של כמודולטורים ביעילות

THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORSF. HOFFMANN-LA ROCHE AG

18/08/2005

05107586.9EP

PCT/EP/2006/065167WO/2007/020213

C07D18919201/08/2006

INHIBITORS OF SERINE PROTEASESפרוטאזות סרין של מעכביםVERTEX PHARMACEUTICALS INCORPORATED

02/08/2005

60/704772US

PCT/US/2006/029988WO/2007/016589

C12N18919314/09/2006


חלבון המבטאים טרנספלסטומיים צמחיםמוכוון–חלל

TRANSPLASTOMIC PLANTS EXPRESSING LUMEN-TARGETED PROTEINBAYER CROPSCIENCE SA

16/09/2005

05356163.5EP

20/09/2005

60/718931US

PCT/EP/2006/066345WO/2007/031547

C07D18919430/08/2006

SUBSTITUTED BENZIMIDAZOLES ASקינאז כמעכבי מותמרים בנזימידאזוליםKINASE INHIBITORSNOVARTIS AG

30/08/2005

60/712539US

30/08/2005

60/713108US

27/10/2005

60/731591US

17/02/2006

60/774684US

PCT/US/2006/034088WO/2007/030377

A61J18919602/08/2006

MULTIPLE CHAMER CONTAINERתאים מספר המכיל מיכלBAXTER INTERNATIONAL INC.

02/08/2005

60/704555US

PCT/US/2006/030064WO/2007/037793

A61J18919702/08/2006

OXYGEN INDICATOR FOR USE INרפואיים במוצרים לשימוש חמצן מחווןMEDICAL PRODUCTSBAXTER INTERNATIONAL INC.

02/08/2005

60/704555US


PCT/US/2006/030051WO/2007/016611

A61J18919802/08/2006

לתוך למתן ופורמולציות רפואיים מוצריםהדם כלי

MEDICAL PRODUCTS AND PARENTERAL FORMULATIONSBAXTER INTERNATIONAL INC.

02/08/2005

60/704555US

PCT/US/2006/030058WO/2007/016615

G06T18919901/08/2006

ומערכות בוליאניות משלימות שיטותמעניין באיזור וידאו תמונת לעיבוד

BOOLEAN COMPLEMENT METHODS AND SYSTEMS FOR VIDEO IMAGE PROCESSING A REGION OF INTERESTHONEYWELL INTERNATIONAL INC.

03/08/2005

11/197158US

PCT/US/2006/029916WO/2007/019140

E04H18920003/08/2006

POOL CLEANING ROBOTמים בריכות לניקוי רובוט.MAYTRONICS LTDבע"מ מיטרוניקס

04/08/2005

11/196737US

PCT/IL/2006/000901WO/2007/015251

C07D18920231/08/2006


לתרכובות ביניים ותוצרי מלאכותיות שיטות בהפרעות בטיפול לשימוש סטריאוסומריות

העצבים ובמערכת העיכול מערכת

SYNTHETIC METHODS AND INTERMEDIATES FOR STEREOISOMERIC COMPOUNDS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERSARYX THERAPEUTICS, INC.

31/08/2005

60/713149US

19/05/2006

60/747762US

PCT/US/2006/034322WO/2007/028073

C12P18920324/08/2006

RNA SENSEMETHODS AND KITS FOR SENSE לייצור ומערכות שיטותRNA SYNTHESISDATASCOPE INVESTMENT CORPORATION

24/08/2005

11/210602US

PCT/US/2006/033338WO/2007/025195

G06F18920624/10/2006

ערכי תיכנות של תועלת להפקת הפרעהבקר של עדיפות

INTERRUPT CONTROLLER UTILISING PROGRAMMABLE PRIORITY VALUESARM LIMITED

21/12/2005

0526007.0GB

PCT/GB/2006/003953WO/2007/071894

G11C18920719/07/2006

MEMORY ACCESSלזיכרון גישהINGENIA TECHNOLOGY LIMITED

03/08/2005

0516003.1GB


03/08/2005

60/707196US

PCT/GB/2006/002676WO/2007/015055

H04L18920830/06/2000

בקשר שידור קצב להגדרת וציוד שיטהאל–חוטית תקשורת המערכת נגדי/הפוך

METHOD AND APPARATUS FOR DETERMINING A REVERSE LINK TRANSMISSION RATE IN A WIRELESS COMMUNICATION SYSTEMQUALCOMM INCORPORATED

02/07/1999

/09346882

US

PCT/US/2000/018322WO/2001/003357

A23J18920917/08/2006

חלבוניות פרקציות עם מבודד סויה חלבוןגבוה מולקולרי משקל בעלות

ISOLATED SOY PROTEIN HAVING HIGH MOLECULAR WEIGHT PROTEIN FRACTIONS AND LOW MOLECULAR WEIGHT PROTEIN FRACTIONSSOLAE, LLC

17/08/2005

60/708947US

17/10/2005

60/727324US

16/08/2006

11/465090US

PCT/US/2006/032121WO/2007/022341


C07D18921016/08/2006

HCVMETHODS FOR THE PREPARATION פולימראז מעכבי להכנת שיטותOF HCV POLYMERASE INHIBITORSPFIZER INC

24/08/2005

60/711042US

04/04/2006

60/744273US

13/06/2006

60/804644US

PCT/IB/2006/002342WO/2007/023381

A61K18921102/08/2006

נקבית בעקרית לטיפול והרכבים שיטותקלומיפן באמצעות

METHODS AND COMPOSITIONS FOR TREATING FEMALE INFERTILITY USING CLOMIPHENEREPROS THERAPEUTICS INC.

05/08/2005

60/706094US

PCT/US/2006/030053WO/2007/019165

C07D18921718/08/2006

סולפומאמידו מגושרים מעכביםסקרטאז גמא של בי–ציקליים

BRIDGED N-BICYLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASEELAN PHARMACEUTICALS, INC.

19/08/2005

60/709961US

PCT/US/2006/032261WO/2007/024651

C22C18921804/08/2005

להפקת ושיטה פלטיניום סגסוגתדבר אותו

PLATINUM ALLOY AND METHOD OF PRODUCTION THEREOF


ALLGEMEINE GOLD- UND SILBERSCHEIDEANSTALT AG

03/08/2005PCT/EP2005/008419EP

PCT/EP/2005/008453WO/2007/014576

A01N18921931/08/2006

של הרבצידיות פורמולציותנוזלית סולפונילאוריאה

LIQUID SULFONYLUREA HERBICIDE FORMULATIONSE.I. DU PONT DE NEMOURS AND COMPANY

01/09/2005

60/713518US

PCT/US/2006/033986WO/2007/027863

C22C18922004/08/2005

להפקת ושיטה פלטיניום סגסוגתדבר אותו

PLATINUM ALLOY AND METHOD OF PRODUCTION THEREOFALLGEMEINE GOLD- UND SILBERSCHEIDEANSTALT AG

03/08/2005PCT/EP2005/008405EP

PCT/EP/2005/008454WO/2007/014577

C07D18922120/06/2007

לניטור בהן ושימושים פירזין של נגזרותהכליות

PYRAZINE DERIVATIVES AND USES THEREOF IN RENAL MONITORINGMALLINCKRODT INC.

22/06/2006

60/815712US

PCT/US/2007/014370WO/2007/149479


H01F18922219/06/2006

LINE TRANSFORMER FOR IMPEDANCEעכבה להתאמת קו שנאיMATCHINGROHDE & SCHWARZ GMBH & CO. KG

09/08/2005

102005037616.9DE

PCT/EP/2006/005863WO/2007/017000

C04B18922403/08/2006

פולימרים של יציבות תמיסות להכנת שיטהאי–אורגניים–אורגניים

METHOD FOR PREPARATION OF STABLE SOLUTIONS OF INORGANIC-ORGANIC POLYMERS

ORION SOLAR PHOTOVOLTAICSבע"מ פוטווולטאיקס סולאר אוריוןLTD

04/08/2005

60/705180US

PCT/IL/2006/000899WO/2007/015249

B82B18922503/08/2006

הכוללים יציבים תרחיפים להכנת שיטהמתכת תחמוצת של ננו–חלקיקים

METHOD FOR PREPARATION OF STABLE METAL OXIDE NANOPARTICLES SUSPENSIONS

BAR-ILAN UNIVERSITYבר-אילן אוניברסיטת04/08/2005

60/705190US

PCT/IL/2006/000898WO/2007/015248

B82B18922603/08/2006

מבנה בעלות אלקטרודות לייצור שיטהפוטואלקטרוכימיים ליישומים ננו–נקבובי

METHOD FOR PRODUCTION OF NANOPOROUS ELECTRODES FOR PHOTOELECTROCHEMICAL APPLICATIONS

BAR-ILAN UNIVERSITYבר-אילן אוניברסיטת


04/08/2005

60/705188US

PCT/IL/2006/000900WO/2007/015250

C07K18922703/08/2006

1.1KV מתח מווסתת האשלגן תעלת כוונון וההפרשה הסינתזה וויסות לשםT בתאי

–?) FACTOR NECROSIS TUMOR? שלTNF)

אדם בבני פציעות או במחלות וטיפול או מזיקות, גבוהות רמות ע"י המתווכות

TNF?– מדי, של נמוכות

MODULATING THE KV1.1 VOLTAGE-GATED POTASSIUM CHANNEL IN T-CELLS FOR REGULATING THE SYNTHESIS AND SECRETION OF TUMOR NECROSIS FACTOR ? (TNF-?) AND TREATING HUMAN DISEASES OR INJURIES MEDIATED BY DETRIMENTALLY HIGH OR LOW

LEVELS OF TNF?-.MINEUET THERAPEUTICS LTDלויטה מיה

03/08/2005

60/704728US

PCT/US/2006/030361WO/2007/019267

H04M18922822/08/2005

MODEM WITH ACOUSTIC COUPLINGאקוסטי זיווג יכולת עם מודםULTRA PROIZVODNJA ELEKTRONSKIH NAPRAV D.O.O.

PCT/EP/2005/009063WO/2007/022788


H01J18923304/12/2003

אור רגישת גלשון דיודת כולל גילוי מערכת DETECTION SYSTEM INCLUDING קשות בסביבות לשימוש

AVALANCHE PHOTODIODE FOR USE IN HARSH ENVIRONMENTS

GENERAL ELECTRIC COMPANY10/12/2002314986US

C07D18926201/09/2006

1Hעם מותמרים –אימידזופירידינים ושיטות הידרוקסי

HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODSPFIZER INC.

02/09/2005

60/713704US

PCT/US/2006/034427WO/2007/028129

A61B18927223/05/2002

COOLING SYSTEM FOR Aפוטוקוסמטי להתקן קירור מערכתPHOTOCOSMETIC DEVICEPALOMAR MEDICAL TECHNOLOGIES, INC.

23/05/2001

60/292827US

18/01/2002

10/052474US

12/03/2002

60/363798US

12/03/2002

60/363871US


PCT/US/2002/016435WO/2002/094116

A61B18927322/09/2006

וחומרי פירפנידון של קפסולרית תצורה מבחינה המתאימים בלתי–פעילים תרופה

פרמצבטית

CAPSULE FORMULATION OF PIRFENIDONE AND PHARMACEUTICALLY ACCEPTABLE EXCIPIENTSINTERMUNE, INC.

22/09/2005

60/720257US

PCT/US/2006/037057WO/2007/038315

F16K18927909/08/2006

FLUID CONTROLLER WITH JOINTחיבור עם נוזלים ווסתFUJIKIN INCORPORATED

10/08/2005

2005-231564JP

PCT/JP/2006/315714WO/2007/018228

A61G18928011/08/2006

התנגדות עבור התקן הכולל למדרגות כסאמכוונות ובלימה מסלול

STAIR CHAIR WITH AN ADJUSTABLE GLIDE TRACK RESISTANCE AND BRAKING DEVICEFERNO-WASHINGTON, INC.

11/08/2005

60/707426US


03/08/2006

11/462064US

PCT/US/2006/031553WO/2007/022037

C12Q18928104/08/2006

וערכה לגוף מחוץ לשימוש איבחונית שיטה בדגימות אנושי פפילומא נגיף לזיהוי

קליניות

IN VITRO DIAGNOSTIC METHOD AND KIT FOR IDENTIFICATION OF HUMAN PAPILLOMAVIRUS IN CLINICAL SAMPLESGENOMICA S.A.U.

05/08/2005

0516145.0GB

PCT/GB/2006/050231WO/2007/017699

C07D18928626/07/2006

פרוטאז ציסטאין של חדשים מעכביםהרפואיים וישומיהם

NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONSHYBRIGENICS SA

05/08/2005

05291683.0EP

05/08/2005

11/197525US

PCT/IB/2006/002637WO/2007/017758


C07D18928707/08/2006

TISSUE PROTECTIVE PEPTIDES ANDושימושיהם רקמות מגיני פפטידיםUSES THEREOFWARREN PHARMACEUTICALS, INC.

05/08/2005

60/705741US

08/08/2005

60/706276US

18/07/2006

60/831737US

PCT/US/2006/031061WO/2007/019545

C22C18928821/08/2006

בעלי לישומים קשיחה ממתכת חומריםגבוהה טמפרטורה

HARDMETAL MATERIALS FOR HIGH-TEMPERATURE APPLICATIONSGENIUS METAL, INC.

19/08/2005

60/710016US

PCT/US/2006/032654WO/2007/022514

A61K18928915/08/2006

הגנה המשרה רוטאווירוס חיסוןמשולבת הטרוטיפית

ROTAVIRUS VACCINE INDUCING HETEROTYPIC CROSS PROTECTION


GLAXOSMITHKLINE BIOLOGICALS S.A.

17/08/2005

0516944.6GB

18/10/2005

0521164.4GB

05/05/2006

0608962.7GB

PCT/EP/2006/008094WO/2007/020078

A61K18929028/08/2006

ARGATROBAN FORMULATIONארגאטרובאן הרכבBAXTER INTERNATIONAL INC.

01/09/2005

60/713403US

PCT/US/2006/033432WO/2007/027565

A61M18929128/08/2006

ANTI-MICROBIAL CATHETERאנטי–חיידקי קטטרI-FLOW CORPORATION

31/08/2005

11/216534US

PCT/US/2006/033375WO/2007/027545

G06T18929206/09/2006

גרפיקה עבור דו–מימדית לעריכה מטפורהתלת–מימדית

2D EDITING METAPHOR FOR 3D GRAPHICSMICROSOFT CORPORATION

09/09/2005

60/715659US

12/12/2005

11/302006US

PCT/US/2006/035158WO/2007/030763


G06T18929406/09/2006

2D/3D COMBINED RENDERINGדו–מימד/תלת–מימד משולב ביצועMICROSOFT CORPORATION

09/09/2005

60/715916US

12/12/2005

11/301799US

PCT/US/2006/035080WO/2007/030728

C07C18929501/03/2007

חומצה של פוספאטי מלח ליצור שיטהאמינית

METHOD FOR PRODUCTION OF PHOSPHATE SALT OF AMINO ACIDCOSMO OIL CO., LTD

13/03/2006

2006-066967JP

PCT/JP/2007/053962WO/2007/119302

C07D18929614/08/2006

PENTACYCLIC KINASE INHIBITORSפנטאציקלי קינאז מעכביGENENTECH, INC.

12/08/2005

60/707902US

PCT/US/2006/031682WO/2007/022102

C07C18929716/08/2006

תפוקות עם תיאואלקילאמינים של הכנהגבוהות

PREPARATION OF THIOALKYLAMINES WITH HIGH YIELDSBAYER CROPSCIENCE AG

24/08/2005

05018347.4EP

PCT/EP/2006/008060June 5, 2008 –התשס"ח ב' בסיון 932

WO/2007/022900

C07D18929812/10/2006

5 ו–3 בעמדות מותמרים פיפרידנים פנילדופאמינית עצבית הולכה של כמאפננים

3.5-DISUBSTITUTED PHENYL-PIPERIDINES AS MODULATORS OF DOPAMINE MEUROTRANSMISSIONNEUROSEARCH SWEDEN AB

13/10/2005

0502254.6SE

PCT/EP/2006/009866WO/2007/042295

H04J18929922/09/2006

של זמנית בו– לבחינה ושיטה מכשיר יחידVSA עם רביםOFDM משדרי

APPARATUS AND METHOD FOR SIMULTANEOUS TESTING OF MULTIPLE ORTHOGONAL FREQUENCY DIVISION MULTIPLEXED TRANSMITTERS WITH SINGLE VECTOR SIGNAL ANALYZERLITEPOINT CORPORATION

23/09/2005

60/596444US

21/09/2006

11/533971US

PCT/US/2006/036995WO/2007/038279

H05K18930324/01/1999

CHIP CARRIER SUBSTRATEשבבים נושא מצע

אנטרקונקט מולטילאייר אמיטק- אדוואנסבע"מ טכנולוג'יס

AMITEC- ADVANCED MULTILAYER INTERCONNECT TECHNOLOGIES LTD.


B60R18930415/08/2006

UNIVERSAL ELECTRONICלרכב ואוניברסלי אלקטרוני משבתIMMOBILIZING FOR A VEHICLE

SALOMON SYDNEY OHAYONאוחיון עמיחי15/08/2005

60/707986US

PCT/IL/2006/000946WO/2007/020637

H01L18930507/08/2006

תפוקה בעלת מיכני לליטוש כימית תרכובתמתכתית שכבה של השטחה עבור גבוהה

HIGH THROUGHPUT CHEMICAL MECHANICAL POLISHING COMPOSITION FOR METAL FILM PLANARIZATIONADVANCED TECHNOLOGY MATERIALS, INC.

05/08/2005

60/706206US

PCT/US/2006/030508WO/2007/019342

C08K18930601/08/2006

פולימר מבוססי בערה מעכבי קצפיםלקצף מקדימים וחומרים סטירני

FLAME RETARDED STYRENIC POLYMER FOAMS AND FOAM PRECURSORSALBEMARLE CORPORATION

08/08/2005

60/706646US

PCT/US/2006/029814WO/2007/019120


F16L18930709/08/2006

DEVICE FOR CONNECTING FLEXIBLEגמישים צנורות לחיבור מתקןHOSESBUCCHI S.R.L.

08/09/2005RN2005A000057IT

PCT/IB/2006/002201WO/2007/029068

C01B18930931/07/2006

ונוזל פולריני תרסיס נוזל ליצור תהליךפולריני תרסיס

PROCESS FOR PRODUCING FULLERENE DISPERSION LIQUID, AND FULLERENE DISPERSION LIQUIDABSIZE INC.

10/08/2005

2005-232390JP

PCT/JP/2006/315178WO/2007/018068

A61K18931004/08/2006

אינפוזיה פרופופול אמולסיית תרכובותשמרנית יעילות בעלות

INTRAVENOUS PROPOFOL EMULSION COMPOSITIONS HAVING PRESERVATIVE EFFICACYBHARAT SERUMS & VACCINES LTD.

05/08/2005

906/MUM/2005IN

PCT/IN/2006/000281WO/2007/052288

H01R18931129/08/2006

וגבס מלט מוצרי של כוללני חוזק שיפורCOMPREHENSIVE STRENGTH IMPROVEMENT OF CEMENT AND GYPSUM PRODUCTSJOSEF ATOON


29/08/2005

60/711694US

PCT/IL/2006/000997WO/2007/026352

E05B18931226/07/2006

פינים הכוללת ומפתח מנעול מערכתבמנעול

A LOCK AND KEY SYSTEM WITH IMPROVED TUMBLERS IN THE LOCKWINLOC AG

05/08/2005

0501782-7SE

PCT/SE/2006/000913WO/2007/018456

A61K18931303/08/2006

כחיסונים וירוס דמויי חלקיקיםלוירוס–פאראמיקסו

VIRUS-LIKE PARTICLES AS VACCINES FOR PARAMYXOVIRUSUNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL

05/08/2005

60/706126US

02/08/2006

11/497888US

PCT/US/2006/030319WO/2007/019247

B24D18931425/08/2006

מבריק מחמם גוף משטח בעל מכשירלייצורו ושיטה

TOOL WITH SINTERED BODY POLISHING SURFACE AND METHOD OF MANUFACTURING THE SAMEHIROSHI ISHIZUKA

25/08/2005

2005-243529JP

31/07/2006

2006-209236JP

PCT/JP/2006/316737WO/2007/023949


A61B18931730/07/2006

FLUID SUPPLY FOR ENDOSCOPEלאנדוסקוף נוזלים להספקת מערכת.STRYKER GI LTDג'י. אי. בע"מ סטריקר

18/08/2005

11/207093US

PCT/IL/2006/000880WO/2007/020624

G06F18931807/09/2006

מוגדל טווח הנותנת באתר כח בקרתזנר פוטודיאודות על אופטי כח לבקרת

IN-SITU POWER MONITOR PROVIDING AN EXTENDED RANGE FOR MONITORING INPUT OPTICAL POWER INCIDENT ON AVALANCHE PHOTODIODESALLIED TELESIS, INC.

09/09/2005

11/223646US

PCT/US/2006/035000WO/2007/030700

A61N18932013/09/2006

חשמלי כח מקור ומתקן יונטופורזה מתקןיונטופורזה למתקן

IONTOPHORESIS DEVICE AND POWER SUPPLY DEVICE FOR IONTOPHORESIS DEVICETTI ELLEBEAU, INC

14/09/2005

2005-267588JP

PCT/JP/2006/318174WO/2007/032398


A61N18932114/09/2006

CATHETER TYPE IONTOPHORESISקטטר מסוג יונטופורזה מתקןAPPARATUSTTI ELLEBEAU, INC

16/09/2005

2005-270862JP

PCT/JP/2006/318239WO/2007/032423

C07D18932207/08/2006

אוקסאזולידינון–קווינולון של היברידיםחיידקים נגד כתרכובות

OXAZOLIDINONE-QUINOLONE HYDRIDS AS ANTIBACTERIAL COMPOUNDSACTELION PHARMACEUTICALS LTD.

08/08/2005PCT/EP05/008573EP

PCT/IB/2006/052714WO/2007/017828

B24B18932308/08/2006

מחשב באמצעות המבוקרת טחינה מכונתנצמד אביזר עבור עדשות ליצירת

COMPUTER-CONTROLLED MILLING MACHINE FOR PRODUCING LENSES FOR CLIP-ON ACCESSORYOPTI-CLIP INTERNATIONAL LLC

08/08/2005

11/198391US

PCT/IL/2006/000914WO/2007/017870


B32B18932415/09/2006

ממשק הכולל לעיצוב הניתן הרכבהיקשרות

MOLDABLE CONSTRUCTION INCORPORATING BONDING INTERFACEMILLIKEN & COMPANY

27/09/2005

11/235941US

11/09/2006

11/518963US

11/09/2006

11/518965US

PCT/US/2006/036278WO/2007/038048

D03D18932519/09/2006

MOLDABLE FABRIC WITHמשתנים מרכיבים עם לעיצוב הניתן מבנהVARIABLE CONSTITUENTSMILLIKEN & COMPANY

27/09/2005

60/720824US

11/09/2006

11/518964US

PCT/US/2006/036650WO/2007/038137

A61K18932909/08/2006

VACCINATION AGAINST DENGUEהדנגה קדחת נגיף זיהום נגד חיסוןVIRUS INFECTIONSANOFI PASTEUR

10/08/2005

60/707038US

22/09/2005

60/719448US

PCT/US/2006/030846WO/2007/021672


H04N18933329/06/2006

VIDEO TRICK MODE SYSTEMמשתנה במהירות וידיאו להקרנת מערכתNDS LIMITED

15/08/2005

60/708151US

PCT/IL/2006/000762WO/2007/020621

A61B18933408/08/2006

EYE-SAFE PHOTOCOSMETIC DEVICEלעין בטוח קוסמטי אור מכשירPALOMAR MEDICAL TECHNOLOGIES, INC.

08/08/2005

60/706505US

PCT/US/2006/030968WO/2007/019536

A61P18933610/08/2006

המכילים עיניים תכשירים לרירית הנדבקים פוליסאככרידים

של מחדש לבניה לגרום המסוגליםהקרנית אפיתל

OPHTHALMIC COMPOSITIONS CONTAINING MUCOADHESIVE POLYSACCHARIDES ABLE TO PROMOTE CORNEAL RE-EPITHELIZATIONOPOCRIN S.P.A.

12/08/2005RM2005A000443IT

PCT/IT/2006/000616WO/2007/020671

C07J18933704/08/2006

של ניטרואוקסי תולדותגלוקוקורטיקואידים

NITROOXY DERIVATIVES OF GLUCOCORTICOIDSNICOX SA

02/09/2005

05019155.0EP

PCT/EP/2006/007746WO/2007/025632


H04N18934013/09/2006

להתקן מחובר יעד התקן לאימות שיטהראשי

METHOD FOR VERIFYING A TARGET DEVICE CONNECTED TO A MASTER DEVICENAGRAVISION S.A.

14/09/2005

05108446.5EP

PCT/EP/2006/066326WO/2007/031540

H04M18934530/06/2006

נייד תקשורת להתקן תוכן לסינון מערכתבה לשימוש ושיטה

A CONTENT FILTERING SYSTEM FOR A MOBILE COMMUNICATION DEVICE AND METHOD OF USING SAMEAGENT MOBILE PTY LTD

12/08/2005

2005100653AU

PCT/AU/2006/000921WO/2007/019599

B82B18934614/08/2006

NANOPARTICLESננוחלקיקיםNANOCO TECHNOLOGIES LIMITED

12/08/2005

0516598.0GB

PCT/GB/2006/003028WO/2007/020416

G21F18934711/08/2006

מאפיין עם קרינה נגד להגנה מכלולמכלים למיקום

RADIATION-SHIELDING ASSEMBLY HAVING CONTAINER LOCATION FEATUREMALLINCKRODT INC.


12/08/2005

60/707789US

PCT/US/2006/031398WO/2007/021947

G21G18934808/08/2006

יכולת בעלת רדיואיזוטופים לייצור מערכתחלקית מיצוי

RADIOISOTOPE GENERATION SYSTEM HAVING PARTIAL ELUTION CAPABILITYMALLINCKRODT INC.

09/08/2005

60/706793US

PCT/US/2006/030766WO/2007/030249

G01F18934903/08/2006

בכוח בשימוש על–קולית זרימה מדידתנמוך

LOW POWER ULTRASONIC FLOW MEASUREMENTFLOWNETIX LIMITED

13/08/2005

0516752.3GB

28/07/2006

0615120.3GB

PCT/GB/2006/002902WO/2007/020378

G01F18935028/07/2006

על–קולי פלסטי מים מונה של לבניה שיטהמוזל

A METHOD OF CONSTRUCTION FOR A LOW COST PLASTIC ULTRASONIC WATER METERFLOWNETIX LIMITED

13/08/2005

0516754.9GB

PCT/GB/2006/002825WO/2007/020375

C07D18935324/08/2006


של ואפסילון דלתא של גבישיות צורותמסילאט אימטיניב

DELTA AND EPSILON CRYSTAL FORMS OF IMATINIB MESYLATENOVARTIS AG

26/08/2005

60/711738US

26/08/2005

60/711737US

29/08/2005

60/712206US

PCT/EP/2006/065662WO/2007/023182

C07C18935428/08/2006

PROCESS FOR THE PRODUCTION OFאנילינים לייצור תהליךANILINESSYNGENTA PARTICIPATIONS AG

30/08/20051416/05CH

PCT/EP/2006/008398WO/2007/025693

C07D18935506/06/2003

PRODRUGS OF EXCITATORY AMINOמעוררות אמינו חומצות של קדם–תרופותACIDSELI LILLY AND COMPANY

11/06/2002

02380120.2EP

11/06/2002

02380121.0EP

03/10/2002

60/415,936US

03/10/2002

60/415,937US

PCT/US/2003/015405WO/2003/104217

C07D18935616/08/2006


לשימוש ושיטות קינאזMAP 38p מעכביבהם

p38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAMEF. HOFFMANN-LA ROCHE AG

25/08/2005

60/712010US

PCT/EP/2006/065330WO/2007/023111

C07D18935727/12/2001

NOVEL COMPOUNDSחדשות תרכובותWARNER-LAMBERT COMPANY LLC

09/01/2001

60/260505US

PCT/IB/2001/002729WO/2002/055519

C07D18935827/12/2001

של פנילאמיד של לסינתזה חדש תהליך–))2–]1–פלואורופניל(–4–)5 חומצהR2,R4–)4–6–הידרוקסי–

–יל(–אתיל[–2אוקסו–טתראהידרו–פיראן––3–פירול–H1–פניל–4–איסופרופיל–2

קרבוקסילית

NOVEL PROCESS FOR THE SYNTHESIS OF 5 - (4 - FLUOROPHENYL) - 1 - [2 - ((2R, 4R)- 4 - HYDROXY - 6 - OXO -TETRAHYDRO - PYRAN - 2 - YL) - ETHYL] - 2 - ISOPROPYL- 4 - PHENYL - 1H - PYRROLE - 3 - CARBOXYLIC ACID PHENYLAMIDEWARNER-LAMBERT COMPANY LLC

09/01/2001

60/260505US

PCT/IB/2001/002729WO/2002/055519

C07D18935927/12/2001

של פנילאמיד של לסינתזה חדש תהליך–R2–2–]1–פלואורופניל(–4–)5 חומצהR4)–4–6–הידרוקסי–

–יל(–אתיל[–2אוקסו–טתראהידרו–פיראן––3–פירול–H1–פניל–4–איסופרופיל–2

קרבוקסילית

NOVEL PROCESS FOR THE SYNTHESIS OF 5 - (4 - FLUOROPHENYL) - 1 - [2 - ((2R, 4R)- 4 - HYDROXY - 6 - OXO -TETRAHYDRO - PYRAN - 2 - YL) - ETHYL] - 2 - ISOPROPYL- 4 - PHENYL - 1H - PYRROLE - 3 - CARBOXYLIC ACID PHENYLAMIDE


WARNER-LAMBERT COMPANY LLC09/01/2001

60/260505US

PCT/IB/2001/002729WO/2002/055519

A61M18936025/07/2006

התקן של לחץ ובקרת לניטור מערכתפצע על לטיפטוף

WOUND IRRIGATION DEVICE PRESSURE MONITORING AND CONTROL SYSTEMRICHARD C. VOGEL

08/08/2005

11/198148US

29/09/2005

11/237880US

09/02/2006

11/350089US

PCT/US/2006/028738WO/2007/019038

C07K18936103/08/2006

לרצפטור הנקשרים פפטידים של שימושיםTPO של

USE OF PEPTIDES THAT BIND TO TPO RECEPTORORTHO-MCNEIL PHARMACEUTICAL, INC.

09/08/2005

11/200416US

PCT/US/2006/030359WO/2007/021572

A61B18936209/08/2006

בעמוד ציריות לפרוצדורות המרה מערכתהשדרה

EXCHANGE SYSTEM FOR AXIAL SPINAL PROCEDURESTRANS1 INC.


09/08/2005

60/706704US

PCT/US/2006/031084WO/2007/021772

H01G18936309/08/2006

מקדם עם משופרת מוארכת אנודהאותה הכולל וקבל מינימלי צפיפות

IMPROVED FLUTED ANODE WITH MINIMAL DENSITY GRADIENTS AND CAPACITOR COMPRISING SAMEKEMET ELECTRONICS CORPORATION

09/08/2005

11/199626US

PCT/US/2006/031025WO/2007/021738

A61K18936410/08/2006

תרפויטיות ושיטות אסטרוגן תרכובותבהן לשימוש

ESTROGEN COMPOSITIONS AND THERAPEUTIC METHODS OF USE THEREOFDRUGTECH CORPORATION

12/08/2005

60/707662US

PCT/US/2006/031153WO/2007/021805

A61B18936612/08/2006


רקמות לניקויי ושיטות מערכות, מכשיריםאופטי באופן

SYSTEMS, DEVICES, AND METHODS FOR OPTICALLY CLEARING TISSUEBOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

12/08/2005

60/707778US

PCT/US/2006/031401WO/2007/021948

C07D18937022/08/2006

–]2,1אימידאזו[ תרכובת ייצור עבור תהליךbפירידאזין

PROCESS FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINE COMPOUNDSUMITOMO CHEMICAL COMPANY, LIMITED.

30/08/2005

2005-248845JP

PCT/JP/2006/316790WO/2007/026621

C07K18937116/01/2001

מסיסות בלתי תרכובות של להמרה שיטה (GLP–1)1 גלוקאגון דמוי פפטיד של

GLP–1 של מסיסה לתרכובת

A METHOD FOR CONVERSION OF INSOLUBLE GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUNDS TO A SOLUBLE GLP-1 COMPOUNDELI LILLY AND COMPANY

27/01/2000

60/178438US

09/08/2000

60/224058US

PCT/US/2001/000010June 5, 2008947 –התשס"ח ב' בסיון

WO/2001/055213

C07D18937415/08/2006

FUSED PYRAZOLE AS p38 MAP קינאזMAP 38p כמעכבי מאוחד פיראזולKINASE INHIBITORSF. HOFFMANN-LA ROCHE AG

25/08/2005

60/712012US

PCT/EP/2006/065297WO/2007/023105

C07D18937529/08/2006

–2–הטרוציקלילסולפוניל, 1 תולדות–H–1 מותמר –)הטרו–(אריל5אמינומתיל,

חומצה הפרשת כמעכבי פירול

1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5-(HETERO)ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORSTAKEDA PHARMACEUTICAL COMPANY LIMITED

30/08/2005

2005-250356JP

31/03/2006

2006-100626JP

PCT/JP/2006/317408WO/2007/026916

A61K18937625/08/2006


בסרטן לטיפולDMXAA הכוללים צירופיםCOMBINATIONS COMPRISING DMXAA FOR THE TREATMENT OF CANCERANTISOMA PLC

26/08/2005

0517386.9GB

02/03/2006

0604114.9GB

PCT/GB/2006/003196WO/2007/023302

A61K18937725/08/2006

בסרטן לטיפולDMXAA הכוללים צירופיםCOMBINATIONS COMPRISING DMXAA FOR THE TREATMENT OF CANCERANTISOMA PLC

26/08/2005051738.7GB

PCT/GB/2006/003207WO/2007/023307

C07D18938116/08/2006



25/08/2005

60/712021US

PCT/EP/2006/065334WO/2007/023114

C07D18938216/08/2006




25/08/2005

60/712007US

PCT/EP/2006/065335WO/2007/023115

C07D18938331/08/2006

–בנזו]4–יל–1–פיפראזינ–4 של תולדותBשל במחלות לטיפול המתאימות [תיופן

המרכזית העצבים מערכת

DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE

FOR THE TREATMENT OF CNS

DISORDERSOTSUKA PHARMACEUTICAL CO., LTD.

31/08/2005

2005-251055JP

PCT/JP/2006/317704WO/2007/026959

G01J18938508/08/2006

דוגמה של וכימות לזיהוי ושיטה מערכתבנוזל המורחפת ביולוגית

SYSTEM AND METHOD FOR THE IDENTIFICATION AND QUANTIFICATION OF A BIOLOGICAL SAMPLE SUSPENDED IN A LIQUIDPOCARED DIAGNOSIS, LTD.

08/08/2005

60/706489US

07/08/2006

11/500163US

PCT/US/2006/030765June 5, 2008 –התשס"ח ב' בסיון 950

WO/2007/019462

A01G18938628/08/2006

IRRIGATION PIPE COMPRISING Aרב–שכבתי איזור המכיל השקייה צינורMULTILAYERED PIPE WALL

NETAFIM LTDבע"מ נטפים07/09/2005

11/220376US

PCT/IL/2006/000992WO/2007/029234

G06F18938826/07/2006

תקשורת פרוטוקלי עבור מפוצל סיוםמוגנים

SPLIT TERMINATION FOR SECURE COMMUNICATION PROTOCOLSRIVERBED TECHNOLOGY, INC.

10/08/2005

60/707804US

18/07/2006

11/489414US

PCT/US/2006/029158WO/2007/021483

C12N18938908/08/2006


הינם אשר גידולים דוחי אנטיגניים פפטידים ( היעילים3GPC )3גליפיקאן– של תולדותאשר בחולים לשימוש

ותכשירי חיובי2A–HLAכ– מסווגים אותם המכילים רוקחות

GLYPICAN-3 (GPC3)-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES USEFUL FOR HLA-A2 POSITIVE PATIENTS AND PHARMACEUTICAL COMPRISING THE SAMEKUMAMOTO UNIVERSITY

09/08/2005

2005-230702JP

PCT/JP/2006/315631WO/2007/018199

C07D18939021/08/2006

–יל(–הטרוציקליות3)אינדול– תולדות1CB קולטן של כאגוניסטים

(INDOL-3-YL)HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTORN.V. ORGANON

23/08/2005

05107725.3EP

PCT/EP/2006/065496WO/2007/023143

A23L18939218/10/2006

מחיות מבוייצות ביצים להכנת שיטה וביצים יוקרתיים מאכל למצרכי מימיות

האמורה בשיטה שימוש תוך מבוייצות

METHOD FOR PREPARING THE OVULATED EGGS OF AQUATIC ANIMALS FOR QUALITY FOODSTUFFS AND OVULATED EGGS PREPARED USING SAID METHODSTIFTUNG ALFRED-WEGENER-INSTITUT FUR POLAR-UND MEERESFORSCHUNG

19/10/2005

102005050723.9DE

PCT/DE/2006/001867WO/2007/045233


C07D18939411/08/2006

פיראזולקרבוקסילית חומצת תולדות בחקלאות לשימוש ותכשירים אניליד

אותם המכילים

SUBSTITUTED PYRAZOLECARBOXYLIC ACID ANILIDE DERIVATIVES AGRICULTURAL COMPOSITIONS CONTAINING THE SAMENIHON NOHYAKU CO., LTD.

12/08/2005

2005-234405JP

07/11/2005

2005-322531JP

18/04/2006

2006-114937JP

PCT/JP/2006/316198WO/2007/020986

C07D18939522/08/2006

METHOD FOR PRODUCINGכלוריד סולפוניל תרכובת ייצור עבור שיטהSULFONYL CHLORIDE COMPOUNDSUMITOMO CHEMICAL COMPANY, LIMITED.

30/08/2005

2005-248846JP

PCT/JP/2006/316813WO/2007/026625

G06F18939707/08/2006

שימוש תוך מומחים משאבים של ניהולנדרשים בפרופילים

MANAGEMENT OF EXPERT RESOURCES USING SEEKER PROFILESXPERTUNIVERSE, INC.

08/08/2005

11/200520US

PCT/US/2006/030796WO/2007/019470


F16L18939909/08/2006

FLUID FLOW DEVICESלנוזלים זרימה התקניSWAGELOK COMPANY

09/08/2005

60/706846US

PCT/US/2006/031096WO/2007/021779

A61K18940010/08/2005

(–4)3,1בבתא– שימוש(–4)3,1אנדוגלוקנוהידרולאז, בתא–

חילוקיות, חומר מכילה גלוקאן, אדמה פונקציה להגדלת וגלוקומנן מינרלי

חיסונית

USE OF ?-1,3(4)-ENDOGLUCANOHYDROLASE, ?-1,3 (4) GLUCAN, DIATOMACEOUS EARTH, MINERAL CLAY AND GLUCOMANNAN TO AUGMENT IMMUNE FUNCTIONSTEVEN BRUCE PUNTENNEY

PCT/US/2005/028529WO/2007/021262

C12N18940211/08/2006

METHODS AND COMPOSITIONS FORיבשות תאיות צורות עבור ותכשירים שיטותDRIED CELLULAR FORMSPRESIDENT AND FELLOWS OF HARVARD COLLEGE

11/08/2005

60/707425US

31/03/2006

60/788133US

PCT/US/2006/031580WO/2007/022053


C22C18940316/08/2006

FINE GRAINED POLYCRYSTALLINEעדין בגירעון גבישי רב שיוף חומרABRASIVE MATERIALELEMENT SIX (PRODUCTION) (PTY) LTD

16/08/2005

2005/06534ZA

PCT/IB/2006/002229WO/2007/020518

C07D18940414/08/2006

בעלות טטרהציקליות בנזופוראן נגזרותתרפואטית פעילות

TETRACYCLIC BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES

PHARMOS CORPORATIONקורפוריישן פארמוס16/08/2005

60/708367US

PCT/IL/2006/000940WO/2007/020631

C07K18940709/08/2006

מחלות ואבחון לטיפול פפטידיםאוטואימוניות

PEPTIDES FOR TREATMENT AND DIAGNOSIS OF AUTOIMMUNE DISEASEARPI MATOSSIAN-ROGERS

11/08/2005

0516527.9GB

18/05/2006

0609920.4GB

18/05/2006

0609921.2GB

PCT/GB/2006/002977WO/2007/017686


H04J18940910/08/2006

PORTABLE DIALER DEVICE ANDנייד לחייגן והתקן שיטהMETHODNIR RON

10/08/2005

60/706780US

PCT/IL/2006/000936WO/2007/017881

A61C18941231/07/2006

להשתלות ושיטה הנעה והתקן מנשאקשורים ורכיבים דנטליות

CARRY AND DRIVE DEVICE AND METHOD FOR DENTAL IMPLANT AND/OR COMPONENTS THEREOFLIFECORE BIOMEDICAL INC.

10/08/2005

11/201175US

PCT/US/2006/029728WO/2007/021519

C07K18941310/08/2006

T סרטן, תאי תאי של פרוליפרציה מעכביוקרטינוציטים

INHIBITORS OF CANCER CELL, T-CELL AND KERATINOCYTE PROLIFERATION4SC AG

10/08/2005

05017391.3EP

PCT/EP/2006/007933WO/2007/017284

C07K18941411/08/2006

מונוציטים של מאוחים פרוטאיניםMCP1 FUSIONS(1MCP)1פרוטאין– של כמוטקטיים

SCHERING CORPORATION12/08/2005

60/707731US

PCT/US/2006/031155


WO/2007/021807

G06F18941511/08/2006

מתוך פריט לבחירת ומכשיר משופר תהליךמידע מאגר

IMPROVED PROCESS AND APPARATUS FOR SELECTING AN ITEM FROM A DATABASEKANNUU PTY LTD.

12/08/2005

2005904378AU

PCT/AU/2006/001151WO/2007/019610

C07D18941608/08/2006

–סולפונילאינדזול3אזיניל– נגזרות6HT–5 לרצפטור כליגנדים המשמשות

AZINYL-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDSWYETH

15/08/2005

60/708317US

PCT/US/2006/030837WO/2007/032833

A61M18941828/08/2006

של ורה–סלולוריזציה דה–סלולריזציהורקמות איברים

DECELLULARIZATION AND RECELLULARIZATION OF ORGANS AND TISSUESREGENTS OF THE UNIVERSITY OF MINNESOTA,

26/08/2005

60/711501US

19/06/2006

60/815242US

PCT/US/2006/033415WO/2007/025233


B31F18941916/08/2006

DRUM FOR A CREASING DEVICEמקמט להתקן תוףTECH-NI-FOLD LTD.

20/08/2005

0517115.2GB

PCT/GB/2006/003057WO/2007/023258

C12N18942019/10/2006

METHOD FOR THE RECOMBINANTפוליפפטיד של רקומביננטי לביטוי שיטהEXPRESSION OF A POLYPEPTIDF. HOFFMANN-LA ROCHE AG

21/10/2005

05023003.6EP

24/05/2006

06010665.5EP

PCT/EP/2006/010067WO/2007/045465

H04N18942129/08/2006

MULTIMEDIA COLORצבעונית מולטימדיה ניהול מערכתMANAGEMENT SYSTEMMICROSOFT CORPORATION

31/08/2005

11/216626US

PCT/US/2006/033822WO/2007/027745

G06F18942229/08/2006

SCRIPT MARKUPלמסמך עריכה סימניMICROSOFT CORPORATION

12/09/2005

60/716293US

23/12/2005

11/318305US

PCT/US/2006/034121WO/2007/032925


A61B18942309/08/2006

להידוק והתקנים כירורגיים מהדקיםכירורגי

SURGICAL FASTENERS AND DEVICES FOR SURGICAL FASTENING

.ENDOGUN MEDICAL SYSTEMS LTDבע"מ רפואיות מערכות אנדוגן11/08/2005

60/706907US

PCT/IL/2006/000917WO/2007/017872

A61N18942410/08/2006

CARDIAC RESYNCHRONIZATIONהלב של מחדש לקיצוב ושיטות מערכותTHERAPY SYSTEMS AND METHODS

ODEM MEDICAL LTDבע"מ מדיקל אודם11/08/2005

60/707155US

PCT/IL/2006/000932WO/2007/017879

E03B18942510/08/2006

של תת–ימיות התחדשויות לתפיסת התקןלהפעלתו ושיטה טריים מים

DEVICE FOR TRAPPING SUBSEA FRESH WATER RESURGENCES AND METHOD FOR THE OPERATION THEREOFMICHEL PERIL

11/08/2005

20050100426GR

PCT/GR/2006/000039WO/2007/017703

F25B18942609/08/2006


על המבוססתBERNOULLI חם משאבתושיטה אצילים גזים

RARE-GAS-BASED BERNOULLI HEAT PUMP AND METHODMACHFLOW ENERGY, INC.

11/08/2005

60/707257US

PCT/IB/2006/002176WO/2007/017741

F03B18942717/08/2006

WAVE ENERGY CONVERSIONגלים אנרגיית המרתSEAPOWER PACIFIC PTY LTD.

17/08/2005

2005904436AU

PCT/AU/2006/001187WO/2007/019640

C07D18942930/03/2006

5,4,3 בעמדות המותמרים פיפרידיניםרנין כמעכבי

3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORSSPEEDEL EXPERIMENTA AG

31/03/2005

66/666556US

16/12/2005

60/750853US

PCT/EP/2006/061197WO/2006/103277

C12P18943009/11/1999

ושימושם אטומים13 בעלי אזאלידיםאנטיביוטיים כחומרים

13-MEMBERED AZALIDES AND THEIR USE AS ANTIBIOTIC AGENTSPFIZER PRODUCTS, INC.

20/11/1998

60/109399US

PCT/IB/1999/001803WO/2000/031097


C07D18943428/08/2006

–הידרוקסי–אתיל(–1–אמינו–2–)7 תולדות (–אוןH3)2–הידרוקסיבנזותיאזול–4

אדנורצפטורים2B של כאגוניסטים

7(-2-AMINO-1-HYDROXY-ETHYL-)4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS ?2 ADRENOCEPTOR AGONISTSASTRAZENECA AB

29/08/2005

0501905-4SE

15/06/2006

0601331-2SE

PCT/SE/2006/000981WO/2007/027134

A61F18943713/08/2006

השמנת למניעת השתלה יכולת בעל מתקןיתר

IMPLANTABLE DEVICE FOR OBESITY PREVENTION

STIMPLANT LTDבע"מ סטימפלנט11/08/2005

60/707227US

PCT/IL/2006/000934WO/2007/017880

A61N18944010/08/2006

ושיטה רפואי טיפול מערכת מבוסס מיקום בגלאי המשתמשים

רדיואקטיביות

MEDICAL TREATMENT SYSTEM AND METHOD USING RADIOACTIVITY BASED POSITION SENSOR


NAVOTEK MEDICAL LTDבע"מ מדיקל נבוטק11/08/2005PCT/IL2005/000871IL

19/10/2005PCT/IL2005/001101IL

16/02/200660/773930US

16/02/200660/773931US

08/06/200660/804178US

PCT/IB/2006/052771WO/2007/017847

A61K18945615/08/2006

של מבוקר לשחרור רוקחות תכשיריבחומצה יציבות שאינן תרופות

CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID LABILE DRUGSSOLVAY PHARMACEUTICALS GMBH

15/08/2005

05107472.2EP

15/08/2005

60/708692US

PCT/EP/2006/065311WO/2007/020259

A61K18945715/08/2006

לבלבית מליבה העשויות כדוריות מיקרוהמעי לציפוי המתאימות

PANCREATIN MICROPELLET CORES SUITABLE FOR ENTERIC COATINGSOLVAY PHARMACEUTICALS GMBH

15/08/2005

05107474.8EP

15/08/2005

60/708526US

PCT/EP/2006/065313WO/2007/020260


C07D18946325/08/2006

היעילות סטרואידיות שאינן תרכובותגלוקוקורטיקואיד קולטן כמאפננות

NON-STEROIDAL COMPOUNDS USEFUL AS GLUCOCORTICOID RECEPTOR MODULATORSN.V. ORGANON

29/08/2005

05107896.2EP

PCT/EP/2006/065696WO/2007/025938

H01L18946807/09/2006

PRODUCING A RADIATION SENSORקרינה חיישן יצורTHALES

23/09/20050509777FR

PCT/EP/2006/066116WO/2007/036417

A61B18947416/07/2006

ויזואלית–אופטית משולבות טכנולוגיות מקבילה ומערכת פסיבית אדום ואינפרה

עור, נבי סרטן מקדמי של וזיהוי לגילוימוקדמת לדיאגנוסטיקה וגידולים

COMBINED VISUAL-OPTIC AND PASSIVE INFRA-RED TECHNOLOGIES AND THE CORRESPONDING SYSTEM FOR DETECTION AND IDENTIFICATION OF SKIN CANCER PRECURSORS, NEVI AND TUMORS FOR EARLY DIAGNOSIS

SMOLIAK YAFIMיפים שמוליק16/08/2005

60/708389US

PCT/IL/2006/000954WO/2007/020643


C07C18948008/05/2002

– טריפלורופרופיל(3,3,3) תרכובתמאלונוניתריל

(3,3,3 -TRIFLUOROPROPYL) MALONONITRILE COMPOUNDSUMITOMO CHEMICAL COMPANY, LIMITED

09/05/2001

2001-138331JP

PCT/JP/2002/004449WO/2002/090320

H04Q18948910/08/2006

מוגבל חוזר לשימוש אלגוריתם ניהול סט תשדורת בקישור שווה שירות דירוג עבור

קדימה העברה של

RESTRICTIVE REUSE SET MANAGEMENT ALGORITHM FOR EQUAL GRADE OF SERVICE ON FORWARD LINK TRANSMISSIONQUALCOMM INCORPORATED

12/08/2005

11/203038US

PCT/US/2006/031403WO/2007/021950

G06F18949520/09/2006

סטטיסטיקות באמצעות פונקציות דירוגבמסמכים שימוש של

RANKING FUNCTIONS USING DOCUMENT USAGE STATISTICSMICROSOFT CORPORATION

21/09/2005

11/231955US

PCT/US/2006/037206WO/2007/035919


A61K18949824/08/2005

CLEAVAGE OF ANTIFOLATEאנטי–פולאטיות תרכובות של ביקועCOMPOUNDSPROTHERICS MEDICINES DEVELOPMENT LIMITED

PCT/GB/2005/003297WO/2007/023243

A61K18950205/10/1999

תאים של הגידול לעיכוב ותכשירים שיטותנאופלסטים

METHODS AND COMPOSITIONS FOR INHIBITING NEOPLASTIC CELL GROWTHGENENTECH, INC.

13/10/1998

60/104080US

PCT/US/1999/023089WO/2000/021996

H04L18950712/07/1999

DEVICEהתקן.SERCONET LTDבע"מ סרקונט

28/07/1998123486US

PCT/US/1999/015644WO/2000/007322

H04L18950812/07/1999

DEVICEהתקן.SERCONET LTDבע"מ סרקונט

28/07/1998123486US

PCT/US/1999/015644WO/2000/007322

A23L18951601/08/2006


הקשורה פקקת למניעת בכולין שימושורידית תוך להזנה

USE OF CHOLINE TO PREVENT THROMBOSIS ASSOCIATED WITH TOTAL PARENTERAL NUTRITIONALAM L. BUCHMAN

16/08/2005

60/708395US

PCT/US/2006/029869WO/2007/021529

H04L18952629/08/2006

MEDIA ACCESS CONTROLלתקשורת בגישה שליטה ארכיטקטורתARCHITECTUREOPTIMAL INNOVATIONS, INC.

01/09/2005

60/713052US

PCT/US/2006/033657WO/2007/027667

C07D18954507/09/2006

כפותחני בהן והשימוש פירימידין נגזרותKCNQ מסוג אשלגן תעלות

PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERSH. LUNDBECK A/S

09/09/2005PA200501262DK

PCT/DK/2006/050039WO/2007/065449

F16L18960421/06/2006

STOP ASSEMBLY FOR PIPEצינורות לצימוד עצירה מכלולCOUPLINGVICTAULIC COMPANY

24/08/2005

11/210376US

PCT/US/2006/024103WO/2007/024326


A61B18960511/08/2006

לטיפול בטיפות–עינייםNGF ב– שימוש העצבים מערכת של בפתולוגיות

אלצהיימר מחלות המרכזית, כגוןופרקינסון

USE OF NERVE GROWTH FACTOR IN EYE-DROPS FOR THERAPY OF PATHOLOGIES OF THE CENTRAL NERVOUS SYSTEM, SUCH AS ALZHEIMER'S AND PARKINSON'S DISEASEANABASIS S.R.L.

19/08/2005RM2005A000447IT

PCT/IT/2006/000620WO/2007/020672

A61L18960718/08/2006

EXENDIN FOR TREATING DIABETESמשקל ולהורדת בסכרת לטיפול אקסנדיןAND REDUCING BODY WEIGHTAMYLIN PHARMACEUTICALS, INC.

19/08/2005

60/709604US

03/03/2006

60/779216US

PCT/US/2006/032354WO/2007/024700

A61M18960803/08/2006

המלאה הזרקה מערכת עבור מחט מכלולההזרקה טרם

NEEDLE ASSEMBLY FOR A PREFILLED SYRINGE SYSTEMCILAG GMBH INTERNATIONAL

30/08/2005

05255298.1EP

PCT/IB/2006/002792WO/2007/026248

C07D18960912/09/2006

4 בעמדה מותמרים –אונים2פירולידין–בהם ושימוש

4-SUBSTITUTED PYRROLIDIN-2-ONES AND THEIR USE


UCB PHARMA S.A.15/09/2005

05020080.7EP

24/10/2005

05023133.1EP

PCT/EP/2006/008852WO/2007/031263

C12N18961122/08/2006

TREATMENT OF INFLAMMATORYלנפיחות הגורמת מעיים במחלת טיפולBOWEL DISEASEITH IMMUNE THERAPY HOLDINGS AB

31/08/2005

0501916-1SE

PCT/SE/2006/000959WO/2007/027132

A61K18961422/11/2005

PHARMACEUTICAL COMPOSITIONSטלמיסרטן של רוקחיים הרכביםOF TELMISARTAN

TEVA PHARMACEUTICALבע"מ פרמצבטיות תעשיות טבעINDUSTRIES LTD.

PCT/US/2005/042700WO/2007/061415

A61K18961518/10/2000

להכנתו ושיטות מלנומה נגד חיסון תרכיבבו ולשימוש

MELANOMA VACCINE AND METHODS OF MAKING AND USING SAMEST. VINCENT'S HOSPITAL AND MEDICAL CENTER OF NEW YORK

18/10/1999

60/240933US

PCT/US/2000/028837WO/2001/028583


A45D18961625/08/2006

HAIRSTYLING DEVICEשיער לעיצוב מכשירMOURAD, JOSEPH

26/08/2005

2005904653AU

PCT/AU/2006/001244WO/2007/022600

C07D18961724/08/2006

והשימוש טטראהידרוקוינולינונים של לרצפטורים כמאפננים בהם

מטבוטרופי גלוטמט

TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORSMERZ PHARMA GMBH & CO. KGAA

24/08/2005PCT/GB2005/003285GB

PCT/GB/2006/003170WO/2007/023290

C10L18961820/10/2004

מתיל שומן חומצת להכנת משופר תהליך טריגליצריד )ביודיזל( משמן אסתר

טרנסאסטריפיקציה באמצעות

IMPROVED PROCESS FOR THE PREPARATION OF FATTY ACID METHYL ESTER (BIODIESEL) FROM TRIGLYCERIDE OIL THROUGH TRANSESTERIFICATIONCOUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH

PCT/IN/2004/000329WO/2006/043281

A23L18961924/12/2004

AN IMPROVED IODIZED SALT AND Aלהכנתו ותהליך משופר מיודד מלחPROCESS FOR ITS PREPARATION


COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH

PCT/IN/2004/000405WO/2006/067798

A61K18962028/08/2006

הנגרמת למחלה ומרפא מונע גורםהדמעות בנוזל מהפחתה

PREVENTIVE OR THERAPEUTIC AGENT FOR DISEASE CAUSED BY DECREASE IN LACRIMAL FLUIDKISSEI PHARMACEUTICAL CO., LTD.

29/08/2005

2005-247563JP

PCT/JP/2006/316836WO/2007/026630

G06M18962131/08/2005

המועברות ביצים לספירת ביצים מונהביצים ערימת של מסוע באמצעות

EGG COUNTER FOR COUNTING EGGS TRANSFERRED BY EGG COLLECTION CONVEYERAGRO SYSTEM CO. LTD

PCT/JP/2005/016351WO/2007/029316

A61K18962228/09/2005

באי–סדרים לטיפול רוקחות תכשיריפנים–אוזניים

PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INNER EAR DISORDERSAURIS MEDICAL AG.


PCT/EP/2005/010478WO/2007/038949

B41M18962306/09/2006

לטנטי משפעל המכילים ציפוי תכשיריסובטרטים לסימון

COATING COMPOSITIONS COMPRISING A LATENT ACTIVATOR FOR MARKING SUBSTRATESCIBA SPECIALTY CHEMICALS HOLDING INC.

15/09/2005

05108480.4EP

PCT/EP/2006/066064WO/2007/031454

H04L18962425/09/2006

לתדרים המחולקת כניסות מרובת מערכת BEAMFORMING טכניקת על והמבוססת

פלט ורבת קלט רבת

MIMO BEAMFORMING-BASED SINGLE CARRIER FREQUENCY DIVISION MULTIPLE ACCESS SYSTEMINTERDIGITAL TECHNOLOGY CORPORATION

29/09/2005

60/722022US

PCT/US/2006/037391WO/2007/041086


C07D18962528/08/2006

חדשים ציקלואלקאנים קרבוקסאמידיםXA פקטור כמעכבי

NOVEL CYCLOALKANE CARBOXAMIDES AS FACTOR XA INHIBITORSF. HOFFMANN-LA ROCHE AG

01/09/2005

05107992.9EP

PCT/EP/2006/065732WO/2007/025949

C07D18962730/08/2006

THIAZOLE DERIVATIVESתיאזול תולדותASTELLAS PHARMA INC.

31/08/2005

2005-252464JP

28/06/2006

2006-177436JP

PCT/JP/2006/317102WO/2007/026761

C12N18962822/08/2005

ציטורעיל וצמדCA6 נגד מונושבטי נוגדןאותן המכיל6CA אנטיגן נגד ספציפי

AN ANTI-CA6 MONOCLONAL ANTIBODY AND A CA6 ANTIGEN SPECIFIC CYTOTOXIC CONJUGATE CONTAINING THE SAMEIMMUNOGEN, INC.

PCT/US/2005/030115WO/2007/024222


C12N18962924/08/2000

CTLA– 4 ל נוגדנים המכילים תכשיריםאנושי

COMPOSITIONS CONTAINING HUMAN CTLA-4 ANTIBODIESMEDAREX, INC.

24/08/1999

60/150452US

PCT/US/2000/023356WO/2001/014424

A61K18963027/04/2001

חומצה של מלח המכיל היממסטתי גורםמחמצנת

A HEMOSTATIC AGENT INCLUDING AN OXYACID SALTBIOLIFE, L.L.C.

28/04/2000

60/200207US

13/06/2000

09/592344US

19/01/2001

09/766513US

PCT/US/2001/013765WO/2001/082896

A61K18963125/08/2006

המכיל מבוקר שחרור עם רוקחות תכשירהיפרומלוז

A CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING HYPROMELLOSEBPSI HOLDINGS, INC.

26/08/2005

60/711724US

PCT/US/2006/033309WO/2007/025182

C08G18963223/08/2006

אמין קבוצות עם פולימרים להכנת שיטותקצה

METHODS FOR PREPARING POLYMERS HAVING TERMINAL AMINE GROUPSENZON PHARMACEUTICALS, INC.


26/08/2005

11/212901US

01/12/2005

11/291546US

PCT/US/2006/032971WO/2007/024981

B01J18963322/08/2006

מיקרוקפסולות לייצור שיטהחד–ורב–שכבתיות

METHOD FOR PRODUCTION OF SINGLE-AND MULTI-LAYER MICROCAPSULES

.TAGRA BIOTECHNOLOGIES LTDבע"מ ביוטכנולוגיות טאגרה22/08/2005

11/208007US

PCT/IL/2006/000977WO/2007/023495

H04L18963422/08/2006

DISTRIBUTED PROTOCOL OVER Aאלחוטי חיבור גבי על מבוזר פרוטוקולWIRELESS CONNECTIONQUALCOMM INCORPORATED

22/08/2005

60/710365US

PCT/US/2006/032769WO/2007/024854


H04B18963522/08/2006

אנטנות של לבחירה והתקן שיטהורטואלית

METHOD AND APPARATUS FOR SELECTION OF VIRTUAL ANTENNASQUALCOMM INCORPORATED

22/08/2005

60/710371US

24/08/2005

60/711144US

27/10/2005

11/261823US

15/03/2006

11/377458US

PCT/US/2006/032860WO/2007/024913

A01N18963824/07/2006

חלבון תכולת להפחתת והתקן שיטותזרע תא נפח במגדילי

METHODS AND APPARATUS FOR REDUCING PROTEIN CONTENT IN SPERM CELL EXTENDERSXY, INC.

29/07/2005

60/704001US

02/09/2005

11/219607US

PCT/US/2006/028846WO/2007/016090

A61B18964014/08/2006

DISPOSABLE CAP FOR ENDOSCOPEלאנדוסקופ פעמי חד כיסוי.STRYKER GI LTDג'י. אי. בע"מ סטריקר

06/09/2005

60/714480US

PCT/IL/2006/000937WO/2007/029230

A61K18964206/09/2006


1לקינז– מונושבטיים אנושיים נוגדניםאקטיבין לקולט הדומה

HUMAN MONOCLONAL ANTIBODIES TO ACTIVIN RECEPTOR-LIKE KINASE 1PFIZER, INC.

07/09/2005

60/715292US

PCT/US/2006/035096WO/2007/040912

C08B18964407/09/2006

שרשרת עם גבישית עמילוזה להכנת תהליךקצרה

A PROCESS FOR THE PRODUCTION OF CRYSTALLINE SHORT CHAIN AMYLOSETATE & LYLE INGREDIENTS AMERICAS, INC.

09/09/2005

60/715832US

PCT/US/2006/034666WO/2007/030507

F01K18964927/06/2006

CONDENSATION METHODעיבוי שיטת

GEA ENERGIETECHNIK GMBH25/08/2005

102005040380.8DE

PCT/DE/2006/001097WO/2007/022738

C07D18965022/09/2006

–4–]5אמינו– תרכובות–5)דיפלואורומתוקסי(פניל[–

של כמעכבות פנילאימידאזולון (BACE) בתא–סקרטאז

AMINO-5-[4-(DIFLUOROMETHOXY) PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS INHIBITORS OF THE BETA-SECRETASE (BACE)WYETH

26/09/2005

60/720589US

PCT/US/2006/036985WO/2007/038271


C12P18965128/03/2002

'–4–דמשופעל–O–3 המכילים תכשירים A (MLA – D3 ) ליפיד מונופוספוריל

( ומונופוספורילLPA) ליפופוליסאכרידיםA (MLA ) ליפיד

COMPOSITIONS COMPRISING 3-O-DEACTIVATED-4'- MONOPHOSPHORYL LIPID A (3D-MLA) LIPOPOLYSACCHARIDES (LPA) AND MONOPHOSPHORYL LIPID A (MLA)CORIXA CORPORATION

30/03/2001

60/280089US

PCT/US/2002/009731WO/2002/078637

C07C18965706/02/2003

N-PHENYL-2-PYRIMIDINE-AMINE–פירימידין–אמין2–פניל–N של נגזרותDERIVATIVESNOVARTIS AG

07/02/2002

0202873.6GB

PCT/EP/2003/001188WO/2003/066613

C07C18965806/02/2003

N-PHENYL-2-PYRIMIDINE-AMINE–פירימידין–אמין2–פניל–N של נגזרותDERIVATIVESNOVARTIS AG


07/02/2002

0202873.6GB

PCT/EP/2003/001188WO/2003/066613

G06T18966017/08/2006

לעיבוד תמונה, תכנית לעיבוד שיטהתמונה לעיבוד תמונה, ומכשיר

IMAGE PROCESSING METHOD, IMAGE PROCESSING PROGRAM, AND IMAGE PROCESSING DEVICENIHON MEDI-PHYSICS CO, LTD.

23/08/2005

2005-241624JP

PCT/JP/2006/316147WO/2007/023723

C25D18966120/09/2006

אלקטרוליזה באמצעות מתכת ציפוי הרכבבמתכת משטח תשתית ציפוי עבור

ELECTROPLATING COMPOSITION FOR COATING A SUBSTRATE SURFACE WITH A METALALCHIMER

20/09/20050509571FR

PCT/FR/2006/050914WO/2007/034116

H01L18966220/09/2006

אלקטרוליזה באמצעות מתכתי ציפוי שיטתבמתכת שטח פני לציפוי

ELECTROPLATING METHOD FOR COATING A SUBSTRATE SURFACE WITH A METALALCHIMER S.A.

20/09/20050509572FR

PCT/FR/2006/050915WO/2007/034117

C07D18966305/09/2006


השימושיות חדשות הטרוביציקליות תולדות טרנספרז פלמיטויל קרניטין של כמעכבים

כבד של

NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASEF. HOFFMANN-LA ROCHE AG

15/09/2005

05108468.9EP

PCT/EP/2006/065989WO/2007/031429

C07D18966421/08/2006

בנזואוקסזול, אוקסזולופירידין, תולדותותיאזולופירידין בנזותיאזול

BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVESF. HOFFMANN-LA ROCHE AG

02/09/2005

05108035.6EP

PCT/EP/2006/065522WO/2007/025897

A61K18966507/09/2006

TREATMENT OF AUTOIMMUNEאוטואימוניות במחלות טיפולDISEASESNOVARTIS AG

09/09/2005

60/715990US

PCT/EP/2006/066150WO/2007/028821


C07D18966705/09/2006

[C– 3,2] –תיאנו – אמינו4 חומצה תולדות–קרבוקסילית7פירידין–

4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVESF. HOFFMANN-LA ROCHE AG

15/09/2005

60/717271US

21/07/2006

60/832460US

PCT/EP/2006/065986WO/2007/031428

C07D18966828/08/2006

INHIBITORS OF SERINE PROTEASESפרוטאזות סרין של מעכביםVERTEX PHARMACEUTICALS INCORPORATED

26/08/2005

60/711530US

PCT/US/2006/033770WO/2007/025307

G07D18966919/07/2006

VERIFICATION OF AUTHENTICITYאמינות אימותINGENIA TECHNOLOGY LIMITED

27/07/2005

0515460.4GB

27/07/2005

60/702732US

PCT/GB/2006/002689WO/2007/012816

C07K18967028/08/2006

עוקבים2רצפטורים– פוליפפטידיםונוגדנים

TRAIL RECEPTOR 2 POLYPEPTIDES AND ANTIBODIESAMGEN, INC.


31/08/2005

60/713433US

31/08/2005

60/713478US

PCT/US/2006/033763WO/2007/027713

A61M18967122/08/2006

MEDICATION DISPENSER ANDעבורו ונשא תרופות מחלקCARRIER THEREFORMEDI-STREAM PTY LTD,

22/08/2005

2005904543AU

PCT/AU/2006/001212WO/2007/022573

G01N18967224/08/2006

CHEMOSENSITIVITY TESTERכמוסנסיטיביות בוחןHEPAHOPE, INC.

24/08/2005

11/210511US

30/08/2005

60/712964US

13/03/2006

60/782029US

23/03/2006

60/785308US

14/04/2006

60/791966US

23/08/2006

11/466730US

PCT/US/2006/033263WO/2007/025154

G01N18967324/08/2006

תרופות לבדיקת חדשים מואצים תהליכיםאנושית ברקמה שימוש ע"י וסריקה

NOVEL ENHANCED PROCESSES FOR DRUG TESTING AND SCREENING USING HUMAN TISSUEHEPAHOPE, INC.


24/08/2005

11/210511US

23/08/2006

11/466730US

PCT/US/2006/033262WO/2007/025153

A61K18967425/08/2006

STEM CELL FUSION MODEL OFסרטון של תאי מיזוג מודלCARCINOGENESISTHE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

25/08/2005

60/711249US

PCT/US/2006/033366WO/2007/025216

C07D18967517/08/2006

סדרים באי וטיפול למניעת גורמיםRYR קולטני באפנון הקשורים

AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYR RECEPTORSTHE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

25/08/2005

11/212413US

PCT/US/2006/032405WO/2007/024717


H04B18967613/09/2005

ומסוף סביבתי רעש להסרת ושיטה מכשירהמכשיר עם המצוייד נייד תקשורת

APPARATUS AND METHOD FOR REMOVING AMBIENT NOISE AND MOBILE COMMUNICATION TERMINAL EQUIPPED WITH THE APPARATUSPISHON ANC CO, LTD

05/09/2005

10-2005-0082380KP

PCT/KR/2005/003011WO/2007/029899

C07D18967719/10/2001

ארומטיות מעגליות תרכבות להכנת תהליךחנקניות

PROCESS FOR PREPARING NITROGENOUS AROMATIC RING COMPOUNDSEISAI R&D MANAGEMENT CO., LTD.

20/10/2000

2000-320420JP

20/12/2000

2000-386195JP

22/02/2001

2001-46685JP

PCT/JP/2001/009221WO/2002/032872

C07D18967923/08/2006

סלקלטיביים כאגוניסטים אימידזול נגזרות2Cאלפא אדרנלין לקולטן פונקציונלית

IMIDAZOLE DERIVATIVES FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTSSCHERING CORPORATION

25/08/2005

60/711398US

PCT/US/2006/032911WO/2007/024944


A61K18968117/08/2006

SUSTAINED-RELEASEמושהה לשחרור תכשירPREPARATIONNISSAN CHEMICAL INDUSTRIES, LTD.

23/08/2005

2005-241776JP

PCT/JP/2006/316181WO/2007/023729

G06K18968419/07/2006

רצועה של מתמשך ליצור ושיטה התקןפגמים ללא נושאת

DEVICE AND METHOD FOR CONTINUOUSLY PRODUCING A DEFECTIVE-FREE CARRIER STRIPBIELOMATIK LEUZE GMBH & CO. KG

23/08/2005

102005041024.3DE

PCT/EP/2006/007084WO/2007/022835

C40B18968522/08/2006

בין אינטרקציה לניתוח ושיטות תכשיריםחלבונים

COMPOSITIONS AND METHODS FOR ANALYZING PROTEIN INTERACTIONSRESEARCH DEVELOPMENT FOUNDATION

22/08/2005

60/710597US

PCT/US/2006/032810WO/2007/024877


C07C18968615/09/2006

עבור ותהליך אקטיבי אופטי דיאמין תולדותהנ"ל ייצור

OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAMEDAIICHI SANKYO COMPANY, LIMITED

16/09/2005

2005-269642JP

PCT/JP/2006/318432WO/2007/032498

C07C18968722/08/2006

PROCESS OF PREPARINGברומופיקרין להכנת תהליךBROMOPICRIN

.BROMINE COMPOUNDS LTDבע"מ ברום תרכובות26/08/2005

60/711272US

PCT/IL/2006/000978WO/2007/023496

A61M18968921/08/2006

הנשמה צינור של בלונית ניפוח כוונוןתוך–קני

ADJUSTMENT OF ENDOTRACHEAL TUBE CUFF FILLING

HOSPITECH RESPIRATION LTDבע"מ הנשמה הוספיטק24/08/2005

60/710678US

30/09/2005

60/721965US

28/12/2005

60/754191US

PCT/IL/2006/000974WO/2007/023492


G01N18969021/08/2006

A METHOD FOR EVALUATION OF Aחן אבני של להערכה שיטהGEMSTONE

GALATEA LTDבע"מ גאלאתיאה22/08/2005

102005039679.8DE

PCT/IB/2006/052884WO/2007/023444

C23C18969316/11/2006

ליצור ושיטה מתכתית קרבוניטריד שכבתמתכתית קרבוניטריד שכבה

METAL CARBONITRIDE LAYER AND METHOD FOR THE PRODUCTION OF A METAL CARBONITRIDE LAYERBOEHLERIT GMBH &CO. KG

17/11/2005A1876/2005AT

22/09/2006A1585/2006AT

PCT/AT/2006/000469WO/2007/056785

C07D18969418/09/2006

לטיפול בהן והשימוש ביפניל נגזרותC בהפטיטיס

BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS CARROW THERAPEUTICS LIMITED

16/09/2005

0518971.7GB

30/05/2006

0610663.7GB

30/05/2006

0610664.5GB

PCT/GB/2006/003469WO/2007/031791

F16L18969621/07/2006

FLUID CONTROL DEVICEנוזלים לוויסות התקן


FUJIKIN INCORPORATED12/09/2005

2005-263231JP

PCT/JP/2006/314468WO/2007/032147

C07D18969731/08/2006

רוקחות ותכשירי פירידאזינון תולדותאותן המכילים

PYRIDAZINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAMEWAKUNAGA PHARMACEUTICAL CO., LTD.

01/09/2005

60/712825US

PCT/JP/2006/317691WO/2007/026950

C07D18969801/09/2006

להכנתן ותהליכים תיומורפולין תולדותTHIOMORPHOLINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOFMITSUBISHI TANABE PHARMA CORPORATION

01/09/2005

2005-253105JP

PCT/JP/2006/317798WO/2007/026966

H04L18970230/08/2006


)גישהSDMAב– ותמיכה מוקדם קידודמרחב( לחלוקת מרובה

TRANSMISSION MODE SELECTION, PRECODING AND SDMA SUPPORTQUALCOMM INCORPORATED

30/08/2005

60/713029US

27/10/2005

60/731014US

10/04/2006

11/401979US

PCT/US/2006/033937WO/2007/027825

C12Q18970520/10/2005

מטופל תגובת לניטור או לניבוי שיטהERBB קולטן לתרופת

METHOD TO PREDICT OR MONITOR THE RESPONSE OF A PATIENT TO AN ERBB RECEPTOR DRUGNATIONAL CANCER CENTER

05/10/2005PCT/GB2005/03823GB

PCT/GB/2005/004036WO/2007/039705

G01R18970624/08/2006

להזזה ושיטה למצעים בחינה מערכתמצעים

WAFER INSPECTION SYSTEM AND A METHOD FOR TRANSLATING WAFERS [PD]

.CAMTEK LTDבע"מ קמטק26/08/2005

60/711427US

PCT/IL/2006/000987WO/2007/023501


G11B18970729/08/2006

חתוך מצע לבחינת ושיטה בחינה מערכתAN INSPECTION SYSTEM AND A METHOD FOR INSPECTING A DICED WAFER


60/712142US

30/08/2005

60/712143US

30/08/2005

60/712144US

PCT/IL/2006/000996WO/2007/026351

B01D18970829/08/2006

פגמים לגילוי ושיטה בחינה מערכתייחוס מסגרת על בהתבסס

AN INSPECTION SYSTEM AND A METHOD FOR DETECTING DEFECTS BASED UPON A REFERENCE FRAME


60/712142US

30/08/2005

60/712143US

30/08/2005

60/712144US

PCT/IL/2006/000995WO/2007/026350


C23C18970929/08/2006

לבחינת ושיטה שלבית רב בחינה מערכתחתוך מצע

A PIPELINED INSPECTION SYSTEM AND A METHOD FOR INSPECTING A DICED WAFER


60/712142US

30/08/2005

60/712143US

30/08/2005

60/712144US

PCT/IL/2006/000994WO/2007/026349

G06T18971027/08/2006

פגמים של אוטומטי לגילוי ומערכת שיטהחזותיות בחינה במכונות בעצמים

METHOD AND SYSTEM FOR AUTOMATIC DEFECT DETECTION OF ARTICLES IN VISUAL INSPECTION MACHINES [EYEQ]


60/711425US

24/08/2006177689IL

PCT/IL/2006/000990WO/2007/023502

G02B18971116/08/2006

קרן של זוויתי בכיסוי לשליטה ושיטה התקןאור

DEVICE AND METHOD FOR CONTROLLING AN ANGULAR COVERAGE OF A LIGHT BEAM


60/711428US


PCT/IL/2006/000951WO/2007/023487

G06T18971224/08/2006

DEVICE AND METHOD FORחפץ לבחינת ושיטה התקןINSPECTING AN OBJECT


60/711432US

PCT/IL/2006/000986WO/2007/023500

G21K18971330/08/2006

תוך ייחוס תמונת ליצירת ומערכת שיטהידועות לא איכות בתבניות שימוש

A METHOD AND A SYSTEM FOR CREATING A REFERENCE IMAGE USING UNKNOWN QUALITY PATTERNS

.CAMTEK LTDבע"מ קמטק01/09/2005170609IL

PCT/IL/2006/001006WO/2007/026360

B01D18971430/08/2006

מרשם–בחינה לקביעת ומערכת שיטהA METHOD AND A SYSTEM FOR ESTABLISHING AN INSPECTION-RECIPE

.CAMTEK LTDבע"מ קמטק01/09/2005170610IL

PCT/IL/2006/001007WO/2007/026361

A61B18971525/08/2006


AN APPARATUS FOR CIRCUMCISING Aזכרי מין איבר של למילה מכשירPENISSHANG JIANZHONG

26/08/2005

200520106272.6CN

PCT/CN/2006/002178WO/2007/022730

H04J18971622/08/2006

גישה לערוץ גישה להשגת ומערכת שיטה במערכת ללוויין מהארץ לקשר אקראי

FDMA– SC

METHOD AND APPARATUS FOR ACCESSING AN UPLINK RANDOM ACCESS CHANNEL IN A SINGLE CARRIER FREQUENCY DIVISION MULTIPLE ACCESS SYSTEMINTERDIGITAL TECHNOLOGY CORPORATION

23/08/2005

60\710599US

PCT/US/2006/032623WO/2007/024791

A22C18971731/08/2006

מזוהם באוויר לטיפול ומתקן שיטהביולוגית

METHOD AND APPARATUS FOR TREATING BIOLOGICALLY CONTAMINATED AIR

.MEGAIR LTDבע"מ מגאייר01/09/2005170605IL

PCT/IL/2006/001010WO/2007/026363

G08B18971911/10/2006

APPARATUS FOR FIRE DETECTION INחשמלי בציוד אש לגילוי מכשירAN ELECTRICAL EQUIPMENT RACKAMRONA AG

04/11/2005

102005052777.9DE

PCT/EP/2006/009825


WO/2007/051517

A61M18972021/08/2006

ושסתוםTמחבר– בצורת אוטם–עצמיTמחבר– בצורת

SELF-SEALING T-PIECE AND VALVED T-PIECEAEROGEN, INC.

23/08/2005

60/710932US

PCT/US/2006/032677WO/2007/024812

A61K18972131/08/2006

נוגדן אזור לייצור פונדקאים תאים רצפימוגברת אפקטור פונקצית בעל קבוע

HOST CELL LINES FOR PRODUCTION OF ANTIBODY CONSTANT REGION WITH ENHANCED EFFECTOR FUNCTIONCENTOCOR, INC.

31/08/2005

60\713055US

31/08/2005

60\712858US

PCT/US/2006/034382WO/2007/028106

A61K18973604/04/2000

VACCINE ADJUVANTSחיסון תרכיבSMITHKLINE BEECHAM BIOLOGICALS S.A.

19/04/1999

9908885.8GB

29/04/1999

09/301829US

PCT/EP/2000/002920WO/2000/062800

C07C18975812/12/2000

ADAMANTANE DERIVATIVESאדמנטאן של נגזרות


ASTRAZENECA AB17/12/1999

9904651-8SE

27/06/2000

0015744.6GB

22/07/2000

0017942.4GB

PCT/SE/2000/002505WO/2001/044170

- תשכ"ז הפטנטים לחוק26 סעיף לפי הודעה1976

NOTICE UNDER SECTION 26 OF THE PATENTS LAW, 5727-1967

קובלו להלן מתפרסמים שפרטיהן הבקשות המעונין הפטנטים. כל לחוק17 סעיף לפי

מהבקשות בקשה פי על פטנט למתן להתנגד חדשים שלושה רשאי, תוך המתפרסמות

הפטנטים לרשם זה, להגיש יומן מתאריך לחוק30 סעיף לפי התנגדות הודעת

ואילך57 בתקנה הקבועה בדרך הפטנטים.1968 – הפטנטים, תשכ"ח לתקנות

The applications, particulars of which are set out below, have been accepted pursuant to Section 17 of the Patents Law. Any person wishing to oppose the grant of a patent on any of the applications published here, may, within three months from the date of this journal, give to the Commissioner of Patents notice under Section 30 of the Patents Law, in the manner prescribed in regulations 57 et seq of the Patents Regulations, 5728-1968

לפי מובאים ויישימים במידה הבקשות פרטיזה: סדר

Particulars of the applications, where applicable, are given in the following order:

Number of application [21] [11]הבקשה מספרTitle of invention [54]האמצאה שם

Application date [22]הבקשה תאריך מדינת – החוץ בקשות של ותאריך מספרהאגוד

[31] [32] [33] Number and date of foreign application – convention country.

.Int.Cl [51]*בינלאומי *סיווגApplication for patent of addition [61] מוסף לפטנט בקשהDivisional application [62]חלוקה בקשת

Applicant [71]המבקשInventor [72]הממציא

International Publication Number [87]הבינלאומית בקשה של מס' פרסום Address for service [74]מסמכים למסירת מען

Abridgement of invention (in the [57]הפירוט( ערוך בה )בשפה האמצאה תקצירlanguage in which the specification is drawn up)

מס' והמדגמים הפטנטים מיומן *הערה: החל לפי הסיווג פטנטים לבקשות ציון ניתן1/06

של הבינלאומי הסיווג של השמינית המהדורה(2006 )משנה פטנטים

*Note: As from Patents and Designs Journal No.1/06, patent applications are classified according to the Eighth Edition of the International Patent Classification (2006)


109014]21][11[

הניתנים חלקיקים עם קרבי ראשלפליטה

WARHEAD WITH EJECTABLE FRAGMENTS

]54[

17.03.1994]22[Int. Cl.8 F42B 012/10, 012/22]51[

בע"מ, מתקדמות לחימה מערכות רפאלחיפה

RAFAEL ADVANCED DEFENSE SYSTEMS LTD.

]71[

]YOAV ME-BAR, ZEEV YAEGER]72יגר מי-בר, זאב יואב- לוי, גלוקסמן

, חיפה6202א' , ת.ד. 10 אלחנן רחוב GLUCKSMAN - LOWY,

10A ELHANAN ST,.P.O.B. 6202 ,

HAIFA 31061

]74[

]57 [A warhead (1) having an explosive charge (2), means (3) for initiating the explosive charge at a desired distance from a target, and projectile means, characterized in that said projectile means comprise a body (5) of packed fragments having a geometry configured to correspond to a desired impact pattern,

which body, upon detonation of the explosive charge is ejected from the warhead to form a cloud of fragments having super-critical density in certain regions which on impact upon the target has a super-critical density of impact sufficient to create percolation cuts and cause localized target shattering.

__________


119135]21][11[

CATALYTIC NUCLEIC ACIDקטליטיות גרעין חומצות של מולקולותMOLECULES

]54[

26.08.1996]22[Int. Cl.8 A61K 048/00, C12N 009/22, 015/11, C12Q 001/68]51[

]GENETICO LTD.]71בע"מ, הרצליה ג'נטיקוושותפיו, כהן ריינהולד

, תל4060 , ת.ד. 21 העם אחד רחוב אביב

REINHOLD COHN AND PARTNERS,

21 AHAD HA'AM ST ,.P.O.B. 4060 ,

TEL AVIV 61040

]74[

]57 [A proto-nucleozyme of a nucleozyme, the nucleozyme having a catalytic activity under a set of conditions, the proto-nucleozyme differing from the nucleozyme in a sequence of one or more nucleotides that is present in the nucleozyme and is absent in the proto-nucleozyme or replaced in the proto-nucleozyme by a different sequence of nucleotides, the proto-nucleozyme not having the catalytic activity of the nucleozyme under said set of conditions,

and the proto-nucleozyme having said catalytic activity in the presence of a non-nucleic acid co-factor, wherein the non-nucleic acid cofactor is not a nucleotide, nucleoside, or a derivative thereof, and wherein the non-nucleic acid cofactor is a molecule which chemically interacts with nucleotides to provide the component missing in the proto-nucleozyme to convert the proto-nucleozyme into a catalytically active nucleozyme.

___________

121793]21][11[

]ISOTOPIC GAS ANALYZER]54איזוטופיים גזים מנתח

17.09.1997]22[Int. Cl.8 G01N 033/497]51[

]EXALENZ BIOSCIENCE LTD.]71בע"מ, ירושלים ביוסיינס אקסלנז LEWIS COLEMAN, EPHRAIMאורן בן קרליבך, אילן קולמן, אפרים לואיס

CARLEBACK, ILAN BEN OREN]72[

]EITAN MEHULAL LAW GROUP,]74 - עורכי דין עורכי - מהולל איתן קבוצת


פטנטים, ,2081 , ת.ד. 10 אבן אבא שדרות

הרצליה

10 ABBA EBEN BLVD,.P.O. B. 2081,

HERZLIYA 46120

]57 [An isotopic gas analyzer for determining the ratio of at least a first and a second isotopic component of a gas, comprising: at least one wavelength-stable source of radiation (49) of wavelengths characteristic of at least one of said at least first and second isotopic components; at least a first sample chamber (44) comprising a first sample of said gas to be analyzed; at least a first reference chamber (41) containing a reference gas comprising said first and second isotopic components; at least a second sample chamber (45) comprising a second sample of said gas to be analyzed; at least a second reference

chamber (42) containing a reference gas comprising said first and second isotopic components; and at least one detector (16) detecting transmission through said at least first sample chamber and transmission through said at least first reference chamber, of radiation of wavelengths characteristic of said first isotopic component of said gas, and transmission through said at least second sample chamber and transmission through said at least second reference chamber, of radiation of wavelengths characteristic of said second isotopic component of said gas.

__________

124794]21][11[

METHOD FOR OBTAINING ANעניין בעל אנזים לקבלת שיטהENZYME OF INTEREST

]54[

06.12.1996]22[US]33[07.12.1995]32[60/008316]31[US07.12.199560/008317US07.12.199560/008311US22.05.199608/651568US02.08.199608/692002

Int. Cl.8 C12N 015/10, C12Q 001/00, 001/68]51[VERENIUM CORPORATION, U.S.A.]71[

WO/1997/020918]87[


ושותפיו, כהן ריינהולד , תל4060 , ת.ד. 21 העם אחד רחוב

אביב



TEL AVIV 61040

]74[

]57 [A method for obtaining an enzyme activity of interest, said method including the steps of:

)a (providing a first library with DNA obtained from at least one microorganism;

)b (binding at least a portion of the coding sequences of the first library to a nucleic

acid probe specific for the enzyme activity or interest to create a DNA subset;

)c (providing a second library which is an expression library using DNA from the DNA subset obtained from step (b); and

)d (screening the second library for the enzyme activity.

__________

125939]21][11[

תאים של פוסספטייזים טירוסין חלבוןהימטופוייטיים

PROTEIN TYROSINE PHOSPHATASES OF HEMATOPOIETIC CELLS

]54[

17.03.1997]22[US]33[22.03.1996]32[08/620526]31[

Int. Cl.8 A61K 038/46, C07K 016/40, C12N 009/16, 015/55, C12Q 001/42, 001/68]51[GENENTECH, INC., U.S.A.]71[

LAURENCE A. LASKY, JILL CHENG

]72[

WO/1997/035019]87[ושות' בע"מ, מ. בן-דוד ירמיהו

,45087, ת.ד. חוצבים המרפא, הר רחוב ירושלים

JEREMY M. BEN-DAVID & CO. LTD,.

HAR HOTZVIM HI-TECH PARK ,P.O.B. 45087 ,

JERUSALEM 91450

]74[

]57 [An isolated non-receptor protein tyrosine phosphatase of hematopoietic stem cells (PTP HSC), which

)1 (is encoded by DNA hybridizing under stringent conditions to the complement of the nucleic acid of SEQ ID NO:1 or SEQ ID NO:16;

)2 (is expressed in early hematopoietic stem cells or progenitor cells;

)3 (its expression is downregulated in differentiated hematopoietic cells; and

)4 (comprises an N-terminal tyrosine phosphatase domain, followed by a region rich in serine, thereonine, and proline, and a carboxy terminal region of about 15 to 25 amino acids rich in basic amino acid residues.

__________


127192]21][11[

RESILIENT CLAMPINGלשימות גמיש הידוק מנגנוןMECHANISM FOR INSERTS

]54[

22.11.1998]22[Int. Cl.8 B26D 001/03]51[

]ISCAR LTD.]71בע"מ, תפן ישקר]GIDEON BARAZANI]72ברזני גדעוןקאי, מיכאל ד"ר

, ת.ד. פטנטים בע"מ, מחלקת ישקר אצל , תפן11

MICHAEL KAI, C/O ISCAR LTD,.

PATENT DIVISION,P.O.B. 11,

TEFEN

]74[

]57 [For use in a cutting tool, the cutting tool comprising a body portion and a clamping portion, a cutting insert clamping mechanism comprising: a base jaw; a clamping jaw having an upper side and a lower side, the lower side opposing the base jaw and comprising a forward clamping surface spaced apart from a rearward clamping surface, the base jaw and the clamping jaw having a gap between them forming an insert receiving pocket having an insert pocket opening at a leading end thereof; a first aperture

extending from a rear section of the insert receiving pocket in a direction generally towards the upper side of the clamping jaw; a first narrow bridge section connecting the clamping jaw to the body portion of the cutting tool; a second narrow bridge section extending generally towards the rearward clamping surface; wherein a first resilience axis of rotation is associated with the first narrow bridge section and a second resilience axis of rotation is associated with the second narrow bridge section.


__________

128652]21][11[

N6 מוחלפי אדנוסין תולדות המכילים רוקחות ותכשירי הטרוציקלית

אותן

HETEROCYCLIC SUBSTITUTED ADENOSINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

]54[

20.08.1997]22[US]33[27.08.1996]32[08/702234]31[

Int. Cl.8 A61K 031/7076, A61P 009/00, C07H 019/16]51[CV THERAPEUTICS, INC., U.S.A.]71[

WO/1998/008855]87[ושות', ט. קולב סנפורד

,2273, ת.ד. , מרמורק4 הגיא שער רחובות

SANFORD T.COLB & CO,. P.O.B. 2273 ,

REHOVOT 76122

]74[

]57 [A compound of the formula:


wherein R1 is an unsubstituted monocyclic heterocyclic group containing from 5 to 7 atoms, at least one of which is selected from the group consisting of N, O, and S(O)0-2 and wherein R1 is not a monocyclic

lactam or imide, and wherein R1 does not contain an epoxide group, and wherein if R1 is an unsaturated monocyclic heterocylic group, then R1 is not a 5-membered ring.

__________

129665]21][11[

CUTTING TOOL ASSEMBLYעבורו ושימה שיבוב כליAND CUTTING INSERT THEREFOR

]54[

29.04.1999]22[Int. Cl.8 B23C 005/20]51[

]ISCAR LTD.]71בע"מ, תפן ישקר]RAFAEL MORGULIS]72מורגוליס רפאל

קאי, מיכאל ד"ר , ת.ד. פטנטים בע"מ, מחלקת ישקר אצל

, תפן11

MICHAEL KAI, C/O ISCAR LTD,.

PATENT DIVISION,P.O.B. 11,

TEFEN

]74[

]57 [A cutting tool assembly rotatable about an axis of rotation (A) and comprising: a tool comprising a tool body and a crown; and a plurality of repleaceable cutting inserts clamped in insert receiving pockets peripherally distributed in the tool; wherein the tool body has a front face divided into a peripheral portion having a periphery, and an inner portion, the peripheral portion has equally peripherally distributed substantially radially directed recesses, is frutso-conical in shape and is inwardly

rearwardly directed from the periphery to the inner portion slanting at an angle (α); the crown has a front face, a rear face, a peripheral side face therebetween and a plurality of peripherally distributed generally radially directed insert receiving slots opening into the front, rear and peripheral side faces, the crown being distinct from the tool body and the tool being adjustable between a disassembled position in which the crown and tool body are separated from each other and an assembled position in which the crown is

June 5, 2008100 –התשס"ח ב' בסיון1

affixed to the tool body with the insert receiving slots of the crown merging with the recesses of the tool body; the insert receiving pockets comprise the insert receiving slots bound axially by the peripheral portion of the tool body front face, when the tool is in the assembled position; each insert receiving pocket has tangential, radial and axial abutment

surfaces, being generally tangentially, radially and axially directed, respectively, for locating the cutting insert therein, the axial abutment surface being a portion of the peripheral portion of the front face of the tool body; each insert receiving pocket is open in a radial direction so that at least a portion of the insert clamped therein extends radially beyond the tool.

__________

130032]21][11[

]HIGH VOLTAGE REED SWITCH]54גבוה למתח ממסר

19.05.1999]22[Int. Cl.8 H01H 051/28]51[

]VLADIMIR GUREVICH]71גורביץ, חיפה ולדימירגורביץ, ולדימיר

, חיפה8 רח' האשחר VLADIMIR GUREVICH,

8 HAESHCHAR ST ,.HAIFA 35844

]74[

]57 [High voltage reed switch relay consisting of a fixed insulating body (1) with a cylindrical chamber (2) and a mobile insulator (10) formed as a cylindrical tube inserted in said chamber, a coil (5) with Π-shaped ferromagnetic core (6) in the fixed insulator and a reed switch (8) eccentric to a ferromagnetic shunt (9) mounted in a mobile insulator characterized that in order to extend the application fields an additional chamber (4) is added to the fixed insulating body in

which an impulse current transformer (16), electronic amplifier (18) and output switching element (15) are located, with the primary winding of the transformer formed as a wire coated with high voltage insulator to be operated under full working voltage of the device, and the secondary winding connected at the electronic amplifier input whose output is connected to the switching element control circuit, such as a thyristor, with the reed switch outputs exiting the mobile insulator and


entering the said additional chamber connected to the same switching element control circuit.

_________

131435]21][11[

או לחלבון ביטוי ספרית להכנת שיטה לדנ"א קוולנטית פפטיד, הקשור

המתקבלת לו, ספריה המקודדבה והשימוש

METHOD OF PRODUCING A PEPTIDE OR PROTEIN COVALENTLY ASSOCIATED WITH ITS ENCODING DNA EXPRESSION LIBRARY, A LIBRARY PRODUCED THEREBY AND USES THEREOF

]54[

18.02.1998]22[GB]33[18.02.1997]32[9703369.0]31[

Int. Cl.8 C07K 014/01, C12N 015/10, 015/31, 015/62, C12Q 001/68, C40B 002/004000 003/004000 004/006000 005/00600

]51[

ISOGENICA LIMITED, UNITED KINGDOM

]71[

WO/1998/037186]87[ושותפיו, כהן ריינהולד




TEL AVIV 61040

]74[

]57 [A method of producing a peptide or protein expression library which displays a diverse population of peptides or proteins, wherein the peptides or proteins are specifically associated with the DNA

encoding them through covalent protein: DNA binding, said method comprising at least the following steps:


)1 (preparing an amplifiable genetic library of DNA molecules which contain

)i (a nucleotide sequence encoding an amino acid sequence wherein the amino acid sequence binds specifically to its encoding sequence through covalent protein: DNA binding (binding moiety), and

)ii (a nucleotide sequence encoding an amino acid sequence for display (display moiety), and

)2 (expressing the genetic library thus formed, wherein said DNA molecule when expressed yields a translation product which contains the display moiety and the binding moiety and wherein said DNA molecule has at least one site of attachment for the binding moiety.

___________

132066]21][11[

של תולדות מונוהידרובנזופורפירין–

גליקול( טטראאלקיל ביס)אתילןאור פעילי כגורמים אסטרים

BIS(ETHYLENE GLYCOL) TETRAALKYL ESTERS OF MONOHYDROBENZOPORPHYRIN DERIVATIVES AS PHOTOACTIVE AGENTS

]54[

06.05.1998]22[US]33[07.04.1997]32[08/852494]31[

Int. Cl.8 A61K 031/409, 038/41, C07D 487/22]51[QLT INC., CANADATHE UNIVERSITY OF BRITISH COLUMBIA, CANADA

]71[


,4060 , ת.ד. 21 העם אחד רחוב אביב תל

REINHOLD COHN AND PARTNERS, 21 AHAD HA'AM ST ,.

P.O.B. 4060 ,TEL AVIV 61040

]74[

]57 [A compound of the formula


and the metallated and/or labeled and/or conjugated forms thereof, wherein each R1 is independently alkyl (1-6C); each n is

independently an integer of 0-6; and R2 is vinyl or a derivative form thereof.

__________

135517]21][11[

A אריתרומיצין –מתיל0–6 של סינתזה – )די–מותמר9 של חדשות נגזרות וכמה

ממנה הנובאות בנזואיל( אוקסים

SYNTHESIS OF 6 - 0 - METHYL ERYTHROMYCIN A AND SOME NOVEL 9 - (DISUBSTITUTED BENZOYL) OXIME DERIVATIVES THEREOF

]54[

17.11.1998]22[US]33[17.11.1997]32[08/972155]31[

Int. Cl.8 C07H 017/08, C12P 019/62]51[ABBOTT LABORATORIES, U.S.A.]71[

WO/1999/025723]87[ושות', כהן שלמה ד"ר

אביב , תל11490 , ת.ד. 124 גבירול אבן DR. SHLOMO COHEN & CO,.

124 IBN GABIROL ST,.P.O.B. 11490 ,

TEL AVIV 62038

]74[

]57 [A process of preparing 6-O-methyl erythromycin A from the 9-oxime erythromycin A derivative comprising the steps of:

)a (benzoylating the 9-oxime group of the 9-oxime erythromycin A derivative;

)b (protecting the 2'-hydroxyl group of the 9-oxime erythromycin A derivative;

wherein steps (a) and (b) may be performed in any order; and


wherein performing said steps in any order results in the formation of 2'-protected 9-benzoyloxime erythromycin A derivative;

)c (methylating the 2'-protected-9-benzoyloxime erythromycin A derivative to form a 2'-protected-6-O-methyl-9-benzoyloxime erythromycin A derivative;

)d (removing the benzoyl and O-protecting groups from the 2'-protected-6-O-methyl-9-benzoyloxime erythromycin A derivative to form 6-O-methyl-9-oxime erythromycin A; and

)e (deoximating the 6-O-methyl-9-oxime erythromycin A to form 6-O-methyl erythromycin A;

wherein the reaction in step(a) is performed with a benzoylating reagent of the formula RCOX, where X is halide and R is a di-substituted benzene, and wherein the substituent groups are selected from Cl, Br, I and alkoxy.Also claimed as new is a compound of the structure

where R5 is a disubstituted benzene, R6 is hydrogen or methyl and R7 and R8 are each

independently hydrogen, trimethylsilyl or an O-protecting group.

__________

135528]21][11[

וירוס של מקפסומר חיסון תכשירלשימוש ושיטות הפטוטמת

PAPILLOMA VIRUS CAPSOMERE VACCINE FORMULATIONS AND METHODS OF USE

]54[

06.10.1998]22[US]33[06.10.1997]32[08/944368]31[

Int. Cl.8 A61K 039/12, C07K 014/025, C12N 015/62]51[LOYOLA UNIVERSITY OF CHICAGO, U.S.A.

]71[





TEL AVIV 61040

]74[


]57 [An antigenic formulation comprising a human papilloma virus capsomere, said capsomere comprising a fusion protein comprising human papilloma virus L1 protein adjacent amino acid residues from a second protein, said L1 protein and said

amino acids from said second protein positioned to inhibit virus-like particle formation, said formulation evoking an immune response which neutralizes human papilloma virus virions.

מבקשה חלוקה בקשותפורסמו. שטרם זו

190554,The applications for division from this application have not yet been published

_________

135604]21][11[

המיוצרים וחלבון טרנסגני, ביצים עוף הביצים ליצירת ושיטות הנ"ל העוף ע"י

הנ"ל והחלבון

TRANSGENIC BIRD, EGGS AND PROTEIN PRODUCED BY SAID BIRD AND METHODS FOR PRODUCING SAID EGGS AND PROTEIN

]54[

15.10.1998]22[US]33[16.10.1997]32[60/062172]31[

Int. Cl.8 A01K 067/00, C12N 015/11, 015/12, 015/85, 015/86, 015/90]51[UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC., U.S.A.AVIGENICS, U.S.A.

]71[





TEL AVIV 61040

]74[

]57 [A transgenic bird having a transgene in the genetic material of its germ-like tissue, wherein the transgene comprises an exogenous gene and a promoter, in operational and positional relationship to

express exogenous gene, and said exogenous gene is expressed in the tubular gland cells of the avian oviduct of the transgenic bird.

__________


137921]21][11[

של ופוליפפטידים חלבוניםB קבוצה סטרפטוקוקוס

GROUP B STREPTOCOCCUS PROTEINS AND POLYPEPTIDES

]54[

17.02.1999]22[US]33[20.02.1998]32[60/075425]31[

Int. Cl.8 A61K 039/09, C07K 014/315, C12N 015/31]51[ID BIOMEDICAL CORPORATION, CANADA

]71[

WO/1999/042588]87[וגולר, וולף, ברגמן

, ירושלים1352, ת.ד. WOLFF, BREGMAN AND GOLLER,

P.O.B. 1352,JERUSALEM 91013

]74[

]57 [An isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide having a sequence selected from the group consisting of SEQ ID NO:39 and SEQ ID NO:44, or a

fragment of said polypeptide, wherein said polypeptide or fragment of said polypeptide retains the capacity to induce an immune response specific for group B streptococcus.



________

138488]21][11[

גרעין , חומצותVEGF–E פוליפפטידים להכנתם, להם, תהליך המקודדות

ושיטות מאכסן תכשירים, וקטורים, תאיכאלה בפוליפפטידים שימוש העושות

VEGF-E POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE SAME, PROCESS FOR THEIR PREPARATION, COMPOSITIONS, VECTORS, HOST CELLS AND METHODS USING SUCH POLYPEPTIDES

]54[

10.03.1999]22[US]33[17.03.1998]32[09/040220]31[US02.11.199809/184216

Int. Cl.8 A61K 038/18, A61P 009/00, 017/02, 019/08, C07K 014/52, C12N 015/19]51[GENENTECH, INC., U.S.A.]71[

WO/1999/047677]87[ושות', ש. הורוביץ

, תל41-45 רוטשילד ציון, שדרות בית אביב

S. HOROWITZ & CO,. ZION HOUSE,

41-45 ROTHSCHILD BLVD,.TEL AVIV 65784

]74[


]57 [An isolated nucleic acid comprising a nucleotide sequence encoding a vascular endothelial cell growth factor-E (VEGF-E)

polypeptide comprising amino acid residues 1 through 345 of Figure 2 as shown in the specification (SEQ ID NO:2).


189573,189572,189571,The applications for division from this application have not yet been published

__________

138632]21][11[

]MULTIPLE VIEW ENDOSCOPES]54מבטים רב אנדוסקופ

21.09.2000]22[Int. Cl.8 A61B 001/00]51[

]MEDIGUS LTD.]71בע"מ, עומר מדיגוס ,MINELU ZONNENSCHEINצ'ינוק זוננשיין, רנדל זוננשיין, אלעזר מנשה

ELAZAR ZONNENSCHEIN, RANDAL B. CHINNOCK

]72[

לוצאטו, את לוצאטושבע , באר5352, ת.ד. תעשייה, עומר גן

LUZZATTO & LUZZATTO, INDUSTRIAL PARK, OMER,

P.O.B. 5352,BEER-SHEVA 84152

]74[

]57 [An endoscope (200) comprising: a single continuous shaft including a sheath (203), an articulation section attached to the distal end of said sheath, a distal tip-attached to the distal end (201A) of said articulation section, and two or more separate optical channels that produce two or more distinct views, each of said optical channels comprising an objective lens (1), located at the distal end of said optical channel and a means of capturing and/or

viewing the image; wherein the objective lens of the separate optical channel, which produces the first of said distinct views is located at a first location, said first location located on said distal tip, and the objective lens of the optical channel, which produces the second of said distinct views is located at a second location, said second location located either on the proximal end of said articulation section or on the sheath of said endoscope; wherein the distance between


said first location and said second location, measured along the longitudinal axis of

_________

139102]21][11[

–אמינו9 חומצה של תולדות הכנת –H6– –דיאוקסו10 ,6– אוקטאהידרו

1– דיאזפיןa /2,1 – //2,1/ פירידאזינו–קרבוקסילית

PREPARATION OF 9-AMINO OCTAHYDRO - 6, 10 - DIOXO- 6H - PYRIDAZINO [1,2-A][1,2] DIAZEPIN - 1 - CARBOXYLIC ACID DERIVATIVES

]54[

26.04.1999]22[FR]33[27.04.1998]32[98/05243]31[

Int. Cl.8 C07K 005/06]51[AVENTIS PHARMA S.A., FRANCE]71[COLETTE COLLADANT, VERONIQUE CROCQ, JOHN PATRICK LARKIN, PATRICK ROUSSEL

]72[

WO/1999/055724]87[צדק, וכהן איתן, פרל, לצר

, הרצליה12688 , ת.ד. 7 שנקר רחוב EITAN, PEARL, LATZER AND COHEN ZEDEK,

P.O.B. 12688 ,HERZLIYA 46733

]74[

]57 [A process for the preparation of a compound of the formula


of SR configuration or a SR+SS mixture wherein R is selected from the group consisting of hydrogen, alkyl of up to 18 carbon atoms and aryl and aralkyl of up to

18 carbon atoms and the –NH2 radical is free or protected, comprising reacting a compound of the formula

where Hal is halogen and alk is an alkyl radical of 1 to 8 carbon atoms with a compound of the formula

where Aryl is an aryl radical of up to 14 carbon atoms to form a compound of the formula

reacting the latter with a basic agent to form a compound of the formula


optionally subjecting the latter compound to an alkylating agent to form a compound of the formula

reacting the latter with a compound of the formula

wherein Hal1 is halogen, Ar is aryl or aralkyl radical of up to 18 carbon atoms, R1 is selected from the group consisting of


Ra, Rb, Rc and Rd are individually selected from the group consisting of alkyl of up to 18 carbon atoms, aryl of up to 18 carbon atoms and monocyclic and polycyclic groups containing at least one nitrogen atom, X is selected from the group consisting of hydrogen, alkyl of 1 to 8

carbon atoms and aryl of up to 14 carbon atoms and R2 is hydrogen or R1 and R2 together with the nitrogen form a monocyclic or polycyclic radical with at least one heteroatom to obtain a compound of the formula

of SR configuration or a SR+SS mixture, reacting the latter with a hydrogenation agent to form a compound of the formula

of SR configuration or a SR+SS mixture, reacting the latter with a condensation agent to obtain a compound of the formula


and optionally deprotecting the amino group to obtain a compound

of formula I wherein the amino group is free.

זו מבקשה חלוקה בקשותפורסמו. שטרם


_________

139478]21][11[

]HYBRID PROTEIN]54היבריד חלבון

12.05.1999]22[DE]33[13.05.1998]32[19821285.

2]31[

Int. Cl.8 A61K 038/16, A61P 037/08, C07K 019/00]51[BIOTECON GESELLSCHAFT FUR BIOTECHNOLOGISCHE ENTWICKLUNG UND CONSULTING MBH, GERMANY

]71[




]74[

]57 [Hybrid protein comprising or consisting of

)i (a protein binding to mastocytes and/or basophils and/or being taken up by these cells ,

)ii (a protease cleaving one or several proteins of the secretion apparatus of the mastocytes and/or basophils.


__________

139911]21][11[ DEVICE FOR DETECTION OFאות הגברת עם ליגנדים לגלוי מכשיר

LIGANDS USING SIGNAL AMPLIFICATION

]54[

12.05.1999]22[US]33[10.06.1998]32[09/095196]31[

Int. Cl.8 G01N 033/543]51[KENT STATE UNIVERSITY, U.S.A.]71[




REHOVOT 76122

]74[

]57 [A device for the detection of ligands comprising:

at least one receptor capable of binding to a ligand to form a receptor-ligand complex, wherein the formation of the receptor-ligand complex produces a signal; and an amplification mechanism, wherein

said amplification mechanism is a lyotropic liquid crystalline material coupled to the receptor, and wherein said amplification mechanism amplifies said signal upon receptor-ligand complex formation.

__________

140265]21][11[

נטולי וסובסטרטים חיסון להכנת שיטהאינטרפרון

METHODS FOR VACCINE PRODUCTION AND INTERFERON DEFICIENT SUBSTRATES

]54[

11.06.1999]22[US]33[12.06.1998]32[60/089103]31[US18.11.199860/108832US29.01.199960/117683

Int. Cl.8 A61K 035/76, 039/12, 039/145, C07K 014/11, C12N 007/00, 007/04, 015/86]51[MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY, U.S.A.

]71[





TEL AVIV 61040

]74[


]57 [Method for vaccine production comprising: propagating in an interferon deficient substrate an attenuated influenza virus having a mutation in the NS1 gene that diminishes or eliminates the ability of the NS1 gene product to antagonize the cellular interferon response; and collecting progeny virus, wherein the interferon

deficient substrate is the allantoic cavity of an immature embryonated egg six to nine days old or an interferon deficient cell line, with the proviso that said virus is not influenza C virus and the interferon deficient substrate is not Vero cells or STAT1(-) cell lines.



__________

140299]21][11[

באופן הפועלת פוטורזיסטורית תרכובותלהדמייה הניתן ואלמנט פוזיטיבי

POSITIVE ACTING PHOTORESIST COMPOSITION AND IMAGEABLE ELEMENT

]54[

14.12.2000]22[Int. Cl.8 B41C 001/10, B41M 005/36, C08F 008/28, G03G 005/047]51[

]KODAK IL LTD.]71פתוח בע"מ, הרצליה אל איי קודאק( בע"מ,1995) ג'י.אי.ארליך

בגין מנחם ,רחוב15 אילון, קומה מגדל גן , רמת11

G.E. EHRLICH (1995) LTD,. AYALON TOWER, 15TH FLOOR,

11 MENACHEM BEGIN ST,.RAMAT GAN 52521

]74[

]57 [A positive-acting thermal resist system comprising a metal sublayer, an alloy sublayer or a printing plate which comprises a substrate having at least one

metal surface having adhered thereto a positive-acting thermal resist layer which comprises an acetal polymer having the general formula:


whereinR1 is –CnH2n+1 where n=1-12;

R2 is a phenol group which may have no substituents or 1 to 3 additional

substituents selected from the group consisting of –OH, -OCH3, Br and –NO2 or -COOH, which may be represented, at least in part, by the formula:

whereinR4=-OH; R5= -OH or-OCH3 or –Br or –O-CH2-C≡CH; and R6 = -Br or –NO2;

R3 = -(CH2)a –COOH or –C≡CH or

whereinR7 = COOH, -(CH2)a COOH, -O-(CH2)a COOHanda = 0 or 1

m = 5-40 mole,%g = 10-60 mole,%

o = 0-20 mole% p = 2-20 mole %, andq = 5-50 mole%; andan infrared absorbing material in an amount of from 0.01 to 20% by weight of said positive-acting thermal resist layer.

__________

140381]21][11[

מחלת וירוס של דלקתיים שיבוטיםמאבחנות ובדיקות ניוקסל, חיסונים

NEWCASTLE DISEASE VIRUS INFECTIOUS CLONES, VACCINES AND DIAGNOSTIC ASSAYS

]54[


17.06.1999]22[EP]33[19.06.1998]32[98202054.

7]31[

Int. Cl.8 A61K 048/00, C12N 007/00, 015/45, 015/86, C12Q 001/70]51[PEPSCAN SYSTEMS B.V., THE NETHERLANDS

]71[

BERNARDUS PETRUS HUBERTUS PEETERS, OLAV SVEN DE LEEUW, GUUS KOCH, ARNOUD LEONARD JOSEF GIELKENS

]72[



P.O.B. 12688 ,HERZLIYA 46733

]74[

]57 [Avian-paramyxovirus cDNA at least comprising 5'-terminal end of the genome of Newcastle Disease Virus (NDV) corresponding to the 5'-terminal end of

NDV as shown in Figure 6 as shown in the specification allowing generating an infections copy of avian-paramyxovirus.

__________

140701]21][11[

אנטי–אמינופוספוליפידי בנוגדן שימוש להכנת שלו האנטיגן קישור באזור או

בסרטן לטיפול תרופה

USE OF AN ANTI-AMINOPHOSPHOLIPID ANTIBODY OR ANTIGEN-BINDING REGION THEREOF FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF CANCER

]54[

12.07.1999]22[US]33[13.07.1998]32[60/092672]31[US02.12.199860/110608

Int. Cl.8 A61K 039/00, 039/395, 047/48, C07K 016/28, 016/46]51[BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, U.S.A.

]71[

WO/2000/002584]87[ , תל4060 , ת.ד. 21 העם אחד רחוב

אביבREINHOLD COHN AND PARTNERS,

]74[



TEL AVIV 61040

]57 [Use of a composition comprising a biologically effective amount of an anti-aminophospholipid antibody, or antigen-binding region thereof, in the manufacture of a medicament for the treatment of

cancer by killing tumor vascular endothelial cells of a vascularized tumor, inducing coagulation in tumor vasculature or destroying tumor vasculature.

__________

140712]21][11[

מוליך מצע להכנת משופרת שיטהפסול לניתוח למחצה

METHOD FOR PREPARING SEMICONDUCTOR WAFER FOR DEFECT ANALYSIS

]54[

03.01.2001]22[Int. Cl.8 G01N 001/28]51[

בע"מ, יוקנעם למחצה מוליכים הנדסת סלעעילית

SELA SEMICONDUCTOR ENGINEERING LABORATORIES LTD.

]71[

( בע"מ,1995) ג'י.אי.ארליך בגין מנחם ,רחוב15 אילון, קומה מגדל

גן , רמת11



]74[

]57 [A method for preparing a semiconductor wafer for defect analysis, the method comprising:

locating a defect, called a target, in a semiconductor wafer; making a series of

saw cuts in the wafer which gradually cut away material near the target so as to produce a slimmed down inspection sample; and trimming said inspection sample to produce a band of material, in which the target is located, suitable for inspection by transmission electron microscopy (TEM).

_________

140731]21][11[

אנטימיקרוביות קפוראמיצין תולדותאותן המכילים רוקחות ותכשירי

ANTIMICROBIAL CAPURAMYCIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

]54[

09.07.1999]22[JP]33[09.07.1998]32[10-194285]31[


JP24.09.199810-269445Int. Cl.8 A61K 031/7072, A61P 031/04, C07H 019/06, C12P 019/28, C12R 001/545]51[SEQUELLA, INC., U.S.A.]71[




]74[


or a pharmaceutically acceptable salt thereof wherein:

R1 is a methyl group, R2 is a methyl group, R4 is a hydroxy group, and X is a methylene group; R1 is a methyl group, R2 is a hydrogen atom, R4 is a hydroxy group, and X is a methylene group; R1 is a methyl group, R2 is a methyl group, R4 is a

hydrogen atom, and X is a methylene group; R1 is a hydrogen atom, R2 is a hydrogen atom, R4 is a hydroxy group, and X is a methylene group; or R1 is a methyl group, R2 is a methyl group, R4 is a hydroxy group, and X is a sulfur atom.



_________

140947]21][11[

המכילים סינרגיסטיים תכשירים הקשורים מצבים עבור וליזין אסקורבאט

החוץ–תאית המטריצה לניוון

SYNERGISTIC COMPOSITIONS COMPRISING ASCORBATE AND LYSINE FOR STATES RELATED TO EXTRA CELLULAR MATRIX DEGENERATION

]54[

17.01.2001]22[Int. Cl.8 A61K 031/195, 031/197, 031/198, 031/375, 045/00]51[MATTHIAS RATH, THE NETHERLANDS

]71[


אביב


21 AHAD HA'AM ST ,.

]74[


P.O.B. 4060 ,TEL AVIV 61040

]57 [Use of ascorbate and at least one fibrinolysis inhibitor for the preparation of

a medicament for the treatment of infections or inflammatory diseases.

___________

141203]21][11[

RADIOTHERAPY VERIFICATIONלרדיותרפיה אימות מערכתSYSTEM

]54[

06.08.1999]22[US]33[06.08.1998]32[60/095528]31[

Int. Cl.8 A61N 005/10]51[WISCONSIN ALUMNI RESEARCH FOUNDATION, U.S.A.

]71[





TEL AVIV 61040

]74[

]57 [A method of verifying patient dose in the operation of a radiotherapy machine having a radiation source operable to produce multiple rays of radiation having controllable fluence and directed across a patient volume to be received by a detector having multiple detector elements providing detector signals at spatially separated points, each detector element receiving radiation from multiple rays, the method comprising the steps of: (a) receiving a treatment plan to operate the radiation source to produce a set of rays of predetermined fluence; (b) operating the

radiotherapy machine according to the received treatment plan; (c) concurrently with step (b) measuring the detector signals; (d) processing the detector signals using a model of the expected attenuation and path of each ray passing from the radiation source through the patient volume to the detector to deduce a fluence of each of the set of rays; and (e) using the deduced fluence and information about the structure of a patient in the patient volume to determine a dose distribution to the patient.


__________

141384]21][11[

בתכשיר המשתמשת איבחון שיטת גורם בתור מלחיו או ציאנין צבע המכיל

NIR לקרינה ניגוד

DIAGNOSTIC METHOD USING A COMPOSITION CONTAINING A CYANINE DYE OR ITS SALT AS A CONTRAST AGENT FOR NIR RADIATION

]54[


16.11.1995]22[DE]33[07.12.1994]32[P4445065.6]31[

Int. Cl.8 A61K 049/00, C09B 023/02, 023/08, 069/10]51[DIVISION FROM 116018]62[INSTITUT FUR DIAGNOSTIKFORSCHUNG GMBH AN DER FREIEN UNIVERSITAT BERLIN, GERMANY

]71[

וגולר, וולף, ברגמן, ירושלים1352, ת.ד.

WOLFF, BREGMAN AND GOLLER, P.O.B. 1352,

JERUSALEM 91013

]74[

]57 [An in-vivo diagnostic near infrared radiation method comprising:

) a (administering a compound of the formula B1-(F-Wn)m (l)wherein l

represents a number from 0 to 6, n represents a number from 0 to 10 and m represents a number from 1 to 100;

B is a biological detecting unit having a molecular weight of up to 30,000 that bonds to specific cell populations or selectively to receptors, or accumulates in tissues or tumours, or generally stays in the blood, or is a macromolecule that bonds non-selectively;

F represents a dye showing maximum absorption in the range of 650 to 1200 nm of the formula

R3 to R12 are same or different, each independently representing a hydrogen atom, a residue B or W, or an alkyl or alkenyl residue containing up to 6 carbon atoms or an aryl or aralkyl residue containing up to 9 carbon atoms, said alkyl, alkenyl, aryl or aralkyl residue optionally carrying an additional residue W or to each pair of adjacent residues R3 to R10 are annealed, with due regard for the interspersed atoms, 5- to 6-member rings that may be saturated, unsaturated or aromatic, and that may optionally carry residue R,R is a halogen atom, a hydroxy, carboxy, acetoxy, amino, nitro, cyano or sulfonic acid group or an alkyl, alkenyl,

hydroxyalkyl, carboxyalkyl, alkoxy, alkoxycarbonyl, sulfoalkyl, alkylamino, dialkylamino or halogenalkyl residue containing up to 6 carbon atoms, an aryl, alkylaryl, hydroxyaryl, carboxyaryl, sulfoaryl, arylamino, diarylamino, nitroaryl or halogenaryl residue containing up to 9 carbon atoms,s and t independently represent the number 0 to 1 on the condition that s and t do not represent the number 1 at the same time,X and Y are same or different, each independently representing an O, S, Se or Te or

-C(CH3)2-, -CH=CH- or –CR13R14-fragment,wherein


R13 and R14 independently represent a hydrogen atom, a residue B or W, or an alkyl or alkenyl residue containing up to 6 carbon atoms or an aryl or aralkyl residue containing up to 9 carbon atoms, the alkyl, alkenyl, aryl or aralkyl residue optionally having an additional residue W;

W represents a hydrophilic group that improves water-solubility, with the n-

octanol-water distribution coefficient of the compound according to formula l being less than or equal to 2.0 for l=0;

as well as their physiologically tolerable salts;

)b (irradiating the compound with light in the near infrared range; and

)c (recording the radiation produced by the compound.

_________

141764]21][11[

שחרור בעלות רוקחיות פורמולציות CGMP של מעכב המכילות מבוקרPDE–5

CONTROLLED-RELEASE PHARMACEUTICAL FORMULATIONS CONTAINING A CGMP PDE-5 INHIBITOR

]54[

04.10.1999]22[GB]33[23.10.1998]32[9823192.1]31[GB27.10.19989826392.4GB16.11.19989825117.6

Int. Cl.8 A61K 045/00]51[PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A., IRELAND

]71[

WO/2000/024383]87[





]74[

]57 [A sustained-release pharmaceutical composition for oral administration for the treatment or prevention of sexual dysfunction containing a cGMP PDE-5 inhibitor, wherein the cGMP PDE-5 inhibitor makes up 5-50% by weight of the formulation, wherein up to 75% by weight of the cGMP PDE-5 inhibitor is released from the formulation into the gastrointestinal tract after a period of time in the range 1-24 hours following administration and:

)a (wherein the cGMP PDE-5 inhibitor is embedded in a matrix from which it is released by diffusion or erosion, or

)b (wherein the cGMP PDE-5 inhibitor is present in a core which is coated with a release-rate-controlling membrane, or

)c (which comprises a core containing the cGMP PDE-5 inhibitor and an outer coating impermeable to the cGMP PDE-5 inhibitor, the outer coating having an aperture for release of the cGMP PDE-5 inhibitor.

_________

141914]21][11[

המכילה קפסולה ליצירת תהליךאיטי בשחרור נוזלית פורמולציה

PROCESS FOR PROVIDING SUSTAINED RELEASE LIQUID DOSAGE FORM

]54[

03.09.1999]22[US]33[09.09.1998]32[60/099619]31[

Int. Cl.8 A61K 009/00, 009/20, 009/48]51[ALZA CORPORATION, U.S.A.]71[

WO/2000/013663]87[לוצאטו, את לוצאטו

שבע , באר5352, ת.ד. תעשייה, עומר גן LUZZATTO & LUZZATTO,

INDUSTRIAL PARK, OMER,P.O.B. 5352,

]74[


BEER-SHEVA 84152

]57 [A process for providing a sustained release liquid dosage form, wherein the process comprises the steps as follows:

)a (blending an osmotic hydrogel and an osmotically effective solute to provide a composition that increases in volume in the presence of an aqueous fluid;

)b (blending a hydroxyalkylcellulose and water to provide a granulation solution;

)c (spraying the granulation solution (b) onto the composition provided in (a) to provide granules;

)d (blending a self emulsifying drug, a surfactant, and a member selected from the group consisting of a mono-and di-glyceride to provide a drug formulation

which is liquid upon administration and adapted to form an emulsion in an aqueous environment;

)e (adding the drug formulation (d) to a capsule;

)f (adding the sprayed composition of (c) to the capsule;

)g (coating the capsule with a semipermeable composition to provide a membrane permeable to an aqueous fluid; and,

)h (providing an exit in the membrane (g) for delivering the drug at a sustained-release and controlled rate over an extended time from the dosage form, and providing a self emulsifying drug.

_________

141972]21][11[

בעזרת הנדסה פולימרי שינוי\תאום החלפת וקבוצות בסיסיותNקבוצות–

צדדית בשרשרת יונים

MODIFICATION OF ENGINEERING POLYMERS WITH BASIC N GROUPS AND ION-EXCHANGE GROUPS IN THE SIDE CHAIN

]54[

12.08.1999]22[DE]33[12.08.1998]32[19836514.

4]31[

Int. Cl.8 C08G 075/02, 075/20, C08L 081/02, 081/06]51[


UNIVERSITAT STUTTGART (INST. FUR CHEMISCHE VERFAHRENSTECHNIK), GERMANY

]71[





JERUSALEM 91450

]74[

]57 [A method for producing an aryl main chain polymer having aryl-containing basic N-groups of the formula

wherein P is a polymer comprising the repeating units:

wherein R3 is hydrogen, alkyl or aryl, and the units R1 and/or R2 are linked by at least

one group selected from the group consisting of:


R7 is an aromatic group containing tertiary basic N, R8 is hydrogen, alkyl or aryl, which optionally contains tertiary basic N, X is hydrogen or an alkyl group, comprising reacting a metallized polymer

P-Me, wherein Me is Li or Na, with one or more aromatic ketones or aldehydes containing tertiary basic N-groups having the formula

to give an intermediate product of the formula:

and protonating or etherifying the intermediate with water or an alkyl halide,

to give the aryl main chain polymer having aryl-containing basic N-groups.

_________

142354]21][11[

מודפס לוח מעגל לייצור ושיטה מערכתשכבתי רב

MULTI-LAYER PRINTED CIRCUIT BOARD FABRICATION SYSTEM AND METHOD

]54[

02.04.2001]22[US]33[08.11.2000]32[09/708160]31[US23.02.200109/792498


Int. Cl.8 G03F 009/00, H05K 001/02]51[]ORBOTECH LTD.]71בע"מ, יבנה אורבוטקבע"מ, אורבוטק

, יבנה215, ת.ד. תעשייה אזור ORBOTECH LTD,.

P.O.B. 215,YAVNE 81102

]74[

]57 [Apparatus for recording an electrical circuit pattern on an upper layer of a multi-layer printed circuit board substrate, comprising: an alignment pattern generator (920) generating an alignment pattern that is visible on the upper surface (904) of the multi-layer printed circuit board substrate, said alignment pattern having a known orientation with respect to an electrical circuit pattern formed on one non-upper

layer of the substrate, said substrate having at least two layers of circuitry already formed thereon; an alignment pattern location sensor (926) sensing a location of the alignment pattern; and an electrical circuit pattern generator (932) recording an electrical circuit pattern on said upper surface in a desired orientation with reference to the alignment pattern.

_________

142759]21][11[

]DANALOGUES OF VITAMIN D]54 ויטמין של אנלוגים

28.10.1999]22[FR]33[02.11.1998]32[98/13747]31[

Int. Cl.8 A61K 000/823000 000/825000 000/833000 000/834000 000/837000 000/841000 031/05, 031/075, 031/085, 031/095, 031/13, 031/21, 031/35, A61P 017/00, 019/00, 019/10, 027/02, 035/00, 037/00, C07C 039/00, 039/15, 039/21,

]51[


043/166, 043/23, 069/017, 069/66, 217/86, 219/34, 323/20, C07D 309/02, C07F 007/08GALDERMA RESEARCH & DEVELOPMENT, S.N.C., FRANCE

]71[




BEER-SHEVA 84152

]74[

]57 [Compounds of the formula

in which:R1 represents a hydrogen atom, a methyl radical or a radical-(CH2)n-OR7, R2 represents a radical –(CH2)n-OR8, n, R7 and R8 having the meanings given below, X-Y

represents a bond chosen from the bonds of the following formulae (a) and (b) which may be read from the left to the right or conversely:

R9 and W having the meanings given below,

R3 represents the chain in vitamin D2 or in vitamin D3,


the dotted lines represent the bond linking the chain to the benzene ring represented in Figure (I), or R3 represents a chain having from 4 to 8 carbon atoms which is substituted with one or more hydroxyl groups, it being possible for the hydroxyl groups to be protected in the form of acetoxy, methoxy or ethoxy, trimethylsilyloxy, tert-butyldimethylsilyloxy, tetrahydropyranyloxy and optionally in addition: which is substituted with one or more linear or branched alkyl groups having from 1 to 6 carbon atoms or cycloalkyl groups and/or which is substituted with one or more halogen atoms and/or which is substituted with one or more CF3 groups and/or in which one or more carbon atoms of the chain are replaced by one or more oxygen, sulphur or nitrogen atoms, it being possible for the nitrogen atoms to be optionally substituted with linear or branched alkyl radicals having from 1 to 6 carbon atoms and/or in which one or more single bonds of the chain are replaced by one or more double and/or triple bonds, R3 being positioned on

the benzene ring at the para or meta position with respect to the X-Y bond,R4, R5 and R6, which are identical or different, represent a hydrogen atom, a linear or branched alkyl radical having from 1 to 6 carbon atoms, a halogen atom, a radical –OR10, a polyether radical having from 2 to 5 carbon atoms interrupted by at least 2 oxygen atoms, R10 having the meaning given below, n being 0, 1 or 2,R7 and R8, which are identical or different, represent a hydrogen atom, an acetyl radical, a trimethylsilyl radical, a tert-butyldimethylsilyl radical, a tetrahydropyranyl radical, R9 represents a hydrogen atom or a linear or branched alkyl radical having from 1 to 6 carbon atoms, W represents an oxygen atom, a sulphur atom, a radical –CH2- or a radical –NH- which may be optionally substituted with a linear or branched alkyl radical having from 1 to 6 carbon atoms, R10 represents a hydrogen atom or a linear or branched alkyl radical having from 1 to 6 carbon atoms, and the optical and geometric isomers of the said compounds of formula (I) as well as their salts.

__________


142929]21][11[

של מקומי לשחרור והתקנים תכשירים לטיפול בהם ושימוש הגס במעי תרופותהגס המעי במחלות מקומי

COMPOSITION OR DRUG DELIVERY DEVICE FOR LOCALIZED DRUG RELEASE IN THE COLON AND USE THEREOF FOR LOCAL TREATMENT OF COLONIC DISEASES

]54[


12.11.1999]22[US]33[12.11.1998]32[09/190127]31[

Int. Cl.8 A61K 009/00, 009/20, C07C 313/04]51[]DEXXON LTD.]71בע"מ, חדרה דקסון .MOSHE FLASHNER, ITZHAK Eפינחסי לרנר, עאדל פלשנר, יצחק משה

LERNER, ADEL PENHASI]72[

WO/2000/028974]87[( בע"מ,1995) ג'י.אי.ארליך




]74[

]57 [A composition or drug delivery device for localized drug release in the colon, said composition or device comprising one or more drugs in a core, and a coating surrounding said core, said coating having an outer surface, wherein said coating comprises water insoluble hydrophilic particulate matter embedded in a water-insoluble carrier, such that when said composition or device enters the

gastrointestinal tract, said particulate matter absorbs liquid, thus forming channels that interconnect said core with said outer surface of said coating and through which channels said one or more drugs are released into the colon, such that at least one of said drugs is preferentially metabolized to a more active metabolite in the colon.

_________


143019]21][11[

HABA DERIVATIVES OF AVIDINושימושן אבידין שלHABA תולדותAND USES THEREOF

]54[

10.11.1999]22[IL]33[10.11.1998]32[126990]31[

Int. Cl.8 A61K 038/02, A61P 043/00, C07D 273/02, C07K 001/13, 014/36, G01N 033/545

]51[


YEDA RESEARCH ANDבע"מ, רחובות ופיתוח למחקר חברה ידעDEVELOPMENT CO. LTD.

]71[

באייר, מרגריטה וילצ'ק, אדוארד מאירהופשטטר מורפורגו, הייקה

MEIR WILCHEK, EDWARD A. BAYER, MARGHERITA MORPURGO, HEIKE HOFSTETTER

]72[

WO/2000/027814]87[ושות', עמי , בן בן-עמי פאולינה

, רחובות94ת.ד. PAULINA BEN-AMI, BEN-AMI & ASSOCIATES,

P.O.B. 94 ,REHOVOT 76100

]74[

]57 [A covalent conjugate or a 4-hydroxyazobenzene-2-carboxylic acid derivative (hereinafter HABA) and an

avidin-type molecule, said conjugate being referred to herein as "HABAyalted avidin" and having the formula:

whereinA is (CH2)n or –CH=CH-, wherein n is an integer from 0-10;

B is (CH2)n wherein n is an integer from 2 to 10;

m is zero or 1; andAv is the residue of an avidin-type molecule selected from the group

consisting of native egg-white avidin, recombinant avidin, deglycosylated avidins, bacterial streptavidin, recombinant streptavidin and truncated streptavidin. Claimed as novel is a cyclic HABA derivative of the formula


_________

143069]21][11[

לייצור וחומרים רקומביננטיות שיטותאפותילון ותולדות אפותילון

RECOMBINANT METHODS AND MATERIALS FOR PRODUCING EPOTHILONE AND EPOTHILONE DERIVATIVES

]54[

19.11.1999]22[US]33[20.11.1998]32[60/109401]31[US10.02.199960/119386US03.03.199960/122620US22.04.199960/130560

Int. Cl.8 A61P 035/00, C12N 015/52, C12P 017/18]51[KOSAN BIOSCIENCES, INC., U.S.A.]71[





TEL AVIV 61040

]74[

]57 [A method to produce epothilone C and/or epothilone D, which method comprises culturing an isolated or recombinant host cell that contains a nucleic acid that codes for expression of Sorangium cellulosum epothilone polyketide synthase ("PKS") but does not

contain a functionally active product of a Sorangium cellulosum epoK gene under conditions wherein the nucleic acid is expressed to obtain a functional PKS, and epothilone C and/or epothilone D are produced.

__________

143403]21][11[

תרופות להכת ותכשירים שימושים באי–סדר טיפולרעילותי עירורי

METHODS AND COMPOSITIONS FOR THE PREPARATION OF MEDICAMENTS FOR TREATING DISORDERS INVOLVING EXCITOTOXICITY

]54[

03.12.1999]22[WO]33[03.12.1998]32[PCT/US98/25676]31[


US27.01.199909/238243US03.06.199909/325602

Int. Cl.8 A61K 038/17, A61P 025/14, 025/16, 025/28, C07K 014/47]51[CURIS, INC., U.S.A.]71[




P.O.B. 4060 ,TEL AVIV 61040

]74[

]57 [Use of a lipophilic modified hedgehog polypeptide in the preparation of a medicament for treating a disorder characterized by loss of dopaminergic and/or GABAergic neurons, wherein said hedgehog polypeptide comprises an amino acid sequence encodable by a nucleic acid sequence that hybridizes under stringent

conditions to a nucleic acid sequence designated in at least one of SEQ ID NOs: 1-9, and wherein said lipophilic modification comprises at least one fatty acid moiety on one or more internal sites or on an N-terminal amino acid residue of the mature hedgehog polypeptide.

_________

143699]21][11[

והחלמת עור בבעיות לאבחון שיטהפצעים

METHOD FOR THE DIAGNOSIS OF SKIN DISORDERS AND WOUND HEALING DISORDERS

]54[

12.06.2001]22[DE]33[20.06.2000]32[10030149.

5]31[

US01.08.200060/222081Int. Cl.8 A61K 038/17, C07K 014/00, C12Q 001/68, G01N 033/567]51[SWITCH BIOTECH AG, GERMANY]71[


אביב



TEL AVIV 61040

]74[

]57 [A method of diagnosing a skin disorder in a patient, said method comprising determining, in a sample from said patient, the level of a nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:34, wherein a level of said nucleic acid in said

sample from said patient that differs from the level in a control sample indicates that said patient has a skin disorder selected from the group consisting of psoriasis, eczema, acne, Urticaria, disorders of pigmentation of the skin, senile skin, and disorders of hair growth and hair metabolism.


_________

143810]21][11[

ולאבחון להגנה השימושי מניעה אמצעיולהכנתו בו לשימוש ושיטה

PROPHYLACTIC ARTICLE USEFUL FOR BOTH PROTECTION AND DIAGNOSIS AND METHOD FOR USE AND PRODUCTION THEREOF

]54[

18.06.2001]22[Int. Cl.8 A61F 006/00, G01N 033/52]51[

אביב שיינפלד, תל אלכסנדרכץ, סביון אמיל

ALEXANDER SCHOENFELDEMIL KATZ

]71[

ושות', שיבולת, ישראלי, רוברטס, זיסמןאביב , תל4ברקוביץ' המוזיאון, רחוב מגדל

SHIBOLETH, YISRAELI, ROBERTS, ZISMAN & CO,.

MUSEUM TOWER,4 BERKOWITZ ST,.

TEL AVIV64238

]74[

]57 [A prophylactic article, comprising:)a (a body shaped to conform to a

mammalian reproductive organ or to a mammalian appendage, said body acting as a physical barrier for protecting the mammalian user from contacting hazardous or infectious material;

)b (a probe for rapidly detecting the presence of hazardous or infectious material, said probe capable of interacting with said hazardous or infectious material and undergoing a visible change in response to said interaction, said probe present upon at least a portion of said body.

________


144998]21][11[

פלסמתית פועמת הקרנה בעל מכשיר תחזיתיות ברצועות אור הוצאת לשם

ביולוגית משמעות של

PULSED PLASMA RADIATION DEVICE FOR EMITTING LIGHT IN BIOLOGICALLY SIGNIFICANT SPECTRAL BANDS

]54[

18.12.2000]22[US]33[20.12.1999]32[467124]31[


Int. Cl.8 A61L 002/08, 002/14, A61N 005/06]51[ROBERT G. JAMES, U.S.A.]71[





JERUSALEM 91450

]74[

]57 [Apparatus for illuminating biological matter with preselected frequency spectra, comprising: a vacuum tube (25) of a generally elongate form defined by a cylindrical exterior wall made of translucent material; an anode formed in one end of said tube; a cathode (26) formed in the other end of said tube; a tubular conductive shield formed around a first portion of said tube adjacent said anode, said tubular shield being electrically connected to said anode; a reflective surface (22) mounted proximate a second portion of said tube adjacent said cathode, said reflective surface comprising conductive material electrically connected to said cathode; a magnetic piece (32) of a generally planar configuration aligned along said reflective surface distal of said second portion of said tube, said magnetic piece being transversely magnetized along

a magnetic direction generally orthogonal to said tube; an enclosure including a handle conformed to receive said first portion of said tube together with said tubular shield, and a reflector extending from said handle over said second portion of said tube together with said reflective surface and said magnetic piece; a source of electrical excitation connected between said anode and said cathode, said source including pulsing means for modulating said electrical excitation in a frequency domain of electrochemical reactions of said biological matter; and gases in said tube of molecular combinations ofH2O = 66%CO2 = 24%N2 = 3%H2CO3 = 3%

-/+5% ,by weight.

_________


145535]21][11[

ואבחון מונוקלוניים, אנטיגנים נוגדניםממאירות במחלות וטיפול

MONOCLONAL ANTIBODIES, ANTIGENS AND DIAGNOSIS AND THERAPY OF MALIGNANT DISEASES

]54[

30.09.1999]22[IL]33[31.03.1999]32[129299]31[

Int. Cl.8 G01N 033/574]51[ ,MOR RESEARCH APPLICATIONSתקוה – בע"מ, פתח מחקרים יישום מור

LTD.]71[

BRITTA HARDY, ABRAHAMנובוגרודסקי הרדי, אברהם בריטהNOVOGRODSKY

]72[

WO/2000/058363]87[ושות', וב ד"ר

, רחובות2189 , ת.ד. 2 רח' פקריס WEBB & ASSOCIATES,

2 PEKERIS ST., P.O.B. 2189,REHOVOT 76121

]74[

]57 [An assay for identifying a tested individual with high probability of having a malignant disease comprising:

)a (contacting a body fluid sample obtained from an individual with at least one of the monoclonal antibodies (mAbs) having a variable region selected from the group consisting of:

)i (a monoclonal antibody having a heavy chain variable region comprising the amino acid sequence of Fig. 1;

)ii (a monoclonal antibody having a Kappa light chain variable region comprising the amino acid sequence of Fig. 2, both figures as shown in the specification;

)iii (a monoclonal antibody having the heavy chain variable region comprising the amino acid sequence of Fig. 1 and the Kappa light chain variable region

comprising the amino acid sequence of Fig. 2;

)iv (a monoclonal antibody having a heavy chain variable region having at least 70% identity to the amino acid sequence of Fig. 1; and

)v (a monoclonal antibody having a Kappa light chain variable region having 70% identity to the amino acid sequence of Fig. 2;

)b (determining the extent of binding of said mAbs to T-cells within said sample; and

)c (comparing the extent of (b) to the extent of binding of the mAbs to T-cells in a sample obtained from a healthy individual, a significant difference between the above two extents of binding indicating that said tested individual has a high

__________

145842]21][11[

PREPARATION OFביולוגית פעילות בעלות מולקולות הכנתBIOLOGICALLY ACTIVE MOLECULES

]54[


13.04.2000]22[IL]33[13.04.1999]32[129427]31[

Int. Cl.8 C07K 014/54, 014/545, C12N 015/19, 015/24, 015/57, C12P 021/02]51[ YEDA RESEARCH ANDבע"מ, רחובות ופיתוח למחקר חברה ידע

DEVELOPMENT CO. LTD.]71[

MENACHEM RUBINSTEIN, DANIELA NOVICK, PIERRE GRABER, BIANLING LIU

]72[

WO/2000/061768]87[בע"מ, לאב אינטר

, יבנה18 הקישון INTERLAB LTD,.

18 HAKISHON ST.YAVNE 81220

]74[

]57 [A method for the production of a biologically active cytokine from its biologically inactive precursor comprising mutating its natural cleavage site to a site which is capable of being cleaved by a protease, and cleaving the mutated inactive

precursor to yield a biologically active cytokine, wherein the cytokine is selected from IL-18β and IL-18 and wherein the natural cleavage site is a caspase-1 cleavage site.

________

146222]21][11[

המכילות בתרכובות שימוש לטיפול תרופות להכנת בנזודיאזפינים

של סדירות לחוסר הקשורים במצבים המכילים רוקחיים ותכשירים תאים מות

אותם

USE OF COMPOSITIONS COMPRISING BENZODIAZEPINES FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DYSREGULATION OF CELL DEATH AND PHARMACEUTICAL COMPOSITIONS THEREOF

]54[

27.04.2000]22[US]33[30.04.1999]32[60/131761]31[


US15.11.199960/165511US24.03.200060/191855

Int. Cl.8 A61K 031/5513, A61P 035/00, C07D 243/14, 401/12, 403/12]51[THE REGENTS OF THE UNIVERSITY OF MICHIGAN, U.S.A.

]71[





TEL AVIV 61040

]74[

]57 [Use of a benzodiazepine compound for the manufacture of a medicament for the treatment of a condition associated with dysregulation of cell death in a subject through induction of cellular apoptosis, wherein the benzodiazepine

compound does not bind to a central benzodiazepine receptor and binds only with low affinity to a peripheral benzodiazepine receptor, wherein the benzodiazepine compound is selected from the group consisting of:

and enantiomers and pharmaceutically acceptable salts thereof: wherein R1 is an aliphatic group having up to 20 carbon atoms and up to 41 hydrogen atoms or an aryl group having up to 20 carbon atoms and up to 20 hydrogen atoms; wherein each of R2 and R3 is independently selected from the group consisting of hydrogen, hydroxy, C1-4 alkoxy, halo, amino, C1-4

alkyl-substituted-amino, acetylamino, hydroxyamino, an aliphatic group having up to 8 carbons and up to 17 hydrogens, an aryl group having from 6 to 14 carbon atoms, and a heterocyclic group having a 3-6 membered ring containing one or more heteroatoms selected from nitrogen, oxygen, and sulfur; and wherein R4 is aliphatic or aryl.

________

146242]21][11[

בעלי אורגניים אור פולטי התקנים גבוהה, מבוססי יעילות

אלקטרופוספורטים

VERY HIGH EFFICIENCY ORGANIC LIGHT EMITTING DEVICES BASED ON ELECTROPHOSPHORESCENCE

]54[


11.05.2000]22[US]33[13.05.1999]32[09/311126]31[

Int. Cl.8 H01L 033/00]51[THE TRUSTEES OF PRINCETON UNIVERSITY, U.S.A.

THE UNIVERSITY OF SOUTHERN CALIFORNIA, U.S.A.

]71[



P.O.B. 12688 ,HERZLIYA 46733

]74[

]57 [An organic light emitting device comprising an anode, a cathode, and an emissive layer, wherein the emissive layer is located between the anode and the

cathode, and the emissive layer comprises a phosphorescent organometallic iridium complex having an aromatic ligand.

________

146267]21][11[

המשמשת אלחוטית תקשורות מערכת CDMA בשיטת רדיו אות תדר באפנון רשתית ממשך פרוטוקול עם בתיאום

GSM A תקשורת

WIRELESS COMMUNICATIONS SYSTEMS UTILIZING CDMA RADIO FREQUENCY SIGNAL MODULATION IN CONJUNCTION WITH THE GSM A-INTERFACE TELECOMMUNICATIONS NETWORK PROTOCOL

]54[

19.06.1998]22[US]33[20.12.1995]32[08/575413]31[


Int. Cl.8 H04B 007/216, H04Q 007/22, 007/30]51[DIVISION FROM 125009]62[QUALCOMM INCORPORATED, U.S.A.

]71[




REHOVOT 76122

]74[

]57 [A base station controller, including:)a (a CDMA RF interface module

configured to provide a bi-directional interface with a subscriber unit;

)b (a GSM A-interface transport module configured to provide a bi-directional interface with GSM MSC;

)c (a transparent signaling transport module, coupled to the CDMA RF interface module and to the GSM A-interface transport module;

)d (signal processing resources; and

)e (a processing and service conversion module, coupled to the signal processing resources, the CDMA RF interface module, the GSM A-interface transport module, and to the transparent signaling transport module, the processing and service conversion module being configured to receive and examine signaling messages from the CDMA RF interface module and the GSM A-interface and to configure and control the signal processing resources in response to such signaling messages.

_________

146363]21][11[

ניידת תחנה להפעלת ושיטה מערכתאיתורית במצב או קול במצב

SYSTEM AND METHOD FOR OPERATING A MOBILE STATION IN A VOICE MODE OR PAGER MODE

]54[

10.05.2000]22[US]33[11.05.1999]32[09/309336]31[

Int. Cl.8 H04B 007/26, H04M 003/00, 011/06, H04Q 007/22, 007/32, 007/38]51[QUALCOMM INCORPORATED, U.S.A.

]71[

WO/2000/069193]87[June 5, 2008104 –התשס"ח ב' בסיון

5

ושות', ט. קולב סנפורד ,2273, ת.ד. , מרמורק4 הגיא שער

רחובות


REHOVOT 76122

]74[

]57 [A system for operating a mobile station in two modes, comprising: a mobile station; and a base station, wherein said mobile station is capable of operating in a first mode suitable for receiving telephone calls and in which said mobile station scans portions of a channel at a first rate; wherein said mobile station is capable of

operating in a second mode suitable for receiving pages only and in which said mobile station scans portions of the channel at a second rate; wherein the first rate is higher than the second rate; and wherein said mobile station is capable of switching between the two modes at the option of the user thereof.

_________

146498]21][11[

ידי על המופעל מחט ללא רפואי מחברלואר

NEEDLE-LESS LUER ACTIVATED MEDICAL CONNECTOR

]54[

01.06.1999]22[Int. Cl.8 A61M 025/00]51[CREATIVE PLASTIC TECHNOLOGY, LLC, U.S.A.

]71[

WO/2001/023026]87[ושות', ש. הורוביץ

, תל41-45 רוטשילד ציון, שדרות בית אביב


41-45 ROTHSCHILD BLVD,.

]74[


TEL AVIV 65784

]57 [A needle-less Luer actuated medical connector having a longitudinal axis, said connector comprising:

)a (a valve housing (20) having a fluid flow passage therein aligned with said longitudinal axis, a valve seat therein, an open end for receiving a compressible valve element and a connection end for connecting said connector to a fluid flow line aligned with said longitudinal axis;

)b (a valve actuator (30) having a fluid flow passage therein having an end aligned with said longitudinal axis of said connector, a valve compressing end wall received in said open end of said housing, and said fluid flow passage extending through said end wall, said valve actuator being mounted in said open end of said housing for rotation about said longitudinal axis with respect to said housing;

)c (a resilient valve element (40) compressed between said valve seat and said valve compressing end wall of said actuator, said valve element having a fluid flow passageway (34) therethrough extending from an axially aligned opening on a first side of said valve element substantially straight through said valve

element to an off-center opening on an opposite side of said valve element; said off-center opening of said fluid passageway in said valve element being aligned with an off-center positioned end of said flow passage in said valve actuator when said actuator is rotated relative to said housing to open said valve and said off-center positioned opening of said passageway in said valve element being circumferentially displaced from said off-center positioned opening of said flow passage in said valve actuator when said actuator is rotated relative to said housing to close the valve;

)d (means connecting said valve element to said housing to prevent relative rotation between said valve element and said housing;

)e (positioning means on said actuator and said housing to hold said actuator in either a valve open position or in a valve closed

position relative to said housing ;) f (restraining means on said housing and

on said actuator for restraining relative axial movement therebetween while permitting relative rotation therebetween.


_________

146608]21][11[

לתוך מידע להכנסת ומערכת שיטהמסמך

METHOD AND SYSTEM FOR PROVIDING INFORMATION IN A DOCUMENT

]54[

24.05.2000]22[AU]33[25.05.1999]32[PQ0559]31[AU30.06.1999PQ1313

Int. Cl.8 B41J 002/175, G06K 015/00, H04N 001/00]51[SILVERBROOK RESEARCH PTY. LTD., AUSTRALIA

]71[





TEL AVIV 61040

]74[

]57 [A method for providing information in a document, including: establishing personalized user content preferences; selecting and formatting information corresponding to the content preferences; and printing the formatted information in a document with at least one user interactive element, the formatted information including visible information having a

spatial extent which corresponds to the user interactive element and coded data,

the coded data being coincident with the visible information and enabling a user to indicate a response to associated information in the document, by interacting with the element using a sensing device which is adapted to sense the coded data when placed in an operative

position relative to the visible information and transmit response data to a computer system using the sensed coded data.


_________

146671]21][11[

IDENTITY-CODED SURFACEמקודדת שזהותו יחוס נקודות עם משטחWITH REFERENCE POINTS

]54[

24.05.2000]22[AU]33[25.05.1999]32[PQ0559]31[AU30.06.1999PQ1313AU15.10.1999PQ3457AU01.12.1999PQ4392

Int. Cl.8 G06K 005/00]51[SILVERBROOK RESEARCH PTY. LTD., AUSTRALIA

]71[





TEL AVIV 61040

]74[

]57 [A region defined in relation to a surface, coded data (3) and additional data (2) being disposed within the region, wherein the coded data comprises machine-readable data which is substantially inscrutable to the average unaided human and is indicative of: a region identity associated with the region;

and a plurality of points within the region, wherein the additional data is human-readable data which is substantially visible to the average unaided human eye, at least some of the additional data being indicative of an interactive element (6), at least some of the coded data in the vicinity of the at least some additional data also


of the at least some additional data also being indicative of the interactive element.

_________

146708]21][11[

תרופות של מושהה לשחרור מערכתפעימות בשתי העיכול במערכת

DELAYED TOTAL RELEASE TWO PULSE GASTROINTESTINAL DRUG DELIVERY SYSTEM

]54[

02.06.2000]22[US]33[04.06.1999]32[09/325748]31[

Int. Cl.8 A61K 009/00, 009/20, 009/28]51[ DEXCEL PHARMAבע"מ, הדרה טכנולוגיות פארמה דקסל

TECHNOLOGIES LTD.]71[

.MOSHE FLASHNER, ITZHAK Eפינחסי לרנר, עאדל פלשנר, יצחק משהLERNER, ADEL PENHASI

]72[

WO/2000/074655]87[( בע"מ,1995) ג'י.אי.ארליך




]74[

]57 [A controlled two pulse delivery device for delivering one or more desired agents to the gastrointestinal tract of a subject in need of the same, wherein said device comprises:

)a (a core comprising said one or more desired agents and a core material that swells in the presence of an aqueous liquid;


)b (an inner coat that surrounds said core, wherein said inner coat does not contain a drug and wherein said inner coat has an outer surface and comprises water-insoluble hydrophilic particulate matter embedded in a water-insoluble carrier such that in the presence of an aqueous liquid, said particulate matter forms channels in said inner coat that interconnect said core with said outer surface of said inner coat for controlling the entry of aqueous liquid to said core, and wherein said inner coat bursts when said core is swollen, thereby releasing said one or more desired agents from said core, such that said inner coat controls release and lag time to release of said one or more desired agents from said core; wherein said water-insoluble carrier includes at least one hydrophobic polymer; and

)c (an outer coat that surrounds said outer surface of said inner coat, wherein said outer coat comprises one or more desired agents which may be identical to or different from the one or more desired agents that are present in said core, said outer coat comprising at least one excipient for controlling immediate or sustained release of said one or more desired agents, wherein said inner coat physically separates said outer coat from said inner core; wherein release of said one or more desired agents from said core and release of said one or more desired agents from said outer coat are separated by a predetermined period of time and such that said immediate or sustained release of said one or more desired agents from said outer core is controlled separately from said release of said one or more desired agents from said core.

_________

147565]21][11[

אופטיים ערוצים מרובת מערכתלבדיקות

MULTIPLE OPTICAL INPUT INSPECTION SYSTEM

]54[

10.01.2002]22[US]33[13.02.2001]32[09/782626]31[

Int. Cl.8 G01R 031/309]51[]ORBOTECH LTD.]71בע"מ, יבנה אורבוטקבע"מ, אורבוטק

, יבנה215, ת.ד. תעשייה אזור ORBOTECH LTD,.

P.O.B. 215,YAVNE 81102

]74[

]57 [A method of inspecting electrical circuits comprising: obtaining first image data relating to at least a part of an electrical circuit; obtaining second image data generally corresponding to said part of the electrical circuit, said second image data including at least some image data for an optical characteristic that is different from

said first image data; generating a first representation of said electrical circuit from said first image data independently of said second image data; modifying said first representation by employing said second image data thereby to produce an enhanced representation of the electrical circuit; and inspecting the enhanced


representation with reference to a reference representation of the

electrical circuit to detect defects in the electrical circuit.



________

147823]21][11[

ארומטיים כירליים קטונים להכנת תהליך שימוש ידי על אלפא–הידרוקסי של

סינטאז באצטוהידרוקסיאציד

PROCESS FOR PREPARING CHIRAL AROMATIC ALPHA- HYDROXY KETONES USING ACETOHYDROXYACID SYNTHASE

]54[

24.01.2002]22[Int. Cl.7 C07C 049/245, C12P 007/26]51[

למחקר בנגב, הרשות בן-גוריון אוניברסיטתופיתוח, באר-שבע

BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY

]71[

ברק, סטניסלב צי'פמן, זאב מאיר דודויאזמנסקי אנג'ל, מריה

DAVID M. CHIPMAN, ZE'EV BARAK, STANISLAV ENGEL, MARIA VYAZMENSKY

]72[




]74[

]57 [A process of preparing an aromatic α-hydroxy ketone of the formula

wherein R is H or C1-6 alkyl, and Ar is aryl, wherein said aryl optionally contains one or more heteroatoms chosen from N, S and O, and optionally consists of fused rings, and said alkyl and aryl are optionally substituted by 1 to 3 substituents chosen

from C1-3 alkyl, C1-3 alkoxy, F, Cl, Br, I, OH, NH2, CN, and NR1R2, wherein R1 and R2 can be independently H or C1-4 alkyl, and said C1-3 alkyl can be further substituted by a substituent chosen from F, Cl, Br, I, and OH; which process


comprises reacting an aldehyde of the formula

with a 2-oxoacid of the formula

wherein Ar and R in formulae (II) and (III) have the meaning defined for formula (I); in the presence of a mixture comprising 2-hydroxy-3-oxoacid synthase chosen from

TSAS and acetohydroxyacid synthase (AHAS), thiamin pyrophosphate (TPP), flavine adenine dinucleotide (FAD), metal ions, and a buffer.

________

147824]21][11[

לביצוע מודולריות ומערכת שיטהנתונים בסיס שאילתות

MODULAR METHOD AND SYSTEM FOR PERFORMING DATABASE QUERIES

]54[

28.07.2000]22[US]33[30.07.1999]32[09/364808]31[

Int. Cl.8 G06F 017/30]51[COMPUTER ASSOCIATES THINK, INC., U.S.A.

]71[




BEER-SHEVA 84152

]74[

]57 [A method for performing database queries, comprising: providing a library of data drivers, each data driver operable to execute a specified database operation; receiving a query request for a database;

identifying from the library data drivers to perform the request using an application independent, intelligent dataset associated with a business intelligence system; determining an order of the data drivers to


perform the request; generating a driver chain including the data drivers in the order; and performing the request by

executing in order the data drivers in the driver chain.

_________

147872]21][11[

CTENASCIN-C NUCLEIC ACIDטנסין- של כליגנדיים גרעין חומצותLIGANDS

]54[

28.01.2000]22[US]33[29.07.1999]32[364902]31[

Int. Cl.8 A61K 047/48, C07H 021/00, C12Q 001/68]51[GILEAD SCIENCES, INC., U.S.A.]71[





TEL AVIV 61040

]74[

]57 [A nucleic acid ligand to tenascin-C identified according to the method comprising:

)a (contacting a candidate mixture of nucleic acids with tenascin-C, wherein nucleic acids having an increased affinity to tenascin-C relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

)b (partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;

)c (amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to tenascin-C, whereby a nucleic acid ligand of tenascin-C may be identified.

_________


148196]21][11[

רוקחות ותכשירי קפוראמיצין תולדותאותן המכילים

CAPURAMYCIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

]54[

18.08.2000]22[JP]33[20.08.1999]32[11/233934]31[

Int. Cl.8 A61K 031/7072, A61P 031/04, 031/06, C07H 019/06, C12P 017/06]51[SEQUELLA, INC., U.S.A.]71[




]74[

]57 [An antimicrobial compound of the formula

a pharmaceutically acceptable ester, ether or N-alkyl derivative thereof, or a pharmaceutically acceptable salt thereof:

)whereinX1 represents an oxygen atom, a sulfur atom or a group of formula –N(R4)-(in which R4 is a hydrogen atom, a C1-C3 alkyl group, or R4, together with R1 and the nitrogen atom to which they are attached, forms a 3- to 7-membered cyclic amine which may have a ring oxygen or sulfur atom);

X2 represents an oxygen atoms, a sulfur atom or a group of formula –N(R5)-(in which R5 is a hydrogen atom, a C1-C3 alkyl group, or R5, together with R2 and the nitrogen atom to which they are attached, forms a 3- to 7-membered cyclic amine

which may have a ring oxygen or sulfur atom);

R1 and R2 are the same or different and each represents:

)1 (a hydrogen atom,)2 (a C6-C10 aryl group which may have

one or more substituents said one or more substituents are selected from Group A, consisting of a halogen atom, a hydroxyl group, an amino group (said amino group may be substituted with one or more C1-C6 alkyl groups), a nitro group, a cyano group, a carboxyl group, a C1-C4 alkoxycarbonyl group, a carbamoyl group, a C1-C10 alkylenedioxy group, a C7-C14 aralkyloxy group, a C1-C16 alkyl group (said alkyl group may be substituted with one or more halogen atoms), a C2-C16


alkenyl group, a C1-C16 alkoxy group (said alkoxy group may be substituted with one or more halogen atoms), a C1-C6 alkylthio group (said alkylthio group may be substituted with one or more halogen atoms), a C6-C10 arylazo group, and a heterocyclic group which has 1-4 ring

nitrogen, sulfur or oxygen atoms;[)3 (a heterocyclic group which has 1-4

nitrogen, sulfur or oxygen atoms and which may have one or more substituents [said one or more substituents are selected from Group B, consisting of an oxo group, a thiooxo group, an imino group, a halogen atom, a hydroxyl group, an amino group (said amino group may be substituted with one or more C1-C16 alkyl groups), a nitro group, a cyano group, a carboxyl group, a C1-C4 alkoxycarbonyl group, a carbamoyl group, a C7-C14 aralkyloxy group, a C1-C16 alkyl group (said alkyl group may be substituted with one ore more halogen atoms), a C2-C16 alkenyl group, a C1-C16 alkoxy group (said alkoxy group may be substituted with one or more halogen atoms), and a C1-C16 alkylthio group (said alkylthio group may be substituted with one or more halogen atoms); (4) a C1-C14 alkyl group which is substituted with one to three C6-C10 aryl groups which may be the same of different and may each have

one or more substituents [said one or more substituents on the aryl group are selected

from Group A] ;)5 (a C1-C14 alkyl group which is

substituted with one to three heterocyclic groups which may be the same or different, have 1-4 nitrogen, sulfur or oxygen atoms and may have one or more substituents [said one or more substituents on the heterocyclic group are selected from Group B];

)6 (a C1-C22 alkyl group which may have one or more substituents [said one or more substituents are selected from Group C, consisting of a halogen atom, a hydroxyl group, an amino group, a nitro group, a cyano group, a carboxyl group, a C1-C4 alkoxycarbonyl group, a carbamoyl group, a C1-C16 alkoxy group (said alkoxy group may be substituted with one or more halogen atoms), and a C1-C16 alkylthio group (said alkylthio group may be substituted with one or more halogen

atoms)] ;)7 (a C2-C22 alkenyl group which may have

one or more substituents [said one or more substituents are selected from those listed in (2) or (3) above or from Group C];

or)8 (a group of the formula

)in which n represents an integer from 1 to 20 and m represents 0 or 2 ;(and R3

represents a hydrogen atom or hydroxyl group; with the proviso that:

a compound wherein X1 and X2 represent a group of formula –NH-, R1 represents a hydrogen atom or a group of formulae


R2 is a hydrogen atom andR3 is a hydroxyl group, anda compound wherein X1 is an oxygen atom, X2 represents a group of the formula

–NH-, R1 represents a hydrogen atom or a methyl group, R2 is a hydrogen atom and R3 is a hydroxyl group are excluded.

__________

148526]21][11[

קטנים וחלקיקים חרקים כנגד מגן רשתלייצורה ושיטה

PROTECTIVE NETTING AGAINST SMALL INSECTS AND FINE PARTICLES

]54[

05.03.2002]22[Int. Cl.8 A01K 013/00]51[

]KLAYMAN METEOR LTD.]71תקווה בע"מ, פתח מטאור קליימןברסלר, אייל ד"ר

גן – , רמת11 תובל DR. EYAL BRESSLER,

11 TOVAL ST., RAMAT GAN 52522

]74[

]57 [A stand-alone non-framed netting, useful for standing in strong terrestrial winds, especially useful for hindering the passage of small insects and any fine particles through said netting; said netting

comprising a plurality of bristly fibers and non-bristly fibers, in the quantitative ratio of 2:1 to 1;4; wherein said non-bristly fibers provide the mechanical stability of said netting.

__________


148634]21][11[

NEUTRON BRACHYTHERAPYניוטרונים בקרינת לריפוי התקןDEVICE

]54[

13.09.2000]22[US]33[13.09.1999]32[395324]31[

Int. Cl.8 A61M 036/12, A61N 005/10]51[ISOTRON, INC., U.S.A.]71[

WO/2001/019450]87[ושות', גבריאלי זליגסון

אביב , תל1426 , ת.ד. 31 רח' יבנה SELIGSOHN GABRIELI & CO,.

31 YAVNE ST,.P.O.B. 1426 ,

TEL AVIV 61013

]74[

]57 [A neutron source for performing neutron brachytherapy, the neutron source comprising: a neutron emitting source material (90), the neutron emitting source material radioactively decaying and releasing helium gas and neutrons during the decay; a capsule (91) within which the neutron emitting source material is encapsulated with capsule walls that do not interfere with the neutrons and the capsule

being sufficiently small so that it can be inserted interstitially into the body of a patient to treat tumor cells locally by releasing neutrons into the tumor cells and damaging the tumor cells with the neutrons; and a guide wire (92) attached to the capsule, the guide wire controlling the positioning of the capsule within the patient.

___________


148864]21][11[

PHARMACEUTICALנימסוליד המכילים רוקחות תכשיריCOMPOSITIONS CONTAINING NIMESULIDE

]54[

27.09.2000]22[IN]33[28.09.1999]32[1297/DE/99]31[

Int. Cl.8 A61K 009/20, 009/22, 031/18, C07C 311/08]51[PANACEA BIOTEC LIMITED, INDIA]71[WO/2001/022791]87[

וגולר, וולף, ברגמן, ירושלים1352, ת.ד.


JERUSALEM 91013

]74[

]57 [A pharmaceutical composition in the form of a compressed, oral solid dosage form consisting of nimesulide as an active agent from 5% to 95% w/w of the composition, one or more release

controlling materials from 2% to 95% w/w of the composition and pharmaceutical excipients from 0% to 90% w/w of the composition.

__________

149029]21][11[

מנוז של גבוה כמות עם חלבוניםלהכנתם ותהליכים

HIGH MANNOSE PROTEINS AND METHODS FOR PRODUCING THE SAME

]54[

17.08.2001]22[US]33[18.08.2000]32[09/641471]31[

Int. Cl.8 A61K 038/47, C07D 211/46, C12N 009/42, 015/56, 015/85]51[SHIRE HUMAN GENETIC THERAPIES, INC., U.S.A.

]71[




]74[

]57 [A method of producing a high mannose glucocerebrosidase (hmGCB), comprising: providing a cell which is capable of expressing a human glucocerebrosidase (GCB); contacting the cell with kifunensine such that the removal

of at least one mannose residue distal to the pentasaccharide core of the precursor oligosaccharide of GCB is prevented; and allowing the cell to produce hmGCB-, to thereby produce an hmGCB preparation.

____________


149141]21][11[

על המבוססות הריון מונעות תרופותלייצורן ושיטה ואסטרוגן פרוגסטרון

CONTRACEPTIVE MEDICAMENT BASED ON A PROGESTERONE AND AN OESTROGEN

]54[

24.10.2000]22[WO]33[25.10.1999]32[PCT/FR99/02587]31[

Int. Cl.8 A61K 031/57, 045/00, A61P 005/30, C07J 001/00]51[LABORATOIRE THERAMEX, MONACO

]71[




P.O.B. 4060 ,TEL AVIV 61040

]74[

]57 [Use of a composition comprising (i) from 0.3 mg 3 mg of estradiol or an ester thereof, (ii) from 0.1 mg to 2.5 mg of nomegestrol acetate and (iii)

pharmaceutically acceptable excipients, in the manufacture of a contraceptive product.

_________

149171]21][11[

]ELISAELISA FOR VEGF]54 באמצעותVEGF בדיקת

15.11.2000]22[US]33[16.11.1999]32[60/165736]31[

Int. Cl.8 G01N 033/53, 033/68]51[GENENTECH, INC., U.S.A.]71[





TEL AVIV 61040

]74[

]57 [A method for detecting multiple isoforms of vascular endothelial growth factor (VEGF) in a biological sample, comprising:

)a (incubating a biological sample with a capture reagent immobilized on a solid support to bind multiple isoforms of VEGF to the capture reagent, wherein the capture reagent comprises a mixture comprising a

polyclonal antibody that binds VEGF and a monoclonal antibody that specifically binds to C-terminal amino acid residues 111-165 of human VEGF; and

)b (separating the biological sample from the immobilized capture reagents;

)c (contacting the bound VEGF bound to the immobilized capture reagent with a detectable antibody that binds to N-


terminal amino acid residues 1-110 of VEGF;

)d (measuring an amount of VEGF bound to the capture reagent using detection means for the detectable antibody.

__________

149226]21][11[

9– –דאוקסו9 של נגזרות להכנת תהליךA –AZA – 9Aהומואריתרומיצין – A

4 בעמדה מותמר

PROCESS FOR PREPARING 4"-SUBSTITUTED-9-DEOXO-9A-AZA-9A- HOMOERYTHROMYCIN A DERIVATIVES

]54[

19.04.2002]22[US]33[27.04.2001]32[60/287203]31[

Int. Cl.8 C07H 005/06, 017/00, 017/08]51[PFIZER PRODUCTS, INC., U.S.A.]71[




]74[

]57 [A process for preparing a compound of the formula

or a pharmaceutically acceptable salt thereof, which comprises reacting a compound of the formula


with an amine of the formula NHR8 R15, in an organic solvent comprising isopropanol; wherein the reaction is carried out at a temperature of at least about 40o C;

wherein :

R3 is –CH2 NR8R15;R8 is C1-C10 alkyl;R15 is H or C1-C10 alkyl.



________

149322]21][11[

METHOD AND SYSTEM FORלקוח בקשת לאימות ומערכת שיטהVERIFYING A CLIENT REQUEST

]54[

25.10.2000]22[US]33[25.10.1999]32[60/161473]31[

Int. Cl.8 G06F 002/100000 013/00, H04L 009/00]51[WATCHFIRE CORPORATION, CANADA

]71[

WO/2001/031415]87[ושות', גבריאלי זליגסון

אביב , תל1426 , ת.ד. 31 רח' יבנה SELIGSOHN GABRIELI & CO,.

31 YAVNE ST,.P.O.B. 1426 ,

TEL AVIV 61013

]74[

]57 [A method for authorizing execution of requested actions transmitted between clients and servers of a data processing system, the method comprising: receiving a plurality of server messages from a server, each server message including a set of actions; simulating execution of each set of actions upon receipt of the plurality of server messages; based on each simulated execution, building or supplementing a list of allowable actions or user-definable inputs to the allowable actions in response to receiving a server message corresponding to the simulated execution; receiving one or more client messages

from one or more clients, each client message including one or more user-requested actions or inputs; comparing the list of allowable actions or user-definable inputs in existence prior to receipt of the one or more client messages to the user-requested actions or inputs; and where the list of allowable actions or user-definable inputs includes the user-requested actions or inputs, authorizing execution of the user requested actions or inputs, and supplementing the list of allowable actions or user-definable inputs upon receipt of a subsequent server message in response to the authorized execution.


_________

149475]21][11[

שימוש המונע נוסף הבטחה התקןקל נשק של מורשה בלתי

SUPPLEMENTARY SAFETY DEVICE OF LIGHT FIREARM TO PREVENT UNAUTHORIZED USE

]54[

05.05.2002]22[IT]33[18.05.2001]32[BS2001A000036]31[

Int. Cl.8 F41A 017/44]51[FABBRICA D'ARMI PIETRO BERETTA S.P.A, ITALY

]71[

צדק, וכהן איתן, פרל, לצר, הרצליה12688 , ת.ד. 7 שנקר רחוב

EITAN, PEARL, LATZER AND COHEN ZEDEK,

P.O.B. 12688 ,HERZLIYA 46733

]74[

]57 [A supplementary safety device that may be inserted into the chamber of light firearms including at least one of shotguns, rifles and handguns, the safety device comprising: a first body (10) including a lock (21) with a rotating pan controlled by a specific key; a second body (11) movably connected to the first body in an axial direction without rotating, between a position of unlocking with a position distant from the first body and a position of locking with a position close to the said first body, said second body being rotationally fixed with said first body; a screw pin (13) driven in rotation without moving axially in the first body, the screw

pin being connected to and controlled by the lock for rotation of said screw pin and to be linked directly or indirectly with the second body for the movement of the second body between the positions of unlocking and locking following the turning of the screw pin; and a flexible element (19) deformable by compression and located between the first and second bodies in order to expand radially and project peripherally from the first and second bodies when the second body is in the locking position, thus creating the locking of the device in the chamber of the barrel in which it is housed, wherein the screw pin is screwed to the second body.


__________

149523]21][11[

SYSTEM AND METHOD FORצורניים נתונים לאבחון ושיטה מערכתANALYSIS OF IMAGERY DATA

]54[

07.05.2002]22[IL]33[20.11.2001]32[146597]31[WO08.01.2002PCT/IL01/01074

Int. Cl.8 A61B 005/00, G06K 009/00]51[ בע"מ, טכנולוג'יס מדיקל מגנוליהפיתוח הרצליה

MAGNOLIA MEDICAL TECHNOLOGIES LTD.

]71[

,GOREN GORDON, DORON DINSTEINגורדון דינשטיין, ברק גורדון, דורון גורןBARAK GORDON

]72[

סורוקר-אגמון, , הרצליה14 שנקר נולטון, רחוב בית

פיתוח

SOROKER-AGMON, 14 SHENKAR ST ,.

HERZLIYA PITUAH 46725

]74[

]57 [A medical diagnostics system having an imagery data analysis application operative in the processing of imagery data for generating meaningful imagery data summaries, the system comprising the elements of: at least one imagery input device to acquire imagery data of at least one subject and to transmit a stream of the acquired imagery data to at least one associated data processing apparatus; at least one data processing device associated with the at least one imagery input device, the data processing device comprising the elements of: at least one data storage device to store the stream of acquired imagery data, to store imagery data

processing control parameters and to store programs constituting the imagery data analysis application; at least one processor device to process the stream of imagery data through the application of the at least one imagery data analysis application; an imagery data analysis application for the generation of meaningful summaries of the imagery data received from the at least one imagery input device, the imagery data analysis application comprises the elements of: an imagery data stream manipulation component to partition the distinct records of the stream of imagery data into specifically sized data blocks; a complexity calculation component to


assign complexity values to the partitioned blocks of the imagery data records; an indicative parameter calculation component; and a final result generating

component; and at least one user interface device to enable at least one user of the system to control suitably the operation of the system.

__________

149954]21][11[

METHOD AND SYSTEM FORטלפון לבקרת ומערכת שיטהTELEPHONE CONTROL

]54[

27.11.2000]22[AU]33[01.12.1999]32[PQ4392]31[

Int. Cl.8 B41J 003/42, 021/00, 029/38, G06K 007/00, 007/10, 019/06, H04M 001/00, 001/72, 003/42

]51[

SILVERBROOK RESEARCH PTY. LTD., AUSTRALIA

]71[





TEL AVIV 61040

]74[

]57 [A method of enabling at least one function of a telephone to be controlled, the telephone being operative to perform the at least one function in response to at least one command from a computer system, the method including the steps of: providing a control interface on a printed media surface containing printed

information relating to the at least one function, the control interface including printed coded data indicative of an identity of the control interface and of at least one reference point of the control interface; receiving, in the computer system, indicating data from a sensing device regarding the identity of the control


interface and a position of the sensing device relative to the control interface, the sensing device, when placed in an operative position relative to the control interface, generating the indicating data

using at least some of the coded data; and effecting, in the computer system and from the indicating data, at least one operation relating to the at least one command.

_________

150030]21][11[

תרופה המכילים תכשיריםלא–סטרואידית אנטי–דלקטית

COMPOSITIONS CONTAINING A NON-STEROIDAL ANTI-INFLAMMATORY DRUG

]54[

30.11.2000]22[GB]33[09.12.1999]32[9929077.7]31[GB09.12.19999929078.5

Int. Cl.8 A61K 009/00]51[RECKITT BENCKISER HEALTHCARE (UK) LIMITED, UNITED KINGDOM

]71[

WO/2001/041733]87[לצר, צדק כהן פרל

, ת.ד.5 , רח' שנקר1 גב-ים מרכז , הרצליה12704

PEARL COHEN ZEDEK LATZER, 5 SHENKAR ST ,.

P.O.B. 12704,HERZLIYA 46733

]74[

]57 [A compressed tablet composition comprising: a granular component comprising a plurality of solidified melt granules of a non-steroidal anti-

inflammatory drug having a melting point in the range of 30-300 oC and incorporating a disintegrant uniformly dispersed therein; characterised in that the


granules comprise a continuous phase of said anti-inflammatory drug obtainable by combining the non-steroidal anti-inflammatory drug in fully molten form with the disintegrant and further

characterised in that the tablet composition comprises silicon dioxide present in an amount of 0.05-5.0% by weight of the composition.

_________

150069]21][11[

של אקראיות בספריות להשתמש שיטות של פעולה לזיהוי אבץ עם אצבע חלבוני

גן

METHODS OF USING RANDOMIZED LIBRARIES OF ZINC FINGER PROTEINS FOR THE IDENTIFICATION OF GENE FUNCTION

]54[

06.12.2000]22[US]33[06.12.1999]32[09/456100]31[

Int. Cl.8 C12N 005/16, 015/10, 015/12, C40B 004/00800]51[SANGAMO BIOSCIENCES, INC., U.S.A.

]71[

CASEY CHRISTOPHER CASE, QIANG LIU, EDWARD J. REBAR, ALAN P. WOLFFE

]72[





TEL AVIV 61040

]74[

]57 [A method of identifying a gene or genes associated with a selected phenotype, the method comprising the steps of:

)a (providing a nucleic acid library comprising nucleotide sequences that encode at least partially randomized zinc finger proteins;

)b (transducing cells with expression vectors, each comprising a nucleotide sequence from the library;

)c (culturing the cells so that zinc finger proteins are expressed in the cells, wherein the zinc finger proteins modulate

gene expression in at least some of the cells;

)d (assaying the cells for a selected phenotype and determining whether or not the cells exhibit the selected phenotype; and

)e (identifying, in cells that exhibit the selected phenotype, the gene or genes whose expression is modulated by expression of a zinc finger protein, wherein the gene so identified is associated with the selected phenotype.


187848,The applications for division from this application have


not yet been published

_________150126]21][11[

–8–)פיפרזיניל)4 קואינולינל(מתיל(בנזאמידים,

אותם המכילים רוקחות תכשירי עבור תרופות בהכנת ושימושם

תרפיה

4(-PIPERAZINYL(8-QUINOLINYL)METHYL)BENZAMIDES,

PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR THERAPY

]54[

15.12.2000]22[SE]33[20.12.199

9]32[9904673-2]31[

Int. Cl.8 A61K 031/395, A61P 029/00, C07D 401/10, 401/14, 405/14, 409/14]51[ASTRAZENECA AB, SWEDEN]71[CHRISTOPHER WALPOLE, NIKLAS PLOBECK, WILLIAM BROWN

]72[


,5352, ת.ד. תעשייה, עומר גן שבע באר



]74[


whereinR1 is selected from

)i (phenyl;

) ii (pyridinyl


)iii (thiophenyl

) iv (furanyl

)v (imidazolyl

)vi (triazolyl

where each phenyl ring and heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C1-C6

alkyl, NO2, CF3, C1-C6 alkoxy, chloro, fluoro, bromo, and iodo; as well as pharmaceutically acceptable salts thereof and isomers thereof.

_________

150172]21][11[

תקשורת ממשק עם רדיו מערכתאוניברסלי

RADIO SYSTEM WITH UNIVERSAL COMMUNICATION INTERFACE

]54[

15.12.2000]22[GB]33[16.12.1999]32[9929634.5]31[

Int. Cl.8 H04B 001/38, 001/40, 001/44, 007/26, H04M 001/00, 001/247]51[SELEX COMMUNICATIONS LIMITED, UNITED KINGDOM

]71[


9


אביב



TEL AVIV 61040

]74[

]57 [A radio system comprising a radio, a switch unit adapted to be connected to the radio and a PTT switch forming part of the switch unit and arranged so that, when operated, it allows a user to transmit over a first communications system using the radio, characterised in that the switch unit

is designed to be releasably connected to the radio and includes a second PTT switch, and in that the system includes means for connecting the second PTT switch so that, when operated, it allows the user to transmit over a second communications system.

___________


150201]21][11[

חדשות, ופיפרזין פיפרידין תולדות רוקחות להכנתן, תכשירי תהליך

בתראפיה ושימושן אותן המכילים

PIPERIDINE AND PIPERAZINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USE THEREOF IN THERAPY

]54[

18.12.2000]22[SE]33[22.12.1999]32[9904738-3]31[

Int. Cl.8 A61K 031/395, A61P 011/00, 019/00, 029/00, 037/02, 043/00, C07D 211/34, 211/54, 241/04, 401/12, 403/04, 403/14, 413/12, 451/02, 471/02, 473/34, 487/02, 495/04, 513/04

]51[

ASTRAZENECA AB, SWEDEN]71[PREMJI MEGHANI, COLIN BENNION

]72[




BEER-SHEVA 84152

]74[


wherein,X represents a nitrogen atom or a group C(R5);

Y represents an oxygen or sulphur atom or a group NR6; either R1 and R2 each independently represent a hydrogen atom

or a C1-C4 alkyl group but do not both simultaneously represent a hydrogen atom, or R1 and R2 together represent a group –

CH2ZCH2;-Z represents a bond, an oxygen or sulphur atom or a group CH2 or NR7; m is 0 or 1;


R3 represents a 5- to 10-membered unsaturated ring system which may comprise from 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents independently selected from halogen, nitro, cyano, NR8R9, C1-C4 alkyl-C(O)NH-, NHR12C(O)-, C1-C4 alkyl-SO2-, C1-C4 alkyl-SO2NH-, C1-C4 alkyl-NHSO2-, C1-C4 alkoxy, and C1-C4 alkyl optionally substituted by one or more fluorine atoms; R4 represents a phenyl or pyridinyl group, each of which is substituted in an ortho position with a substituent selected from halogen, C1-C4 alkoxy, C1-C4 alkylthio, and C1-C4 alkyl optionally substituted by one or more fluorine atoms, the phenyl or pyridinyl group being optionally further substituted by one or more substituents independently selected from halogen, cyano, hydroxyl, C1-C4 alkylthio, C1-C4 alkyl, -NH-, NHR18, C1-C4 alkyl-, C1-C4

alkyl-SO2-, C1-C4 alkyl-SO2NH-, C1-C4 alkyl-NHSO2-, C1-C4 alkyl-C(O)NH-, C1-C4 alkyl-NHC(O)-, -D-G, C1-C4 alkoxy optionally substituted by –NR14R15 or by R16, and C1-C4 alkyl optionally substituted by one or more fluorine atoms or by one or more hydroxyl groups, or R4 represents a 9- or 10-membered unsaturated bicyclic ring system selected from naphthyl, benzimidazolyl, quinolinyl, indolinyl, isoquinolinyl, benzofuranyl, isobenzofuranyl, benzothienyl, indolyl, isoindolyl, benzthiazolyl and benzoxazolyl, the bicyclic ring system being optionally substituted by one or more substituents independently selected

from halogen, oxo C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylthio and –NR10R11 ;

D represents an oxygen atom or a group (CH2)n or CH2NH;n is 1, 2 or 3;

G represents a piperazinyl, morpholinyl or 2, 5-diazabicyclo [2.2.1] heptyl group, or G represents a piperidinyl group optionally substituted by amino;

R5 represents a hydrogen atom, or a hydroxyl or C1-C4 alkoxy group; R6 represents a hydrogen atom, or a cyano, nitro, hydroxyl, C1-C4 alkyl or C1-C4 alkoxy group;

R7, R8 and R9 each independently represent a hydrogen atom or a C1-C4 alkyl group; R10 and R11 each independently represent a hydrogen atom or a C1-C4 alkyl group, or R10 and R11 together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated heterocyclic ring comprising one or two ring nitrogen atoms; R12 represents a hydrogen atom, or a C1-C14 alkyl group optionally substituted by amino; R13 represents a hydrogen atom, or a C1-C4 alkyl group optionally substituted by hydroxyl; R14 and R15 each independently represent a hydrogen atom or a C1-C4 alkyl group optionally substituted by hydroxyl, or R14 and R15 together with the nitrogen atom to which they are attached form a 5- or 6- membered saturated heterocyclic ring comprising one or two ring nitrogen atoms; and R16 represents a 1-(C1-C4-alkyl)-piperidinyl group; with the proviso that when m is 0, X is N and Y is O, then R4 does not represent 2-benzothiazolyl; or a pharmaceutically acceptable salt or

__________


150366]21][11[

–פיפראזיניל,1–פאניל–4 תולדות פיפראזיניל, –פיפרידיניל

וטטרההידרופירידיל

4-PHENYL-1-PIPERAZINYL,-PIPERIDINYL AND –TETRAHYDROPYRIDYL DERIVATIVES

]54[

22.12.2000]22[DK]33[30.12.1999]32[PA199901887]31[

Int. Cl.8 A61K 031/395, A61P 025/00, C07D 295/04, 401/06, 401/12, 403/06, 403/12]51[H. LUNDBECK A/S, DENMARK]71[WO/2001/049679]87[

ושותפיו, הס יצחק ד"ראביב , תל6451 , ת.ד. 279 הירקון רחוב

DR. YITZHAK HESS & PARTNERS, 279 HAYARKON ST,.

P.O.B. 6451 ,TEL AVIV 61063

]74[


wherein W is C, CH or N, and the dotted line emanating from W indicates a bond when W is C and no bond when W is N or CH;

R1 and R2 are independently selected from hydrogen and halogen, provided at least one of R1 and R2 is a halogen atom;

R3 is selected from hydrogen, halogen, C1-

6-alkyl, C2-6-alkenyl, C2-6-alkynyl,

trifluoromethyl, C1-6-alkoxy, aryloxy, aralkoxy, hydroxy, amino C1-6-alkylamino, di(C1-6-alkyl) amino, nitro and cyano; n is 2, 3, or 5;

X is CH, CO, CS, SO or SO2; andQ is an optionally substituted 1-indolinyl group of the formula


wherein R4, R5, R6, R7, R8 and R9 are independently selected from hydrogen, halogen, trifluoromethyl, nitro, cyano, C1-6-alkyl, C2-6-alkenyl, C2-6-alkenyl, C1-6-alkoxy, C1-6alkylthio, C1-6-alkylsulfonyl, hydroxy, hydroxy-C1-6 alkyl, amino, C1-6-

alkylamino, di(C1-6-alkyl) amino, acyl, aminocarbonyl, C1-6-alkylaminocarbonyl and di(C1-6-alkyl) aminocarbonyl; and any of its enatiomers and acid addition salts thereof.



__________

150736]21][11[

MODIFIED VACCINIA VIRUS(MVA) ששונה אנקארה ווציניה נגיףANKARA (MVA)

]54[

10.03.2001]22[DK]33[14.03.2000]32[PA200000410]31[

Int. Cl.8 C12N 007/00, 007/08, 015/39, 015/863]51[BAVARIAN NORDIC A/S, DENMARK

]71[




P.O.B. 4060 ,TEL AVIV 61040

]74[

]57 [A modified vaccinia virus Ankara adapted for growing in cells

of a continuous cell line, wherein said cell line is a Vero cell line.



_________

150842]21][11[


–פירולידין,1–אוקסו–2 תולדותבהן והשימוש להכנתם תהליכים

2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES

]54[

21.02.2001]22[GB]33[23.02.2000]32[0004297.8]31[

Int. Cl.8 A61K 031/4015, A61P 025/08, C07D 207/27, 403/04, 409/04]51[UCB, S.A., BELGIUM]71[WO/2001/062726]87[


אביב



TEL AVIV 61040

]74[

]57 [Compounds of the formula

or a pharmaceutically acceptable salt thereof,wherein X is –CA1NR5R6 or or –CA1-R8; A1 and A2 are indepdnently oxygen, sulfur or – NR9; R1 is hydrogen, C1-20 alkyl alkyl, aryl or –CH2R1a wherein R1a is aryl, heterocycle, halogen, hydroxy, amino, nitro or cyano; R3 is hydrogen, halogen, thiol, nitro, nitrooxy, cyano, azido, carboxy, amido, sulfonic acid, sulfonamide, C1-20 alkyl, alkenyl, alkynyl, ester, ether, aryl, heterocycle, alkynyloxy, acyloxy, oxyester, oxamido, alkylsulfonyloxy, alkylsulfinyloxy, arylsulfonyloxy, arylsulfinyloxy, aryloxy, aralkoxy, heterocyclooxy or a thio derivative, acyl derivative, sulfonyl derivative or sulfinyl derivative; R3a is hydrogen, halogen, C1-C20 alkyl, alkenyl, alkynyl or aryl; R5, R6 and R9 are the same or different and each is independently

hydrogen, hydroxy, C1-20 alkyl, aryl, heterocycle or an oxy derivative; and R8 is hydrogen, hydroxy, thiol, halogen, C1-20 alkyl, aryl, heterocycle or a thio derivative; each alkyl may independently be optionally substituted by 1 to 5 halogen, hydroxy, thiol amino, nitro, cyano, thiocyanate, acyl, acyloxy, sulfonyl derivative, sulfinyl derivative, alkylamino, carboxy, ester, ether, amido, azido, cycloalkyl, sulfonic acid, sulfonamide, thio derivative, oxyester, oxyamido, heterocycle, vinyl, C1-5 alkoxy, C6-10 aryloxy, or C6-10 aryl; each aryl may independently be optionally substituted by 1 to 5 halogen, hydroxy, thiol, amino, nitro, cyano, acyl, acyloxy, sulfonyl, sulfinyl, alkylamino, carboxy, ester, ether, azido, suflonic acid, sulfonamide, alkylsulfonyl, alkylsulfinyl, alkylthio, oxyester, oxyamido, aryl, C1-6 alkoxy,


C6-10 aryloxy, C1-6 alkyl, C1-6 haloalkyl; each heterocycle may independently be optionally substituted by one or more alkyl, halogen, hydroxy, thiol, amino, nitro, cyano, thiocyanato, acyl, acyloxy, sulfonyl derivative, sulfinyl derivative, alkylamino, carboxy, ester, ether, amino azido, cycloalkyl, sulfonic acid, sulfonamide, thio derivative, oxyester, oxyamido, heterocycle, vinyl, C1-5 alkoxy, C6-10 aryloxy or C6-10 aryl; each alkenyl and alkynyl may independently be optionally substituted by at least one halogen, hydroxy, thiol, amino, nitro, cyano, aryl or heterocycle; with the provisos that at least one of R3 and R3a is

other than hydrogen; and that when the compound is a mixture of all possible isomers, X is –CONR5R6, A2 is oxygen and R1 is hydrogen, methyl, ethyl, or propyl then substitution on the pyrrolidine ring is other than mono-, di-methyl or mono- ethyl; and that when R1 and R3a are both hydrogen, A2 is oxygen and X is –CONR5R6 then R3 is different from carboxy, ester, amido, substituted oxo-pyrrolidine, methyl, naphthyl, phenyl optionally substituted by oxy derivatives or in the para position by an halogen atom.Claimed as novel are neurological intermediate compounds of the formula

wherein X, R1, R3 and R3a are as defined above and Q1 together with the

oxygen to which it is attached is a leaving group.


170181,170071,The applications for division from this application have not yet been published

___________

150848]21][11[

]MAGNETIC COUPLING SYSTEM]54מגנטית צימוד מערכת

22.07.2002]22[Int. Cl.8 F04D 013/10, F16D 007/00]51[

]MAYTRONICS LTD.]71יזרעאל בע"מ, עמק מיטרוניקסוגולר, וולף, ברגמן



]74[


]57 [A magnetic coupling system (10), comprising: a housing (2) having a tightly closable cover member (4) and defining a dry domain; an electric motor (8) mountable inside said housing and fixedly attached to said cover member by means of a hollow base member (12), said motor having a first drive shaft (16), a driving end of the first drive shaft entering and being mountable in said base member; a first disk-like member (24) keyed to the driving end of said first drive shaft; a first ferromagnetic tubular section (30) fixedly attached to a rim (28) of said disk-like member, a first unit of permanent magnets (32) comprised of a plurality of permanent magnets fixedly attached to the inside surface of said first ferromagnetic tubular section; a chamber (34) delimited by a substantially cylindrical wall (36) and constituted by a first, substantially bowl-like structure (35), descending from said cover member and separating the dry domain prevailing below outside the

chamber from a wet domain prevailing above and inside the chamber; a second disk-like member (38) keyed to, or integral with, a second drive shaft (40) mounted in bearing means (46, 48) said second drive shaft being located outside of said dry domain and adapted to drive an impeller (54); a second ferromagnetic tubular section (42) fixedly attached to the rim of said second disk-like member; a second unit of permanent magnets (44) comprised of a plurality of permanent magnets fixedly attached to the outside surface of said second ferromagnetic tubular section and facing said first unit of magnets, said chamber wall being interposed with clearance between the first and the second unit of permanent magnets; wherein said first unit of permanent magnets, when rotated by said first drive shaft, drags along the second unit of permanent magnets by magnetic effect, thereby causing said second drive shaft to be rotated and to operate said impeller.

__________


150965]21][11[

לכיב מניעתי או תרפויטי גורם ולמחלת הגס המעי של דלקתי תולדת המכיל קרוהן

דיאמינוטריפלואורומתילפירידין

THERAPEUTIC OR PREVENTIVE AGENT FOR ULCERATIVE COLITIS AND CROHN'S DISEASE CONTAINING A DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVE

]54[

30.01.2001]22[JP]33[31.01.2000]32[2000-22817]31[

Int. Cl.8 A61K 031/44, A61P 001/00, C07D 213/72, 405/12, 409/12]51[ISHIHARA SANGYO KAISHA LTD., JAPAN]71[SHUICHI YOTSUYA, HIROHIKO KIMURA, TADAO BAMBA

]72[

WO/2001/056568]87[ – דין עורכי מהולל – איתן קבוצתפטנטים, עורכי

, ת.ד.10 אבן אבא שדרות , הרצליה2081

EITAN MEHULAL LAW GROUP, 10 ABBA EBEN BLVD,.

P.O. B. 2081,HERZLIYA 46120

]74[

]57 [A therapeutic or preventive agent for ulcerative colitis and Crohn's disease, containing as an active ingredient a

diaminotrifluormethylpyridine derivative represented by the formula


or its salt:wherein X is a –CW1R1 group a, –COCOR2 group, a –CW1NHCOR2 group, a –C(=W1)W2R3 group or a –CW1N(R4)R5 group; Y is an alkyl group, a –CW3R6 group, a – COCOR7 group, a –NHCOR7 group, a –C(=W3)W4R8 group, a –(NH)nSO2R9 group, a –(NH)mSO2R9 group, a –(NH)mSO2OR10 group or a –(NH)mSO2N(R11)R12 group; each of R1, R6 and R9 which are independent of one another, is a chain hydrocarbon group which may be substituted, a monocyclic hydrocarbon group which may be substituted, a polycyclic hydrocarbon group which may be substituted, a monocyclic heterocycle group which may be substituted or a polycyclic heterocycle group which may be substituted; each of R2 and R7 which are independent of each other, is an alkyl group which may be substituted, an alkoxy group which may be substituted, a phenyl group which may be substituted or a phenoxy group which may be substituted; each of R3, R8 and R10 which are independent of one another, is

an alkyl group which may be substituted, an alkenyl group which may be substituted, an alkynyl group which may be substituted, a cycloalkyl group which may be substituted or a benzyl group which may be substituted; each of R4, R5, R11 and R12 which are independent of one another, is an alkyl group which may be substituted; each of W1, W2, W3 and W4 which are independent of one another, is an oxygen atom or a sulfur atom; and m is 0 or 1, excluding a case where one of X and Y is a –COCF2X1 group (wherein X1 is a hydrogen atom, a halogen atom, an alkyl group or a haloalkyl group), and the other is a –COCF2X2 group (wherein X2 is a hydrogen atom, a halogen atom, an alkyl group, a haloalkyl group or an alkylcarbonyl group), a –COOX3 group (wherein X3 is an alkyl group which may be substituted or a phenyl group which may be substituted) or a –COX4 group (wherein X4 is an alkyl group, a haloalkyl group, an alkenyl group, an alkynyl group, a phenyl group which may be substituted, a furanyl group or a naphthyl group).

__________

151106]21][11[

וחומרים אזלאסטין המכיל תכשיר לאוקוטריאן פעולת על המשפיעים

עיניים / דלקת האף בדלקת לטיפול

COMBINATION OF AZELASTINE WITH SUBSTANCES WHICH INFLUENCE LEUKOTRIENE ACTION FOR THE TREATMENT OF RHINITIS/CONJUNCTIVITIS

]54[

05.02.2001]22[DE]33[17.02.2000]32[10007203.

8]31[

Int. Cl.8 A61K 031/55, 045/00, 045/06]51[June 5, 2008107 –התשס"ח ב' בסיון

9

MEDA PHARMA GMBH & CO. KG, GERMANY

]71[

HILDEGARD KUSS, JURGEN ENGEL, ISTVAN SZELENYI

]72[

WO/2001/060407]87[( בע"מ,1995) ג'י.אי.ארליך




]74[

]57 [Pharmaceutical preparation for the treatment of allergic and/or vasomotor rhinitis or allergic conjunctivitis which is suitable for topical or oral administration of single doses, with the following ingredients, separately or together:

)a (an effective amount of azelastine;)b (an effective amount of a leukotriene

antagonist or of one of its

pharmaceutically acceptable salts selected from a group consisting of a leukotriene D4

antagonist or a 5-lipoxygenase inhibitor or a FLAP antagonist ;

)c (converntional physiologically acceptable carriers and/or extenders or excipients.

__________

151134]21][11[

רפלוקס ובמחלת בצרבת לטפול מתקןאלחוטית אנרגיה אספקת בעל

HEARTBURN AND REFLUX DISEASE TREATMENT APPARATUS WITH WIRELESS ENERGY SUPPLY

]54[

08.02.2001]22[US]33[09.02.2000]32[09/501266]31[

Int. Cl.8 A61B 017/12, A61F 002/06]51[OBTECH MEDICAL AG, SWITZERLAND

]71[



P.O.B. 12688 ,HERZLIYA 46733

]74[

]57 [A heartburn and reflux disease treatment apparatus comprising: a restriction device (4) implantable in a patient, who suffers from heartburn and

reflux disease, for engaging the stomach close to the cardia or engaging the esophagus, to form a restricted food passageway in the stomach or esophagus,


the restriction device being operable to change the restriction of the food passageway; an energy transmission device (10) for wireless transmission of energy from outside the patient's body to inside the patient's body; and an energy transforming device (6) implantable in the patient and comprising at least one electrical junction element having a positive region and a negative region, the

junction element being capable of creating an electric field between the positive and negative regions when exposed to the energy transmitted by the energy transmission device, the electric field producing electrical energy for use in connection with the operation of the restriction device including to enlarge or restrict the food passageway, when the restriction device is implanted.

_________

151249]21][11[

ועיכוב לטיפול בציאנוקינולינים שימושהגס במעי פוליפים

USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS

]54[

06.03.2001]22[US]33[13.03.2000]32[524196]31[

Int. Cl.8 A61K 031/47, A61P 001/00, C07D 215/48, 401/12, 405/12, 413/12, 491/04]51[WYETH HOLDINGS CORPORATION, U.S.A.

]71[





TEL AVIV 61040

]74[

]57 [Use of a compound of the formula


wherein:X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono-,di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, and benzoylamino;n is 0-1;

Y is --NH--, --O--, --S--, or –NR;--R is alkyl of 1-6 carbon atoms;

R1, R2, R3, and R4 are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynoyloxymethyl of 4-9 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio, of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsuphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carbalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, aminoalkyl of 1-4 carbon atoms, N-alkylaminoalkyl of 2-7 carbon atoms, N,N-dialkylaminoalkyl of 3-14 carbon atoms, phenylamino, benzylamino,


R5 is alkyl of 1-6 carbon atoms, alkyl optionally substituted with one or more halogen atoms, phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, nitro, cyano, or alkyl of 1-6 carbon atoms groups;

R6 is hydrogen, alkyl of 1-6 carbon atoms, or alkenyl of 2-6 carbon atoms;R7 is chloro or bromo;

R8 is hydrogen, alkyl of 1-6 carbon atoms, aminoalkyl of 1-6 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-12 carbon atoms, N-cycloalkylaminoalkyl of 4-12 carbon atoms, N-cycloalkyl-N-alkylaminoalkyl of 5-18 carbon atoms, N,N-dicycloalkylaminoalkyl of 7-18 carbon atoms, morpholino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, piperidino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, N-alkyl-piperidino-N-

alkyl wherein either alkyl group is 1-6 carbon atoms, azacycloalkyl-N-alkyl of 3-11 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-8 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms, chloro, fluoro, or bromo;

Z is amino, hydroxy, alkoxy of 1-6 carbon atoms, alkylamino wherein the alkyl moiety is of 1-6 carbon atoms, dialkylamino wherein each of the alkyl moieties is of 1-6 carbon atoms, morpholino, piperazino, N-alkylpiperazino wherein the alkyl moiety is of 1-6 carbon atoms, or pyrrolidino;m=1-4, q=1-3, and p=0-3;

any of the substituents R1, R2, R3 or R4 that are located on contiguous carbon atoms can together be the divalent radical –O–

C(R8)2 –O;--or a pharmaceutically acceptable salt thereof with the proviso that when Y is –


NH--, R1, R2, R3, and R4 are hydrogen, and n is 0, X is not 2-methylphenyl;

for the preparation of a medicament for treating or inhibiting colonic polyps in a

mammal susceptible to the formation of colonic polyps.

__________

151350]21][11[

מסויימים אירועים לזיהוי והתקן שיטהניידת תחנה ביישום

METHOD AND APPARATUS FOR A MOBILE STATION APPLICATION TO IDENTIFY SPECIFIED EVENTS

]54[

29.03.2001]22[US]33[30.03.2000]32[09/539495]31[

Int. Cl.8 H04B 007/26, H04L 012/56, 029/06]51[QUALCOMM INCORPORATED, U.S.A.

]71[




REHOVOT 76122

]74[

]57 [A method for a mobile station application to identify a plurality of specified events, the method comprising: communicating between a mobile station communication protocol stack and a communication network; communicating between the mobile station communication protocol stack and the mobile station

application through a mobile station application interface; enabling, by the mobile station application interface, at least one of the specified events based on the state of the mobile station application interface; and identifying, by the mobile station application, the specified events that are enabled.

__________June 5, 2008 –התשס"ח ב' בסיון 108

4

151417]21][11[

פירידין, פירימידין, פיראזין תולדות ותכשירי באריל המותמרות וטריאזיןאותן המכילים רוקחות

ARYL SUBSTITUTED PYRIDINE, PYRIMIDINE, PYRAZINE AND TRIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

]54[

12.03.2001]22[US]33[10.03.2000]32[60/188188]31[

Int. Cl.8 A61K 031/395, C07D 213/24, 213/60, 241/14, 251/14, 251/24]51[EURO-CELTIQUE S.A., LUXEMBOURG

]71[




]74[


or a pharmaceutically acceptable salt, ester, amide or solvate thereof, wherein :

Y is

provided that when Y is R7, R1 is aminocarbonyl ;

A1, A2 and A3 are independently CR2 or N, provided that A1, A2 and A3 are not all N at the same time;

R1 is selected from the group consisting of alkyl optionally substituted with halogen, halo (C1-6) alkyl, hydroxy (C1-6) alkyl,

amino (C1-6) alkyl, hydroxy, nitro, C1-6 alkyl, alkoxy, and amino, amino, alkylthio, C(O)R8, SO2R8, OC(O)NH2, 2-imidazolinyl, 2-imidazolyl, 3-pyrazolyl, 5-isoxazolyl, and 3-(1,2,4) – triazolyl; each R2 is selected from the group consisting of hydrogen, alkyl, alkenyl or alkynyl optionally substituted with halogen, halo


(C1-6) alkyl, hydroxy (C1-6) alkyl, amino (C1-6) alkyl, hydroxy, nitro, C1-6 alkyl, alkoxy, and amino, halogen, hydroxy, cycloalkyl, cyano, amino, alkylamino, dialkylamino, alkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aralkylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, and aralkylcarbonylamino; R3, R4, R5, and R6 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, haloalkyl, hydroxyalkyl, hydroxy, nitro, amino, cyano, amido, carboxyalkyl, alkoxyalkyl; ureido, acylamino, thio, acyloxy, azido, alkoxy, carboxy, carbonylamido and alkylthiol; R7 is alkyl optionally substituted with halogen, halo (C1-6) alkyl, hydroxy (C1-6) alkyl, amino (C1-6) alkyl, hydroxy, nitro, C1-6 alkyl, alkoxy, and amino;

R8 is selected from the group consisting of alkyl, alkenyl, alkynyl, OR9, amino ,

alkylamino, dialkylamino, alkenylamino, alkenylamino, dialkylaminoalkenyl, dialkylaminoalkylamino, dialkylaminoalkenylamino, alkylaminoalkenylamino, hydroxyaminoalkenylamino, cycloalkyl, heterocycloalkyl, cycloalkylalkyalmino, heterocycloalkylamino, aryl, arylalkyl, arylalkenyl, arylalkynyl, and arylalkylamino, all of which can be

optionally substituted with halogen, halo (C1-6) alkyl, hydroxy (C1-6) alkyl, amino (C1-6) alkyl, hydroxy, nitro, C1-6 alkyl, alkoxy, and amino, provided that R8 is not OR9 when R1 is SO2R8; whereinR9 is selected from the group consisting of hydrogen, alkyl optionally substituted with halogen, halo (C1-6) alkyl, hydroxy (C1-6) alkyl, amino (C1-6) alkyl, hydroxy, nitro, C1-6 alkyl, alkoxy, and amino, and an alkali metal; andX is one of O, S, NH, or CH2 when Y is other than R7; orX is one of O, S, NH, CH2 or absent when Y is R7;with the provisos that:

)1 (R2 is not methoxy if R5 is trifluromethyl, R6 is H, X is O and R1 is SO2CH2Ph;

)2 (R2 is not NH2 if R1 is methylthio, X is O and two of A1, A2 and A3 are N;

)3 (R2 is not methyl if R1 is SO2R8, wherein R8 is methylphenyl, R3 and R4 are methoxy, X is S and two of A1, A2 and A3 are N; or

)4 (R2 is not CCl3 if R1 is CCl3, X is S and two of A1, A2 and A3 are N;

)5 (R1 and R2 are not both NH2 if X is O or S and two of A1, A2 and A3 are N; or

)6 (R2 is not alkylcarbonylamino if R1 is NH2; X is O; R3, R4, R5 and R6 are each hydrogen; and A1 and A3 are N.

__________

151518]21][11[

–4,3,1 – – אלקוקסי5 – – פניל3 ושיטה מותמר – און2– אוקסדיאזול

להכנה

SUBSTITUTED 3-PHENYL- 5-ALKOXY- 1,3,4- OXDIAZOL-2 –ONE AND METHOD FOR ITS PREPARATION

]54[

20.02.2001]22[DE]33[07.03.2000]32[19910968.

3]31[

DE18.01.200110102265.4Int. Cl.8 A61K 031/4245, A61P 003/06, C07D 271/113, 413/12, 413/14]51[


SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY

]71[



P.O.B. 12688 ,HERZLIYA 46733

]74[


in which the meanings are:R1 C1-C6-alkyl, C3-C9-cycloalkyl, it being possible for both groups to be substituted one or more times by phenyl, C1-C4-alkyloxy, S-C1-C4-alkyl, N(C1-C4-alkyl)2, and for phenyl in turn to be substituted one or more times by halogen, C1-C4-alkyl, C1-C4-alkyloxy, nitro, CF3; andR2, R3, R4 and R5 independently of one another hydrogen, halogen, nitro, C1-C4-alkyl, C1-C9-alkyloxy;

C6-C10-aryl-C1-C4-alkyloxy, C6-C10-aryloxy, C6-C10-aryl, C3-C8-cycloalkyl or O-C3-C8-cycloalkyl, each of which may be substituted once, twice or three times by halogen, CF3, C1-C4-alkyloxy or C1-C4-alkyl;

2-oxopyrrolidin-1-yl, 2, 5-dimethylpyrrol-1-yl or NR6-A-R7, with the proviso that R2, R3, R4 and R5 are not simultaneously hydrogen, and at least one of the radicals R2, R3, R4 or R5 is the radical 2-oxopyrrolidin-1-yl, 2, 5-dimethylpyrrol-1-yl or NR6-A-R7, withR6 hydrogen, C1-C4-alkyl or C6-C10-aryl-C1-C4-alkyl, where aryl may be substituted by halogen, CF3, C1-C8-alkyloxy or C1-C4-alkyl;A a single bond, COn, SOn or CONH;

n 1 or 2;R7 hydrogen;

C1-C18-alkyl or C2-C18-alkenyl, each of which may be substituted once to three times by C1-C4-alkyl, halogen, CF3, C1-C4-alkyloxy, N(C1-C4-alkyl)2, -COOH, C1-C4-alkyloxycarbonyl, C6-C12-aryl, C6-C12-aryloxy, C6-C12-arylcarbonyl, C6-C10-aryl-C1-C4-alkyloxy or oxo, where aryl in turn may be substituted by halogen, C1-C4-alkyl, aminosulfonyl or methylmercapto;

C6-C10-aryl-C1-C4-alkyl, C5-C8-cycloalkyl-C1-C4-alkyl, C5-C8-cycloalkyl, C6-C10-aryl-C2-C6-alkenyl, C6-C10-aryl, diphenyl, diphenyl-C1-C4-alkyl, indanyl, each of which may be substituted once or twice by C1-C18-alkyl, C1-C18-alkyloxy, C3-C8-cycloalkyl, COOH, hydroxyl, C1-C4-alkylcarbonyl, C6-C10-aryl-C1-C4-alkyl, C6-C10-aryl-C1-C4-alkyloxy, C6-C10-aryloxy, nitro, cyano, C6-C10-aryl, fluorosulfonyl, C1-C6-alkyloxycarbonyl, C6-C10-arylsulfonyloxy, pyridyl, NHSO2-C6-C10-aryl, halogen, CF3 or OCF3, where alkyl may be substituted again by C1-C4-alkyloxycarbonyl, CF3 or carboxyl, and aryl by halogen, CF3 or C1-C4-alkyloxy; or the group Het-(CH2)r-, with r=0, 1, 2 or 3 and Het = saturated or unsaturated 5-7-


membered heterocycle which may be benzo-fused and substituted by C1-C4-alkyl, C6-C10-aryl, halogen, C1-C4-alkyloxy, C1-C4-alkyloxycarbonyl, C6-C10-aryl-C1-C4-alkyl, C6-C10-aryl-C1-C4-alkylmercapto or nitro, where benzo-fused

aryl may in turn be substituted by halogen, C1-C4-alkyloxy or CF3 and alkyl in arylalkyl by methoxy and CF3, and the pharmacologically suitable salts and acid addition salts thereof.

__________

151592]21][11[

משתנה אופטי כוח בעלות משקפיים אופטי כוח לבקרת ושיטה הראיה לשיקום

העדשה של

VARIABLE OPTICAL POWER SPECTACLES FOR EYESIGHT REHABILITATION AND METHODS FOR LENS OPTICAL POWER CONTROL

]54[

04.09.2002]22[Int. Cl.8 G02C 007/00]51[

בקרמן, חיפה יוסףבקרמן, חיפה אנטולי

JOSEF BEKERMANANATOLY BEKKERMAN

]71[

( בע"מ,1992) כלכלי וייעוץ גולד-פטנטים, חיפה43 רובינשטיין

GOLD-PATENTS & FINANCIAL SERVICES LTD,.

43 RUBINSTEIN ST,.HAIFA 34987

]74[

]57 [Eyesight rehabilitation optical device for improving the eyesight of a user, said optical device comprises: at least one liquid lens (14) of two liquid lenses, each liquid lens comprises two juxtaposed transparent membranes (20) that confine an amount of transparent liquid in a gap (22) between said two juxtaposed transparent membranes, wherein at least one of said two juxtaposed transparent membranes is an elastic membrane having changeable curvature that changes upon change in the amount of transparent liquid; a rim (12) for supporting said at least one liquid lens of two liquid lenses opposite an eye of the user; two shafts (16) provided on said rim, wherein at least one shaft of said two shafts is provided with a cavity (27) that is fluidically connected to said

gap in the liquid lens that resides next to said at least one shaft, and wherein said cavity is provided with additional transparent liquid; a flexible container (25) that is connected to said at least one shaft, wherein said flexible container is fluidically connected to said cavity; whereby portions of said additional transparent liquid adds up to the amount of transparent liquid in the gap between said two juxtaposed transparent membranes upon changes in the inclination of the two shafts from substantially horizontal position to a position in which the liquid lens is downwardly moved, and wherein when the user wears the optical device and inclines his head forwards, the curvature of the liquid lens is changed while rendering the liquid lenses autofocus features.


_________

151626]21][11[

להכנתן, קווינאזולין, תהליך תרכובות אותן המיכלים רוקחות תכשירי

ליצירת תרופות בייצור בהן והשימוש ו/או היווצרותכלי–דם נוגדת השפעה כלי–דם חדירות המפחיתה השפעה

חם דם בעלת בחיה

QUINAZOLINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS FOR THE PRODUCTON OF AN

]54[


ANTIANGIOGENIC AND /OR VASCULAR PERMEABILITY REDUCING EFFECT IN A WARM-BLOODED ANIMAL

03.04.2001]22[EP]33[07.04.2000]32[00400967.

6]31[

EP07.04.200000400968.4EP13.04.200000401034.4EP13.04.200000401033.6

Int. Cl.8 A61K 031/505, A61P 035/00, C07D 239/94, 403/00, 417/02]51[ASTRAZENECA AB, SWEDEN]71[WO/2001/077085]87[

ושות', ש. הורוביץ , תל41-45 רוטשילד ציון, שדרות בית

אביב


41-45 ROTHSCHILD BLVD,.TEL AVIV 65784

]74[


]wherein:ring A is phenyl;Z is –O-, -NH- or –S;-

m is an integer from 0 to 5 inclusive;R1 is hydrogen, hydroxy, halogen, nitro, trifluormethyl, cyano, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylthio, or –NR5R6 (wherein R5 and R6, which may be the same or different, are hydrogen or C1-3 alkyl); R2 is hydrogen, hydroxy, halogeno, C1-3 alkyl, C1-3 alkoxy, trifluoromethyl, amino or nitro; R3 is hydroxy, halogeno, C1-3 alkyl, C1-3 alkoxy, C1-3 alkanoyloxy, trifloromethyl, cyano, amino or nitro;

X1 is –O-, -CH2-, -S-, -SO-, -SO2-, NR7-, -NR7CO-, -CONR7-, -SO2NR7 – OR –NR7SO2-, (wherein R7 is hydrogen, C1-3 alkyl or C1-3 alkoxy C2-3 alkyl);

R4 is selected from one of the following groups:

)1– (Y1X2COR8 [wherein –Y1 – is a C2-5 alkylene chain wherein each methylene group (other than that of the α-carbon) is optionally substituted by 1 substitutuent independently selected from hydroxy, halogeno, amino and C1-4 alkanoyloxy, provided that there is at least 1 and no more than 3 substituents on the C2-5


alkylene chain; X2 is –O- or –NR9- (in which R9 is hydrogen, C1-3 alkyl or C1-3 alkoxy C2-3 alkyl) and R8 is C1-3 alkyl, -NR10R11 or –OR12 (wherein R10, R11 and R12, which may be the same or different, are hydrogen, C1-3 alkyl or C1-3 alkoxy C2-3 alkyl)];

)2– (Y2-X3R13 [wherein –Y2- is C2-5 alkylene, C3-5 alkenylene or C3-5 alkynylene wherein each methylene group (other than that of the α-carbon) is optionally substituted by 1 substituent independently selected from hydroxy, halogeno, amino and C1-4 alkanoyloxy, provided that there is at least 1 substituent and no more than 3 substituents on the alkylene, alkenylene or alkynylene chain; X3 is –O-, -S-, -SO-, -SO2-, -OCO-, NR7CO-, -CONR7-, SO2NR7- -NR7SO2 – or –NR7 – (wherein R7 is as herein defined) and R13 is hydrogen or C1-3 alkyl, wherein the C1-3 alkyl group may bear one or two substituents selected from oxo, hydroxy, halogeno and C1-4 alkoxy];

)3– (Y1-X6C1-5 alkylR14 [wherein Y1 is as herein defined and X6 is –O-, -S-, -SO-, -SO2-; -NR7CO-, -CONR7-, -SO2NR7-m –NR7SO2 or –NR7 – (wherein R7 is as herein defined ) and R14 is C3-7 cycloalkyl or a 3 to 7 membered saturated or partially saturated heterocyclic group containing up to 3 ring heteroatoms selected independently from O, S and N, wherein the carbocyclic or heterocyclic group is optionally substituted by one or two substituents selected from oxo, hydroxy, halogeno, C1-4 alkyl, (wherein the C1-4 alkyl group is optionally substituted by 1 or 2 substituents selected from hydroxy, cyano, halogeno, amino, nitro, morpholino, C3-5 cycloalkyl, piperidin-1-yl), C2-4 alkenyl, C2-4 alkynyl, C1-4 hydroxyalkyl, C1-4 alkoxy, carbamoyl, C1-3 alkylcarbamoyl, N,N-di(C1-3 alkyl) carbamoyl, C2-4 alkanoyl, C1-4 alkoxycarbonyl, C1-4 alkylthio, C1-4 alkylsulphinyl, C1-4 alkylsulphonyl, C2-4 alkanoylamino, N-C1-3 alkyl-C2-4 alkanoylamino,

N-C1-3 alkylsulphamoyl, N,N-di-[C1-3 alkyl] sulphamoyl, C1-3 alkanesulphonylamino and N-C1-3 alkyl-C1-

3 alkanesulphonylamino, or R14 is a pyridone group, a phenyl group or a 5 or 6-membered aromatic heterocylic group containing 1 to 3 ring heteroatoms independently selected from O, N and S, and wherein the pyridone, phenyl or heterocyclic group is optionally substituted by up to 5 substituents selected from halogeno, amino, C1-4 alkyl, C1-4 alkoxy, C1-4 hydroxyalkyl, C1-4 hydroxyalkyl, C1-4

aminoalkyl, C1-4 alkylamino, C1-4

hydroxyalkoxy, carboxy, cyano, C1-4

alkylthio, C1-4 alkylsulphinyl, C1-4

alkylsulphonyl, N-C1-3 alkylsulphamoyl, N, N-di-[C1-3 alkyl] sulphamoyl, C1-3 alkanesulphonylamino, N-C1-3 alkanesulphonylamino, -CONR10R11 and –NR10COR11 (wherein R10 and R11 are as

herein defined);[)4– (Y1-X4C1-5 alkyl X5X15 [wherein Y1 is

as herein defined and X4 and X5 which may be the same or different are each –O-, -S-, -SO-, -SO2-, -NR7CO-, -CONR7-, -SO2NR7-, -NR7SO2-or –NR7-(wherein R7 is as herein defined and R15 is hydrogen or C1-3 alkyl)];

)5– (Y1-O-C1-3 alkyl (wherein Y1 is as herein defined) provided that X1 is –O-, -

S-, -SO- or –SO2;-)6– (Y2-R16 (wherein –Y2- is as herein

defined and R16 is a saturated or partially saturated 3 to 7 membered heterocyclic ring containing up to 3 heteroatoms selected from O, S and N [wherein the heterocylic ring is optionally substituted by up to 3 substituents selected from oxo, hydroxy, halogeno, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl and C3-7 cycloalkyl (wherein C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl and C3-

7 cycloalkyl are themselves optionally substituted by up to 3 substituents selected from hydroxy, halogeno, cyano, C1-3 alkyl, C1-3 alkoxy, C1-3 alkanoyloxy, trifluoromethyl, amino, nitro and R14 as herein defined), C1-4 alkoxy, carbamoyl,


C1-4 alkylcarbamoyl, N-N-di(C1-4 alkyl) carbamoyl, C2-4 alkanoyl, C1-4 alkoxycarbonyl, C3-7 cycloalkyl, C1-4 alkylthio, C1-4 alkylsulphinyl, C1-4 alkylsulphonyl, C2-4 alkanoylamino, N-C1-3 alkyl-C2-4 alkanoylamino, N-C1-3 alkylsulphamoyl, N,N-di-[C1-3 alkyl] sukphamoyl, C1-3 alkanesulphonylamino and N-C1-3 alkyl-C1-3 alkanesulphonylamino] or R16 is a pyridone group, a phenyl group or a 5 or 6-membered aromatic heterocyclic group containing 1 to 3 ring heteroatoms independently selected from O, N and S, and wherein the pyridone, phenyl or heterocylic group is optionally substituted by up to 5 substituents selected from halogeno, amino, C1-4 alkyl, C1-4 alkoxy, C1-4 hydroxyalkyl, C1-4 aminoalkyl, C1-4 alkylamino, C1-4 hydroxyalkoxy, carboxy, cyano, C1-4 alkylthio, C1-4 alkylsulphinyl, C1-4 alkylsulphonyl, N-C1-3 alkylsulphamoyl, N,N-di-[C1-3 alkyl] sulphamoyl, C1-3 alkanesulphonylamino, N-C1-3 alkyl-C1-3 alkanesulphonylamino, -CONR10R11 and –NR10COR11 (wherein R10

and R11 are as herein defined);[)7– (Y2-X6-R14 (wherein Y2, X6 and R14 are

as herein defined); and)8– (Y2-NR17R18 [wherein Y2 is as herein

defined and R17 and R18 are independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or C1-3 alkoxy C1-6 alkyl (wherein any alkyl group in R17 or R18 is optionally substituted by up to 2 substituents selected from hydroxy, halogeno, C1-3 alkyl, C1-3 alkoxy, C1-3 alkanoyloxy, trifluoromethyl, cyano, amino or nitro)];provided that when:m is an integer from 1 to 3;R1 is methoxy; R2 is hydrogen; Z is –NH;-

R3 is halogeno or C1-3 alkyl; andX1 is –O-; thenR4 is not selected from one of the following three groups:

)a– (C2-5 alkyl R19 (wherein R19 is piperidin-4-yl which may bear one or two

substituents selected from hydroxy, halogeno, C1-4 alkyl, C1-4 hydroxyalkyl and C1-4 alkoxy);

) b– (C2-5 alkenyl R19 (wherein R19 is as defined herein);

)c– (C2-5 alkynyl R19 (wherein R19 is as defined herein);

wherein any alkylene, alkenylene or alkynylene chain in groups (a) to (c) above are optionally substituted by one or more substituents selected from hydroxy, halogeno and amino]; or a salt thereof.


__________

151672]21][11[

אינפרא מונחי טילים מפני הגנה מערכתאדום

PROTECTION SYSTEM AGAINST INFRA-RED GUIDED MISSILES

]54[

10.09.2002]22[Int. Cl.8 F41H 011/02]51[



]71[

]PATRICK BAR-AVI, ARYE PICK]72פיק בר-אבי, אריה פטריקבע"מ, פרידמן מרק ד"ר

ז'בוטינסקי , רח54אביב, ק. משה מגדל , רמת- גן7

DR. MARK FRIEDMAN LTD,. MOSHE AVIV TOWER, 54TH

FLOOR ,7 JABOTINSKY ST ,.

RAMAT GAN 52520

]74[

]57 [A system for illuminating and thereby defeating an infrared guided threat (18) to an aircraft comprising:

)a (at least two non-laser light sources (58);

)b (a trigger configured to activate said at least two non-laser light sources to generate at least two light beams, said light beams overlapping to produce a composite

beam (72) of enough illumination power density to jam or destroy an infrared seeker of the infrared guided threat; and

)c (a DIRCM control system (24), configured to aim said composite beam at the infrared guided threat, thereby illuminating the infrared guided threat with said composite beam thereby jamming or destroying said infrared seeker.


___________

151706]21][11[

כללית קריאה הודעת של דינמית הכרהריקה

DYNAMIC RECOGNITION OF AN EMPTY GENERAL PAGING MESSAGE

]54[

30.03.2001]22[US]33[31.03.2000]32[09/540797]31[

Int. Cl.8 H04B 001/707, 007/26, H04Q 007/32, 007/38]51[QUALCOMM INCORPORATED, U.S.A.

]71[




REHOVOT 76122

]74[

]57 [A method for use by a remote unit in a wireless communication system of processing base station signals, comprising: receiving raw data samples of a message from a base station; decoding said raw data samples to obtain decoded

data samples; comparing said decoded data samples with a reference pattern before said decoded data samples are parsed; determining the contents of said message as the reference pattern in a memory.


__________

151708]21][11[

חיפוש חלון גודל של דימוי כוונוןהסיגנל לכוח בתגובה

DYNAMIC ADJUSTMENT OF SEARCH WINDOW SIZE IN RESPONSE TO SIGNAL STRENGTH

]54[

30.03.2001]22[US]33[31.03.2000]32[09/540922]31[

Int. Cl.8 H04B 001/707, H04Q 007/38]51[QUALCOMM INCORPORATED, U.S.A.

]71[




REHOVOT 76122

]74[

]57 [A method for determining a size of a search window, the method comprising: measuring a strength of a PN encoded signal transmitted by a preferred base station; selecting the size of the search

window based on said strength of said PN encoded signal; and searching for a PN encoded signal transmitted by a neighboring base station by using the search window.


__________

151834]21][11[

לגוף המאפשר בגדים לאוורור מכשירהמכשיר לייצור ושיטה לנשום האדם

CLOTHING VENTILATION DEVICE ALLOWING THE HUMAN BODY TO BREATHE AND METHOD FOR PRODUCING THE DEVICE

]54[

18.01.2002]22[IT]33[24.01.2001]32[PD01A000016]31[

Int. Cl.8 A41D 027/28]51[GEOX S.P.A., ITALY]71[WO/2002/058494]87[




]74[

]57 [A ventilation device to be applied to items of clothing in order to allow the human body to breathe, comprising:

an assembly with through holes (12), composed of an outer band (13) of material that is at least partially transparent and

impermeable provided to be arranged externally with respect to the human body, and a membrane (16) which is impermeable to water and permeable to vapor, provided for being arranged internally towards the human body,


characterized in that said assembly further comprises a layer provided to be placed in view and made of natural or synthetic fabric, natural or synthetic leather, and at least one layer of adhesive polymeric

material for mutually joining said outer band and said layer to be placed in view, said membrane being sealed at least perimetrically to said assembly on the side of said layer to be placed in view.

__________

152107]21][11[

]STENT FABRICATION METHOD]54סטנט לייצור שיטה

29.06.1997]22[US]33[30.10.1996]32[08/742422]31[

Int. Cl.8 A61F 002/06]51[DIVISION FROM 121186]62[

]MEDINOL LTD.]71בע"מ, תל-אביב מדינול עורכי – דין עורכי מהולל – איתן קבוצת


הרצליה



]74[

]57 [A sheet for fabricating a stent having a longitudinal lumen having a longitudinal axis comprising:

)a (a flat piece of metal provided with a plurality of stent patterns, each of said patterns comprising a plurality of flexible connected cells (50), each of said flexible cells comprising:

)a (a first member (51) having a longitudinal component (77) having a first

end and a second end (61) ;)b (a second member having a longitudinal

component (78) having a first end and a second end (62) ;

)c (a third member having a longitudinal component having a first end and a second end;


)d (a fourth member (60) having a longitudinal component having a first end and a second end;

)e (a first loop defining a first angle disposed between said first end of said member and said first end of said second member;

)f (a second loop defining a second angle disposed between said second end of said third member and said second end of said fourth member, and disposed generally opposite to said first loop;

)g (a first flexible compensating member having a first end and a second end disposed between said first member and said third member, said first end of said first flexible compensating member communicating with said second end of said first member and said second end of said first flexible compensating member communicating with said first end of said third member, said first and said second ends disposed a variable longitudinal distance from each other;

)h (a second flexible compensating member having a first end and a second end disposed between said second member and said fourth member, said first end of said second flexible compensating member communicating with said first end of said fourth member, said first and said second ends disposed a variable longitudinal distance from each other, said first and said second flexible compensating member differentially expandable or compressible when said stent is bent in a curved direction away from said longitudinal axis of said lumen; and

)i (said first, said second, said third, and said fourth members and said first and said second loops, and said first and said second flexible compensating members disposed so that as said stent is expanded the distance between said first and said

second flexible compensating member increases and the longitudinal component of said first, second, third and fourth members decreases while said first and said second loops remain generally opposite to one another, the ends of said first and said second flexible compensating member open so as to increase said variable longitudinal distance between said first and said second ends of said first flexible compensating member and so as to increase said variable longitudinal distance between said first and said second ends of said second flexible compensating member so as to compensate for the decreasing of the longitudinal component of said first, second, third, and fourth members and substantially lessen the foreshortening of said stent upon its expansion; each of said plurality of stent patterns having a first long side and a second long side, said first long side provided with a plurality of pairs of engagement trough, said second long side provided with a plurality of pairs of engagement protrusions, said plurality of pairs of engagement troughs and said plurality of pairs of engagement protrusions disposed substantially opposite each other, each of said plurality of pairs of said engagement troughs comprising a first engagement trough and a second engagement trough, said engagement troughs sized and disposed to receive and engage said engagement protrusions when said sheet is deformed and rolled into a tubular shape, each pair of said engagement troughs provided with a bridge disposed between said first engagement trough and said second engagement trough, wherein said first loop, said second loop, said first compensating member, and said second compensating member are wider than said first, second, third and fourth members.


_________

152109]21][11[

]STENT FABRICATION METHOD]54סטנט לייצר שיטה

29.06.1997]22[US]33[30.10.1996]32[08/742422]31[

Int. Cl.8 A61F 002/06]51[DIVISION FROM 121186]62[

]MEDINOL LTD.]71בע"מ, תל-אביב מדינול - עורכי דין עורכי - מהולל איתן קבוצת


הרצליה



]74[

]57 [An expandable stent having a longitudinal lumen having a longitudinal axis comprising:

a stent pattern comprising a plurality of flexible connected cells (50), each of said flexible cells comprising:

)a (a first member having a longitudinal component (77) having a first end and a second end;

)b (a second member having a longitudinal component (78) having a first end and a second end;

)c (a third member having a longitudinal component having a first end and a second end;

)d (a fourth member (60) having a longitudinal component having a first end and a second end;

)e (a first loop defining a first angle disposed between said first end of said first member and said first end of said second member;

)f (a second loop defining a second angle disposed between said second end of said third member and said second end of said fourth member, and disposed generally opposite to said first loop;

)g (a first flexible compensating member or flexible link (67) having a first end a second end disposed between said first member and said third member, said first end of said first flexible compensating member or flexible link communicating with said second end of said first member and said second end of said first flexible compensating member or flexible link communicating with said first end of said third member, said first and said second ends of said first flexible compensating


member or flexible link disposed a variable longitudinal distance from each other;

)h (a second flexible compensating member or flexible link having a first end and a second end disposed between said second member and said fourth member, said first end of said second flexible compensating member or flexible link communicating with said second end of said fourth member, said first and said second ends of said second flexible compensating member or flexible link disposed a variable longitudinal distance from each other, said first and said second flexible compensating members or flexible links differentially extendable or compressible when said stent is bent in a curved direction away from the longitudinal axis of said longitudinal lumen; and

)i (said first, said second, said third, and said fourth members and said first and said second loops, and said first and said second flexible compensating members or flexible links disposed so that as said stent is expanded the distance between said first and said second flexible compensating members or flexible links increases and the longitudinal component of said first, second, third, and fourth members decreases while said first and said second

loops remain generally opposite to one another, the ends of said first and said second flexible compensating members or flexible links open so as to increase said variable longitudinal distance between said first and said second ends of said first flexible compensating member or flexible link and so as to increase said variable longitudinal distance between said first and said second ends of said second flexible compensating member or flexible link so as to compensate for the decreasing of the longitudinal component of said first, second, third, and fourth members and substantially lessen the foreshortening of said stent upon its expansion;

said stent pattern having a first long side and a second long side, said first long side provided with a plurality of pairs of engagement troughs, said second long side provided with a plurality of pairs of engagement protrusions, said plurality of pairs of engagement troughs and said plurality of pairs of engagement protrusions disposed substantially opposite each other, each of said plurality of pairs of said engagement troughs comprising a first engagement trough and a second engagement trough, said engagement troughs attached to said engagement protrusions.

____________


152132]21][11[

DIRECTORY SEARCHINGבספריה לחיפוש ומערכות שיטותMETHODS AND SYSTEMS

]54[

06.04.2001]22[AU]33[07.04.2000]32[PQ6785]31[

Int. Cl.8 G06F 017/30]51[COMPUTER ASSOCIATES THINK, INC., U.S.A.

]71[




BEER-SHEVA 84152

]74[

]57 [A method of arranging and searching for data in a database comprising: creating a first table for storing data comprising at least one data entry, the data entry comprising a plurality of data components, the first table comprising one row for each data entry; and creating a second table for storing the plurality of data components of the data entry of the first table, the second table comprising one row for each of the

plurality of data components of the data entry of the first table; and searching the rows of the second table to identity a particular one of the plurality of data components; and returning the given data entry from the first table that includes the particular one of the plurality of data components in response to identifying the particular one of the plurality of data components in the second table.


____________

152238]21][11[

מסנן בחומר לטיפול ותהליכים תכשיריםמשופרת סינון ליעילות

COMPOSITIONS AND PROCESSES FOR TREATING FILTER MATERIAL FOR IMPROVED FILTRATION EFFICIENCY

]54[

30.04.2001]22[US]33[28.04.2000]32[60/200343]31[

Int. Cl.8 B01D 039/00, C08F 251/02, C08J 007/00, C08K 003/20]51[PURADYN FILTER TECHNOLOGIES INCORPORATED, U.S.A.

]71[

MOHAN L. SANDUJA, CARL HOROWITZ, LINA ZILBERMAN, PAUL THOTTATHIL

]72[





JERUSALEM 91450

]74[

]57 [A coating composition for the chemical grafting of an oil, fuel, coolant or air filter material, the composition comprises: about 30-50% by weight of an aqueous acrylic resin wherein the aqueous acrylic resin is an acrylic copolymer, about

3-11% by weight of a high molecular weight silicone in an aqueous suspension, about 20-40% by weight of deionizied, distilled or otherwise pure water, about 5-16% by weight of a binder, about less than 1% by weight of a catalyst, and about less than 1% by weight of a graft initiator.

_________

152248]21][11[

–b8ב– מותמרים אסטראטריאנים כאסטרוגנים לשימוש הידרוקרביל

יחודיים

8 BETA – HYDROCARBYL-SUBSTITUTED ESTRATRIENES FOR USE AS SELECTIVE ESTROGENS

]54[

12.04.2001]22[DE]33[12.04.2000]32[10019167.

3]31[

US26.05.200060/207370Int. Cl.8 A61K 031/565, A61P 005/30, C07J 001/00, 041/00]51[


BAYER SCHERING PHARMA AG, GERMANY

]71[





TEL AVIV 61040

]74[

]57 [8β-Substituted estra-1,3,5(10)-triene derivatives of the formula

in whichR2 means a hydrogen atom, a halogen atom; a radical R18 – or R18-O-, whereby R18 means a hydrogen atom or a straight-chain or branched-chain, saturated or unsaturated hydrocarbon radical with up to 6 carbon atoms, a trifluoromethyl group; a group R19SO2-O-, in which R19 is an R20R21N group, whereby R20 and R21, independently of one another, mean a hydrogen atom, a C1-C5-alkyl radical, a group C(O)R22, in which R22 represents an optionally substituted, straight-chain or branched-chain, saturated or unsaturated in up to three places, optionally partially or completely halogenated hydrocarbon radical with up to 10 carbon atoms, an optionally substituted C3-C7-cycloalkyl radical, an optionally substituted C4-C15-cycloalkylalkyl radical or an optionally substituted aryl, heteroaryl or aralkyl radical, or, together with the N-atom, means a polymethylenimino radical with 4 to 6 C atoms or a morpholino radical; R3 means a group R18-O-, R19SO2-O or –O-

C(O)R22, with R19 and R22 in each case in the meaning that is indicated under R2, whereby a hydrogen atom, a trifluoromethyl group, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, heptyl or hexyl radical, or an aryl, heteroaryl or aralkyl radical can stand for R18; R6 and R7 each means a hydrogen atom or together an additional bond; R6 and R7, independently of one another, mean a hydrogen atom, a halogen atom, a group R18-O-R19SO2-O- or R22, with R18, R19 and R22 in each case in the meaning that is indicated under R2;

R8 means a straight-chain or branched-chain, optionally partially or completely halogenated alkyl or alkenyl radical with up to 5 carbon atoms, an ethinyl or prop-

1-inyl radical;R9 means a hydrogen atom, a straight-chain or branched-chain, saturated or unsaturated hydrocarbon radical with up to 5 carbon atoms, or together with R11 means an additional bond; R11 means a hydrogen atom or together with R9 or together with


R12 means an additional bond; R11 means a hydrogen atom, a halogen atom, a saturated or unsaturated, optionally partially or completely halogenated hydrocarbon radical, which has a maximum linear chain length of 4 carbon atoms, or a group –X-R18, in which X is an oxygen or sulfur atom, and R18 is an alkyl radical with 1 to 3 carbon atoms;

R12 means a hydrogen atom or together with R11 means an additional bond;


R15 means a hydrogen atom or together with R14 or together with R16 means an additional bond;


R15' and R16', independently of one another, means a hydrogen atom, a halogen atom, a group R18-O-, R19SO2-O-, R19SO2-O- or –R22, with R18, R19 and R22 in each case in the meaning that is indicated under R2;

R17 and R17' each mean a hydrogen atom; a hydrogen atom and a halogen atom; a hydrogen atom and a benzyloxy group; a hydrogen atom and a group R19SO2-O-; a group R18 and a group –C(O)R22 or –O-C(O)R22; a group R18-O- and a group R18-; a group R18-O- and a group –O-C(O)R22, in all above cases with R18, R19 and R22 in each case in the meaning that is indicated under R2; orR17 and R17' together mean a group =CR23R24, in which R23 and R24, independently of one represent a hydrogen atom and a halogen atom, or together an oxygen atom; excluding the compounds of general formula (I)', in which

R3 is a hydroxy, or acetyl group, and simultaneouslyR2 represents a hydrogen atom,R6, R6', R7 and R7' in each case represent a hydrogen atom;R8 represents a methyl group,R9 represents a hydrogen atom orR9 and R11 together represent an additional bond,R11' and R12 in each case represent a hydrogen atom,R14, R15, R15', R16 and R16' in each case represent a hydrogen atom, andR17 and R17' for a β-(2-bromoacetyl) oxy group and a hydrogen atom; for a β-acetyl group and a hydrogen atom; orR17 and R17' together represent an oxygen atom,wherein:

a C4-C15-cycloalkylalkyl radical has 3 to 7 carbon atoms in the cycloalkyl portion; and the alkyl portion has up to 8 carbon atoms; an aryl radical is a phenyl, 1- or 2-naphthyl radical or a heteroaryl radical; an aralkyl radical is a radical that contains in the ring up to 14, preferably 6 to 10 C atoms and in the alkyl chain 1 to 8 C atoms;

the alkyl groups or hydrocarbon radicals can be partially or completely fluorinated or substituted by 1-5 halogen atoms, hydroxy groups or C1-4-alkoxy groups; one or more hydroxyl groups at C atoms 3, 16 and 17 can be esterified with an alphatic, straight-chain or branched-chain, saturated or unsaturated C1-14 mono- or polycarboxylic acid or an aromatic carboxylic acid or with an α-or β-amino acid.

___________

152301]21][11[

SPACE WEATHER PREDICTIONבחלל אוויר מזג לחיזוי ושיטה מערכתSYSTEM AND METHOD

]54[

18.04.2001]22[US]33[18.04.2000]32[552161]31[


Int. Cl.8 G01W 001/10, G06F 019/00]51[CARMEL SYSTEMS LLC, U.S.A.]71[





TEL AVIV 61040

]74[

]57 [A system for predicting space weather comprising:

)a (a source of current solar energetic particle data;

)b (a processor capable of accessing the data source, wherein the processor predicts

a space weather event based on recognizing a complex pattern in the current solar energetic particle data, the pattern being derived from three or more historical solar energetic particle measurements.

__________

152323]21][11[

בעלי עבר מכל העוטפים חוטים שרווליליצורם ושיטות התרחבות יכולת

WRAP-AROUND CABLE SLEEVES HAVING AN EXPANDABLE BODY PORTION AND METHODS OF MAKING SAME

]54[

18.04.2001]22[US]33[24.04.2000]32[556230]31[

Int. Cl.8 H02G 015/02]51[TYCO ELECTRONICS CORPORATION, U.S.A.

]71[


5


אביב



TEL AVIV 61040

]74[

]57 [A wrap-around cable sleeve for environmentally sealing a cable section, said wrap-around cable sleeve comprising: a longitudinally extending body comprising an electrically insulating material and having a longitudinally extending portion with a corrugated lateral cross-section; wherein the longitudinally extending portion has a flexural modulus of between about 4,000 and 100,000 psi;

wherein the longitudinally extending portion defines a portion of a cable chamber, wherein the cable chamber extends at least substantially around the cable section when the body is wrapped around the cable section; and wherein the cable chamber has a range taking in a radial direction of at least about 15 percent.

_________

152712]21][11[

מהירה קצב להתאמת והתקן שיטה קצב בעל נתונים בשידור סגור במעגל

מארזים של גבוה

METHOD AND APPARATUS FOR FAST CLOSED-LOOP RATE ADAPTATION IN A HIGH RATE PACKET DATA TRANSMISSION

]54[

11.05.2001]22[US]33[12.05.2000]32[09/570210]31[

Int. Cl.8 H04L 012/56, H04Q 007/22]51[QUALCOMM INCORPORATED, U.S.A.

]71[




REHOVOT 76122

]74[


]57 [An apparatus for adjusting an open loop rate control process, comprising: an estimation element at the access terminal for determining a quality value associated with a forward link channel; an open loop rate control element coupled to the estimation element for generating a plurality of data rate request messages, wherein the open loop rate control element uses the quality value received from the estimation element for determining the contents of the plurality of data rate request messages; a closed loop rate

control element and a decoder for generating a plurality of indicator messages based on either the quality value from the estimation element or an error value from the decoder, wherein the decoder is configured to decode a plurality of interleaved data slots and gap slots received on the forward link channel; a controller coupled to the decoder and the estimation element for enabling the closed loop rate control element in accordance with a set of threshold values.



____________

152966]21][11[

עקיבת מערכת הכולל רמונים מטולמשופרת מטרה

GRENADE LAUNCHER WITH ENHANCED TARGET FOLLOW-UP SYSTEM

]54[

20.11.2002]22[Int. Cl.8 F41G 005/00]51[

בע"מ, לחימה אמצעי לפיתוח רשות רפא"לחיפה

RAFAEL ARMAMENT DEVELOPMENT AUTHORITY LTD.

]71[

EYAL BERKOVICH, SHIMONחכמיאן ברקוביץ', שמעון אילCHACHAMIAN

]72[


צביון, יורם , ת.ד. התעשיה , פארק2 רח' הטוחן

, פרדס-חנה3148

YORAM TSIVION, 2 HATOHEN ST,.

P.O.B. 3148,PARDESS HANA 38900

]74[

]57 [A system for enhancing target follow-up by a gunner of an automatic grenade launcher (AGL), comprising: a system-mount (54); said AGL cradle (46); an axle (50) for vertically rotating said cradle; an electric motor (52) for providing torque to said axle; said AGL-sight borne

by a sight-mount; a mount-break means for freezing the vertical angle of said sight-mount with respect to said system-mount, and a disengageable linear lock (64) for fixing a vertical angular movement of said sight to said AGL cradle.

___________

____________

153162]21][11[

ממוגרפיה תמונות לניתוח עבודה תחנתממוחשב

WORKSTATION FOR COMPUTERIZED

ANALYSIS IN MAMMOGRAPHY

]54[

28.11.2002]22[Int. Cl.8 A61B 006/00, G06K 009/00]51[

בע"מ, דיאגנוסיס איידד קומפיוטר סימנסירושלים

SIEMENS COMPUTER AIDED DIAGNOSIS LTD.

]71[

במברגר, יעקב נתן לייכטר, פיליפ יצחקמרלה

ISAAC LEICHTER, PHILIPPE NATHAN BAMBERGER, NICOLAS J. MERLET

]72[

ושות' בע"מ, מ. בן-דוד ירמיהו ,45087, ת.ד. חוצבים המרפא, הר רחוב

ירושלים



JERUSALEM 91450

]74[


]57 [A method of separating and collating mammogram records, said method including the steps of: scanning at least one radiological film mammogram (420) relating to a patient thereby to obtain at least one digitized image of the at least one film mammogram; storing the at least one digitized image in a memory (425); providing and scanning a separator film having identifiable features which when scanned identify the film as a separator film (440), and including positioning the

separator film immediately after the at least one radiological film of a patient; and repeating said steps of scanning, storing, and providing for the remaining film mammorgrams of N patients in a film mammogram queue, where N≥1; wherein the digitized images generated subsequent to each scanned separator film are stored separately from the stored digitized images obtained from prior scanned film mammograms.

__________

153208]21][11[

ROLLING RAZOR AND SHAVINGגילוח ושיטת מסתובב גילוח סכיןMETHOD

]54[


01.06.2001]22[US]33[23.06.2000]32[09/603816]31[

Int. Cl.8 B26B 021/52]51[ROLLING RAZOR, INC., U.S.A.]71[




REHOVOT 76122

]74[

]57 [A shaving razor comprising: a first set of blades having a face defining a first plane; a second set of blades having a face defining a second plane; a short neck with a first end coupled to a shaving head and a

second end, the first and the second set of blades coupled to the shaving head; and an open cylindrically shaped handle affixed to the second end of the short neck.

___________

153231]21][11[

]WET MILLING PROCESS]54רטובה לטחינה תהליך

22.06.2001]22[GB]33[28.06.2000]32[0015856.8]31[GB22.05.20010112496.5

Int. Cl.8 A61K 009/00]51[SMITHKLINE BEECHAM P.L.C., UNITED KINGDOM

]71[




BEER-SHEVA 84152

]74[


]57 [Process for preparing a finely divided preparation of a drug substance comprising wet milling a suspension of the drug substance in a mill having at least one

chamber and agitation means, said chamber(s) and/or said agitation means comprising internally lubricated nylon.

___________

153263]21][11[

METHOD FOR DIAGNOSINGבתינוק עוית–מעיים לאבחנת שיטהCOLIC IN AN INFANT

]54[

09.06.2000]22[Int. Cl.8 A61K 049/00]51[CROSSCARE RESEARCH & DEVELOPMENT LIMITED, IRELAND

]71[




]74[

]57 [Use of a β-D-galactosidase enzyme for the manufacture of a diagnostic agent for diagnosing colic type in an infant exhibiting one or more symptoms characteristic of unspecified colic, which comprises the steps of:

)a (optionally measuring in said infant at least one parameter indicative of unspecified colic;

)b (orally administering a liquid formulation of a β-D-galactosidase enzyme separately, simultaneously with or sequentially to a lactose-containing feed; and

)c (determining at selected intervals of time any alteration in said infant of colic-type symptoms.

_________

153324]21][11[

ביונק תת–חום למניעת והתקנים שיטות לקור חשיפה של ארוכות תקופות במשךקיצוני

METHODS AND DEVICES FOR PREVENTION OF HYPOTHERMIA IN A MAMMAL DURING PROLONGED EXPOSURE TO EXTREME COLD

]54[


07.06.2001]22[US]33[09.06.2000]32[60/210664]31[

Int. Cl.8 A61F 007/00]51[THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, U.S.A.

]71[




REHOVOT 76122

]74[

]57 [A method for preventing a change in the core body temperature of a mammal under cold conditions, said method comprising:

)a (a detecting a requirement for thermal energy input in said mammal; and

)b (contacting a surface of a portion of said mammal in response to the presence of said requirement with a warm termperature medium under negative pressure

conditions for a period of time sufficient to introduce thermal energy into the core body of said mammal, to substantially maintain constant the core body temperature of said mammal in cold conditions in water or at about 30 degrees Fahrenheit or less; whereby the core body temperature of said mammal is prevented from changing under said cold conditions.

__________

153435]21][11[

לסביבה ידידותית מיזוג מערכתחממה עבור במיוחד מתאימה

ENVIRONMENTALLY FRIENDLY CONDITIONING SYSTEM PARTICULARLY FOR A GREENHOUSE

]54[

14.06.2001]22[US]33[15.06.2000]32[60/212081]31[

Int. Cl.8 A01G 009/24]51[


בנגב, הרשות בן-גוריון אוניברסיטתשבע ופיתוח, באר למחקר


]71[




BEER-SHEVA 84152

]74[

]57 [A system for conditioning an indoor space, comprising: a ducting (80) having an open inlet end (82) and an outlet end (84); water provision system (20) adapted to provide droplets of water within said ducting; air circulation means adapted to

induce an airflow from outside said ducting through said ducting via said inlet end; diffusion arrangement at said outlet end having an outlet area greater than the inlet area thereof.

___________

153496]21][11[

חומצה של גרגר דמוי מוצר של אסתר או פאראהידרוקסיבנזואית

ותהליך פאראהידרוקסיבנזואית חומצההנ"ל של הכנה עבור

GRANULAR PRODUCT OF PARAHYDROXYBENZOIC ACID OR PARAHYDROXYBENZOIC ACID ESTER AND PROCESS FOR PREPARING THE SAME

]54[

18.04.2002]22[JP]33[20.04.2001]32[2001-

122933]31[

Int. Cl.8 B01J 002/00, 002/22, C07C 065/00, 065/03, 069/88]51[KABUSHIKI KAISHA UENO SEIYAKU OYO KENKYUJO, JAPAN

]71[

WO/2002/085835]87[ושותפיו, הס יצחק ד"ר ]DR. YITZHAK HESS & PARTNERS,]74אביב , תל6451 , ת.ד. 279 הירקון רחוב


279 HAYARKON ST,.P.O.B. 6451 ,

TEL AVIV 61063

]57 [A granular product of parahydroxybenzoic acid or its ester, characterized in that said product has an

average particle size of equal to or more than 150 µm and a hardness of 10-3000g.

__________

153679]21][11[

ותכשירי פוליציקליות קסנתון תולדותאותן המכילים רוקחות

POLYCYCLIC XANTHONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

]54[

29.06.2001]22[GB]33[29.06.2000]32[0016020.0]31[

Int. Cl.8 A61K 031/7004, A61P 031/04, C07D 493/04, C07H 017/04]51[INSTITUTO BIOMAR, S.A., SPAIN]71[WO/2002/000663]87[

וגולר, וולף, ברגמן, ירושלים1352ת.ד.


JERUSALEM 91013

]74[



where each R1 is the same or different and can be hydrogen, C1-C18 alkyl, C2-C18 alkenyl, benzyl, alkali metal, aryl, wherein the aryl group may be carbocyclic having 6 or 10 carbon atoms or heterocyclic having

5 to 12 carbon atoms, acyl (RCO-), wherein R is C1-C18 alkyl, and/or a mono-, di-, or trisaccharide; R2 and R3 can be hydrogen, alkyl, or together R2 and R3 form an unsaturated bond.

___________

153797]21][11[

ע"י מתווך מגוונים רצפים סידורטרנספוסון

TRANSPOSON MEDIATED MULTIPLEX SEQUENCING

]54[

05.07.2001]22[US]33[07.07.2000]32[60/216381]31[

Int. Cl.8 C12Q 001/68]51[AVENTIS PHARMACEUTICALS INC., U.S.A.

]71[



P.O.B. 12688 ,HERZLIYA 46733

]74[

]57 [A process for parallel, transposon-mediated sequencing of DNA, the process comprising:

)i (providing one or more target DNA sequences, each inserted into a vector at an insertion site;


)ii (amplifying each target DNA-containing vector and pooling them wherein each target DNA sequence is represented in the pool in an substantially equal amount per kb;

)iii (exposing the pool of target DNA-containing vector to a selectable transposon, wherein the selectable transposon integrates into the target DNA-containing vectors at substantially random sites to form a pool of target DNA-and transposon-containing vectors;

)iv (transforming cells with the pool of target DNA-and transposon-containing vectors and isolating and growing a representative number of individual transformants into cultures under selection conditions;

)v (performing a polymerase chain reaction on DNA from each culture, wherein the polymerase chain reaction uses a pair of primers complementary to the 3' ends of the vector sequence at the insertion site and has an extension time during each

reaction cycle sufficient to efficiently produce a full-length copy of the vector sequence but too short to efficiently produce a full-length copy of the vector

sequence with the transposon inserted ;)vi (measuring the amount of DNA

produced in each polymerase chain reaction; and

)vii (sequencing the transposon flanking regions of the target DNA-containing vectors from those cultures corresponding to polymerase chain reactions which produced substantial amounts of DNA.

___________

153829]21][11[

ETHERNET ADAPTINGאתרנט להתאמת התקןAPPARATUS

]54[

15.10.2001]22[DE]33[05.01.2001]32[10100363.

3]31[

Int. Cl.8 H04L 012/46, 012/56, 029/06]51[INFINEON TECHNOLOGIES AG, GERMANY

]71[

WO/2002/054701]87[ , תל4060 , ת.ד. 21 העם אחד רחוב

אביבREINHOLD COHN AND PARTNERS,

]74[



TEL AVIV 61040

]57 [An Ethernet adapting apparatus for data transfer between a standard Ethernet data pump (10) and an Ethernet medium access controller via telecommunication medium (4) comprising:

)a (a dual mode media independent interface (9) which emulates in a PHY-mode the standard Ethernet medium access controller and which emulates in a MAC-mode the Ethernet medium access controller;

)b (a switching device (14) for setting the dual mode media independent interface in the PHY-mode or in the MAC-mode;

)c (a data buffer (11) for storing at least one Ethernet data package to be transferred between the standard Ethernet data pump and the Ethernet medium access controller; and

)d (a 10BASES® data modem (not shown) connected to the telecommunication medium, wherein the 10BASES® data modem reframes the data stored in the data buffer to 10BASES® data frames sent via the telecommunication medium; and wherein the dual mode media independent interface comprises a serial management interface connectable via a SMI-data line to an Ethernet medium access controller or a standard Ethernet data pump for the exchange of SMI-data frames including SMI-messages, and a data flow interface connectable via a data bus to an Ethernet medium access controller or a standard Ethernet data pump for the exchange of Ethernet data packages.

__________

153837]21][11[

–פניל–פירידין4 של נגזרות1ניורוקינין– רצפטור של כאנטגוניסטים

4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS

]54[

20.07.2001]22[EP]33[24.07.2000]32[00115846.]31[


8Int. Cl.8 A61K 031/4427, 031/455, A61P 025/00, 043/00, C07D 213/22, 213/24, 213/60, 213/72, 213/78, 401/04, 403/04, 413/04

]51[

F. HOFFMANN-LA ROCHE AG, SWITZERLAND

]71[




BEER-SHEVA 84152

]74[

]57 [Compounds of the formulas

whereincompounds of formula IA are those whereinR1 is 1, 2, 4-triazol-1-yl and R2 is methyl, orR1 is 2-hydroxy-ethylamino and R2 is methyl, orR1 is 4-hydroxy-3,4,5,6-tetrahydro-pyridin-1-yl and R2 is methyl, orR1 is 4-(2-hydroxy-ethoxy)-3,4,5,6-tetrahydro-pyridin-1-yl and R2 is methyl, orR1 is 3-hydroxy-pyrrolidin-1-yl and R2

is methyl, orR1 is 4-hydroxy-3,4,5,6-tetrahydro-pyridin-l-yl and R2 is chloro, andcompounds of formula IB are those wherein

R1 is 2-hydroxy-ethylamino and R2 is methyl, orR1 is 2-hydroxy-ethylamino and R2 is chloro, orR1 is 2,3-dihydro-[1,4]oxazin-4-yl and R2 is methyl, orR1 is acetylamino and R2 is methyl, orR1 is acetyl-methylamino and R2 is methyl, orR1 is cyclopropane carboxylic acid amide and R2 is methyl, orR1 is cyclopropane carboxylic acid methylamide and R2 is methyl, orR1 is imidazol-l-yl and R2 is methyl,and pharmaceutically acceptable acid addition salts thereof.

__________

153941]21][11[

TECHNIQUE FOR POWER ברשתות הספק לויסות טכנולוגיהCONTROL IN OPTICAL

]54[


NETWORKSאופטיות

14.01.2003]22[Int. Cl.8 H04B 010/08, 010/17]51[

]ECI TELECOM LTD.]71תקוה בע"מ, פתח אי.סי.איי. טלקוםבע"מ, אי. סי. איי. טלקום

תקוה , פתח30הסיבים רחוב ECI TELECOM LTD,.

30 HASIVIM ST,.PETACH TIKVA 49517

]74[

]57 [A method for maintaining a required value of power per optical channel in a chain of optical nodes connected by optical fiber spans, wherein at least some of said nodes including optical amplifiers with controllable gains; the method comprising performing automatic gain control at said optical amplifiers so that, in the frame of power gain of an optical amplifier, to compensate a preceding span loss; said span loss being power loss on an optical fiber span incoming said amplifier, obtaining information from a preceding node in the chain about a value of measured output power (MOP) of the preceding node, measuring input power

(MIP) at a following node, obtaining a difference between the MOP of the preceding node and the MIP of the following node to calculate the span loss between the two nodes, wherein the automatic gain control is performed at the amplifier of the following node in response to the calculated span loss;

the method additionally comprises obtaining, from said preceding node, information about power loss (ΔPL) which has not been compensated at the preceding node, thereby ensuring distributed compensation of power loss changes if they occur in one or more spans of the chain.

__________

154062]21][11[

איבר עם לאינטראקציה ושיטה סידורבגוף פנימי

ARRANGEMENT AND METHOD FOR INTERACTING WITH AN INTERNAL BODY ORGAN

]54[

04.07.2001]22[SE]33[27.07.2000]32[0002778-9]31[

Int. Cl.8 A61M 031/00]51[June 5, 2008111 –התשס"ח ב' בסיון

9

Q MED AB, SWEDEN]71[WO/2002/009802]87[



P.O.B. 12688 ,HERZLIYA 46733

]74[

]57 [An arrangement to be passed through a body cavity for interacting with an internal body organ, comprising:

an elongate sheath (3) having at least one interior passage, said sheath having a proximal end and a distal end, said distal end being open and in communication with said at least one passage; and at least two elongate structural elements (15), each structural element having a proximal end (17) and a distal end (19); wherein the structural elements are inserted in said at least one passage so that at least a distal portion (19) of each element extends there through in the longitudinal direction of the sheath; wherein the structural elements are

arranged to be displaced relative to the sheath from a first position, in which the distal end of each structural element is located inside said at least one passage and in which the arrangement is intended to be passed through a body cavity, to a second position, in which a distal portion of each structural element extends through the open distal end of the sheath and at least partly in the transverse direction away from the sheath for distending and/or expanding interaction between the distal end of each structural element and a body organ approached by the arrangement through a body cavity.

__________

154094]21][11[

של חלקיקים המכיל תוצר ליצור שיטה –5,3,1 – –דימתיל5, 3 – טטראהידרו

– תיאון2 – תיאדיאזין

METHOD FOR THE PRODUCTION OF A PARTICLE – CONTAINING PRODUCT OF TETRAHYDRO-3,5-DIMETHYL-1,3,5 –THIADIAZIN-2 –THIONE

]54[


16.08.2001]22[DE]33[17.08.2000]32[10040194.

5]31[

Int. Cl.8 A01N 043/88, C07D 285/34]51[BASF AKTIENGESELLSCHAFT, GERMANY

]71[





TEL AVIV 61040

]74[

]57 [A process for the preparation of a particulate tetrahydro-3,5-dimethyl-1,3,5-thiadiazine-2-thione product by combining a first aqueous solution comprising methylammonium N-methyldithiocarbamate with a second aqueous solution comprising formaldehyde, followed by separation and drying of the resulting solid, which

comprises combining the first and the second aqueous solutions in such a way that the ratio between the concentrations of dithiocarbamate functions and of formaldehyde is essentially constant in the reaction mixture over time during duration of the reaction, and separating the solid from the resulting suspension.

__________

154132]21][11[

משתמש של תפר ללא ניידות איפשורקצר בטווח אלחוטית רשת בסביבת

ENABLING SEAMLESS USER MOBILITY IN A SHORT-RANGE WIRELESS NETWORKING ENVIRONMENT

]54[

08.08.2001]22[US]33[11.08.2000]32[637742]31[

Int. Cl.8 H04L 012/28, 012/56, 029/06, H04Q 007/34, 007/38]51[SYMANTEC CORPORATION, U.S.A.

]71[




REHOVOT 76122

]74[

]57 [A method of enabling seamless user mobility in a short-range wireless networking environment, comprising the

steps of: providing one or more portable client devices, each of the client devices equipped with a short-range wireless


communications capability for communicating in the short-range wireless networking environment; providing a plurality of Handoff Management Points (HMPs), each of the HMPs equipped with a short-range wireless link for communication with the client devices and a link to a networking environment wherein one or more application programs residing on one or more application server can be accessed; providing a Handoff Core Server to manage the HMPs; dynamically making a selected one of the HMPs operational, further comprising the steps of: obtaining an Internet Procotol (IP)

address for the selected HMP; discovering by the selected HMP, an identity of the Handoff Core Server; and initiating, by the selected HMP, an HMP presence protocol exchange with the Handoff Core Server, further comprising the step of sending a registration request to the Handoff Core Server to register the selected HMP with the Handoff Core server; obtaining a registration response from the Handoff Core Server; and if the registration response is successful, periodically refreshing the selected HMP's registration with the Handoff Core Server.

__________

154220]21][11[

פנילאצטיוניטרילים להכנת תהליךמותמרים

PROCESS FOR THE PREPARATION OF SUBSTITUTED PHENYLACETONITRILES

]54[

21.08.2001]22[IN]33[30.08.2000]32[705/MAS/00]31[

Int. Cl.8 C07C 213/02, 217/64, 253/30, 255/37]51[SANDOZ AG, SWITZERLAND]71[WO/2002/018325]87[


אביב


P.O.B. 4060 ,TEL AVIV 61040

]74[

]57 [A process for the preparation of a compound of the formula


wherein R1 is unsubstituted or substituted alkyl, comprising reacting a compound of the formula

with a compound of the formula

in the presence of an aqueous base and a phase transfer catalyst.

___________

154593]21][11[

–)הטראואריל3 חומצות של תולדות 1 – אזטידין – – אוקסו2אצטאמידו( –

אנטי–בקטרליים כגורמים סולפניות

3(-HETEROARYL ACETAMIDO-)2-OXO- AZETIDINE-1-SULFONIC ACID DERIVATIVES AS ANTIBACTERIAL AGENTS

]54[

14.09.2001]22[US]33[14.09.2000]32[60/232617]31[

Int. Cl.8 C07D 417/00]51[PANTHERIX LIMITED, UNITED ]71[


KINGDOMWO/2002/022613]87[



P.O.B. 6451 ,TEL AVIV 61063

]74[

]57 [A compound selected from the group consisting of a Syn isomer of a racemate and an optical isomer of 3-(heteroaryl

acetamido)-2-oxo-axetidine-1-sulfonic acid and of the formula

whereinM is hydrogen or pharmaceutically acceptable salt forming cation;X is CH, N or C-halogen;

R is C1-C3 alkyl which is unsubstituted or substituted with at least one of (a) a halogen atom,

)b (OR5 wherein R5 is hydrogen, CONH2 provided that, when R is methyl, it cannot be substituted with both a halogen atom and OR5;

R1 and R2 independently are OH, COOH, CONH2, NH2, dimethylamino, OCH3, NO2, CN, optionally substituted phenyl or C1-C3 alkyl; or

R1 and R2 together are –O-CH=CH-CH2-, -O-CH2-CH2-O-, -CH2-CH2-CH2-, -CH2-

CH2-CH2-CH2,--CH=CH-CH=CH-or-CH=C(OH)-

C(OH)=CH- which together with the carbon atoms to which they are bound form a 5 membered or six membered cyclic ring; and R3 and R4 independently are hydrogen, optionally substituted C1-C3 alkyl, optionally substituted phenyl or C3-C6 cycloalkyl; orR3 and R4 together with C to which they are attached are C3-C6 cycloalkyl.

__________

154594]21][11[

]SWEET DOUGH TRAY]54מתוק בצק מגש06.09.2001]22[

US]33[11.09.2000]32[09/659034]31[Int. Cl.8 A21D 010/02]51[SOCIETE DES PRODUITS NESTLE S.A., SWITZERLAND

]71[

WO/2002/019829]87[




P.O.B. 6451 ,TEL AVIV 61063

]74[

]57 [A ready-for-use dough product comprising: a tray (10) comprising a top surface (14) and a plurality of recesses, wherein the recesses each have at least one side (16) attached to or continuous with the top surface of the tray and a bottom (12) that is attached to or continuous with the at least one side, wherein the recess defines a

volume adapted to contain dough, and at least one bending line between the recesses where the tray is predisposed to bend; and uncooked refrigerated or frozen sweet dough in an amount at least equal to about 70 percent of the volume of the recesses and disposed at least partially within the recesses..

___________

154684]21][11[

HEAD ASSEMBLY FORהגנה מסילת לקצה ראש מכלולGUARDRAIL EXTRUDER TERMINAL

]54[

31.08.2001]22[US]33[31.08.2000]32[60/229486]31[

Int. Cl.8 E01F 015/14]51[THE TEXAS A&M UNIVERSITY SYSTEM, U.S.A.

]71[




BEER-SHEVA 84152

]74[

]57 [A head assembly (10) for use with a guardrail installation, comprising: a rail feeder chute (16), comprising: a first side portion (40) disposed on a traffic side of

the head assembly, and a second side portion disposed opposite the traffic side of the head assembly, the first and second side portions being generally parallel with


each other and being generally parallel with a central, longitudinal axis (70) of the rail feeder chute; the first and second side portions being configured to receive a rail member (12) therebetween; an upstream end (50); a downstream end having upper and lower edge portions that form respective acute angles with the central, longitudinal axis; each of the upper and lower edge portions terminating adjacent to and being coupled with respective rounded members that extend perpendicular to the central, longitudinal axis and the first and second side portions; and wherein the respective rounded members extend further downstream than the upper and lower edge portions, the rounded members providing blunt, rounded termination points to the rail feeder chute at the downstream end, during impact with support posts of the guardrail installation; and an impact portion (14) coupled to the upstream end of the rail feeder chute and comprising: an impact plate positioned to face oncoming traffic, the impact plate having a greater height than width, an upper overhang extending upwardly, and a lower overhang extending downwardly; top and bottom members forming a coupling between the rail feeder

chute and the impact plate; first and second side members cooperating to form a throat (66) configured to receive the rail member as it is forced through the impact plate; the first side member being positioned adjacent the traffic side to the head assembly and including a curved portion (44) that extends away from the traffic side as the first member extends away from the rail feeder chute, the first side member being configured to direct the rail member away from the the roadway during an end-on collision; the second side member being positioned opposite the traffic side of the head assembly and terminating at a vertical brace (56) that extends generally perpendicular to the central, longitudinal axis of the rail feeder chute; the top and bottom members each having a traffic side edge (72) positioned to face a roadway, the traffic side edge being approximately parallel with the central, longitudinal axis of the rail feeder chute; and a connecting plate (46) coupled between the impact plate and the first portion of the first side member, the connecting plate providing an axis of force transmission for the head assembly, wherein the axis of force transmission is offset from the central, longitudinal axis of the head assembly.

__________


154719]21][11[

עבור לרשת בטוחה גישה אספקתטווח–קצר של אלחוטיים מיחשוב התקני

PROVIDING SECURE NETWORK ACCESS FOR SHORT RANGE WIRELESS COMPUTING DEVICES

]54[

27.08.2001]22[US]33[08.09.2000]32[09/657745]31[US25.05.200109/866297

Int. Cl.8 G09C 001/00, H04L 009/08, 012/28, 012/46, 012/56]51[SYMANTEC CORPORATION, U.S.A.]71[




REHOVOT 76122

]74[

]57 [A method of enabling secure network access in a short-range wireless networking environment, comprising the steps of: providing one or more portable client devices, each of the client devices equipped with a short-range wireless communications capability for communicating in the short-range wireless networking environment; receiving, by a network access point, a communication from a selected one of the client devices; determining, by the network access point, that the selected client device does not have a valid session key for encryption;

obtaining, by the network access point, user credentials for a user of the selected client device; authenticating, by the network access point, the user credentials by contacting an authentication server; establishing the valid session key when the authenticating step completes successfully; and using the established session key, by the selected client device and the network access point, to encrypt packets that are transmitted over a link between the selected client device and the network access point.


__________

154808]21][11[

בעל תוהד סינוסואידלי דירבון מעגלחשמליים עומסים עבור משתנה תדירות

VARIABLE FREQUENCY SINUSOIDAL RESONANT DRIVER FOR ELECTRICAL LOADS

]54[

06.03.2003]22[Int. Cl.8 H02M 007/42]51[

למחקר בנגב, הרשות בן-גוריון אוניברסיטתשבע ופיתוח, באר


]71[

]SHMUEL BEN-YAAKOV]72יעקב בן שמואללוצאטו, את לוצאטו



BEER-SHEVA 84152

]74[

]57 [Apparatus for providing, to an electrical load, a sinusoidal signal, generated by Resonant-Based inverter having variable operating frequency, comprising:

)a (a Resonant Frequency Controller (RFC), (900) said RFC being capable of comparing the operating frequency of said sinusoidal signal to a desired frequency and outputting a corresponding signal, for

controlling at least one parameter determining said resonance frequency, for obtaining said desired frequency;

)c (a Direct Current (DC) power supply (801), for powering said inverter;

)d (a current/voltage controlled Steering Switching Assembly (SSA) (802), for providing the current required by said resonant circuitry;

)e (a Zero Crossing Detector (ZCD) (803), for detecting the instants at which said


sinusoidal signal crosses a zero value, and for outputting a corresponding indication signal at each instant; and

)f (a Soft Switching Controller (SSC) (804), the input of which accepts said

indication signal, for adjusting the switching times of power switches contained in said SSA to said instants.

_________

154894]21][11[

AUTONOMOUS FOCUSING OFעצמאי אופטי למיקוד מערכתSTARING SYSTEMS

]54[

12.03.2003]22[Int. Cl.8 G02B 001/00, 007/04]51[

בע"מ, לחימה אמצעי לפיתוח רשות רפא"לחיפה

RAFAEL ARMAMENT DEVELOPMENT AUTHORITY LTD.

]71[

]EHUD CHISHINSKY]72פפושדו נבו, דני צישינסקי, יצחק אהודצביון, יורם

, ת.ד. התעשיה , פארק2 רח' הטוחן , פרדס-חנה3148



]74[

]57 [A system for autonomously focusing of a staring device system, comprising: an imaging array onto which a focusing lens assembly focuses rays collected by an

objective lens; at least one lighting element for illuminating said imaging array; and a means for retro-reflecting light scattered and reflected from said imaging array.


_________

155042]21][11[

]DEHUMIDIFIER SYSTEM]54אויר לייבוש מערכת

11.11.1998]22[WO]33[16.11.1997]32[PCT/IL97/00372]31[

Int. Cl.7 F24F 003/14]51[DIVISION FROM 136127]62[

]DRYKOR, LTD.]71בע"מ, עתלית דרייקורWO/1999/026026]87[

בע"מ, רוחני ושות',קניין פנסטר , ת.ד. אריה , קרית1 כניסה12 בזל

תקוה , פתח10256

FENSTER & COMPANY, INTELLECTUAL PROPERTY LTD,.

12 BASEL ST,.ENTRANCE 1,P.O.B. 10256,

PETACH TIKVA

]74[

]57 [An air modifying device (10) including: an enclosure (112) including apparatus for modifying air entering the apparatus via an air inlet and having an air outlet for the modified air; a first conduit (14) having an entrance for air and an exit communicating with the inlet; a second conduit (16) having an exit and an entrance

communicating with the outlet; and a mounting surface adapted for mounting the device on a partition (118) such that the enclosure is on a first side of the partition and the entrance to the first conduit and the exit from the second conduit are situated on a second side of the partition.


__________

155120]21][11[

של מוצק במצב לסינתזה תהליך אלדהידים, קיטונים, אוקסימים

הידרוקסאמיות חומצות

PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES AND HYDROXAMIC ACIDS

]54[

17.12.1997]22[US]33[19.12.1996]32[032453]31[US24.12.1996033881

Int. Cl.8 C07C 045/00, 047/00, 049/00, C08F 212/08, 212/36]51[DIVISION FROM 130040]62[AVENTIS PHARMACEUTICALS INC., U.S.A.

]71[




REHOVOT 76122

]74[

]57 [A polymeric tetrafluorophenyl hydroxylamine resin compound of the formula


A is absent or a group of formula –X1-Z-whereinX1 is –CHR- or –CHR-Y-CO-(CH2)n-wherein R is H, alkyl, phenyl, or phenyl substituted with-H, alkyl, alkoxy, halogen, nitrile or –NO2, Y is -O- or NH-, n is an

integer from 1 to 6, and Z is –O- or –NH-; R3 and R4 are independently –H, alkyl, phenyl, or phenyl substituted with one or more substituents selected from alkyl, alkoxy, halogen, nitrile and –NO2; and P1 is H or an amine protecting group.

___________

155286]21][11[

גלאי עבור גבוהה בצפיפות גמיש מחברTC

HIGH DENSITY FLEX INTERCONNECT FOR CT DETECTORS

]54[

08.04.2003]22[US]33[19.04.2002]32[125951]31[

Int. Cl.8 A61B 006/03, G01T 001/00]51[GE MEDICAL SYSTEMS GLOBAL TECHNOLOGY COMPANY, LLC, U.S.A.

]71[

ושות', גבריאלי זליגסוןאביב , תל1426 , ת.ד. 31 רח' יבנה

SELIGSOHN GABRIELI & CO,. 31 YAVNE ST,.

P.O.B. 1426 ,TEL AVIV 61013

]74[

]57 [A detector module, comprising: a photosensor array (106) having a first width; and a flexible cable operationally

(118) coupled to said photosensor array, said cable having a width greater than said first width.


_________

155319]21][11[

לשליטה אזיד המכיל ותכשיר שיטהמזיקים באורגניזמים

AZIDE METHOD AND COMPOSITION FOR CONTROLLING DELETERIOUS ORGANISMS

]54[

09.10.2001]22[US]33[10.10.2000]32[60/238943]31[

Int. Cl.8 A01N 025/00, 059/00]51[AUBURN UNIVERSITY, U.S.A.]71[





TEL AVIV 61040

]74[

]57 [A composition for controlling a population of a deleterious organism comprising: an ionic azide; an azide stabilizer comprising an amine selected from the group consisting of ethanolamine,

dimethylamine, ethylamine, butylamine, diethylamine, diethanolamine, and phenylethylamine in an amount sufficient to stabilize the azide; and a liquid dispersal medium.

___________


155386]21][11[

בהם חדשים, השימוש –אזאינדולים7 ושיטות4 פוספודיאסטראזה כמעכבילהכנתם

7-AZAINDOLES, USE THEREOF AS PHOSPHODIESTERASE 4 INHIBITORS AND METHOD FOR PRODUCING THE SAME

]54[

25.10.2001]22[DE]33[27.10.2000]32[10053275.

6]31[

US30.10.200060/244342Int. Cl.8 A61K 031/437, A61P 011/00, C07D 471/04]51[ELBION AG, GERMANY]71[WO/2002/034747]87[


אביב


P.O.B. 4060 ,TEL AVIV 61040

]74[

]57 [7-Azaindoles of the formula

in whichn can be 1 or 2 andR1 represents

-C1 to –C10 alkyl, linear or branched, unsubstituted or substituted one or more times with –OH, -SH, -NH2, -NHC1 to –NHC6 alkyl, -N(C1 to C6-alkyl)2, -NHC6 to –NHC14 aryl, - N(C6 to C14 aryl)2, -N(C1 to C6 alkyl) (C6 to C14 aryl), -NO2, -CN, -F, -Cl, -Br, -I, -O-C1 to –O-C6 alkyl, -O-C6 to –O-C14 aryl, -S-C1 to –S-C6 alkyl, -S-C6 to –S-C14 aryl, -SO3H, - SO2C1 to –SO2C6 alkyl, -SO2C6 to –SO2C14 aryl, -OSO2C6 alkyl, -OSO2C6 to –OSO2C14 aryl, -COOH,

-(CO)C1 to –(CO)C5 alkyl, with mono-, bi- or tricyclic, saturated or monounsaturated or polyunsaturated carbocylic compounds with 3 to 14 ring elements, with mono-, bi- or tricyclic saturated or monounsaturated or polyunsaturated heterocyclic groups with 5 to 15 ring elements and 1 to 6 hetero atoms, which preferably are N, O and S, it being possible for the C6 to C14 aryl groups and the carbocyclic and heterocyclic substituents, in turn, to be unsubstituted or monosubstituted or polysubstituted with R4, -C2 to C10 alkenyl, monounsaturated or polyunsaturated,


linear or branched, unsubsituted or monosubstituted or polysubstituted with –OH, -SH, -NH2, -NHC1 to – NHC6 alkyl, -N(C1 to C6 – alkyl)2, -NHC6 to –NHC14 aryl, -N(C6 to C14 aryl)2, -N(C1 to C6 alkyl) (C6 to C14 aryl), -NO2, -CN, -F, -Cl, -Br, -I, -O-C1 to –O-C6 alkyl, -O-C6 to –O-C14 aryl, -S-C1 to –S-C6 alkyl, -S-C6 to –S-C14 aryl, -SO3H, -SO2C1 to –SO2C6 alkyl – SO2C6 to –SO2C14 aryl, -OSO2C1 to –OSO2C6 alkyl, -OSO2C6 to –OSO2C14 aryl, - COOH, -(CO)C1 to –(CO)C5 alkyl, with mono-, bi- or tricyclic, saturated or monounsaturated or polyunsaturated carbocyclic compounds with 3 to 14 ring elements, with mono-, bi- or tricyclic saturated or monounsaturated or polyunsaturated heterocyclic groups with 5 to 15 ring elements and 1 to 6 hetero atoms, which preferably are N, O and S, it being possible for the C6 to C14 aryl groups and the carbocyclic and heterocyclic substitutents, in turn, to be

unsubstituted or monosubstituted or polysubstituted with R4, R2 and R3 may be the same or different, it being possible for only one of the two to represent hydrogen and furthermore, R2 and R3 can represent –C1-C5 alkyl, unsubstituted or monosubstituted or polysubstituted with –OH, -SH, -NH2, -NHC1 to –NHC6 alkyl, -N(C1 to C6-alkyl)2, -NO2, -CN, -F, -Cl, -Br-, -I, -O-C1 to –O-C6 alkyl, -S-C1 to –S-C6 alkyl, -phenyl, -pyridyl –phenyl, unsubstituted or monosubstituted or polysubstituted with –OH, -SH, -NH2, - NHC1 to –NHC3 alkyl, -N(C1 to C3-alkyl)2, -NO2, -CN, -COOH, -COOC1 to –COOC3 alkyl, -F, -Cl, -Br-, -O-C1 to –O-C3 alkyl, -S-C1 to –S-C3 alkyl, -pyridyl, unsubstituted or monosubstituted or polysubstituted with –NO2, -CN, -COOH, -COOC1 to –COOC3 alkyl, -Cl, -Br-, -O-C1 to –O-C3 alkyl, -S-C1 to –S-C3 alkyl as well as

furthermore, the –NR2R3 group can represent together

andR4 represents

-H, -OH, -SH, -NH2, -NHC1 to –NHC6 alkyl, -N(C1 to C6 alkyl)2, NHC6 to NHC14 aryl, N(C6 to C14 aryl)2, -N(C1 to C6 alkyl) (C6 to C14 aryl), -NHCOC1 to –NHCOC6 alkyl, -NO2, -CN, -COOH, -COOC1 to

COOC6 alkyl, -(CO)C1 to –(CO)C6 alkyl, -(CS)C1 to –(CS)C6 alkyl, -F, -Cl, -Br, -I, -O-C1 to –O-C6 alkyl, -O-C6 to –O-C14 aryl, -S-C1 to –S-C6 alkyl, -S-C6 to –S-C14 aryl, -SOC1 to –SOC6 alkyl, -SO2C1 to –SO2C6 alkyl, with the proviso that when n = 1 there is no concurrent


R1 = -C1 to C6 alkylR2 = -H or –C1 to C5 alkyl and

R3=

where R and R' are independently –C1 to C6 alkyl with or without single or multiple halogen substitution, -C2 to C6 alkenyl, -C3 to C6 cycloalkyloxy, -C3 to C6 cycloalkyl-C1 to C6 alkyl, -C1 to C6 alkylthio, -C3 to C6

cycloalkylthio, -C3 to C6 cycloalkyl-C1 to C6 alkylthio, -C1 to C6 alkoxy, hydroxyl, halogen, nitro, -CF3, -C2F5, -OCF3, -SCF3, -

SO2CF3, -SO2F, formyl, -C2 to C6 alkanoyl, cyano, substituted or unsubstituted phenyl, -NR"2, -CONR"

2, -COOR"orR + R' together are a 5-membered carbocycle or heterocycle ,

andR" = -H or –C1 to C6 alkyl.

___________

155447]21][11[

NITROGENOUS AROMATICחנקניות ארומטיות מעגליות תרכבותRING COMPOUNDS

]54[

19.10.2001]22[JP]33[20.10.2000]32[2000-

320420]31[

JP20.12.20002000-386195JP22.02.20012001-46685

Int. Cl.8 A61K 031/47, A61P 035/00, C07D 213/74, 213/75, 215/48, 239/47, 401/12, 405/12, 409/12, 413/12

]51[

EISAI R&D MANAGEMENT CO., LTD., JAPAN

]71[

YASUHIRO FUNAHASHI, AKIHIKO TSURUOKA, MASAYUKI MATSUKURA, TORU HANEDA, YOSHIO FUKUDA, JUNICHI KAMATA, KEIKO TAKAHASHI, TOMOHIRO MATSUSHIMA, KAZUKI MIYAZAKI, KEN-ICHI NOMOTO, TATSUO WATANABE, HIROSHI

]72[

WO/2002/032872]87[]JEREMY M. BEN-DAVID & CO. ]74ושות' בע"מ, מ. בן-דוד ירמיהו



LTD,. HAR HOTZVIM HI-TECH PARK ,

P.O.B. 45087 ,JERUSALEM 91450


]wherein A is a group represented by the formula:

]wherein W is a carbon atom; Ra13 is a

hydrogen atom; Ra12 is a cyano group or a group represented by the formula:

)wherein Va12 and Va13 are each independently a hydrogen atom, a C1-6

alkyl group which may have one or more substituents selected from [group A], a C2-6

alkenyl group which may have one or more substituents selected from [group A], a C2-6 alkynyl group which may have one or more substituents selected from [group A], a C3-8 alicyclic hydrocarbon group which may have one or more substituents selected from [group A], a C6-14 aryl group which may have one or more substituents selected from [group A], a 5- to 14-membered heterocyclic group which may

have one or more substituents selected from [group A] or a 5- to 14-membered aromatic heterocyclic group which may have one or more substituents selected

from [group A] ;(and Ra11 is a group represented by the formula

-Va21-Va22-Va23 (wherein Va21 is a C1-6

alkylene group which may have one or more substituents selected from [group A], a single bond or a group represented by the formula:


Va22 is a single bond, an oxygen atom, a sulfur atom, -CO-, -SO-, -SO2-, -CONRa14-, -SO2NRa14, -NRa14SO2-, -NRa14CO-or –NRa14- (wherein Ra14 is a hydrogen atom, a C1-6 alkyl group which may have one or more substituents selected from [group A] or a C3-8

alicyclic hydrocarbon group which may have one or more substituents selected from [group A]); and Va23 is a hydrogen atom, a C1-6 alkyl group which may have one or more substituents selected from [group A], a C2-6 alkenyl group which may have one or more substituents selected from [group A], a C2-6

alkynyl group which may have one or more substituents selected from [group A], a C3-8 alicyclic hydrocarbon group which

may have one or more substituents selected from [group A], a 5- to 14-membered heterocyclic group which may have one or more substituents selected from [group A] or a 5- to 14-membered aromatic heterocyclic group which may have one or more substituents selected from [group A])]; X is an oxygen atom or a sulfur atom; E and Y represent as follows:

)1 (E is a group represented by the formula –NR2-, and Y is a phenyl group which may have one or more substituents selected from [group A], a pyridyl group which may have one or more substituents selected from [group A] or a group represented by the formula:

)wherein W11 and W12 are each independently a carbon atom which may have one or more subtituents selected from

[group A] or a nitrogen atom ;(

)2 (E is a single bond, and Y is a group represented by the formula:

)wherein W13 is a carbon atom which may have one or more substituents selected

from [group A] or a nitrogen atom ,(which

may have one or more substituents selected from [group A];

R1 and R2 are each independently a hydrogen atom, a C1-6 alkyl group which


may have one or more substituents selected from [group A], a C2-6 alkenyl group which may have one or more substituents selected from [group A], a C2-6

alkynyl group which may have one or more substituents selected from [group A], a C3-8 alicyclic hydrocarbon group which may have one or more substituents selected from [group A], a C2-7 acyl group which may have one or more substituents selected from [group A] or a C2-7 alkoxycarbonyl group which may have one or more substituents selected from [group A]; and Z is a group represented by the formula –Z11-Z12 (wherein Z11 is a single bond, an oxygen atom, a sulfur atom, -CO-, -SO2- or a C1-6 alkylene group which may have one or more substituents selected from [group A] and Z12 is a hydrogen atom, a C1-6 alkyl

group which may have one or more substituents selected from [group A], a C2-6

alkenyl group which may have one or more substituents selected from [group A], a C2-6 alkynyl group which may have one or more substituents selected from [group A], a C3-8 alicyclic hydrocarbon group which may have one or more substituents selected from [group A], a C6-14 aryl group which may have one or more substituents selected from [group A], a 5- to 14-membered heterocyclic group which may have one or more substituents selected from [group A], a 5- to 14-membered aromatic heterocylic group which may have one or more substituents selected from [group A], or a group represented by the formula:

)wherein Z31, Z33 and Z34 are each independently a methylene group, -CO-, -NH- or –O-, and Z32 is a single bond, a

methylene group, -CO-, -NH- or-O ,[((-a pharmaceutically acceptable salt or a hydrate thereof, wherein [group A] has the following members:

P...halogens, (2) hydroxyl, (3) thiol, (4) nitro, (5) nitrile, (6) oxo, (7) azido, (8) guanidine, (9) hydrazine, (10) isocyano, (11) cyanate, (12) isocyanate, (13) thiocyanate, (14) isothiocyanate, (15) nitroso, (16) carbamido(ureido), (17) formyl, (18) C1-6 imidoyl, (19) optionally halogenated or hydroxylated C1-6 alkyl groups, C2-6 alkenyl groups, C2-6 alkynyl groups, C3-6 cycloalkyl groups, C3-6 cycloalkenyl groups, C3-6 cycloalkenyl groups, C3-6 cycloalkynyl groups, C1-6 alkoxy groups, C2-6 alkenyloxy groups, C2-6

alkynyloxy groups, C3-6 cycloalkyloxy

groups, C1-6 alkylthio groups, C2-6 alkenylthio groups, C2-6 alkynylthio groups, C3-6 cycloalkylthio groups or C1-6 alkylenedioxy groups, (20) C6-14 aryl groups, (21) 5- to 14-membered heterocyclic groups, (22) carboxyl, (23) trifluoromethyl, (24) C6-14 aryl-C1-6 alkyl groups, (25) 5-to 14-membered heterocyclic C1-6 alkyl groups or (26) the group represented by the formula –Vxx1 –Vxx2 –Vxx3 –Vxx4 (wherein Vxx2 and Vxx3 are each independently (1) a single bond, (2) oxygen, (3) sulfur, (4) –CO-,(5)-SO-(6)-SO2-,(7)-N,Rxx1-, (8)-CONRxx1-, (9)-NRxx1CO-, (10) –SO2NRxx1-, (11)-NRxx1SO2-, (12) –O-CO-, (13) –C(O)O-, (14) –NRxx1C(O)O-(15)-NRxx1C(O)NRxx2, (16)-O-C(O)NRxx1-, (17) –O-C(O)O-, (18) a C1-6 alkylene group, (19) a C2-6 alkenyl group, (20) a C1-6 alkynyl group (21) a C3-8 alicyclic hydrocarbon group, (22) a C6-14


aryl group, (23) a 5- to 14-membered heterocyclic group or (24) a 5- to 14- membered aromatic heterocylic group; and Vxx4, Rxx1 and Rxx2 and Rxx2 are each independently (1) hydrogen, (2) a C1-6 alkyl group, (3) a C2-6 alkenyl group, (4) a C1-6

alkynyl group, (5) a C3-8 alicyclic hydrocarbon group, (6) a C6-14 aryl group, (7) a 5- to 14-membered heterocyclic group, (8) a 5- to 14-membered aromatic heterocyclic group or (9) a C1-6 alkoxy group.


189677The applications for division from this application have not yet been published

__________

155449]21][11[

stp מסוג פרוטוקול לשיפור שיטה התומכותETHERNET ברשתותVLAN ברשתות

TECHNOLOGY FOR IMPROVING STP PROTOCOLS IN ETHERNET NETWORKS SUPPORTING VLANS

]54[

15.04.2003]22[Int. Cl.8 H04L 012/46, 012/56]51[

]ECI TELECOM LTD.]71תקוה בע"מ, פתח אי.סי.איי. טלקום ,IDAN KASPIT, NOAM GOLDBERGבלטר גולדברג, איגור כספית, נעם עידן

IGOR BALTER]72[

בע"מ, אי. סי. איי. טלקוםתקוה , פתח30הסיבים רחוב

ECI TELECOM LTD,. 30 HASIVIM ST,.

PETACH TIKVA 49517

]74[

]57 [A method for utilizing a Spanning Tree Protocol STP in an Ethernet network wherein a number of VLANs are defined and a plurality of Ethernet switching nodes (A, B, C, D, E, F, G, H) are interconnected via their ports (A1,…,H4) so that each of the ports is initially assigned to one or more VLANs, and each of the VLANs is intended to enable traffic between two or more edge ports (D3, B3), the method being characterized in that, upon establishing a new STP topology related

to one or more VLANs, it comprises initiating a pruning procedure of a broadcast domain of at least one of said one or more VLANs to obtain a sub-tree for each pruned VLAN in the new STP topology, wherein each said subtree being bound by the edge ports assigned to the corresponding pruned VLAN, thereby eliminating broadcast traffic of each said pruned VLAN to any Ethernet switch extending beyond the obtained corresponding sub-tree.


__________

155563]21][11[

SYSTEM AND METHOD FORמצלמה לכיול ושיטה מערכתCAMERA CALIBRATION

]54[

25.10.2001]22[US]33[26.10.2000]32[09/697605]31[

Int. Cl.8 H04N 005/225, 007/18, 017/00]51[IMOVE INC., U.S.A.]71[





JERUSALEM 91450

]74[

]57 [A method for calibrating a panoramic camera system that captures overlapping single view images that are seamed together into a panorama, the method comprising: capturing a first single view image of a structure, the first single view image including first indicia along an edge of the structure; capturing a second single view image of the structure, the second single view image including second indicia along the same edge of the structure, wherein the first and second single view images are to be seamed

together along the edge; and adjusting one or more camera parameters for a first camera element within the panoramic camera system and adjusting one or more camera parameters for a second camera element within the panoramic camera system to seam together the first indicia with the second indicia, wherein the first single view image is captured by the first camera element and the second single view images is captured by the second camera element.


__________

155922]21][11[

מילוי חומר עם ארוג'ל מורכב חומרסיבי

AEROGEL COMPOSITE WITH FIBROUS BATTING

]54[

21.12.2001]22[US]33[22.12.2000]32[60/257437]31[

Int. Cl.8 B32B 015/04, D04H 001/02]51[ASPEN AEROGELS, INC., U.S.A.]71[




REHOVOT 76122

]74[

]57 [A composite article (10) to serve as a flexible, durable, light-weight insulation product, said article comprising a lofty

fibrous batting sheet (12) and a continuous aerogel (11) through said batting.


___________

156006]21][11[

צבאית פעילות לאימון ושיטה מערכתעירוני בשטח

SYSTEM AND METHOD FOR TRAINING IN MILITARY OPERATIONS IN URBAN TERRAIN

]54[

15.11.2001]22[US]33[22.11.2000]32[721138]31[

Int. Cl.8 F41G 003/26]51[CUBIC CORPORATION, U.S.A.]71[





TEL AVIV 61040

]74[

]57 [A system for training players in an urban combat environment, comprising: at least one stationary area effects weapon simulator including a first infrared emitter; a plurality of sets of infrared detectors, each set being worn by a player; and a plurality of player units, each player unit being carried by a player and connected to

a corresponding set of infrared detectors for logging hits on the corresponding set of detectors of infrared energy emitted from the first infrared emitter in the stationary area effects weapon simulator or a second infrared emitter mounted on a mobile small arms weapon.


__________

156034]21][11[

METHOD AND APPARATUS FORביהלום זר גוף מיקום עבור ומתקן שיטהLOCATING INCLUSIONS IN A DIAMOND

]54[

03.12.2001]22[EP]33[04.12.2000]32[00204323.

0]31[

Int. Cl.8 G01N 021/88]51[DIAMCAD N.V., BELGIUMSERGUEI BORISOVISH SIVOVOLENKO, RUSSIA

]71[

WO/2002/046725]87[ושותפיו, הס יצחק ד"ר

אביב , תל6451 , ת.ד. 279 הירקון רחוב DR. YITZHAK HESS & PARTNERS,


TEL AVIV 61063

]74[

]57 [A method for locating inclusions in a diamond, wherein said diamond is fixed on a holder, characterized in that a scan is taken of the outer surface of the diamond at an arbitrary initial position; the inclusion in the diamond is observed in at least a first and second direction of observation, wherein the translation and rotation for

every direction of observation is registered with reference to the initial position, wherein the registered translations and rotations and the scan of the outer surface are fed into a computer in order to locate the inclusion with respect to the outer surface of said diamond.

__________


156075]21][11[

חיווט באמצעות רב–משימתי מחשבוירטואלי

COMPUTER MULTI-TASKING VIA VIRTUAL THREADING

]54[

26.10.2001]22[US]33[24.11.2000]32[721695]31[

Int. Cl.8 G06F 009/38, 009/45, 009/455, 009/46, 009/48, 009/54]51[CATHARON PRODUCTIONS, INC., U.S.A.

]71[





TEL AVIV 61040

]74[

]57 [A method for operating a computer, comprising: storing in a computer memory a plurality of pseudocode instructions, at least some of said pseudocode instructions comprising a plurality of machine code instructions; for each of a plurality of tasks or jobs to be performed by the computer, automatically creating a respective virtual thread of execution context data including (a) a memory location of a next one of said pseudocode instructions to be executed in carrying out the respective task or job and (b) the values of any local variables required for carrying out the respective

task or job, a plurality of said tasks or jobs each entailing execution of a respective one of said pseudocode instructions comprising a plurality of machine language instructions; processing each of said tasks or jobs in a respective series of time slices or processing slots under the control of the respective virtual thread; and in every context switch between different virtual threads, undertaking such context switch only after completed execution of a currently executing one of said pseudocode instructions.

_________


156147]21][11[

גלי של הכוח וויסות עבור ומתקן שיטהV–BAND TR מודול עבור מילימטר

METHOD AND DEVICE FOR REGULATING THE POWER OF MILLIMETER WAVES FOR A V-BAND TR MODULE

]54[

09.11.2001]22[DE]33[04.12.2000]32[10060332.

7]31[

Int. Cl.8 H01P 001/15, 001/22]51[EADS DEUTSCHLAND GMBH, GERMANY

]71[




TEL AVIV 61063

]74[

]57 [Method to control the power of millimeter waves for a V-band TR module at a frequency in the range of 50 GHz and higher, the method comprising the acts of: separating the transmitting and receiving path via two SPDT (single pole double throw) MMIC switches; for the

transmission, using the first SPDT MMIC switch as a variable attenuator and the second SPDT MMIC switch as a detector for the output power; and by way of an electronic control circuit, the control of the output power to a defined level is achieved.

__________


156258]21][11[

שייר בעל פפטיד של לסינטזה תהליךטריפתופן

PROCESS FOR THE SYNTHESIS OF A PEPTIDE HAVING A TRP RESIDUE

]54[

19.12.2001]22[IE]33[22.12.2000]32[2000/1079]31[

Int. Cl.8 C07K 001/04, 001/06, 001/10, 007/08, 007/23]51[IPSEN MANUFACTURING IRELAND LIMITED, IRELAND

]71[





TEL AVIV 61040

]74[

]57 [A process for making a peptide of the formulapGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2, (I)wherein the His residue is protected with a tosyl group and the indole –NH of any Trp residue is protected which comprises the steps of:

)a (attaching a cesium-salt of Boc-Gly onto a chloromethylated polystyrene resin to yield Boc-Gly-resin;

)b (deblocking Boc-Gly-resin by mixing the Boc-Gly-resin with a mixture of a Boc-deblocking organic acid to yield an organic acid salt of H2N-Gly-resin;

©neutralizing the organic acid salt of H2N-Gly-resin with a base to yield H2N-Gly-resin;

)d (coupling H2N-Gly-resin with a Boc-α –amine protected amino acid, said protected amino acid corresponding to the amino acid defined for formula (I) in the order shown from the C-terminal to the N-terminal, which comprises,

)i (reacting H2N-Gly-resin with the Boc-α –amine protected amino acid in the presence of a peptide coupling agent to yield a Boc-blocked coupled product;

)ii (deblocking the Boc group from the Boc-blocked coupled product by mixing the Boc-blocked coupled product with a Boc-deblocking organic acid to yield a coupled product;

)iii (reacting the coupled product with a next Boc-α –amine protected amino acid in the presence of a peptide coupling agent to yield a Boc-blocked coupled product;

)iv (deblocking the Boc group from the Boc-blocked coupled product by mixing the Boc-blocked coupled product with a Boc-deblocking organic acid to yield a next coupled product;

)v (repeating steps (d)(iii) and (d)(iv) until the N-terminal amino acid of the peptide of formula (I) has been coupled, the Boc group of the N-terminal amino acid has been deblocked and the tosyl side chain protecting group of the His residue has


been removed to yield a protected completed peptide-resin;

)e (cleaving and deprotecting the protected completed peptide-resin to yield the peptide of formula (I), wherein said cleaving and deprotecting comprises:

)i (making a solution of the protected completed peptide-resin in a methanol/inert polar aprotic solvent mixture;

)ii (cooling the solution to about 0oC to 10oC;

)iii (bubbling ammonia gas or ethylamine gas slowly and maintaining cooling until the solution is well saturated with

ammonia to yield a saturated solution ;)iv (mixing the saturated solution without

cooling for 15-36 hours until >95% of free methyl ester is converted to the corresponding amide, when ammonia gas is used, or the corresponding ethylamide, when ethylamine gas is used;

)f (isolating said peptide from said solution.

__________

156436]21][11[

רוקחיים ותכשירים תיאזול נגזרותאותם המכילים

THIAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

]54[

19.12.2001]22[GB]33[20.12.2000]32[0031107.6]31[

Int. Cl.8 A61K 031/421, 031/426, A61P 003/08, 043/00, C07D 263/32, 263/34, 277/22, 277/32

]51[

GLAXO GROUP LIMITED, UNITED KINGDOM

]71[





TEL AVIV 61040

]74[


or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, wherein: R1 and R2 which are bonded to

the same carbon atom may together with the carbon atom to which they are bonded form a 3-6 membered cycloalkyl ring, and


at least one of R1 and R2 must be other than H; X2 is O, or S; R3, R4, and R5 are independently H, C1-3 alkyl, OCH3, CF3, allyl, or halogen; one of Y and Z is N, the other is S or O; R6 and R7 are independently H, phenyl, benzyl, fluorine

OH, C1-6 alkyl, alkyl, R6 and R7 may, together with the carbon atom to which they are bonded, represent a carbonyl group; R9 is H, CF3 or CH3; each R8 is independently CF3, C1-3 alkyl, OCH3 or halogen; y is 1 or 2.

__________

156732]21][11[

מיסבים של חוזרת לעטיפה והתקן שיטה רצועת של רצופה ליציקה מכונה של

מתכת

PROCESS AND DEVICE FOR APPLYING A RELEASE AGENT TO THE ROLLS OF A MACHINE FOR THE CONTINUOUS CASTING OF METAL STRIPS

]54[

05.02.2002]22[FR]33[08.02.2001]32[01/01724]31[

Int. Cl.8 B22D 011/06]51[NOVELIS, INC., CANADA]71[WO/2002/062508]87[


אביב



TEL AVIV 61040

]74[

]57 [A process for coating the rolls of a twin-roll continuous casting machine including the application of at least one release product to said rolls using spray means forming at least one release product jet said release product containing a

release agent and a carrier fluid, characterised in that it includes an adjustment of the composition of said release product while it is applied to said rolls without modifying the flow of the spray means.

_________

156886]21][11[

]INJECTION UNIT]54הזרקה יחידת

21.11.2001]22[US]33[23.02.2001]32[791374]31[

Int. Cl.8 B22D 017/00, 017/20, B29C 045/17]51[HUSKY INJECTION MOLDING SYSTEMS LTD., CANADA

]71[

WO/2002/066183]87[



אביב



TEL AVIV 61040

]74[

]57 [An injection assembly comprising: a barrel assembly (30), and a carriage assembly (34); the barrel assembly including first (44) and second (48) barrel portions having an axial bore therethrough, and a first barrel coupler (46), the location of the first barrel coupler defining a boundary between the first barrel portion and the second barrel portion; the carriage

assembly including a first carriage coupler to engage the first barrel coupler, and a carriage actuator (56, 58) for linking with a stationary platen of a clamp unit (12); wherein the first barrel coupler, in use, interlocks with the first carriage coupler to secure the barrel assembly in the carriage assembly, thereby isolating the second barrel portion from axial carriage force.

__________


157401]21][11[

כלי של אווירי לחימוש ושיטה מערכתטייס

APPARATUS AND SYSTEM FOR THE AIR-TO-AIR ARMING OF AERIAL VEHICLES

]54[

14.08.2003]22[Int. Cl.8 B64D 001/00, F41A 009/00]51[

]NIR PADAN]71יצחק שדה פדן, מושב נירסורוקר-אגמון,

פיתוח , הרצליה14 שנקר נולטון, רחוב בית SOROKER-AGMON,

14 SHENKAR ST ,.HERZLIYA PITUAH 46725

]74[

]57 [An apparatus for the air-to-air transfer of at least one ordnance unit from a first airborne aerial vehicle to a second airborne aerial vehicle, the apparatus comprising: an ordnance storage rack within a cargo space of the first airborne aerial vehicle to provide pre-transfer storage space to an at least one ordnance unit; a pylon installed on the second airborne aerial vehicle and intended to receive an at least one ordnance unit transferred from the first airborne aerial vehicle to the second airborne aerial vehicle; an at least one transferable ordnance unit positioned prior to transfer on the ordnance storage rack located

within the cargo space of the first airborne aerial vehicle; an extendible arm assembly attached to the first airborne aerial vehicle, the arm first end is attached to the body of the first airborne aerial vehicle, the arm second end provided with freedom of movement; an ordnance transfer assembly coupled to said extendible arm, adapted to provide for the transfer of the at least one ordnance unit from the first airborne aerial vehicle onto the pylon on the second airborne aerial vehicle; and a power generator device to provide power for the movement of the arm and the ordnance transfer assembly.


_________

157424]21][11[

מערך עבור אחיד לא רעידות חסר פיצוי רקורסיבי מסנן עם אינפרא–אדום גלאי

נמוכים מעביר מרחבי

DITHERLESS NON-UNIFORMITY COMPENSATION FOR INFRARED DETECTOR ARRAYS WITH RECURSIVE SPATIAL LOW PASS FILTERING

]54[

15.02.2002]22[US]33[16.02.2001]32[09/785833]31[

Int. Cl.8 H04N 005/217, 005/33]51[RAYTHEON COMPANY, U.S.A.]71[




BEER-SHEVA 84152

]74[

]57 [A ditherless method of compensating non-uniformities among detector elements of an infrared detector array that captures images of a scene, where each detector element of the array has at least one neighbor, comprising the steps of: determining whether there is relative motion of at least a portion of the scene and the detector array; if there is relative motion, performing a non-uniformity compensation process as follows: receiving two sets of output values, each

set representing two matrices of output data from said array, the sets being from a first field and a second field detected by the array at different times; applying any previously calculated offset correction values to the output values; for the first field, subtracting output values of neighbors in a first direction from detector element values; for the second field, subtracting output values of neighbors in a second direction from detector element values; adding the results of the two


subtracting steps; "dividing" the sum by four, thereby obtaining new offset correction values; updating any previously calculated offset correction values with the

new offset correction values; and repeating the above steps for a desired number of iterations.

__________

157502]21][11[

בעלי סיבים עם משתנה פיזור מפצה מודות בעלי וממירים מועטות מודות

להחלפה הניתנות

ADJUSTABLE DISPERSION COMPENSATOR WITH FEW MODE FIBERS AND SWITCHABLE MODE CONVERTERS

]54[

20.08.2003]22[US]33[04.09.2002]32[10/234287]31[

Int. Cl.8 G02B 006/02, 006/42, H04J 014/00]51[FITEL U.S.A. CORPORATION, U.S.A.

]71[

SIDDHARTH RAMACHANDRAN]72[ושות' בע"מ, מ. בן-דוד ירמיהו



HAR HOTZVIM HI-TECH PARK ,

]74[


P.O.B. 45087 ,JERUSALEM 91450

]57 [Method comprising:)a (transmitting an optical signal through a

first mode converter (MC) having a first switched state for converting the optical signal from a first mode to a second mode and a second switched state that does not convert the optical signal light from the first mode to the second mode,

)b (transmitting the optical signal through a first length of optical fiber having length L1, said first length of optical fiber supporting at least the first mode and the second mode, and having a first dispersion value when the optical signal is in the first mode and a second dispersion value when the optical signal is in the second mode,

©transmitting the optical signal through a second mode converter (MC) having a first switched state for converting the signal from the second mode to a mode different from the second mode and a second switched state that does not convert the signal light from the second mode to a different mode, and wherein the second MC may be switched with the first MC in the first switched state and may be switched with the first MC in the second switched state, thereby producing an optical signal output,

)d (switching the first MC to the first switched state to produce an optical signal output with the first dispersion value, and

)e (switching the first MC to the second switched state to produce an optical signal output with the second dispersion value.

___________

157724]21][11[

אוקסזול תרכובות להכנת תהליך ותרכובות5 בעמדה מותמרות

5 בעמדה מותמרות אימידאזול

PROCESS FOR PRODUCING 5-SUBSTITUTED OXAZOLE COMPOUNDS AND 5-SUBSTITUTED IMIDAZOLE COMPOUNDS

]54[

20.03.2002]22[JP]33[23.03.2001]32[2001-

84092]31[

JP23.03.20012001-84183JP23.03.20012001-84184

Int. Cl.8 C07D 233/64, 263/00, 263/32]51[NIPPON SODA COMPANY LTD., JAPAN

]71[





TEL AVIV 61040

]74[


]57 [A process for the preparation of a 5-substituted oxazole or 5-substituted imidazole, characterized in that p-tolylsufonylmethylisocyanide synthesized from N-(p-tolysulfonylmethyl) formamide with phosphorus oxychloride, phosgene or diphosgene, and a tertiary amine, which is

not isolated and purified as crystals, is reacted with an aldehyde or a compound represented by the formula [1]: R1CH=NR2

(wherein, R1 and R2 are optionally substituted phenyl, optionally substituted heterocyclic group or optionally substituted alkyl).

___________

157827]21][11[

מעוצב חלון מבנה עם מחוזק ליטוש כרגמיש או

REINFORCED POLISHING PAD WITH A SHAPED OR FLEXIBLE WINDOW STRUCTURE

]54[

29.03.2002]22[US]33[30.03.2001]32[823685]31[

Int. Cl.8 B24B 037/04]51[LAM RESEARCH CORPORATION, U.S.A.

]71[

EUGENE Y. ZHAO, KANG JIA, MICHAEL DAVID STEIMAN, HERBERT ELLIOT LITVAK, CHRISTIAN DAVID FREDERICKSON

]72[





JERUSALEM 91450

]74[

]57 [An optical window structure, comprising: a support layer (330), the layer including a reinforcement layer (330b) and a cushioning layer (330a), the cushioning layer being disposed above the reinforcement layer; a polishing pad (102) the polishing pad being attached to a top surface of the support layer; an optical

window opening (206); and a shaped optical window (372), the shaped optical window being configured to at least partially protrude into the optical window opening in the support layer and the polishing pad during operation, and the shaped optical window being separated from a side wall of the polishing pad.


__________

157998]21][11[

או אדמות של במזיקים טיפולגופרית תרכובות באמצעות סובסטרטים

PESTICIDE TREATMENT OF SOILS OR SUBSTRATES WITH SULPHUR COMPOUNDS

]54[

04.03.2002]22[FR]33[19.03.2001]32[01/03674]31[

Int. Cl.8 A01N 025/18, 041/00]51[ARKEMA FRANCE, FRANCE]71[WO/2002/074083]87[


אביב



TEL AVIV 61040

]74[

]57 [Pesticidal (nematicidal, fungicidal, insecticidal and bactericidal) treatment of soils or plant substrates by fumigation, with a cumulative effect, characterised in that at least one sulphur compound of the

formula R-S-Sx-R1 is applied to the soil or the substrate at a dose between 150 and 1000 kg/ha: in which formula R represents an alkyl or alkenyl radical containing from 1 to 4 carbon atoms, x is a whole number


equal to 0 or 1 and R1 represents an alkyl or alkenyl radical containing from 1 to 4 carbon atoms.

_________

158220]21][11[

KNEE PROSTHESIS WITH Aמתכופף ציר עם לברך תותבFLEXION HINGE

]54[

15.04.2002]22[EP]33[25.04.2001]32[01110261.

3]31[

Int. Cl.8 A61F 002/38]51[WALDEMAR LINK GMBH & CO. KG, GERMANY

]71[





TEL AVIV 61040

]74[

]57 [Knee prosthesis including a flexion hinge which is formed by a hinge fork with two branches (8) lying opposite each other, by a centre part (14) which is to be fitted into the hinge fork transversely with respect to a flexion axis of the latter, and by a hinge pin which, after the centre part has been fitted into the hinge fork, is to be

mounted, by movement in its longitudinal direction, in aligned hinge bores of the hinge fork and of the centre part, wherein the hinge pin is formed by two pin stumps which, in an assembly position, are arranged inside the centre part and, in a mounted position, partially protrude from the latter.


_____________

158221]21][11[

KNEE PROSTHESIS WITHלסיבוב מיסב עם לברך תותבROTATION BEARING

]54[

15.04.2002]22[EP]33[25.04.2001]32[01110260.

5]31[


]71[





TEL AVIV 61040

]74[

]57 [Knee prosthesis, consisting of a femoral component (1), a tibial component (3) and an intermediate piece (10, 10') which connects these and forms a flexion bearing (11) with the femoral component and a rotation bearing (14, 15) with the tibial component, which rotation bearing

can optionally be locked relative to the tibial component characterized in that the intermediate piece is alternatively provided with a projection (25) which engages in a matching recess (25) in the tibial component.


__________

158229]21][11[

נטול–מחט שסתום בעל שפופרת מתאם גדלים בעל שפופרת סגרי עם לשימוש

שונים

VIAL ADAPTER HAVING A NEEDLE-FREE VALVE FOR USE WITH VIAL CLOSURES OF DIFFERENT SIZES

]54[


07.02.2003]22[US]33[08.02.2002]32[072052]31[

Int. Cl.8 A61J 003/00, A61M 039/00]51[CARDINAL HEALTH 303, INC., U.S.A.

]71[




]74[

[57] A vial adapter for interconnecting with vial closures of different diameter, each closure having a seal, comprising: an adapter housing (23) having a first end with an inner periphery with a circular array of claws, and having a second end, the housing having a thickness at the inner periphery; and a sharpened cannula (33) extending from the first end of the adapter housing for penetrating a seal of a vial closure to establish fluid communication between the vial and the first end; wherein the array of claws comprises: a first set of claws (29) extending radially inwardly

from the inner periphery, each of which has a first length; and a second set of claws (31) extending radially inwardly from the inner periphery, each of the second set of claws having a second length that is longer than the first length of the first set of claws, each of the second set of claws adapted such that when the vial adapter is placed over a closure exceeding a selected diameter, each of the second set of claws will deflect and plastically deform thereby permitting the second set of claws to accommodate the larger closure.

_________

158259]21][11[

SYSTEM FOR GENERATINGאקראיים דמויי רצפים ליצירת מערכתPSEUDORANDOM SEQUENCES

]54[


05.04.2002]22[US]33[06.04.2001]32[60/282349]31[US23.10.2001046601

Int. Cl.8 H03M 007/00, H04J 013/00]51[INTERDIGITAL TECHNOLOGY CORPORATION, U.S.A.

]71[





TEL AVIV 61040

]74[

[57] A system for generating an OVSF code comprising: a binary counter for providing a binary count comprising a plurality of sequential M-bit binary numbers, each binary number being ordered from most significant bit to least significant bit; bit reordering means, for selectively reordering the bits of each said binary number from least significant bit to

most significant bit; an index selector, for providing an M-bit binary identification of said OVSF code; and a logical reduction means having a first input from the reordering means and a second input from the index selector and having an output; whereby the desired OVSF code is output from said output.

_________

158475]21][11[

המכילים עשבים קוטלי בנזואילציקלוהקסאנדיאונים

צמחים ומגיני

HERBICIDES COMPRISING BENZOYLCYCLOHEXANEDIONES AND SAFENERS

]54[

09.04.2002]22[DE]33[21.04.200

1]32[10119721.7]31[

Int. Cl.7 A01N 035/06, 041/10, 043/08, 043/40, 043/48, 043/80, 055/10, 057/10]51[BAYER CROPSCIENCE AG, GERMANY]71[WO/2002/085120]87[


צדק, וכהן איתן, פרל, לצר ,12688 , ת.ד. 7 שנקר רחוב

הרצליה


P.O.B. 12688 ,HERZLIYA 46733

]74[

[57] A herbicidal composition comprising(A) a herbicidally effective amount of one or more compounds of the formula

in which the symbols and indices have the following definitions:R1 is nitro, amino, halogen, cyano, (C1-C4)-alkyl, (C2-C4)-alkenyl, (C2-C4)-alkynyl, (C1-C4)-haloalkyl, (C2-C4)-haloalkenyl,-(C2-C4)-haloalkynyl, (C1-C4)-haloalkoxy, (C1-C4)-haloalkylthio, (C1-C4)-alkoxycarbonyl, (C1-C4)-alkylsuffonyl, (C1-C4)-alkylsulfinyl, (C1-C4)-alkylthio, (C1-C4)-alkoxy, (C1-C4)-alkoxy-(C1-C4)-alkoxy, (C1-C4)-alkylcarbonyl, (C1-C4)-alkylaminosulfonyl, (C1-C4)-dialkylaminosulfonyl, (C1-C4)-alkylcarbamoyl, (C1-C4)-dialkylcarbamoyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C4)-alkylamino or (C1-C4)-dialkylamino; R2 is (C1-C4)-haloalkoxy-(C1-C4)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkoxy-(C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C6)-cycloalkoxy-(C1-C4)-alkyl, (C3-C6-cycloalkyl-(C1-C4)-alkoxy, tetrahydrofuran-2-yl-methoxy-(C1-C4)-alkyl, tetrahydrofuran-3-yl-methoxy-(C1-C4)-alkyl, or a heterocyclic radical from the group consisting of isoxazol-3-yl and

4,5-dihydroisoxazol-3-yl which is substituted by a radical from the group consisting of cyanomethyl, ethoxymethyl and methoxymethyl; R3 is OR5, cyano, halogen, cyanato, thiocyanato, ((C1-C4)-alkylthio, (C1-C4)-alkylsulfinyl, (C1-C4)-alkylsulfonyl, (C2-C4)-alkenylthio, (C2-C4)-alkenylsulfinyl, (C2-C4)-alkenylsulfonyl, (C2-C4)-alkynylthio, (C2-C4)-alkynylsulfinyl, (C2-C4)-alkynylsulfonyl, (C1-C4)-haloalkylthio, (C2-C4)-haloalkenylthio, (C2-C4)-haloalkynylthio, (C1-C4)-haloalkylsulfinyl, (C2-C4)-haloalkenylsufinyl, (C2-C4)-haloalkynylsulfinyl, (C1-C4)-haloalkylsulfonyl, (C2-C4)-haloalkenylsulfonyl or (C2-C4)-haloalkynylsulfonyl; R4 is (C1-C4)-alkyl;R5 is hydrogen, (C1-C4)-alkyl, (C1-C4)-haloalkyl or (C1-C4)-alkoxy-(C1-C4)-alkyl; a is 0, 1, 2 or 3; b is 0, 1 or 2; and(B) an antidote-active amount of one or more compounds from groups (a) to (e):(a) compounds of the formulae

in which the symbols and indices have the following definitions:

n' is a natural number from 1 to 5; preferably from 1 to 3;


T is a (C1- or C2-) alkanediyl chain which is unsubstituted or substituted by one or

two (C1-C4)-alkyl radicals or by [(C1-C3)-alkoxy] carbonyl;W is a radical from the group

m' is 0 or 1;R17, R19 are identical or different and are hydrogen, halogen, (C1-C4)-alkyl, (C1-C4)- alkoxy, nitro or (C1-C4)-haloalkyl; R18, R20 are identical or different and are OR24, SR24, NR24 R25 or a saturated or unsaturated 3- to 7-membered heterocyle containing at least one nitrogen atom and up to 3 heteroatoms which is bonded by the nitrogen atom to the carbonyl group in (II) or (III) and is unsubsituted or substituted by radicals from the group consisting of (C1-C4)-alkyl, (C1-C4)-alkoxy and unsubsituted or substituted phenyl, preferably a radical of the formula OR24, NHR25 or N(CH3)2, in particular of the formula OR24;R24 is hydrogen or an unsubsituted or substituted aliphatic hydrocarbon radical, preferably having a total of from 1 to 18 carbon atoms; R25 is hydrogen, (C1-C6)-alkyl, (C1-C6)-alkoxy or substituted or unsubsituted phenyl; R26 is hydrogen, (C1-C8)-alkyl, (C1-C8)-haloalkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-hydroxyalkyl, (C3-C7)-cycloalkyl or tri-(C1-C4)-alkylsilyl;R27, R28, R29 are identical or different and are hydrogen, (C1-C8)-alkyl, (C1-C6)-haloalkyl, (C3-C12)-cycloalkyl or substituted or unsubstituted phenyl;R21 is (C1-C4)-alkyl, (C1-C4)-haloalkyl, (C2-C4)-alkenyl, (C2-C4)-haloalkenyl, (C3-C7)-cycloalkyl, preferably dichloromethyl;R22, R23 are identical or different and are hydrogen, (C1-C4)-alkyl, (C2-C4)-alkenyl,

(C2-C4)-alkynyl, (C1-C4)-haloalkyl, (C2-C4)-haloalkenyl, (C1-C4)-alkylcarbamoyl-( C1-C4)-alkyl, (C2-C4)-alkenylcarbamoyl-( C1-C4)-alkyl, (C2-C4)-alkoxy-( C1-C4)-alkyl, (C1-C4)-alkyl, (C1-C4)-alkoxy-( C1-C4)-alkyl, dioxolanyl-( C1-C4)-alkyl, thiazolyl, furyl, furylalkyl, thienyl, piperidyl, substituted or unsubstituted phenyl, or R22 and R23 together form a substituted or unsubstituted heterocyclic ring, preferably an oxazolidine, thiazolidine, piperidine, morpholine, hexahydropyrimidine or benzoxazine ring;(b) one or more compounds from the following group: 1,8-naphthalic anhydride, methyl diphenylmethoxyacetate, cyanomethoxyimino (phenyl) acetonitrile (cyometrinile), 1, 3-dioxolan-2-ylmethoxyimino (phenyl) acetonitrile (oxabetrinil), 4'-chloro-2,2,2-trifluoroacetophenone O-1,3-dioxolan-2-ylmethyl oxime (fluxofenim),4,6-dichloro-2-phenylpyrimidine (fenclorim), benzyl 2-chloro-4-trifluoromethyl-1,3-trifluoromethyl-1,3-thiazole-5-carboxylate (flurazole), 2-dichloromethyl-2-methyl-1,3-dioxolane (MG-191),N-(4-methylphenyl)-N'-(1-methyl-1-phenylethyl) urea (dymron),1-[4-(N-2-methoxybenzoylsufamoyl) phenyl]-3-methylurea,1-[4-(N-2-methoxybenzoylsulfamoyl) phenyl]-3,3-dimethylurea,1-[4-(N-4,5-dimethylbenzoylsulfamoyl) phenyl]-3-methylurea,


1-[4-(N-naphthoylsulfamoyl) phenyl]-3,3-dimethylurea,(2,4-dichlorophenoxy) acetic acid (2, 4-D),(4-chlorophenoxy) acetic acid,(R,S)-2-(4-chloro-o-tolyloxy) propionic acid (mecoprop),4-(2,4-dichlorophenoxy) butyric acid (2,4-DB),(4-chloro-o-tolyloxy) acetic acid (MCPA),4-(4-chloro-o-tolyloxy) butyric acid,

4-(4-chlorophenoxy) butyric acid,3,6-dichloro-2-methoxybenzoic acid (dicamba),1-(ethoxycarbonyl)ethyl 3,6-dichloro-2-methoxybenzoate (lactidichlor)and their salts and esters, preferably (C1-C8);(c) N-acylsulfonamides and their salts of the formula

in whichR30 is hydrogen, a carbon-containing radical such as a hydrocarbon radical, a hydrocarbon-oxy radical, a hydrocarbon-thio radical or a heterocyclyl radical, each of the 4 last-mentioned radicals being unsubstituted or being substituted by one or more identical or different radicals selected from the group consisting of halogen, cyano, nitro, amino, hydroxyl, carboxyl, formyl, carboxamide, sulfonamide and radicals of the formula –Za-Ra, each hydrocarbon moiety preferably having 1 to 20 carbon atoms and a carbon-containing radical R30 inclusive of substituents preferably having 1 to 30 carbon atoms;R31 is hydrogen or (C1-C4)-alkyl, preferably hydrogen, orR30 and R31 together with the group of the formula –CO-N- are the residue of a 3- to 8-membered saturated or unsaturated ring; R32 is identical or different and is halogen, cyano, nitro; amino, hydroxyl, carboxyl, formyl, CONH2, SO2NH2 or a radical of the formula –Zb-Rb;R33 is hydrogen or (C1-C4)-alkyl, preferably H;

R34 is identical or different and is halogen, cyano, nitro, amino, hydroxyl, carboxyl, CHO, CONH2, SO2NH2 or a radical of the formula –Zc-Rc;Ra is a hydrocarbon radical or a heterocyclyl radical, each of the two last-mentioned radicals being unsubstituted or substituted by one or more identical or different radicals selected from the group consisting of halogen, cyano, nitro, amino, hydroxyl, mono-and di-[(C1-C4)-alkyl]amino, or an alkyl radical in which a plurality, preferably 2 to 3, non-adjacent CH2 groups are in each case replaced by one oxygen atom;Rb, Rc are identical or different and are a hydrocarbon radical or a heterocyclyl radical, each of the two last-mentioned radicals being unsubstituted or substituted by one or more identical or different radicals selected from the group consisting of halogen, cyano, nitro, amino, hydroxyl, phosphoryl, halo-(C1-C4)-alkoxy, mono-and di-[(C1-C4)-alkyl]amino, or an alkyl radical in which a plurality, preferably 2 or 3, non-adjacent CH2 groups are replaced in each case by one oxygen atom;Za is a divalent group of the formula –O-, -S-, -CO-, -CO-O-, -CO-S-, -O-CO-, -S-


CO-, -SO-, -SO2-, -NR*-, -CO-NR*-, -NR*-CO-, -SO2-NR*- or –NR*-SO2-, the bond given on the right-hand side of each of the divalent groups being the bond to the radical Ra, and the radicals R* in the 5 last-mentioned radicals independently of each other being in each case H, (C1-C4)-alkyl or halo- (C1-C4)- alkyl;Zb, Zc independently of one another are a direct bond or a divalent group of the formula –O-, -S-, -CO-, -CS-, -CO-O-, -CO-S-, -O-CO-, -S-CO-, -SO-, -SO2-, -NR*-, -SO2-NR*-, -NR*-SO2-, -CO-NR*- or

–NR*-CO-, the bond given on the right-hand side of each of the divalent groups being the bond to the radical Rb or Rc and the radicals R* in the 5 last-mentioned radicals independently of one another being in each case H, (C1-C4)-alkyl or halo-(C1-C4)-alkyl;n is an integer from 0 to 4, preferably 0, 1 or 2, in particular 0 or 1, andm is an integer from 0 to 5, preferably 0, 1, 2 or 3, in particular 0, 1 or 2;(d) acylsulfamoylbenzamides optionally also in salt form, of the formula

in whichX3 is CH or N;R35 is hydrogen, heterocyclyl or a hydrocarbon radical, the two last-mentioned radicals optionally being substituted by one or more identical or different radicals selected from the group consisting of halogen, cyano, nitro, amino, hydroxyl, carboxyl, CHO, CONH2, SO2NH2 and Za-Ra;R36 is hydrogen, hydroxyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C1-C6)-alkoxy, (C2-C6)-alkenyloxy, the five last-mentioned radicals optionally being substituted by one or more identical or different radicals selected from the group consisting of halogen, hydroxyl, (C1-C4)-alkyl, (C1-C4)-alkoxy and (C1-C4)-alkylthio, orR35 and R36 together with the nitrogen atom to which they are attached are a 3-to 8-membered saturated or unsaturated ring;

R37 is halogen, cyano, nitro, amino, hydroxyl, carboxyl, CHO, CONH2, SO2NH2 or –Zb-Rb;R38 is hydrogen, (C1-C4)-alkyl, (C2-C4)-alkenyl or (C2-C4)-alkynyl;R39 is halogen, cyano, nitro, amino, hydroxyl, carboxyl, phosphoryl, CHO, CONH2, SO2NH2 or Zc-Rc;Ra is a (C2-C20)-alkyl radical whose carbon chain is interrupted once or more than once by oxygen atoms, or is heterocyclyl or a hydrocarbon radical, the two last-mentioned radicals optionally being substituted by one or more identical or different radicals selected from the group consisting of halogen, cyano, nitro, amino, hydroxyl, mono-and di-[(C1-C4)-alkyl]amino;Rb, Rc are identical or different and are a (C2-C20)-alkyl radical whose carbon chain is interrupted once or more than once by oxygen atoms, or a heterocyclyl or a hydrocarbon radical, the two last-


mentioned radicals optionally being substituted by one or more identical or different radicals selected from the group consisting of halogen, cyano, nitro, amino, hydroxyl, phosphoryl, (C1-C4)-haloalkoxy, mono-and di-[(C1-C4)-alkyl]amino; Za is a divalent unit selected from the group consisting of O, S, CO, CS, C(O)O, C(O)S, C(O)S, SO, SO2, NRd, C(O)NRd or SO2NRd; Zb, Zc are identical or different

and are a direct bond or a divalent unit selected from the group consisting of O, S, CO, CS, C(O)O, C(O)S, SO, SO2, NRd, SO2NRd or C(O)NRd; Rd is hydrogen, (C1-C4)-alkyl or (C1-C4)-alkyl or (C1-C4)-haloalkyl; r is an integer from 0 to 4, and q in the event that X3 is CH, is an integer from 0 to 5 and, in the event that X is N, is an integer from 0 to 4;(e) compounds of the formula

in which the symbols and indices have the following definitions:X is CH or N,p in the event that X = N, is an integer from 0 to 2 and, in the event that X = CH, is an integer from 0 to 3;R40 is halogen, (C1-C4)-alkyl, (C1-C4)-haloalkyl, (C1-C4)-alkoxy, (C1-C4)-haloalkoxy, nitro, (C1-C4)-alkylthio, (C1-C4)-alkylsulfonyl, (C1-C4)-alkoxycarbonyl, phenyl or phenoxy, the two last-mentioned radicals being unsubstitued or substituted by one or more, preferably up to three, identical or different radicals from the group consisting of halogen, (C1-C4)-alkyl, (C1-C4)-haloalkyl, (C1-C4)-alkoxy, nitro and cyano;

R41 is hydrogen or (C1-C4)-alkyl, andR42 is hydrogen, (C1-C8)-alkyl, (C3-C6)-cycloalkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl or aryl, each of the aforementioned carbon-containing radicals being unsubstituted or substituted by one or more, preferably up to three, identical or different radicals from the group consisting of halogen, nitro, cyano, hydroxyl, (C1-C8)-alkoxy, in which one or more, preferably up to three, CH2 groups may be replaced by oxygen, (C1-C4)-alkylthio, (C1-C4)-alkenyloxy and (C2-C4)-alkynyloxy, inclusive of the stereoisomers and the agriculturally customary salts.

__________

158481]21][11[

SYNTHESIS OF VERIFICATIONודאות שפות של בניהLANGUAGES

]54[

10.06.2002]22[US]33[15.06.2001]32[09/880888]31[

Int. Cl.8 G06F 009/45]51[]VERISITY LTD.]71העין בע"מ, ראש וריסיטי

YARON KASHAI, MATTHEW JOHN ]72[


MORLEYWO/2002/103517]87[


גן , רמת11



]74[

[57] A method for at least semi-automatically translating code written in a first language to a second target language, the first language featuring structural constraints and featuring dynamic behavior, wherein the first language features a hierarchy of objects, such that relationships between the objects are determined by constraints, the method comprising: detecting an underlying

control structure for the code in the first language; creating a static framework of resources for supporting the dynamic behavior of the code written in the first language; and mapping the dynamic behavior to the second target language according to said static framework of resources and said underlying control structure.

_________

158515]21][11[

]LASER RANGE FINDER]54לייזר טווח מד

17.05.1999]22[US]33[18.05.1998]32[09/080437]31[

Int. Cl.8 G01C 003/08, G02B 005/30, H04N 007/00]51[DIVISION FROM 138684]62[


LITTON SYSTEMS, INC., U.S.A.]71[WO/1999/060787]87[




]74[

[57] A laser range finder apparatus, said apparatus comprising: a laser light source (110) for projecting a pulse of laser light (110a) toward an object in a scene, the range to which is to be determined, so that a portion of said projected laser light illuminates the object and is reflected back toward said apparatus; an image intensifier tube (14) receiving reflected laser light from the object and substantially upon receiving the reflected laser light

responsively providing an electrical output, said image intensifier tube carrying a pre-amplifier circuit amplifying said electrical output; a timer device (130) for measuring a time interval from projection of said pulse of laser light until a time of said electrical output by said image intensifier tube; and a calculator (134) determining the range from the apparatus to the object using said time interval and the speed of light as a measuring standard.

__________

158535]21][11[

טיפול עבור וקאום שקית עם מכשירבלחץ

DEVICE WITH VACUUM BAG FOR PRESSURE THERAPY

]54[

21.10.2003]22[SI]33[21.10.2002]32[SIP-

200200258]31[

Int. Cl.8 A61F 005/37, A61H 007/00]51[JOZE JELENC, REPUBLIC OF SLOVENIA

]71[

VOGRIN SASA]72[



ירושלים



JERUSALEM 91450

]74[

[57] A device with vacuum bag for pressure therapy, comprising a vacuum bag, a control and measuring unit, a housing (1), and special liner clothing (5), characterized in that a control and measuring unit is equipped with a pressure gauge (2) and with vacuum pump connections (3), to which suction tubes (4) for sucking the air from the bag are attached; that the bag has six evenly arranged connections (6) for the suction tubes and a measuring connection (7) for a measuring tube, which links the interior of the bag with the pressure gauge, so that the under-pressure is measured directly in the

bag; that special liner clothing is provided for the user, the liner clothing comprising several pieces designed for different parts of the body and that the said clothing pieces are made of two layers of fabric sewn together with longitudinal seams to form pockets, filled with granulated material; that the granulated material fits tight to the body because also the air between the granules is sucked out, when the air is sucked out of the vacuum bag; that the liner clothing pieces are bound together by means of hook and loop fasteners.

__________

158678]21][11[

עם בצירוף שומניות בחומצות שימושתרופה בהכת אנזים מעכב

USE OF FATTY ACIDS TOGETHER WITH ENZYME INHIBITOR IN THE PREPARATION OF A MEDICAMENT

]54[

09.05.2002]22[


GB]33[09.05.2001]32[011282.0]31[Int. Cl.8 A61K 031/19, 031/20, 031/405, 031/415, A61P 019/02, 025/28, 035/00]51[AMARIN NEUROSCIENCE LIMITED, UNITED KINGDOM

]71[

DAVID FREDERICK HORROBIN]72[WO/2002/089787]87[


ירושלים



JERUSALEM 91450

]74[

[57] Use of a fatty acid preparation containing: (a) more than 70% eicosapentaenoic acid (EPA) or eicosapentaenoic acid derivative and less than 10% docosahexaenoic acid or a docosahexaenoic acid derivative and less than 10% linoleic acid or a linoleic acid derivative; and(b) an enzyme inhibitor selected from an inhibitor of COX-1 and/or COX-2, an inhibitor of LOX and an inhibitor of one or more of the FACL enzymes in the preparation of a medicament for the treatment of any of the following diseases or disorders: any form of psychiatric

disease including schizophrenia, schizoaffective disorders, schizotypy, depression, anxiety, bipolar disorder, mania, borderline personality disorder, alcoholism and attention deficit hyperactivity disorder or any other psychiatric illness; and any form of neurological or neurodegenerative disease including Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis or any other "triplet repeat" disease, multi-infarct or other form of dementia, multiple sclerosis, chronic fatigue and epilepsy.

_________

158722]21][11[

מאפיינים ושליפת לגילוי ושיטה מערכתופסיבי רציף איתור של ביישומים

SYSTEM AND METHOD FOR DETECTION AND FEATURE EXTRACTION IN PASSIVE COHERENT LOCATION APPLICATIONS

]54[

06.05.2002]22[US]33[04.05.2001]32[60/288493]31[

Int. Cl.8 G01S 007/292, 013/00, 013/50, 013/87]51[LOCKHEED MARTIN CORPORATION, U.S.A.

]71[

KEVIN W. BAUGH, ROBERT H. BENNER

]72[

WO/2002/091009]87[סורוקר-אגמון,

, הרצליה14 שנקר נולטון, רחוב בית SOROKER-AGMON,

14 SHENKAR ST ,.HERZLIYA PITUAH 46725

]74[


פיתוח

[57] A passive coherent location radar system having a detection and feature extraction processing sub-system to detect targets and determine target parameters from ambiguity surface data of an ambiguity surface, comprising: a peak/noise discriminator to compare previous ambiguity surface data to said ambiguity surface data and to update bins correlating to said previous ambiguity

surface data; new bins identified by said peak/noise discriminator for new target echoes within said ambiguity surface; a peak associator to group said bins and said new bins identified by said peak/noise discriminator to form peak detections correlating to said targets; and a parameter estimator to estimate said target parameters from said peak detections.

__________

158740]21][11[

וכלים בין-חולייתי דיסק פרוטזהלהתאמה

INTERVERTEBRAL DISC PROSTHESIS AND FITTING TOOLS

]54[

03.05.2002]22[FR]33[04.05.2001]32[01/05982]31[

Int. Cl.8 A61F 002/44]51[LDR MEDICAL, FRANCE]71[JACQUES BEAURAIN, JOEL DELECRIN, MICHAEL ONIMIS, HERVE CHATAIGNTER, JEROME

]72[


STEIBWO/2002/089701]87[

בע"מ, פרידמן מרק ד"ר ז'בוטינסקי , רח54אביב, ק. משה מגדל

, רמת- גן7



RAMAT GAN 52520

]74[

[57] An intervertebral disc prosthesis for replacement of a fibrocartilaginous disc between adjacent elements of a spinal column, comprising:an upper plate (3) comprising an internal face and an external face adapted to support one of the adjacent elements of the spinal column; a lower plate (1) comprising an internal face and an external face adapted to support the other of the adjacent elements of the spinal column; a nucleus (2) displaceable in translation or rotation or both with respect to the upper plate and the lower plate, the nucleus comprising an upper face, a lower face, and a perimeter surface; loadbearing sliding surfaces (23) comprising a contact

surface disposed on the internal face of the upper plate and a complementary contact surface disposed on the upper face of the nucleus and a contact surface disposed on the internal face of the lower plate and a complementary contact surface disposed on the lower face of the nucleus; and a stop (4) comprising plural parts including a peripheral part (1) of the nucleus disposed along the perimeter surface of the nucleus and a stop surface (12) protruding from at least one of the upper plate and the lower plate, said plural parts of the stop being arranged to limit the displacement of the nucleus in translation or rotation or both with respect to at least one of the upper plate and the lower plate.

_________

158840]21][11[


אלחוטית להצפנה ושיטה מערכתבכבל פעילים גידים ממערכת

WIRELESS CRYPTOGRAPHIC FILL SYSTEM AND METHOD

]54[

12.11.2003]22[US]33[13.11.2002]32[292442]31[

Int. Cl.8 G06F 002/100000 G06K 017/00, H04L 009/10]51[HARRIS CORPORATION, U.S.A.]71[


אביב



TEL AVIV 61040

]74[

[57] A cryptographic fill system (20) for providing a cryptographic key to a host processor (26) for enabling secure operations by the host processor, the system comprising: a portable fill device (22) configured to encode at least one cryptographic key; a host portion (24) configured to be communicatively coupled to the host processor (26); and a wireless communications system (28) configured to communicate said cryptographic key of

said device to said host portion to enable secure operations by the host processor; wherein said fill device and said host portion include mutually engageable physical components (38, 39) configured to prevent unauthorized access to the cryptographic key while the cryptographic key is communicated from said fill device to said host portion by the wireless communications system.

__________

158870]21][11[

MECHANICAL STRUCTUREחופש דרגות שש המספק מכני מבנהPROVIDING SIX DEGREES OF FREEDOM

]54[

13.11.2003]22[


Int. Cl.8 B25J 009/06]51[בע"מ, חיפה ופיתוח למחקר הטכניון מוסד

בע"מ, לחימה אמצעי לפתוח רפאל- רשותחיפה

TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.

RAFAEL-ARMAMENT DEVELOPMENT AUTHORITY LTD.

]71[

MOSHE SHOHAM, RONEN BENבמברגר בן-חורין, חגי שהם, רונן משהHORIN, HAGAY BAMBERGER

]72[




]74[

[57] Mechanical structure providing motion in six degrees of freedom, which comprises:(a) a main plate (11);(b) a base (61);(c) at least three supporting structures (14), each comprising a lower, bridge-like section supported by the base, and an upper section connected to said bridge section and to said main plate, wherein:(I) said bridge-like structure comprising two supporting plates, two intermediate plates, (22, 24) and one middle plate (23), all being serially connected one to another by means of four transversal hinges;(II) each pair of said supporting plates being slidable in linear displacement parallel to the base;

(III) said upper section comprising two plates (26, 27), a lower plate connected to said middle plate by means of a hinge transversal to said lower plate but longitudinal with respect to said middle plate, and an upper plate connected to said lower plate by means of a longitudinal hinge and to said main plate by means of a transversal hinge;(d) at least six linear motors connected each to a corresponding supporting plate, for applying a force thereon in order to effect a linear displacement of said plate; and(e) control means for determining the linear displacement of each linear motor.


__________

158880]21][11[

למחצה דו–מפלסי מטריצה מפסקעצמאי באופן המסונכרן

SELF-SYNCHRONIZING HALF DUPLEX MATRIX SWITCH

]54[

20.08.2002]22[US]33[22.08.2001]32[60/313825]31[

Int. Cl.8 G06F 013/00]51[AVOCENT CORPORATION, U.S.A.]71[





TEL AVIV 61040

]74[

[57] A datalink for operatively linking one or more computers to one or more computer peripheral devices and monitors remotely located from said one or more computers, the datalink comprising: a plurality of master state devices, each including a master transceiver for operatively linking one of said computers to the datalink, and each constructed and adapted to receive a stream of computer data packets from a computer connected thereto, to sample the computer data packets into a stream of consecutive computer samples, and to load the

consecutive computer samples, sample-by-sample, into a stream of master frames, one sample per master frame; one or more slave state devices, each including a slave transceiver for operatively linking one or more peripheral devices to the datalink, and each constructed and adapted to receive one or more streams of peripheral data packets from peripheral devices connected thereto, to sample the peripheral data packets into one or more streams of consecutive peripheral samples, and to load said peripheral samples into a stream of slave frames; and a matrix switch


including: cross-point connection circuitry providing switchable paths between selected master state devices and selected one or more slave state devices; and a processor, out of the switchable paths, controlling the establishment of said switchable paths, wherein each said master state device is further constructed and adapted to send as a downstream transmission a master frame in its stream of master frames to a slave transceiver connected thereto via a datalink path, to be decoded at the slave transceiver connected thereto into a stream of computer data packets and, wherein each slave state device is further constructed and adapted

to send as an upstream transmission a slave frame in its stream of slave frames to a master transceiver connected thereto via a path in the datalink, said one of the slave frames to be decoded at the master transceiver connected thereto into streams of peripheral data packets, said selected master state devices self-synchronizing communications with said selected one or more slave state devices independently of each other's downstream transmissions of available computer data bits and awaiting receipt of upstream transmission of corresponding available peripheral data bits.

__________

158925]21][11[

METHOD OF COLOUR MARKINGבצבע פולימריים חומרים סימון שיטתPOLYMERIC MATERIAL

]54[

04.06.2002]22[GB]33[12.06.2001]32[0114266.0]31[

Int. Cl.8 C08J 007/00, G03C 001/73]51[CIBA SPECIALTY CHEMICALS HOLDING INC., SWITZERLAND

]71[

WO/2002/101462]87[



אביב



TEL AVIV 61040

]74[

[57] Method of colouring a polymeric material, characterized in that a polymeric material containing

(a) a latent acid of the formula

wherein ring A can contain one or more hetero atoms and/or can contain an anelated ring, R1 is hydrogen, alkyl, alkenyl, aryl,R2, R3, R4 and R5 independently of each other are hydrogen or a functional substituent, andR stands for C1-C6 alkyl, -Z1-Q1, or –Z2-Q2,wherein Z1 is a single bond, S, NH or O, and Q1 is a heterocyclic ring system having from 5 to 9 ring atoms selected from C, S, O and N, with at least 2 carbon atoms in the ring system, preferably Q1 stands for morpholine, pyridine, which may be substituted one to three times with C1-C4 alkyl or hydroxy, mercaptobenzoxazole, mercaptobenzthiazole, and wherein Z2 stands for C1-C4 alkylene, which can be substituted by C1-C4 or Q3, wherein Q3

stands for phenyl which can be substituted one to three times with C1-C4 alkyl, hydroxy, C5-C8 cycloalkyl and/or a heterocylic ring system having from 5 to 9 ring atoms selected from C, S, O and N, with at least 2 carbon atoms in the ring system, and Q2 stands for phenyl which can be substituted one to three times with C1-C4 alkyl, hydroxy, C5-C8 cycloalkyl and/or a heterocyclic ring system having from 5 to 9 ring atoms selected from C, S, O and N, with at least 2 carbon atoms in the ring system, with the proviso that the hydrogen atom at the C-atom in α-position to R can be split off by irradiation(b) a colour former and(c) optionally further ingredientsis irradiated with a UV-laser using UV-light of 285 to 400 nm.

__________158982]21][11[

COOLING SYSTEM FOR Aפוטוקוסמטי להתקן קירור מערכתPHOTOCOSMETIC DEVICE

]54[

23.05.2002]22[US]33[23.05.2001]32[60/292827]31[US18.01.200210/052474US12.03.200260/363798US12.03.200260/363871

Int. Cl.8 A61B 018/18]51[


PALOMAR MEDICAL TECHNOLOGIES, INC., U.S.A.

]71[




REHOVOT 76122

]74[

[57] A photocosmetic device for use on an area of a patient's skin comprising: a treatment head for use in close proximity to the patient's skin; at least one source (125) for generating electromagnetic radiation positioned within the treatment head and configured to project radiation onto the area of skin; a cooling surface

thermally coupled to the at least one source; and a mechanism to direct phase change substance onto the cooling surface such that at least a portion of said substance changes its phase following contact with said surface in response to absorbing heat therefrom.




_________

159149]21][11[

המבוססים סוספנסיה בצורת תרכיזיםשמן על

OIL-BASED SUSPENSION CONCENTRATES

]54[

10.06.2002]22[DE]33[21.06.2001]32[10129855.

2]31[


Int. Cl.8 A01N 025/04]51[BAYER CROPSCIENCE AG, GERMANY

]71[




P.O.B. 4060 ,TEL AVIV 61040

]74[

[57] Oil-based suspension concentrates, consisting of at least one agrochemical active compound which is solid at room temperature, at least one penetration promoter selected from alkanol alkoxylates of the formulaR-O-(AO)mHin whichR represents straight-chain or branched alkyl having 4 to 20 carbon atoms,AO represents an ethylene oxide radical, a propylene oxide radical, a butylene oxide radical or mixture of ethylene oxide and

propylene oxide radicals or butylene oxide radicals andm represents from 2 to 30,at least one vegetable oil,at least one non-ionic surfactant or dispersing aid and/or least one anionic surfactant or dispersing aid and optionally one or more additives from the groups consisting of the emulsifying agents, the antifoam agents, the preservatives, the anti-oxidants, the colourants and/or the inert filling materials.

___________

159163]21][11[

עבור נגיעה המונעת מסביב סגירהאלקטרוניים מעגלים

ANTI-TAMPERING ENCLOSURE FOR ELECTRONIC CIRCUITRY

]54[

02.12.2003]22[US]33[20.12.2002]32[10/326726]31[

Int. Cl.8 H01L 023/02]51[]VERIFONE ISRAEL LTD.]71העין בע"מ, ראש ישראל וריפון]YITZCHAK COHEN, ARNON AVIV]72אביב כהן, ארנון יצחק



]74[


REHOVOT 76122רחובות

[57] An electronic circuit assembly comprising: a plurality of printed circuit boards (46) including electrical circuits, said plurality of printed circuit boards defining a protected enclosure including at least one protected enclosure wall defining printed circuit board and a protected enclosure surrounding edge defining printed circuit board; and electronic

components (50), located within said protected enclosure, mounted on at least one of said plurality of printed circuit boards in electrical communication with said electrical circuits, said electronic components including at least an anti-tamper circuit and a destruct circuit operated by said anti-tamper circuit.

___________

159316]21][11[

פרטיות להבטחת ושיטה מערכתשיחה משתתפי

SYSTEM AND METHOD FOR SECURING PRIVACY OF CHAT PARTICIPANTS

]54[

28.06.2002]22[US]33[09.07.2001]32[09/901332]31[

Int. Cl.8 H04L 029/06]51[TELEFONAKTIEBOLAGET LM ERICSSON (PUBL), SWEDEN

]71[



P.O.B. 1352,]74[


JERUSALEM 91013

[57] A method for providing privacy to a client accessing a chat application on a chat server, comprising the steps of: transmitting a request for the chat application from the client to a first proxy server; transmitting the request for the chat application from the first proxy server to a second proxy server; providing a unique ID to the first proxy server from the second proxy server responsive to the request; transmitting the request for the chat application and the unique ID from

the second proxy server to the chat server; transmitting a response and the unique ID from the chat server to the second proxy server responsive to the request; storing the response at the second proxy server with the unique ID; accessing the stored response from the first proxy server by providing the unique ID, and erasing the stored response and the unique ID in the second proxy server responsive to an access by the first proxy server.

__________

159411]21][11[

מיסב עם יחד מצומדת תותבת ברךמסתובב

COUPLED KNEE PROSTHESIS WITH A ROTATIONAL BEARING

]54[

21.06.2002]22[EP]33[27.06.2001]32[01115511.

6]31[


]71[

WO/2003/002039]87[



אביב



TEL AVIV 61040

]74[

[57] A knee-joint prosthesis, consisting of: a femoral component that has sliding condylar surfaces (20), which surfaces are rigidly interconnected, tibia component (2) that is non-rotatably connected to tibia plateau (7), which plateau comprises: sliding tibial surfaces (21) interacting with the sliding condylar surfaces, and mating arrangement that together with the femoral component defines pivot and, together with the tibia component, defines rotary

bearing whose rotation axis (12) is inclined with respect to the tibia; characterized in that, in the side view or on the sagittal section, normal to the area to the sliding tibial surfaces, in which area said surfaces interact with the sliding condylar surface and in which area a load is transferred mainly in the extended position, is disposed at a smaller angle to the tibia than the angle between the rotary bearing axis and the tibia.

___________159447]21][11[


גזי של החום חתימת להפחתת מתקןפליטה

DEVICE FOR REDUCING THE SIGNATURE OF HOT EXHAUSTING GASES

]54[

21.06.2001]22[Int. Cl.8 B60K 013/04]51[FORSVARETS MATERIELVERK, SWEDEN

]71[

URBAN MATHIASSON]72[WO/2003/004296]87[



P.O.B. 12688 ,HERZLIYA 46733

]74[

[57] A device for reducing the signature of hot gases from an exhaust (7) of a unit, said device comprising a mixing element (9) for mixing the hot gases with fresh air from the exterior of the unit to form a gas mixture to be discharged to the exterior of the unit, and a protecting component (10)

which relative to the unit is arranged outside the mixing element or parts thereof, said protecting component reducing reflection of incoming surveillance radiation and including through ducts for passing at least parts of the gas mixture to the exterior.

___________

159494]21][11[

–2–'6 נגזרות )פוספונומתאוקסי(אלקוקסי

נגד פעילות בעלות פירימידיןנגיפים

6-2(-'PHOSPHONOMETHOXY)ALKOXY PYRIMIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY

]54[

28.06.2002]22[US]33[29.06.200

1]32[60/302212]31[

Int. Cl.8 A61K 031/662, A61P 031/12, C07F 009/00, 009/6512]51[REGA STICHTING V.Z.W., BELGIUM]71[


THE INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC, CZECH REPUBLICWO/2003/002580]87[

ושותפיו, כהן ריינהולד ,4060 , ת.ד. 21 העם אחד רחוב

אביב תל


P.O.B. 4060 ,TEL AVIV 61040

]74[

[57] A compound of the formula

whereR1 is H, amino or methylsulfanyl;

R2 is methyl, halo, -N(R5)2, hydroxy, protected hydroxy or a group of the formula

R3 is independently H, methyl, hydroxymethyl, halomethyl or protected hydroxymethyl; R4 is H or halo;X independently is oxygen, sulfur or a bond;

Z independently is hydroxy, an ester or amide;R5 is independently H, C1-C8 alkyl or protecting group; and* designates a chiral carbon atom; andsalts and solvates thereof.

___________

159648]21][11[

EYE PROTECTION METHODSהעיניים להגנת ושיטה התקןAND APPARATUS

]54[

30.12.2003]22[US]33[19.03.2003]32[60/455583]31[US29.12.200310/745580

Int. Cl.8 A61F 009/00]51[June 5, 2008118 –התשס"ח ב' בסיון

5

GPT GLENDALE, INC., U.S.A.]71[ושותפיו, כהן ריינהולד




TEL AVIV 61040

]74[

[57] An eye protection apparatus, comprising:a selectively darkenable element (102); and a controller (200) that detects a trigger signal (410) that triggers an emission of

diffuse light, and causes transmission of a darken signal that causes the selectively darkenable element to darken in conjunction with the emission of the diffuse light.

__________

159653]21][11[

ELECTRO-HOLOGRAPHICאלקטרו-הולוגרפית עדשהLENS

]54[

30.12.2003]22[Int. Cl.8 G03H 001/00]51[

הלוי-פוליץ, חיפה יעקבפישר, חיפה אוריאל

JACOB HALEVY-POLITCHURIEL FISCHER

]71[

לצר, צדק כהן פרל , ת.ד.5 , רח' שנקר1 גב-ים מרכז

, הרצליה12704

PEARL COHEN ZEDEK LATZER, 5 SHENKAR ST ,.

P.O.B. 12704,HERZLIYA 46733

]74[


[57] An electro-optic system for concentrating a light beam (84) that is incident from a moving light source onto at least one predetermined target, the system comprising: at least one of a plurality of layers of electro-holographic lens devices comprising: an active layer (3) made from a transparent photo-refractive material, whose refractive index may be locally modified by locally applying an electric field; an array of electrodes (2) in a predetermined density, provided adjacent the active layer for locally providing electric fields across an array of

predetermined locations in the active layer; a tracking unit (22) for tracking the position of the light source; a control unit (5) for applying and controlling application of electric fields in a dynamically controllable predetermined location obtained from the tracking unit, the information relating to the location of the light source for creating a dynamically changing holographic fringe pattern across the active layer, creating a dynamically changing concentrating lens, so as to continuously focus the light beam onto the at least one predetermined target.

__________

159660]21][11[

]PROTECTIVE HEADGEAR]54מגן ראש כיסוי

10.07.2002]22[GB]33[13.07.2001]32[0117140.4]31[

Int. Cl.8 A42B 001/08]51[SCOTT INTERNATIONAL LIMITED, UNITED KINGDOM

]71[





]74[

[57] A shell for fitting withing a headcap to provide a degree of protection from impacts, said shell being of a generally concave shape, and being formed with a pair of slots (6), one on each side of the shell characterised by each slot opening into the back side (4) of the shell and extending forwards in a generally back to front direction towards the front (3) of the shell over a greater proportion of the front-to-back length of the shell, so as to effectively divide the shell into different regions, together making up said concave shape: a top region (7) extending, when

worn, back to front over the top to the head and merging into a front region (8) which extends, when worn, across the front of the head and two lateral regions (10) extending, when worn, back to front across respective sides of the head and merging into the front region, and wherein each slot separates a respective lateral region from the top region and the slots being of a width sufficient to enable the respective lateral region to be flexed towards and away from the top region to thereby enable the size of the shell to be altered to accommodate a range of head sizes..

____________

159910]21][11[

בסיס על העובדת חשמלית גילוח מכונתפעימות

PULSED ELECTRIC SHAVER]54[

21.07.2002]22[US]33[23.07.2001]32[60/306892]31[US05.02.200260/354019

Int. Cl.8 B26B 019/00]51[RADIANCY, INC., U.S.A.]71[

WO/2003/009976]87[ , ת.ד. אריה , קרית1 כניסה12 בזל

תקוה , פתח10256FENSTER & COMPANY,

INTELLECTUAL PROPERTY LTD,.]74[



PETACH TIKVA

[57] A hair cutting apparatus comprising:a structure (506), a portion (512) of which being adapted for placement against a skin surface (524) where hair is to be cut; a heat generator (300) comprising one or more heat elements at least one of said heat elements being juxtaposed with said

portion; and a controller (320) that controls the power source to provide pulsed heating of said one or more heat elements characterized in that said one or more heat elements are positioned to touch the hair and are heated to a temperature sufficient to cut hair.


__________

159971]21][11[

]ELECTRIC SHAVER]54חשמלית גילוח מכונת

21.07.2002]22[US]33[23.07.2001]32[60/306892]31[US05.02.200260/354019

Int. Cl.8 B26B 019/00]51[RADIANCY, INC., U.S.A.]71[

WO/2003/009977]87[בע"מ, רוחני ושות',קניין פנסטר

, ת.ד. אריה , קרית1 כניסה12 בזל תקוה , פתח10256

FENSTER & COMPANY, INTELLECTUAL PROPERTY LTD,.


PETACH TIKVA

]74[

[57] A hair cutting apparatus comprising: a structure (506), a portion (512) of which beign adapted for placement against a skin surface (524) where hair is to be cut; and a heat generator (300) comprising one or more heat elements heated to a temperature sufficient to cut hair, at least one of said heat elements being juxtaposed

with said portion, characterized in that said one or more heat elements are positioned to touch said skin; and in that it includes a controller (320) that controls said heat generator to prevent heat from being applied continuously in a single area for sufficient time to cause skin damage.


__________

160070]21][11[

התקנים עבור אלקטרו–מגנטי מיגוןאלקטרוניים

EMI SHIELDING FOR ELECTRONIC PACKAGES

]54[

26.07.2002]22[US]33[01.08.2001]32[09/921062]31[


Int. Cl.8 H01L 023/552]51[INTERNATIONAL BUSINESS MACHINES CORPORATION, U.S.A.

]71[

WO/2003/012867]87[עו"פ, בע"מ עמיתים אלפאפטנט

שמש , בית55 רח' ראובן ALPHAPATENT LTD,.

55 REUVEN ST,.BET SHEMESH 99544

]74[

[57] An electronic package incorporating shielding against the emissions of electromagnetic interference (EMI); comprising: a circuitized substrate (12) of a dielectric organic material having opposite first and second surfaces, said first surface having a first portion and second portion; an electrically-conductive ring-shaped continuous ground band (32) being embedded in said substrate extending proximate the perimeter of said substrate and extending between said second portion of said first surface and said second surface; a semiconductor chip (14) being arranged on said first portion of said first surface; a plurality of electrically conductive circuit members (16) being positioned on said first portion of said first surface of said substrate each being electrically coupled to said semiconductor chip; a lid member (18) comprising an electrically conductive material being arranged on a surface of said semiconductor chip distal from the surface facing said substrate, said ground band being electrically connected with at least one electrically conductive member

arranged on the second surface of said substrate, said lid member and at least one said electrically conductive circuit member on said first portion of the first surface of said substrate so as to impart an electromagnetic shield to said electronic package, a compliant and electrically conductive adhesive (20) being arranged between said semiconductor chip and said lid member, and an electrically conductive stiffener (24) being positioned on said second portion on the first surface of said substrate, said stiffener being electrically connected to at least one of said electrically conductive circuit members on said first portion on said first surface of said substrate, to at least one electrically conductive member on the second surface of said substrate through said electrically conductive ground band and in electrical connection with said lid member, an electrically conductive adhesive being arranged between said striffener and said ground band and between said stiffener and said lid member so as to form said electrical connections between said elements.

__________


160154]21][11[

ושרוול ליבה הכולל ודומיו דנטלי שתלהדבקה ידי על המחוברים קרמי

DENTAL IMPLANT OR THE LIKE COMPRISING A CORE AND A CERAMIC SLEEVE ASSEMBLED BY BONDING

]54[

17.07.2002]22[FR]33[03.08.2001]32[01/10428]31[

Int. Cl.8 A61C 008/00]51[SUDIMPLANT COMPANY, FRANCE]71[WO/2003/013385]87[

עורכי – דין עורכי מהולל – איתן קבוצתפטנטים,

,2081 , ת.ד. 10 אבן אבא שדרות הרצליה



]74[

[57] An implant for dental use or the like, of the type of implant comprising a metallic or synthetic core (1) and an external ceramic sheath (2) at least partially enveloping the core, these being connected to each other by adhesive bonding, characterised in that the external ceramic sheath is formed by a sleeve distinct from the core, attached to the latter by sliding fitting and fixed by adhesive bonding, forming between them a space

(3) for the adhesive of sufficient volume to absorb impacts that an implant undergoes, thus fulfilling a damping role, without for all that causing any consequent play between the core and the ceramic sleeve, and in that the space for adhesive formed between the corresponding walls of the core and sleeve is formed by a separation J between these walls of between approximately 80 and 150 microns.


___________

160337]21][11[

עם נמוכה עלות בעלת חסם של שרווליתזיהוי מתקן

LOW COST TOURNIQUET CUFF WITH IDENTIFICATION APPARATUS

]54[

08.08.2002]22[US]33[14.08.2001]32[930341]31[

Int. Cl.8 A61B 017/135]51[WESTERN CLINICAL ENGINEERING LTD., CANADA

]71[

JAMES ALLEN MCEWEN, KEVIN BRYANT INKPEN, MICHAEL JAMESON, KENNETH L. GLINZ

]72[





JERUSALEM 91450

]74[

[57] A low cost tourniquet cuff with identification apparatus, comprising: an outer strip (68); an inner strip (80)

positioned against the outer strip; a gas-tight seal (104) joining the inner strip to the outer strip to form a cuff having a physical characteristic wherein the cuff


includes an inflatable bladder (60) of a length greater than the circumference of a limb at a selected location; and a cuff connector (20) carried on the cuff and communicating pneumatically with the bladder for releasably connecting to a tourniquet instrument to establish a gas-tight passageway between the bladder and

the instrument, wherein the cuff connector includes identification means (32) indicative of the physical characteristic and detectable by the tourniquet instrument upon establishment of the gas-tight passageway irrespective of whether the gas-tight passageway is pressurized.

__________


160486]21][11[

CITALOPRAM FOR THEגבוהה דם בלחץ לטיפול ציטאלופרםTREATMENT OF ELEVATED BLOOD PRESSURE

]54[

13.03.2003]22[HU]33[14.03.2002]32[P0200980]31[

Int. Cl.8 A61K 031/343, 045/00, A61P 009/12, C07D 307/00, 307/87]51[EGIS GYOGYSZERGYAR RT., HUNGARY

]71[





TEL AVIV 61040

]74[

[57] Use of citalopram or a pharmaceutically acceptable salt thereof for the preparation of pharmaceutical compositions suitable for the treatment of

elevated (high) blood pressure, normalization of blood pressure or the decrease of blood pressure and/or prevention of elevated blood pressure.

__________

160692]21][11[

MALLEABLE CRYOSURGICALנמוכה בטמפרטורה לניתוח חשיל בוחןPROBE

]54[

19.09.2002]22[US]33[20.09.2001]32[09/957337]31[

Int. Cl.8 A61B 017/00]51[ENDOCARE, INC., U.S.A.]71[

WO/2003/024313]87[ושות', כהן שלמה ד"ר

אביב , תל11490 , ת.ד. 124 גבירול אבן DR. SHLOMO COHEN & CO,.

124 IBN GABIROL ST,.P.O.B. 11490 ,

TEL AVIV 62038

]74[

[57] A malleable cryosurgical probe, comprising:(a) a cryostat assembly, comprising:(i) an elongated shaft assembly (12) having at least one malleable segment (28) thereof and a closed distal end (34), said shaft

assembly, including: at least one freezing portion (24); at least one thermally insulated portion; and a thermally insulating element positioned about said thermally insulated portion, said thermally insulated element being adjustably


positionable to control the location, size and shape of said freezing portion,(ii) a cryostat (14) operably associated with said elongated shaft assembly, comprising: a cryostat inlet (42) for receiving gas entering said cryostat; a cryostat outlet (44); and a heat exchanger having a distal end positioned proximally from said freezing portion, said heat exchanger being positioned between said cryostat outlet and said cryostat inlet, said heat exchanger for receiving gas from said cryostat inlet and providing heat transfer between gas flowing within said cryostat and fluid exterior thereto; and,(iii) a plurality of longitudinally spaced Joule-Thomson nozzles (16) in fluid communication with said cryostat outlet, said plurality of Joule-Thomson nozzles for expanding gas expelled therefrom, the expanded cold fluid communicating with

said at least one freezing portion to provide cooling thereof; and, (b) a cryoprobe assembly (18), comprising: a handle assembly for supporting said cryostat assembly, said handle assembly having an outer diameter greater than said freezing portion and said thermally insulated portion, said handle assembly, comprising: an anchor (48) securely connected to said cryostat assembly; an o-ring (50) secured to said anchor for preventing fluid from escaping through said handle assembly: and a handle securely connected to said anchor; and, a fluid supply line assembly connectable to a fluid source at one end and to said cryostat inlet at a second end, wherein said heat exchanger is positioned at a location longitudinally spaced from said at least one freezing portion and inside a volume formed by said handle assembly.

_________

160887]21][11[

למיטת מיטה מעמד לחיזוק חיבור מתקןמשאית

FASTENING ASSEMBLY FOR SECURING BEDLINER TO TRUCK BED

]54[

15.03.2004]22[TH]33[18.03.2003]32[030300021

8]31[

Int. Cl.8 B60R 013/01, B62D 025/20, 027/00]51[AEROFLEX INTERNATIONAL CO., ]71[


LTD., THAILANDלוצאטו, את לוצאטו



BEER-SHEVA 84152

]74[

[57] A fastening assembly for securing a bed linear to a truck bed, the truck bed having an inward extended bed rail, the bed liner having at least one hole (42), the fastening assembly comprising: a base member (1) for engaging a clamp member (4) through the bed liner hole, the base member including a back surface that is pressed by the clamp member with the bed liner wall and the bed rail in between, the base member having at least one extended direction control rod (14) unitarily formed thereon and extending generally perpendicularly from the back surface for insertion through the bed liner hole, the clamp member having at least one continuous closed cross-sectional through

hole for insertion of the extended direction control rod of the base member therein, the hole of the clamp member can be moved along the extended direction control rod of the base member when the clamp member is assembled to the base member, the hole extending through the clamp member from a first side to a second side, the first side facing the base member and the second side facing away from the base member in an assembled position, the clamp member able to be inserted through the hole in the bed liner wall when the clamp member is engaged with the base member; and a tie-down ring for attaching to the base member.

___________


160924]21][11[

STABILIZATION OF AMRUBICINאמרובצ'ין הידרוכלוריד של ייצובHYDROCHLORIDE

]54[

22.10.2002]22[JP]33[23.10.2001]32[2001-

324591]31[

JP23.10.20012001-324596Int. Cl.8 A61K 031/704, A61P 035/00, C07H 005/06, 015/252]51[SUMITOMO CHEMICAL COMPANY, LIMITED, JAPANDAINIPPON SUMITOMO PHARMA CO., LTD., JAPAN

]71[




TEL AVIV 61063

]74[

[57] A stabilized amrubicin hydrochloride composition which comprises 92 to 97% by weight of

amrubicin hydrochloride and 3 to 8% by weight of water.

__________

161077]21][11[

]CUTTING TOOL]54חיתוך כלי

20.09.2002]22[US]33[02.10.2001]32[09/969234]31[

Int. Cl.8 B23B 051/02]51[KENNAMETAL INC., U.S.A.]71[


, ירושלים1352ת.ד. WOLFF, BREGMAN AND GOLLER,


]74[

[57] A rotary cutting tool comprising: a shank having a receiver comprising: a

shank guide at a trailing end of the receiver; opposing shank drive keys at a


leading end of the receiver; and a shank locator axially between the shank guide and the shank drive keys, the shank drive keys each comprising an axially extending shank drive key radical stop surface that is disposed at an angle relative to a plane extending through a central axes of the receiver; and a head having a connector comprising: a head guide at a trailing end of the connector; opposing head drive keys at a leading end of the connector; and a

head locator portion axially between the head guide and the head drive keys, the head drive keys each comprising an axially extending head drive key radial stop surface that is disposed at an angle relative to a plane extending through a central axes of the connector, wherein each shank drive key radial stop surface is adapted to angularly align with a corresponding head drive key radial stop.

__________

161214]21][11[

COMPOSITIONS FOR DELIVERYתרופות תערובת של לנתינה תכשיריםOF DRUG COMBINATIONS

]54[

03.10.2002]22[US]33[03.10.2001]32[60/326671]31[US17.12.200160/341529US15.02.200260/356759CA23.04.20022383529US07.08.200260/401984US06.09.200260/408733

Int. Cl.8 A61K 009/00]51[CELATOR PHARMACEUTICALS, INC.

]71[




]74[


[57] A pharmaceutical composition for parenteral administration, comprising particulate delivery vehicles having associated therewith at least a first antineoplastic agent and a second antineoplastic agent, wherein said first and second agents are in a

mole ratio which exhibits a non-antagonistic cytotoxic or cytostatic effect and wherein said first and second agents are associated with the delivery vehicles to maintain a non-antagonistic ratio in the blood on administration.



__________

161238]21][11[

חבילות של לקופסאות אלקטרוני התקןעבורן הפעלה ושיטות

ELECTRONIC DEVICE FOR PACKET BOXES AND RELATED OPERATING METHOD

]54[

07.10.2002]22[DE]33[09.10.2001]32[10149622.

2]31[

Int. Cl.8 A47G 029/14, G07C 009/00, G07F 017/12]51[DEUTSCHE POST AG, GERMANY]71[BORIS MAYER, GUELDERN TUNA]72[WO/2003/032789]87[





]74[

[57] An electronic parcel compartment system with a user interface, whereby the user interface has a means for acquiring information from users of the electronic parcel compartment system, characterized in that the electronic parcel compartment system has a means for assigning the users

to user groups and in that the electronic parcel compartment system is provided with a system control that allows a user to have access to a selection of several functions of the electronic parcel compartment system, depending on the user group to which the user belongs.


___________

161239]21][11[

חבילות תאי של מערכות לבקרת שיטותאלקטרוניות

METHOD FOR CONTROLLING ELECTRONIC PARCEL COMPARTMENT SYSTEMS

]54[

07.10.2002]22[DE]33[09.10.2001]32[10149619.

2]31[

Int. Cl.8 A47G 029/14, G07C 009/00, G07F 017/12]51[DEUTSCHE POST AG, GERMANY]71[WO/2003/032788]87[





]74[

[57] A method for controlling electronic parcel package compartment systems, characterized in that data for controlling the electronic parcel compartment system is stored on a server and converted into control commands for controlling the parcel compartment system, in that a checking procedure is carried out in the

area of a server to see whether changes have been made in the data stored on the server and in that the control commands are transmitted via an interface to the parcel compartment system as soon as a predefinable number of changes have been made to the data stock.

__________

161632]21][11[

]METHOD AND APPARATUS FOR ]54 בתנאי לשליטה ומכשיר שיטה


CONTROLLING ATMOSPHERICאטמוספירהCONDITIONS

25.12.2002]22[IL]33[25.12.2001]32[147287]31[

Int. Cl.8 A01G 015/00, E01H 013/00]51[ של המחקר לפיתוח חברה יישום

בירושלים, ירושלים העברית האוניברסיטהYISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM

]71[





TEL AVIV 61040

]74[

[57] A method of controlling atmospheric conditions in a portion of the atmosphere containing microscopic water droplets dispersed therein so as to produce their desired coalescence and precipitation, the method including:(a) providing a predetermined amount of a seeding material having uncharged seeding elements of a predetermined size distribution;(b) calculating a predetermined polarity and charge magnitude of seeding elements

by using a collision model describing collisions between said charged seeding elements and said microscopic water droplets;(c) electrically charging the uncharged seeding elements so as to produce charged seeding elements having said predetermined polarity and charge magnitude, and(d) seeding said charged seeding elements in said portion of the atmosphere.

___________

161736]21][11[

BENZOPHENONE DERIVATIVESמזה מלחים או בנזופאנון תולדותOR SALTS THEREOF

]54[

13.11.2002]22[JP]33[16.11.2001]32[2001-

351217]31[

JP18.07.20022002-209382Int. Cl.7 A61K 031/185, 031/192, A61P 019/02, 029/00, C07C 059/90, 065/34, 065/40, 069/738, 069/76, 069/88, 069/94, 217/76, 235/42, 255/54, 259/10, 271/64, C07D 209/48, 239/88, 241/08, 257/04, 261/12, 333/22

]51[

TOYAMA CHEMICAL CO., LTD., ]71[


JAPANWO/2003/042150]87[



P.O.B. 6451 ,TEL AVIV 61063

]74[

[57] A benzophenone derivative of the formula:

whereinR1 represents a substituted or unsubstituted heterocyclic group, a substituted phenyl group, or a substituted or unsubstituted alkyl group;Z represents a substituted or unsubstituted alkylene group;R2 represents a substituted or unsubstituted heterocylic group, a substituted or unsubstituted heterocyclic carbonyl group or a protected or unprotected carboxyl group;R3 represents a hydrogen atom, a halogen atom, a cyano group, a nitro group, a protected or unprotected carboxyl group, a protected or unprotected hydroxyl group, a protected or unprotected amino group, a mercapto group, a carbamoyl group or a substituted or unsubstituted alkyl, alkenyl, cycloalkyl, aryl, aralkyl, alkoxy, aryloxy,

acyl, alkoxycarbonyl, aryloxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, acylamino, alkylsulfonylamino, arylsulfonylamino or heterocyclic group;R4 represents a substituted or unsubstituted alkoxy, cycloalkyloxy, cycloalkenyloxy, alkyl, cycloalkyl, heterocyclic-oxy or heterocyclic group;R3 represents a hydrogen atom, a halogen atom or a hydroxyl group, provided that, when R1 represents a substituted or unsubstitued alkyl group, R4 represents a substituted or unsubstituted cycloalkyloxy group, an alkoxy group substituted with a substituted or unsubstituted phenyl or heterocylic group or a substituted or unsubstituted heterocylic-oxy group, or a salt thereof.

__________

161922]21][11[

RECLOSABLE POURINGחוזרת לסגירה הניתן מזיגה אלמנטELEMENT

]54[


26.11.2002]22[DE]33[26.11.2001]32[10157685.

4]31[

Int. Cl.8 B65D 005/74]51[SIG ALLCAP AG, SWITZERLAND]71[WO/2003/045797]87[


אביב



TEL AVIV 61040

]74[

[57] A reclosable pouring element for being applied to a multilayer composite packaging, particularly a parallelepiped-shaped cardboard/plastic composite packaging, with a base body (1) and a pouring tube (3) that is integrally joined thereto in an articulated fashion and simultaneously designed as an opening element for puncturing the packaging wall

of the packaging in a weakened zone provided for this purpose, characterized in that the pouring tube is joined to the base body by means of a surrounding flexible membrane (4) and folded flat in the closed state, namely such that the flatly folded pouring tube is clamped in a sealed fashion between a clamping edge (8) and a clamping crosspiece (10) of the base body.

_________

162526]21][11[

]INSECT HOLDER]54לחרקים מתקן

20.12.2002]22[EP]33[22.12.2001]32[01310854.

3]31[

Int. Cl.8 A01K 049/00]51[


INSCENTINEL LIMITED, UNITED KINGDOM

]71[





TEL AVIV 61040

]74[

[57] An insect holder for holding an insect of a particular type, the holder comprising a housing (40) with a chamber adapted to receive said insect, an inlet to the chamber through which said insect can pass to enter the chamber, a head opening (56) to the chamber adapted to permit the head of said insect in the chamber to pass therethrough to the exterior of the housing while retaining the insect in the housing, and retaining means for retaining said insect in the chamber with the head to the

insect protruding through the head opening to the exterior of the housing, such that the insect is unable to turn around in the chamber, wherein the retaining means comprise a collar or barb (70) locatable between the head and thorax, between the thorax and abdomen or behind the abdomen of an insect in the chamber, and wherein the collar or bard is movable between an open position and a closed or latched position.

__________


162552]21][11[

למחצה חדירה מרובעת ממברנהלייצורה ותהליך

COMPOSITE SEMIPERMEABLE MEMBRANE AND PRODUCTION PROCESS THEREOF

]54[

16.06.2004]22[JP]33[18.06.2003]32[2003-

172955]31[

JP29.08.20032003-306322Int. Cl.8 B01D 067/00, 069/12, 071/56]51[TORAY INDUSTRIES, INC., JAPAN]71[


אביב



TEL AVIV 61040

]74[

[57] A composite semipermeable membrane which comprises a separating functional layer comprising polyamide formed on a porous substrate film, wherein a monofunctional primary amine or an aliphatic acyl group is bound to or adsorbed in the inside or on the surface of the separating functional layer; wherein the composite semipermeable membrane removes boron while satisfying the following relationship when seawater at 25oC having a pH of 6.5, a boron concentration of 5 ppm and a total

dissolved solids (TDS) concentration of 3.5% by weight is permeated under an operation pressure of 5.5 MPa; boron removal ratio (%)≥95-4 x membrane permeation flow rate (m3/m2•day) and wherein the composite semipermeable membrane has a TDS transmission coefficient which is 3 x 10-8 m/s or less, when seawater at 25oC having a pH of 6.5, a boron concentration of 5 ppm and a TDS concentration of 3.5% by weight is permeated under an operation pressure of 5.5 MPa.

___________

162801]21][11[

הדבקות ולמניעת פצעים לריפוי תכשירלפצעים תחבושות

PREPARATION FOR WOUND HEALING AND PREVENTION OF BANDAGE ADHESION TO THE WOUND

]54[

15.01.2003]22[CZ]33[18.01.2002]32[PUV02-

12746]31[

Int. Cl.8 A61L 015/00, 026/00]51[CPN SPOL S.R.O., CZECH REPUBLIC

]71[

WO/2003/059404]87[צדק, וכהן איתן, פרל, לצר EITAN, PEARL, LATZER AND, הרצליה12688 , ת.ד. 7 שנקר רחוב


COHEN ZEDEK, P.O.B. 12688 ,

HERZLIYA 46733

]74[

[57] Preparation for wound healing and prevention of adhesion to the wound characterized by the content of a physiologically acceptable salt of

hyaluronic acid having the molecular weight from 200 000 to 2 500 000, iodine and potassium iodide.

____________

162942]21][11[

במחליפי לשימוש הפיץ מחורץ צינורחום

REVERSIBLE GROOVED TUBE FOR HEAT EXCHANGERS

]54[

10.03.2003]22[FR]33[12.03.2002]32[02/03067]31[

Int. Cl.8 F28F 001/40]51[TREFIMETAUX S.A., FRANCE]71[WO/2003/076861]87[


אביב



TEL AVIV 61040

]74[

[57] Grooved metal tubes, of thickness Tf at the bottom of the groove, outer diameter De, intended for the manufacture of heat exchangers operating in evaporation or condensation or in reversible mode and using a phase transition coolant, said tubes being grooved internally with N helical ribs of an apex angle α, height H, base

width LN and helical angle β, two consecutive ribs being separated by a typically flat-bottomed groove of width LR, with a pitch P equal to LR+LN, and wherein said tubes show a Cavallini factor at least equal to 3.1, the tubes further comprising an axial grooving creating in said ribbing notches with a triangular profile with a


rounded top, said top showing an angle y ranging from 25 to 65o, said top is at a distance h from the bottom of said grooves ranging from 0 to 0.2 mm, characterised in that,(a) the outer diameter De is between 4 and 20 mm,(b) the number N of ribs ranges from 46 to 98, particularly as a function of the diameter De,

(c) the rib height H ranges from 0.18 mm to 0.40 mm, particularly as a function of the diameter De,(d) the apex angle α ranges from 15o to 30o,(e) the helical angle β ranges from 18o to 35o so as to obtain simultaneously a high heat exchange coefficient both in evaporation and condensation, a low pressure loss and the lightest possible tube.

__________

162969]21][11[

יחידות הכוללים פוליתיאופנים בקבלים אלקילנאוקסיתיאתיאופן

אלקטרוליטים

POLYTHIOPHENES HAVING ALKYLENEOXYTHIATHIOPHENE UNITS IN ELECTROLYTE CAPACITORS

]54[

12.07.2004]22[DE]33[14.07.2003]32[10331673.

6]31[

Int. Cl.7 C08G 075/00, H01G 009/025]51[H.C. STARCK GMBH, GERMANY]71[


אביב


P.O.B. 4060 ,TEL AVIV 61040

]74[

[57] Electrolyte capacitor comprising:a layer of an oxidizable metal;

a solid electrolyte;contacts;


characterized in that it comprises, as the solid electrolyte, polythiophenes having repeating units of the general formula (I)

or repeating units of the general formulae (I) and (II),

where A is an optionally substituted C1-C5-alkylene radical,R is a linear or branched, optionally substituted C1-C18-alkyl radical, an optionally substituted C5-C12-cycloalkyl radical, an optionally substituted C6-C14-aryl radical, an optionally substituted C7-

C18-aralkyl radical, an optionally substituted C1-C4-hydroxyalkyl radical or a hydroxyl radical,x is an integer from 0 to 8 andin the case that a plurality of R radicals are bonded to A, may be the same or different, and optionally counterions.

__________

163133]21][11[

]BACKFLOW PREVENTER]54חוזרת זרימה מונע

21.07.2004]22[Int. Cl.8 E03C 001/10]51[

אגודה נוזלים להולכת א.ר.י. אביזריםחרוב כפר בע"מ, קיבוץ חקלאית שתופית

A.R.I. FLOW CONTROL ACCESSORIES AGRICULTURAL COOPERATIVE ASSOCIATION LTD.

]71[


אביב



TEL AVIV 61040

]74[

[57] A reduced pressure zone backflow preventer (10) comprising a body (12) formed with an inlet port (14) accommodating an inlet check valve assembly (120) and an outlet port accommodating an outlet check valve assembly (122), said check valve assemblies extending along a coaxial axis coinciding with a longitudinal axis of the body, a central space (60) formed between

said check valves accessible through a service opening in the body, a relief valve assembly (70) received within the central space and a drain port (88) extending from said space; said relief assembly is responsive to pressure differential between the inlet port and the space by a flow passage (210) extending between the inlet port and an upper side (220) of a pressure diaphragm (72) of the relief valve


assembly; wherein the entire body is made of plastic material and wherein the space accommodates a retention member (68) fixedly receivable within the space and extending between the check valve

assemblies so as to bear axial loads applied by said check valves, though without transferring axial loads between said check valve assemblies.

__________

163425]21][11[

PERSONAL DESCENTאישי נסיגה מתקןAPPARATUS

]54[

18.02.2003]22[US]33[28.02.2002]32[10/085291]31[

Int. Cl.8 A62B 001/12]51[BORIS GELMAN, TURKEY]71[WO/2003/072199]87[


גן , רמת11



]74[

[57] A portable, lightweight apparatus for use by a user for safely descending from a high elevation, said apparatus comprising:(a) a drum (12) rotatably mounted on a mounting frame (14);(b) a body securing device (40) for securing said mounting frame to the body of the user; and(c) a line (20) wound around the drum, said line having a first end attached to the drum and a second end (22) for attachment to any fixed object at the high elevation;

such that the user may conveniently use the device to safely descend from the high elevation by attaching the mounting frame to the user's body and the second end of the line to the fixed object at the high elevation; and (d) a descent control device comprising an oil damper including a shaft coaxially coupled to said drum wherein drum rotation causes said oil damper to pump oil through a channel against resistance, said resistance exerting a


retarding force against said rotation of said drum thereby controlling the rate of descent of the user.

__________

163427]21][11[

צילנדרים בעל פנימית בעירה מנועלהפעלתו ושיטה משולבים

INTERNAL COMBUSTION ENGINE WITH COUPLED CYLINDERS AND METHOD FOR OPERATING IT

]54[

10.08.2004]22[Int. Cl.8 F01C 003/02, F02B 053/00]51[

]LEONID GERBER]71גרבר, ירושלים לאונידגרבר, לאוניד

, ירושלים417/3 יעקב נווה LEONID GERBER,

417/3 NEVE YAKOV, JERUSALEM

]74[

[57] A rotary internal combustion engine (2) comprising:(a) a stator (4) containing a single toroidal volume;(b) a rotor (20), at least a portion of which travels a path defined by said toroidal volume;wherein said rotor and said stator define between them at least a first pair (24) of toroidal cylinders deployed within said single toroidal volume, said pair of toroidal cylinders being in selective fluid

communication such that a first of said pair of toroidal cylinders performs intake and compression strokes, a resultant compressed fuel/air mixture is transferred to a second (22) of said pair of toroidal cylinders, in which combustion occurs and expansion and exhaust strokes are performed, and during each cycle there is at least one period when said first and second toroidal cylinders are isolated and at least one period when said selective fluid communication is established so as to


allow said transfer of said compressed fuel/air mixture.

___________

163493]21][11[

]MARKING DEVICE]54סימון מכשיר

12.02.2003]22[AU]33[13.02.2002]32[PS0489]31[

Int. Cl.8 B41J 002/01, B41K 001/36]51[SILVERBROOK RESEARCH PTY. LTD., AUSTRALIA

]71[




BEER-SHEVA 84152

]74[

[57] A marking device for printing indicia on print media, the marking device including: a housing (10); a printing mechanism (30) within the housing, including; a printing means for printing said indicia; storage means for storing information required to print said indicia;

moving means for moving said printing means with respect to said housing and said print media during printing, processor means for processing said information and for controlling said printing means to print said indicia as said printing means is moved with respect to said print media.


__________

163574]21][11[

–N[ – 3 של ד' אסטר להכנת תהליך בוטילקוסיקרבונילאמינו( – )טרט

חומצה – אמינואתיל2פרופיל[ – פוספונית

PROCESS FOR THE PREPARATION OF A DIESTER OF N – [3 – (T- BUTYLOXYCARBONYLAMINO) - PROPYL] – 2 –AMINOETHYL PHOSPHONIC ACID

]54[

31.07.1998]22[US]33[08.01.1997]32[905091]31[

Int. Cl.8 C07F 009/00, 009/40, 009/645]51[DIVISION FROM 134082]62[WYETH, U.S.A.]71[




P.O.B. 4060 ,TEL AVIV 61040

]74[

[57] A process for the preparation of N-[3-(t-butyloxycarbonylamino) propyl]-2-aminoethylphosphonic acid di-C1-C6 alkyl ester which comprises reacting a

vinylphosphonate di-C1-C6 alkyl ester with 3-aminopropyl carbamic acid 1,1-dimethylethyl ester.

_________


163785]21][11[

ENERGETIC PLASTICIZER FORנפץ חומר מטעני עבור אנרגטי מרכךEXPLOSIVE CHARGES

]54[

29.08.2004]22[Int. Cl.8 C06B 025/12]51[



]71[

בע"מ, פרידמן מרק ד"ר ז'בוטינסקי , רח54אביב, ק. משה מגדל

, רמת- גן7



RAMAT GAN 52520

]74[

[57] An energetic material suitable for high-energy, plastic-bonded, explosive charges, the material comprising an energetic plasticizer including an energetic

nitrobutyl formal, wherein a composition of said energetic plasticizer contains at least 50%, by weight, of said energetic nitrobutyl formal.



_________

163907]21][11[

HAND-HELD SELF DEFENSEמוחזק–ביד עצמית להגנה מתקןDEVICE

]54[

06.03.2003]22[US]33[11.03.2002]32[10/093695]31[

Int. Cl.8 B05B 011/04, F41H 009/00, G01F 011/00]51[]CHAIM DAVIDIAN]71דוידיאן, בצרה חיים

WO/2003/076881]87[בע"מ, פרידמן מרק ד"ר




RAMAT GAN 52520

]74[

[57] A self-defense device (16) for holding in a single hand of a user, the self-defense device comprising:(a) a chamber including:

(i) a rigid outer wall (10) having a butt for bracing the device against a palm of the hand, and


(ii) a flexible outer wall (13) attached to said rigid outer wall, and(b) an ejection assembly including:(i) a tube (28) extending through said chamber, and having a first end for fluidly communicating therewith;(ii) a valve (44) attached to said tube, for opening and closing thereof;(iii) a mechanism attached to said valve and configured to alter a position of said valve using a single digit of the single

hand while grasping the device in a firing position, and(iv) a nozzle (24) attached to a second end of said tube and communicating with an environment external to the device,said chamber being designed and configured such that external pressure exerted upon said flexible outer wall increases an internal pressure of said chamber, such that fluid is forcefully and directedly ejected from the device through said tube and out said nozzle.

___________

164095]21][11[

הקשורות במחלות לטיפול תכשירלקויה תאית ביןGAP בתקשורת

COMPOSITION FOR TREATMENT OF DISEASES INVOLVING DEFECTIVE GAP JUNCTIONAL COMMUNICATION

]54[

21.03.2003]22[US]33[21.03.2002]32[60/366363]31[

Int. Cl.8 A23G 001/00, A23K 001/16, A61K 031/353, A61P 003/06]51[MARS, INCORPORATED, U.S.A.]71[





TEL AVIV 61040

]74[


[57] Use of a compound selected from a cocoa flavanol and an oligomer thereof in the manufacture of a medicament, food, nutraceutical or dietary supplement for use

in treating a subject suffering from cognitive dysfunction, wherein the cocoa flavanol has the structure:

and the oligomer is a compound or pharmaceutically acceptable salt thereof of the formula

whereinn is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;R is 3-(α)-OH, 3-(β)-OH;bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;

a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;X, Y and Z are selected from the group consisting of monomeric units A or hydrogen, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen.


___________

164475]21][11[

OIL RECOVERY ANDשמנים וספיחת סביבתי לניקוי תכשיריםENVIRONMENTAL CLEANUP COMPOSITIONS

]54[

03.04.2003]22[AU]33[08.04.2002]32[PS1612]31[

Int. Cl.8 B01D 039/14, B01J 020/26]51[DAVID CHARLES ROBINSON, AUSTRALIA

]71[



P.O.B. 12688 ,HERZLIYA 46733

]74[

[57] An oil adsorbent polymeric composition for adsorption of chemicals and hydrocarbons from land and water, the adsorbent composition including

polyethylene/vinyl acetate copolymer, catalyst, cross linking agent, lubricant, blowing agent and bulking agent, wherein said lubricant is a fatty acid.

_________

164553]21][11[

APPARATUS FORחונה רכב של בסביבה לשליטה מערכתCONTROLLING THE ENVIRONMENT OF A PARKED VEHICLE

]54[

22.04.2003]22[US]33[22.04.2002]32[60/375038]31[US11.09.2002241208

Int. Cl.8 B60H 001/22]51[IDLEAIRE TECHNOLOGIES CORP., U.S.A.

]71[





TEL AVIV 61040

]74[


[57] A unit (10) for providing services to a stationary vehicle (11) through an opening (19) in said vehicle comprising: a head unit (18) having a generally mating configuration with said opening; said head unit having a body portion and a cover (34); said cover adapted to open into said vehicle to provide access to said services; a

closure mechanism adapted to release said cover permitting opening of said cover only when said head is located in said opening and further adapted to prevent said head from separating from said opening if said cover is not closed on said head.

__________

164747]21][11[

SYSTEM AND METHOD FORנשק פגיעת להערכת ושיטה מערכתMUNITION IMPACT ASSESSMENT

]54[

05.06.2000]22[US]33[26.11.1999]32[09/449750]31[

Int. Cl.8 F42B 015/04]51[DIVISION FROM 136565]62[

]TADIRAN SPECTRALINK LTD.]71בע"מ, חולון ספקטרלינק תדיראן]MOSHE SHNAPS]72שנפס משהבע"מ, פרידמן מרק ד"ר




RAMAT GAN 52520

]74[

[57] A system for determining the impact success of a self guided munition (10) which is launched or dropped from a platform, the system comprising an impact verification assembly (24) being

integrateable into the self guided munition, said impact verification assembly including:


(a) a processing unit (26) for receiving and processing information from an onboard guidance system (18) of the self guided munition, said information pertaining to an in-flight trajectory position of the self guided munition prior to impact, said processing unit further being for generating a signal including information pertaining to an accuracy of said in-flight trajectory position of the self guided munition prior to impact with respect to a target; and

(b) a transmitter (28) being in communication with said processing unit, said transmitter being for transmitting said signal generated by said processing unit in a manner receivable by a receiving device of the platform; wherein said signal pertaining to said accuracy of said in-flight trajectory position of the guided munition prior to impact includes information indicating an impact success or an impact failure of the self guided missile.

__________

164873]21][11[

טבע הליכי להאצת ותהליך מבנה ממי–ים, שתיה מי של מתמשכת להפקה

וגלי הרוח השמש אנרגיית ניצול ידי עלהים

PROCESS AND STRUCTURE FOR SUPERACCELERATING NATURE, PRODUCING A CONTINUOUS SUPPLY OF FRESH WATER FROM SALT WATER BY USING SOLAR, WIND AND WAVE ENERGY

]54[

30.04.2003]22[US]33[02.05.2002]32[60/377,769]31[

Int. Cl.8 B01D 003/02, 005/00, C02F 001/14]51[DESAL, LLC, U.S.A.]71[



P.O.B. 12688 ,HERZLIYA 46733

]74[


[57] A process for desalinating water, said process comprising providing a blackened surface (46) in contact with a body of water so as to heat air and evaporate said water from said blackened surface; channeling said heated air and water vapor upward through a vertical Venturi wind shaft (10) creating an adiabatic pressure variance so as to release

said water vapor into a first chamber of a series of interconnected chambers (5) allowing said water vapor to condense within said chambers; draining said desalinated water from said chambers; expelling said heated air from said chambers; and, retaining said desalinated water.

_________

165071]21][11[

תת–קבוצה להמריץ היכולת עם פפטידנפוצה טרשת מחוליT תאי– של

PEPTIDE CAPABLE OF STIMULATING A SUBGROUP OF T-CELLS FROM MULTIPLE SCLEROSIS PATIENTS

]54[

28.03.1991]22[US]33[30.03.1990]32[502559]31[

Int. Cl.8 A61K 038/17, A61P 025/00, 029/00, C07K 007/08, 014/47, 014/705, 014/725

]51[

DIVISION FROM 97709]62[AUTOIMMUNE, INC., U.S.A.

BRIGHAM AND WOMEN'S HOSPITAL, U.S.A.

]71[


רחובות


REHOVOT 76122

]74[

[57] A peptide the amino acid sequence of which is all or a segment of the sequence SEQ ID NO: 2 provided that said segment comprises a portion of the

sequence SEQ ID NO: 1 sufficient to impart to said peptide the property of stimulating, as determined by proliferation assay, the subgroup of T-cells of the DR2+


type from remitting-relapsing multiple sclerosis patients that is reactive with another peptide the sequence of which consists of SEQ ID NO:1, said peptide

stimulating said subgroup of T-cells to about the same degree as said another peptide.

__________165621]21][11[

CUTTING TOOL AND CUTTINGעבורו חיתוך ושימת חיתוך כליINSERT THEREFOR

]54[

07.12.2004]22[Int. Cl.8 B23C 005/08, 005/22, B23D 027/04]51[

]ISCAR LTD.]71בע"מ, תפן ישקר]GIL HECHT, EHUD LEVANON]72לבנון הכט, אהוד גיל

בע"מ, ישקר, תפן11, ת.ד.

ISCAR LTD,. P.O.B. 11,

TEFEN 24959

]74[

[57] A cutting insert (14) comprising: an upper surface (26), a lower surface (28) and a peripheral surface therebetween, the peripheral surface comprising: opposing forward (30) and rear (32) surfaces and opposing side surfaces (34) extending between the forward and rear surfaces, a through bore (36) extending between the forward and rear surfaces, the upper

surface comprising a rake surface (38), the forward surface comprising a forward relief surface (40) and the intersection of the rake surface and the forward relief surface forming a forward cutting edge (44) the lower and rear surfaces being generally V-shaped in both a first cross-section and a second cross-section, respectively.


____________

165854]21][11[

חתוך ראשי שני בעלת חיתוך שימתמנוגדים

CUTTING INSERT HAVING TWO OPPOSITE CUTTING HEADS

]54[

16.06.2003]22[AT]33[21.06.2002]32[GM400/2002]31[

Int. Cl.8 B23B 027/04]51[CERATIZIT AUSTRIA GESELLSCHAFT M.B.H, AUSTRIA

]71[



P.O.B. 12688 ,HERZLIYA 46733

]74[

[57] Cutting insert (1) having two cutting heads (2, 2') which lie opposite one another in relation to its longitudinal axis A and which are connected together by a centre part which is offset inwards in the direction of the longitudinal axis A, so that the centre part is narrower than the cutting heads, and wherein each cutting head comprises an end-face cutting edge (3) which extends substantially transversely to the longitudinal axis A and two lateral cutting edge portions (4) which extend substantially in the direction of the longitudinal axis A of the cutting insert, wherein the associated flanks of the cutting

edges form an angle α1 of less than 90o with a plane Pr through the highest point of the cutting edges parallel to the longitudinal axis A, wherein the flanks of the lateral cutting edge portions of the two opposite cutting heads, which are disposed on the same side of the cutting insert, in each case lie in a common plane E, characterised in that the end-face cutting edge is circular, and that the lateral cutting edges extend away from the end-face cutting edge in a downward sloping manner at an angle α2 in the range of 5o to 25o in relation to the plane Pr.


__________166089]21][11[

EVAPORATIVE DUPLEXנגדית בזרימה מתאדה כפול חום מחליףCOUNTERHEAT EXCHANGER

]54[

15.07.2003]22[US]33[20.07.2002]32[60/397322]31[US28.10.200260/421754

Int. Cl.8 B01F 003/04, B01J 012/00, F28C 001/00]51[IDALEX TECHNOLOGIES, INC., U.S.A.

]71[

LELAND E. GILLAN, ALAN D. GILLAN, VALERIY S. MAISOTSENKO, TIMOTHY L. HEATON

]72[

WO/2004/009225]87[בע"מ, פרידמן מרק ד"ר




RAMAT GAN 52520

]74[

[57] A duplex exchanger (22); comprising:a first heat exchanger (24) including a first main flow channel (28) and a first counterheat channel (30) joined in flow communication therewith; a second heat exchanger (26) including a second main

flow channel (32) and a second counterheat channel (34) joined in flow communication with said first heat exchanger; and means for injecting an evaporative coolant into said first counterheat channel.


__________

166505]21][11[

מבחנות של מהירה לוויברציה התקןדגימות המכילות

DEVICE FOR FAST VIBRATION OF TUBES CONTAINING SAMPLES

]54[

16.07.2003]22[FR]33[01.08.2002]32[02.09832]31[FR25.02.200303.02308

Int. Cl.8 B01F 011/00, C12N 015/10, G01N 001/28]51[BERTIN TECHNOLOGIES S.A., FRANCE

]71[





TEL AVIV 61040

]74[

[57] Apparatus for rapidly vibrating tubes containing samples, in particular biological samples, the apparatus comprising a disk (12) for supporting the tubes (24), means for preventing the disk from turning about its own axis, and means for driving the disk in oscillating motion about a center of rotation situated on the axis of the disk,

wherein the disk is supported and centered on an elastically-suspended portion (26) of the apparatus by means of two concentric bearings (28, 30) mounted one within the other, one of the bearings being of the spherical type enabling the disk to execute oscillating motion about the center of rotation.


___________

166759]21][11[

פרסום ומערכת רכב לחנית גובלעליו הנסמכת

VEHICLE BARRIER/ADVERTISEMENT SYSTEM

]54[

14.08.2003]22[US]33[27.08.2002]32[10/228437]31[

Int. Cl.8 E01C 011/22]51[BUMPADS, INC., U.S.A.]71[

SCOTT J. FENIMORE, RICHARD MILITANA

]72[

WO/2004/065695]87[צביון, יורם

, ת.ד. התעשיה , פארק2 רח' הטוחן , פרדס-חנה3148



]74[

[57] A vehicle barrier/advertisement system comprising:a vehicle barrier (14) having a vertical front face (16) and a vertical rear face (18) and a horizontal upper face (20) and a pair of angled intermediate faces (12) therebetween, the barrier also having a generally horizontal lower face with a plurality of recesses (24) extending between the front and rear faces and with a

pair of end faces (26), the barrier being fabricated of concrete with at least two vertical securement holes (28) therethrough extending between the upper and lower faces offset from the ground with bars (30) extending through the holes and into the ground for securement purposes; a barrier cover (32) having a vertical front face and a vertical rear face (36) and a horizontal upper face (38) and a


pair of angled intermediate faces (40) the cover also having a generally horizontal lower opening, the cover being sized and shaped to be securely positioned over a vehicle parking barrier; a plurality of straps (48), each strap having a central extent positioned within a recess, each strap having end extents (52) extending through an associated slot (46) in the cover, each end extent having a lower

toothed surface and an associated toothed keeper receiving the end extents and positioned in contact with an associated slot for holding the cover in contact with the barrier, and an advertisement sheet (58) having an interior surface (60) positioned with respect to an angled intermediate face of the cover, the sheet also having an exterior surface with advertising indicia thereon.

___________

167092]21][11[

APPARATUS FOR COOLINGבסככות בקר לקירור מתקןCATTLE IN SHEDS

]54[

01.01.2004]22[Int. Cl.8 A01K 001/00]51[

]ARIEH JEHUDA POLAK]71- אביב פולק, תל יהודה אריהWO/2005/065447]87[




]74[

[57] Apparatus for cooling cattle, particularly cows, which are distributed to predetermined locations, particularly distributed in rows, and more particularly in a shed, which comprises:(I) a plurality of fans (12), arranged in a configuration such that an air stream generated by each of said fans is directed

to a corresponding predetermined location of the cattle;(II) a support (16) to which each corresponding fan is mounted, said support being slid with a shaft (21) which is rotatably mounted in a sleeve (19) attached to a static element (15);


(III) actuating means for concurrently actuating and concurrently stopping all of said fans;(IV) kinematic connecting means between two adjacent fans for concurrently controlling the direction of the streams of air generated by said fans, wherein said kinematic connecting means comprises, for each of said fans, a two-way continuous flexible member (30) which passes around each shaft of said two adjacent fans and a

gearing (33) carried by said flexible member; and(V) transmission means for transmitting rotation from a preceding fan to a second fan, wherein said transmission means comprises a first gear wheel (23) rotatable with the preceding fan and a second gear wheel (25) rotatable with the second fan, said gearing carried by said flexible member meshing with said first and second gear wheels.

לתקנות35 לתקנה בהתאם נבחן זה פירוט1968 – הפטנטים, תשכ"ח

This specification was examined in accordance with regulation 35 of the Patent Regulations, 5728 - 1968

__________

167226]21][11[

כדוריות–מיקרו המכילים תכשיריםאנטי–דלקתיות תכונות בעלות

COMPOSITIONS CONTAINING MICROSPHERES WITH ANTI-INFLAMMATORY PROPERTIES

]54[

04.09.2003]22[US]33[04.09.2002]32[10/234274]31[

Int. Cl.8 A61F 009/00, A61K 009/00]51[]POLYHEAL LTD.]71בע"מ, נשר פוליהיל

WO/2004/021942]87[ושות', וב ד"ר

, רחובות2189 , ת.ד. 2 רח' פקריס WEBB & ASSOCIATES,

2 PEKERIS ST., P.O.B. 2189,REHOVOT 76121

]74[


[57] A therapeutic composition, contained in a package for storing and mixing the composition from which the composition can be dispensed and applied to an ocular surface, said composition comprising about 0.001-25% by weight of microspheres in suspension, said microspheres being capable of forming

multi-point contacts with a cellular membrane and said microspheres being substantially non-biodegradable during the period of therapy; and a pharmaceutically acceptable carrier for said microspheres, said microspheres being substantially insoluble in said carrier.

___________

167721]21][11[

לטיסה להתקן ושיטה היגוי מערכתמונחת

STEERING SYSTEM AND METHOD FOR GUIDED FLYING APPARATUS

]54[

29.03.2005]22[Int. Cl.8 F42B 010/66]51[

ISRAEL AEROSPACEבע"מ, לוד לישראל האוירית התעשיהINDUSTRIES LTD.

]71[


אביב



TEL AVIV 61040

]74[

[57] A steering system for use in a traveling guided flying apparatus, the system comprising: an outer housing (111), an inner housing, a plurality of support fins extending radially inwardly from the outer housing and holding the inner housing thereon; the outer housing and the inner housing defining a ram air inlet at a nose of the forward portion, defining an annular inlet air passage (115), defining an annular pressure chamber (116), and outlet air passage between an inside wall of the outer housing and an outside wall of the inner housing; a plurality of exhaust outlets (120) arranged in the outer housing; a plurality of separately controlled valves mounted at the exhaust outlets; the valves being configured to vary the flow of escaping air through the exhaust outlets; a target seeker

mounted at the nose of the forward portion and configured for sensing a target and producing a target sensor signal representative of the relative location of the target, at least one pressure sensor (119a) mounted in the pressure chamber and configured for measuring the gas pressure therein and producing a pressure sensor signal representative of changes of gas pressure in the pressure chamber; a control unit mounted within the flying apparatus and operatively coupled to the controlled valves, the target seeker, and the pressure sensor, said control unit being responsive to said target sensor signal and said pressure sensor signal, and configured for controlling flight of the guided projectile by generating a valve control signal and providing said valve control signal to said plurality of separately


controlled valves, an electrical power source module mounted within the flying apparatus and operable to provide electrical power required for operating said

target seeker, said at least one pressure sensor and said plurality of separately controlled valves.

__________

167816]21][11[

אוטומטית לבקרה או לחלוקה שסתוםמגנטי שדה המכיל וממושכת

VALVE FOR AUTOMATIC AND CONTINUOUS FLUID FLOW DISTRIBUTION AND REGULATION COMPRISING A MAGNETIC SEAL

]54[

29.09.2003]22[ES]33[02.10.2002]32[P200202241]31[

Int. Cl.8 F16K 011/072, 031/08]51[IRRIMON, S.A.U., SPAIN]71[WO/2004/031633]87[


רחובות


REHOVOT 76122

]74[

[57] Continuous automatic fluid flow control and distributor valve, with a magnetic seal, of the type of valves that permit the flow of a fluid to be distributed among three inlet (7', 7'') and outlet (7) ways, one of which is shared and remains open all the time, and the other two and are the progressive opening and closing type, characterised in that its structure is made up of the following items: a cylindrically-shaped seal made up of two identical ferromagnetic discs (1), which enclose

between them another smaller-diameter concentric disc (2) and a permanent magnet, the rims (3) of the two outer discs being bevel-cut towards the inner magnetic disc, with the result that the three discs conjointly define a perimeter groove that acts as a housing for a spring ring (4) which forms the direct means of sealing, a valve case or body composed of two superimposed parts (5, 5'), one of which forms the rolling track of the outer discs with the beveled rims of the seal and is of


ferromagnetic material, being provided with an intercommunicating chamber (6) between the fluid distribution ways (inlets and outlets), which are of dimensions that permit small movements to take place in its interior owing to the rolling of the seal, the axes of the inlet ways and of the outlet way or vice versa being disposed perpendicularly, seal movement means composed of: a bi-metal conductor (8)

capable of contracting when an electrical voltage is applied to it, causing with its contraction the movement of the seal limited by lateral stops (10); and an opposing spring (9), disposed to keep the seal in dynamic equilibrium or take it up to its home position when no electrical voltage is applied to the bi-metal conductor.

__________

167905]21][11[

STRUCTURE COUPLER ANDעבורו ומחבר למבנים חיבורCOUPLER THEREFOR

]54[

07.04.2005]22[Int. Cl.8 B64G 001/64, F42B 015/10, 015/36]51[

ISRAEL AEROSPACEבע"מ, לוד לישראל האוירית התעשייהINDUSTRIES LTD.

]71[

ושותפיו, כהן ריינהולד ]REINHOLD COHN AND ]74 , תל4060 , ת.ד. 21 העם אחד רחוב June 5, 2008123 –התשס"ח ב' בסיון

1

,PARTNERSאביב 21 AHAD HA'AM ST ,.

P.O.B. 4060 ,TEL AVIV 61040

[57] A coupler (36) comprising a lower lug (40) and an upper lug (42) each formed with a locking recess engageable with a corresponding locking piece (52) slidingly received within a cavity (50) extending between lugs; said locking piece is displaceable between a locked position in which it engages the locking recess of each of said upper lug and lower lug where said lugs are tightly coupled to one another, and an open position in which it disengages

from the recesses to allow detaching of the lugs from one another; and further wherein at least one of said upper lug and lower lug and the locking piece are formed with one or more ejecting surfaces to facilitate disengagement and separation of the lugs from one another and sliding displacement of the locking piece, and further comprising a power activated separation system for displacing the locking piece into its open position.

____________

168177]21][11[

]PRINT CARTRIDGE]54למדפסת דיו מחסנית

30.06.2000]22[Int. Cl.8 B41J 002/175]51[DIVISION FROM 153526]62[SILVERBROOK RESEARCH PTY. LTD., AUSTRALIA

]71[




BEER-SHEVA 84152

]74[

[57] A print cartridge (10) comprising:a support arrangement (14); an ink supply container (58) arranged within the support

arrangement; and a supply of print media (34) rotatably received about the ink supply container.


___________

168706]21][11[

עם תרמי דיו להזרקת מדפסת ראש מספר עם מחלקים העשויים מחממים

של טיפה להוצאת ושיטה נמוך אטומיהמדפסת מראש בועה היוצרת נוזל

THERMAL INK JET PRINTHEAD WITH HEATERS FORMED FROM LOW ATOMIC NUMBER ELEMENTS AND A METHOD OF EJECTING A DROP OF BUBBLE FORMING LIQUID FROM THE PRINTHEAD

]54[

17.11.2003]22[US]33[23.11.2002]32[10/302618]31[

Int. Cl.8 B41J 002/05]51[SILVERBROOK RESEARCH PTY. LTD., AUSTRALIA

]71[




BEER-SHEVA 84152

]74[

[57] An ink jet printhead (1) comprising:a plurality of nozzles (3); and at least one respective heater element (10) corresponding to each nozzle, wherein each heater element is formed of solid material more then 90% of which, by atomic proportion, is constituted by at least one periodic element having an atomic number below 50, each heater element is arranged for being in thermal contact with a bubble forming liquid; each heater element is configured to heat at least part of the bubble forming liquid to a

temperature above its boiling point to form a gas bubble therein thereby to cause the ejection of a drop (16) of the bubble forming liquid through the nozzle corresponding to that heater element; and wherein the bubble which each heater element is configured to form is collapsible and has a point of collapse, and wherein each heater element is configured such that the point of collapse of a bubble formed thereby is spaced from that heater element.


___________

168707]21][11[

עם תרמי דיו להזרקת מדפסת ראשנמוכה חימום מסת

THERMAL INK JET PRINTHEAD WITH LOW HEATER MASS

]54[

17.11.2003]22[US]33[23.11.2002]32[10/302617]31[

Int. Cl.8 B41J 002/05]51[SILVERBROOK RESEARCH PTY. LTD., AUSTRALIA

]71[




BEER-SHEVA 84152

]74[

[57] An ink jet printhead (1) comprising: a plurality of nozzles (3); and at least one respective heater element (10), which includes solid material, corresponding to each nozzle, wherein each heater element is in thermal contact with a bubble forming liquid, and each heater element has a mass of less than 10 nanograms of the solid material and is heated to a temperature

above the boiling point of the bubble forming liquid, thereby to heat at least part of the bubble forming liquid to a temperature above said boiling point to form a gas bubble therein, thereby to cause the ejection of a drop of said bubble forming liquid through the nozzle corresponding to that heater element.


___________

169629]21][11[

מימדים3 אוביקט ליצירת מערכתפעיל דיגיטלי

DIGITALLY ACTIVE 3-D OBJECT CREATION SYSTEM

]54[

09.01.2004]22[AU]33[16.01.2003]32[200390018

0]31[

Int. Cl.8 B41J 002/01, D04H 001/16, G06F 019/00]51[SILVERBROOK RESEARCH PTY. LTD., AUSTRALIA

]71[




BEER-SHEVA 84152

]74[

[57] A three dimensional object creation system that prints objects layer by layer, the system including a plurality of

printheads (102, 108, 112), the system printing at least part of each of multiple layers (110, 114, 118) simultaneously.


_________

173240]21][11[

]STENT GRAFT]54מורכב סטנט

30.12.1999]22[US]33[31.12.1998]32[60/114731]31[US20.01.199960/116726

Int. Cl.8 A61F 002/06, A61L 031/10]51[DIVISION FROM 143922]62[ANGIOTECH PHARMACEUTICALS, INC., CANADAUNIVERSITY OF BRITISH COLUMBIA, CANADA

]71[




]74[

[57] A stent graft comprising an agent that induces the in vivo adhesion of the stent

graft to a vessel wall without releasing said agent.

__________


180248]21][11[

EPIMERISATION OF ALLYLICאלליים אלכוהולים של אפימריזציהALCOHOLS

]54[

22.08.2005]22[US]33[01.09.2004]32[60/606135]31[

Int. Cl.8 A61K 031/59, C07C 401/00]51[LEO PHARMA A/S, DENMARK]71[WO/2006/024296]87[


אביב



TEL AVIV 61040

]74[

[57] A method of epimerising an epimer or epimeric mixture of a compound comprising a side chain of the formulae

at the position of the carbon atom to which the hydroxy group and R3 are attached to; by contacting said epimer or epimeric mixture with an acid in the presence of water; wherein R3 is alkyl, alkenyl, alkynyl, or cycloalkyl, optionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxycarbonyl, halogen, hydroxy, methoxy, and ethoxy; wherein the carbon marked with an asterisk is connected by a single bond to the C-17 carbon atom of a

vitamin D analogue fragment; or wherein the carbon marked with an asterisk is connected by a single bond to a fragment of a precursor for the synthesis of a vitamin D analogue at its C-17 analogous position; wherein the fragment of a precursor for the synthesis of a vitamin D analogue is a fragment of a steroid ring system or a fragment of a CD ring system of a steroid; wherein the fragment of the steroid ring system is represented by the formula


wherein the fragment of a CD ring system of a steroid is represented by formulas

wherein PG represents hydrogen or a hydroxy protecting group;

wherein the vitamin D analogue fragment is represented by any one of the fragments


wherein R1 and/or R2 may be the same or different and represent hydrogen or a hydroxy protecting group.

לתקנות35 לתקנה בהתאם נבחן זה פירוט1968 – הפטנטים, תשכ"ח

This specification was examined in accordance with regulation 35 of the Patent Regulations, 5728 - 1968

__________

185384]21][11[

רמות להורדת רוקחיים הרכבים והורדת ( בפלסמהA) ליפופרוטאין

קרדיווסקולריות למחלות סיכון גורמי

COMPOSITIONS FOR LOWERING PLASMA LIPOPROTEIN(A) AND RISK FACTORS OF CARDIOVASCULAR DISEASES

]54[

03.10.2001]22[US]33[03.10.2000]32[60/237186]31[

Int. Cl.8 A61K 045/00, A61P 009/00]51[DIVISION FROM 155238]62[MATTHIAS RATH, U.S.A.]71[



P.O.B. 12688 ,HERZLIYA 46733

]74[

[57] Composition of biochemical substances comprising ascorbic acid, ascorbyl palmitate, beta-, gamma-, delta-tocopherol-mix, beta-carotene, biotin, calcium ascorbate, calcium glycinate, carotenoid mix, cholecalciferol, chromium glycinate, citrus bioflavonoids, coenzyme Q10, copper glycinate, cyanocobalamin, d-alpha-tocopherol, d-calcium pantothenate, dicalcium phosphate, folic acid, inositol,

L-arginine, L-carnitine, L-cysteine, L-lysine, L-proline, L-selenomethionine,magnesium ascorbate, magnesium glycinate, manganese chelate, molybdenum glycinate, niacin, niacinamide, potassium chelate, pycnogenol, pyridoxine, riboflavin, thiamine, and zinc glycinate, wherein the composition is in therapeutically effective


amounts to lower plasma concentration of a lipoprotein in a mammal.


שטרם זו לבקשה הורה בקשתפורסמה

155238The parent application from which this application has been divided has not yet been published

___________

April 13, 2008889 –התשס"ח ח' בניסן

PATENTSפטנטים

שניתנו פטנטיםPATENTS GRANTED

154668136283

שחודשו פטנטיםPATENTS RENEWED

9404994042940219402094006940029398393695941839415294147941289411994113941129407710918510909510867710755794243942419421794186109251109245109242109222109219109216109206109186109308109287109284109271109270109267109263109254109389109381109366109350109338109327109318109316115707111369111361109472109466109427109395109390123287123074122575119660119527119526119474118579123963123961123952123949123943123942123819123727124073124069124044124033123998123981123969123967124195124190124146124145124129124104124089124085127240127239127070126971126734125602125464124253129633129139128701127610127588127527127448127433131318130880130646130369130363130093130089129940131894131849131832131821131746131726131593131592131994131977131974131969131965131962131913131900132192132166132160132107132101132068132047132002132258132256132246132240132236132217132214132208132301132296132293132286132276132275132271132259132379132364132357132351132339132325132319132303132481132435132424132415132403132392132390132380132940132844132819132749132563132548132494132493135036135020134368134286133777133282133067133039137691137471136218136076135930135361135343135287139109138982138980138955138444138443138034137809143959143149142629141899141395141145140980139687145950145933145922145548145546145307144777144153148200147894147871147293147285146681146660146233148925148875148694148684148475148327148304148216149138149054149041149021148988148979148961148926149957149923149824149625149227149188149165149159150949150744150737150690150480150359150182150154151752151715151603151349151330151135151054151053152570152409152349152340152247152073151874151816153535153511153509153304153301153110152820152687154835154797154668154646154616154252153739153587

April 13, 2008122 –התשס"ח ח' בניסן1

155695155428155425155359155271155229155066155065157277157051156631156623156554156260156051155862158110157994157795157761157733157647157646157542158709158621158551158434158373158295158284158240161792161420161254160238160189159186159075158833166727166160165403164977164466162686162637161796

179148169302168911166920

April 13, 2008 –התשס"ח ח' בניסן 1222

חידוש אגרת תשלום אי בגלל פקעו שתוקפם פטנטיםPATENTS NOT IN FORCE DUE TO NON-PAYMENT OF RENEWAL

FEES

914289142591424914239142291398913779132110681210678510678210675910672410672010671091438106873106872106864106846106844106830106825106821121654121644121636121615121589121568119134106891128500128465128160127616125435121675121666121662128734128713128688128668128667128664128661128613

154393144926138652128748128739

בקשות הוגשו שלגביהם פטנטים פרק פי על ההגנה תקופת להארכת

Patents for which applications have been filed for extension of the patent


term under chapter 4, part B1 of theהפטנטים לחוק1ב' ד' סימןPatents Law

136727


NOTICEהודעה לחוק60 סעיף לפי

1967הפטנטים, תשכ"ז-Under section 60 of the Patent Law, 5727-1967

תוקפו להחזר בקשה הוגשה מטה, המפורט הפטנט של

אי מחמת פקע שתוקפו החידוש אגרות תשלום

הקבועות:

Application has been filed for the restoration of the patent recorded below, which has lapsed through non-payment of the prescribed renewal fees:

109269No. of Patentמס' הפטנט 8/1996Acceptance published inמס': ביומן פורסם קיבול

journal no::Proprietorsהפטנט: בעל שם

)אגש"ח( בע"מ תעשיות מגן פלסטיקPLASTIC MAGEN INDUSTRIES (A.S.C.) LTD.

:Title of inventionהאמצאה: שםחום מחליף

HEAT EXCHANGER להתנגד רשאי אדם כל

תוך האמורה לבקשה יומן מתאריך חודשים שלושה שנקבע זה, כפי פטנטים ובתקנה לחוק61 בסעיף

הפטנטים, לתקנות921968תשכ"ח-

Any person may oppose the said application within three months from the date of this Patents Journal, as prescribed by section 61 of the law and by regulation 92 of the Patent Regulations, 5728-1968






הקבועות:




פורת מיכאלMICHAEL PORAT

:Title of inventionהאמצאה: שםדם מוביל מחטמאיבר בהוצאת דם התפרצות למניעת אמצעים

SYSTEM FOR PREVENTION OF BLOOD SPURTS FROM BLOOD VESSELS DURING REMOVAL OF NEEDLE

להתנגד רשאי אדם כל תוך האמורה לבקשה יומן מתאריך חודשים שלושה שנקבע זה, כפי פטנטים ובתקנה לחוק61 בסעיף








הקבועות:




NDS LIMITED:Title of inventionהאמצאה: שם

משתמש של הדדי תפעול משוב מערכתUSER INTERACTION FEEDBACK SYSTEM









הקבועות:




בע"מ תעשיתית טכנולוגיה טירובTAIROB INDUSTRIAL TECHNOLOGY LTD.

:Title of inventionהאמצאה: שםתבלינים לחלוקת מכשיר

APPARATUS FOR DISPENSING SEASONINGS להתנגד רשאי אדם כל









הקבועות:




פורת מיכאלMICHAEL PORAT

:Title of inventionהאמצאה: שםגמיש צינור של וחיתוך לסגירה ושיטה מכשיר

DEVICE AND METHOD FOR CLAMPING AND CUTTING A FLEXIBLE DEFORMABLE TUBE









הקבועות:




כץ דניאלDANIEL KATZ

:Title of inventionהאמצאה: שםמרחוק נתונים ואיסוף לשליטה ומערכת שיטה

SYSTEM AND METHOD FOR REMOTE SUPERVISORY CONTROL AND DATA ACQUISITION









הקבועות:




פורת מיכאלSTARBURST TECHNOLOGIES LIMITED

:Title of inventionהאמצאה: שםפנים מסכת

FACE MASK להתנגד רשאי אדם כל





NOTICEהודעה הפטנטים, לחוק66 סעיף לפי

1967תשכ"ז-Under section 66 of the Patents Law, 5727-1967

רשות ניתנה כי בזאת מודעמס' הפטנט בקשת לבעלת

122705This is to notify that permission has been granted to the owner of Patent Application No.

11/2000Acceptance published in journalביומן פורסם הקיבול דבר בקשת של הפירוט את לתקן

האמורה הפטנטTo amend the specification of the said Patent Application.

למתן להתנגד רשאי אדם כל חודשים שלושה תוך הרשות

זה, כפי פטנטים יומן מתאריך ובתקנה לחוק67 בסעיף שנקבע

הפטנטים, התשכ"ח- לתקנות991968.

Any person may oppose such grant of permission within three months from the date of this Patents Journal, as prescribed by section 67 of the Law and by regulation 99 of the Patent Regulations, 5728-1968.


בפנקס רשומים בפרטים שינוייםCHANGES IN PARTICULARS ENTERED IN REGISTER

בעלות שינויCHANGES IN PROPRIETORSHIP

:144654No. of Patentמס' פטנט::Previous Proprietorsהקודמים: הבעלים

CURIS, INC.:New Proprietorsהחדשים: הבעלים

ES CELL INTERNATIONAL PTE LTD.


EREZ NISSAN-COHENניסן-כהן ארז:New Proprietorsהחדשים: הבעלים

בע"מ הלוחות לכל - לך סימפל


:New Proprietorsהחדשים: הבעליםES CELL INTERNATIONAL PTE LTD.

טעויות תיקוניCORRIGENDA


Journal 1/2008 יומןP. 339 Patent application No. 156347 156347מס' פטנט בקשת339ע' Delete the application. הבקשה את מחק .The application was published by mistake. בטעות פורסמה הבקשה .The application has not yet been accepted and is not open to the public

לעיון פתוחה ואיננה קובלה לא עוד הבקשה הציבור

Journal 1/2008 יומןP. 326 Patent No. 154803 154803מס' פטנט326ע' Correct priority claim to- ל קדימה דין תקן -

PCT/SE00/01994 13.10.2000 SE

ביומן המופיעים למדינת קודיםCOUNTRY CODES APPEARING IN THIS JOURNAL

Code Country or OrganizationAR Argentina


AT AustriaAU AustraliaBA HerzegovinaBE BelgiumBR BrazilCA CanadaCH SwitzerlandCN ChinaCU CubaCZ Czech RepublicDE GermanyDK DenmarkEC EcuadorEP European Patent OfficeES SpainFI FinlandFR FranceGB United KingdomGE GeorgiaGR GreeceGT GuatemalaHR CroatiaHU HungaryIE IrelandIL IsraelIN IndiaIT ItalyJP JapanKR Republic of KoreaLK Sri LankaLU LuxembourgLV LatviaMX Mexico

MY MalaysiaNL The NetherlandsNO NorwayNZ New ZealandPL PolandPT PortugalRU Russian Federation


SE SwedenSG SingaporeSI SloveniaSK SlovakiaTH ThailandTR TurkeyTW TaiwanUA UkraineUS United States of AmericaUY UruguayUZ UzbekistanWO World Intellectual Property Organization (W.I.P.O.)ZA South Africa

DESIGNS מדגמיםשנרשמו מדגמים

DESIGNS REGISTERED

41896April 13, 2008123 –התשס"ח ח' בניסן

9

Class 28(03) סוג24. 1.2006

LA TWEEZ ISRAEL LTD. בע"מ ישראל טוויז להLuminous tweezer מאירה פינצטה

42553Class 3(01) סוג

6. 6.2006SMITHKLINE BEECHAM CORPORATION

Pill case לגלולה קופסאConvention date (U.S.A.)

הברית( )ארצות אמנה תאריך 8.12.2005 הברית( )ארצות האמנה תאריך

42589, 42590Class 4(02) סוג

8. 6.2006THE GILLETTE COMPANY

Toothbrush שיניים מברשתConvention date (OHIM)

הברית( )ארצות אמנה תאריך 27.4.2005 )אוהיים( האמנה תאריך

42704, 42708, 42709,42713, 42171, 42718

Class 14(03) סוגRESEARCH IN MOTION LTD.

Handheld communication device ידני תקשורת מכשירConvention date (U.S.A.)



18. 10.2006YAIR MESULAM משולם יאירFood and water heater ואוכל מים לחימום מתקן

43236Class 21(02) סוג

23. 10.2006GAD IRSAY עירשי גדTennis ball collection basket לכדורי-טניס איסוף סלסלת

43270Class 25(01) סוג

1. 11.2006April 13, 2008 –התשס"ח ח' בניסן 124

0

PROFILE GLASS LTD. בע"מ גלס פרופילProfile פרופיל

43313Class 24(02) סוג

13. 11.2006Q-CORE LTD. בע"מ קור קיוControl handle for peristaltic pump פריסטלטית למשאבה בקרה ידית

43316Class 24(02) סוג

13. 11.2006Q-CORE LTD. בע"מ קור קיוControl unit for a peristaltic pump פריסטלטית למשאבה בקרה יחידת

43318Class 24(02) סוג

13. 11.2006Q-CORE LTD. בע"מ קור קיוPassive mechanical interface for a peristaltic pump

למשאבה פסיבי מכני מימשק פריסטלטית


15. 11.2006BACARDI AND COMPANY LIMITED

Bottle בקבוקConvention date (Liechtenstein)

הברית( )ארצות אמנה תאריך 17.5.2006 )ליכטנשטיין( האמנה תאריך

43424Class 11(01) סוג

3. 12.2006GERALDO LTD. בע"מ ג'ראלדוJewel תכשיט


19. 12.2006SOCIETE DES PRODUITS NESTLE S.A.

Ice cream cone גלידה גביעConvention date (Switzerland)

הברית( )ארצות אמנה תאריך 22.6.2006 )שוויץ( האמנה תאריך


43634, 43635, 43636Class 19(08) סוג

17. 1.2007VISA INTERNATIONAL SERVICE ASSOCIATION VISA U.S.A. INC.

Card כרטיסConvention date (U.S.A.)


43657Class 23(02) סוג

22. 1.2007MOSHE PAZ AND EFRAT HAGAI חגי ואפרת פז משהFilter for sewage outlet הביוב למערכת פילטר

43939, 45453, 45456Class 24(04) סוג

12. 3.2007GLAXO GROUP LIMITED

Inhaler משאףConvention date (United Kingdom)

תאריךהברית( )ארצות אמנה

14.9.2006 )הממלכה האמנה תאריך המאוחדת(


17. 4.2007MENSASHE ROGOTNER רוגוטנר מנשהTray מגש


18. 4.2007GLAXOSMITHKLINE CONSUMER HEALTHCARE GMBH & CO KGDispenser מנפקConvention date (United Kingdom)

תאריךהברית( )ארצות אמנה

20.10.2006 )הממלכה האמנה תאריך המאוחדת(

44160Class 21(01) סוג

10. 5.2007ALEKSEI EPSHTEIN אפשטיין אלכסייGame משחק

44262, 44263Class 19(03) סוג


31. 5.2007ARGO DEVELOPMENT AND MANUFACTURING LTD.

בע"מ וייצור פיתוח ארגו

Device for coupling material to a surface למשטח חומר להצמדת התקני

44275, 44278, 4428044284, 44285, 44286,

44287, 44291Class 2(02) סוג

5. 6.2007DIESEL S.P.A.

Pants מכנסיים

44316Class 21(01) סוג

7. 6.2007ICHIBAN SPORT LTD. בע"מ ספורט איצ'בןTraining doll אימונים בובת

44394, 44395, 44396Class 13(03) סוג

18. 4.2007BTICINO S.P.A.

Protective box for electrical חשמל למכשיר הגנה תיבתConvention date (OHIM)



5. 7.2007TAMMY COHEN RAZ AND NITZAN COHEN RAZ

רז כהן וניצן רז כהן תמי

Baby Carrier לתינוק מינשא

44531, 44532, 44534,44535, 44536

Class 10(07) סוג19. 7.2007

ZENITH INTERNATIONAL SA


Watch dial שעון חוגת

44546Class 12(12) סוג

23. 7.2007TAMMY COHEN RAZ AND NITZAN COHEN RAZ

צ'וקראן זכריה

Baby Carrier עגלה

44552, 44553, 44554,44555

Class 25(01) סוג24. 7.2007

EXTAL LTD. בע"מ אקסטלProfile פרופיל


30. 7.2007AMIT LEVI לוי עמיתBottle crusher בקבוקים מכווץ

44580Class 25(03) סוג

30. 7.2007CAESARE LANDSCAPE DESIGN LTD.

בע"מ בנוסף עיצוב קיסריה

Pergola פרגולה


1. 8.2007YOSEF HEIMAN הימן יוסףContainer מיכל


9. 8.2007AMINACH BEDDING & FURNITURE MANUFACTURING LTD.

ומזרונים רהיטים תעשית עמינח

Mattress מזרן


12. 8.2007


RAF-KO CLEANING UTENSILS INDUSTRIES LTD.

בע"מ ניקוי כלי תעשיות רפקו

Container מיכל


12. 8.2007PLASTO-VACK (1990) LTD. ( בע"מ1990) פלסטו-ווקContainer מיכל


12. 8.2007SMART FIBER AG

PERFORATED DEODORANT BALL

מחורר כדורי ריחות מפיג

Convention date (OHIM)הברית( )ארצות אמנה תאריך

28.2.2007 )אוהיים( האמנה תאריך


13. 8.2007SHLOMO ASHKENZAI אשכנזי שלמהHanger מתלון


19. 8.2007ISCAR LTD. בע"מ ישקרCutting insert חיתוך שימת

44664Class 25(01) סוג

20. 8.2007IGAL BLECHER בלכר יגאלProfile פרופיל

44680Class 19(04) סוג

26. 8.2007RONI BLANKLEDER בלנקלדר רוניDisplay rack תצוגה התקן

44683, 44684, 44685


Class 25(01) סוג

28. 8.2007EXTAL LTD. בע"מ אקסטלProfile פרופיל


29. 8.2007+3CM LTD. בע"מ אם סי שלוש פלוסInsole רפידה


30. 8.2007KETER PLASTIC LTD. בע"מ פלסטיק כתרTable שולחן

44741Class 10(02) סוג

3. 9.2007BULGARI TIME (SWITZERLAND) S.A.

WATCH שעוןConvention date (OHIM)


44757Class 12(11) סוג

4. 9.2007ITAY DROR דרור איתיBicycle אופניים

44777, 44901Class 25(01) סוג

10. 9.2007KETER PLASTIC LTD. בלגזל שרוןTable פרופיל



11. 9.2007AVNER FALK פלק אבנרStorage device for container מיכל לאחסון מתקן

44829Class 28(03) סוג

24. 1.2006LA TWEEZ ISRAEL LTD. בע"מ ישראל טוויז להTweezer case לפינצטה מארז


25. 9.2007BRITA GMBH

WATER PITCHER WITH FILTER מסנן עם מים קנקןConvention date (Germany)

הברית( )ארצות אמנה תאריך 5.4.2007 )גרמניה( האמנה תאריך

44884Class 23(01) סוג

14. 10.2007BERMAD CS LTD. חקלאית שיתופית ברמז-אגודה

בע"מHydraulic control valve הידראולי בקרה שסתום


16. 10.2007DANI GASSNER גסנר דניMoney Box חיסכון קופת


6. 11.2007GENADI IVANOV איבאנוב גינאדיHandle for bags לשקיות ידית

45070, 45071Class 23(04) סוג

15. 11.2007


SARA LEE HOUSHOLD AND BODY CARE NEDERLAND B.V.Air deodorizing apparatus אוויר לבישום מתקןConvention date (OHIM)


45183, 45184, 45185,45186, 45187, 45188, 45189, 45190, 45191,45192, 45193, 45194, 45195, 45196, 45197,45198, 45199, 45200,45201, 45202, 45204,


12. 12.2007GAZIT SHOES T. VINER LTD. בע"מ ובניו ט. וינר גזית נעליShoe נעל


12. 12.2007GAZIT SHOES T. VINER LTD. בע"מ ובניו ט. וינר גזית נעליShoe נעל


12. 12.2007GAZIT SHOES T. VINER LTD. בע"מ ובניו ט. וינר גזית נעליSole סוליה


שחודשו מדגמיםDESIGNS RENEWED

2981229748296752954729546295452954429291299102990929908298762987529831298142981337307300403003929991299902996829912299113775937758377383769637694376933765237584379363793437933379303792637910378643782838080380793807838077380763807537994379923821738216380863808538084380833808238081

412073855738455382513822438218


שבוטלו מדגמיםDESIGNS VOID

2296920737206982069620654206532062320622285502853428533285322852428508285002297028593285912859028589285622856128557285513692736926369253692236920286332861728615369423694136940369393693736930369293692836974369733697236966369653694636944369433701237004370033698136980369793697736975

370193701837013

Dr. Meir NoamCommissioner of Patents,Designs and Trade Marks

נועם מאיר ד"רהפטנטים, המדגמים רשם

מסחר וסימני


שקובלו לבקשות מפתחותINDICES OF APPLICATIONS ACCEPTED

NAME INDEXשמי מפתח

אגודה נוזלים להולכת א.ר.י. אביזרים163133 בע"מ חקלאית שתופית

148526 קליימן אבי בנגב, הרשות בן-גוריון אוניברסיטת

147823 ופיתוח למחקר בנגב, הרשות בן-גוריון אוניברסיטת

154808, 153435 ופיתוח למחקר147565, 142354 בע"מ אורבוטק

159653 פישר אוריאל ,153941 בע"מ אי.סי.איי. טלקום

155449143810 שיינפלד אלכסנדר

143810 כץ אמיל151592 בקרמן אנטולי

121793 בע"מ ביוסיינס אקסלנז167092 פולק יהודה אריה

119135 בע"מ ג'נטיקו

142929 בע"מ דקסון בע"מ טכנולוגיות פארמה דקסל

146708155042 בע"מ דרייקור

בע"מ לישראל האוירית התעשיה167721 בע"מ לישראל האוירית התעשייה167905

130032 גורביץ ולדימיר158481 בע"מ וריסיטי159163 בע"מ ישראל וריפון

163907 דוידיאן חיים

בע"מ ופיתוח למחקר חברה ידע143019 ,145842

151592 בקרמן יוסף של המחקר לפיתוח חברה יישום

בירושלים העברית האוניברסיטה161632

159653 הלוי-פוליץ יעקב

129665, 127192 בע"מ ישקר ,129665, 127192 בע"מ ישקר

165621165621 בע"מ ישקר

163427 גרבר לאוניד

בע"מ טכנולוג'יס מדיקל מגנוליה149523

138632 בע"מ מדיגוס152109, 152107 בע"מ מדינול בע"מ ופיתוח למחקר הטכניון מוסד

158870145535 בע"מ מחקרים יישום מור

150848 בע"מ מיטרוניקס

157401 פדן ניר

בע"מ דיאגנוסיס איידד קומפיוטר סימנס153162

בע"מ למחצה מוליכים הנדסת סלע140712149322 בע"מ סנקטום

167226 בע"מ פוליהיל

140299 בע"מ אל איי קודאק148526 בע"מ מטאור קליימן

לחימה אמצעי לפיתוח רשות רפא"ל154894, 152966 בע"מ בע"מ מתקדמות לחימה מערכות רפאל

109014 ,151672 בע"מ מתקדמות לחימה מערכות רפאל

163785 בע"מ לחימה אמצעי לפתוח רפאל- רשות

158870

164747 בע"מ ספקטרלינק תדיראן

April 13, 2008 –התשס"ח ח' בניסן i

A.R.I. FLOW CONTROL ACCESSORIES AGRICULTURAL COOPERATIVE ASSOCIATION LTD. 163133ABBOTT LABORATORIES 135517AEROFLEX INTERNATIONAL CO., LTD. 160887ALCAN RHENALU 156732ALEXANDER SCHOENFELD 143810ALZA CORPORATION 141914AMARIN NEUROSCIENCE LIMITED 158678ANATOLY BEKKERMAN 151592ANDRE BENHAMOU 160154ANGIOTECH PHARMACEUTICALS, INC. 173240ARIEH JEHUDA POLAK 167092ARKEMA FRANCE 157998ASPEN AEROGELS, INC. 155922ASTRAZENECA AB 150126, 150201, 151626AUBURN UNIVERSITY 155319AUTOIMMUNE, INC. 165071AVENTIS PHARMA S.A. 139102AVENTIS PHARMACEUTICALS INC. 153797AVENTIS PHARMACEUTICALS INC. 155120AVI KLAYMAN 148526AVIGENICS 135604AVOCENT CORPORATION 158880

BASF AKTIENGESELLSCHAFT 154094BAVARIAN NORDIC A/S 150736BAYER CROPSCIENCE AG 158475BAYER CROPSCIENCE AG 159149BAYER SCHERING PHARMA AG 152248BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY 147823BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND

DEVELOPMENT AUTHORITY 153435, 154808BERTIN TECHNOLOGIES S.A. 166505Biogen Idec MA Inc. 143403BIOTECON GESELLSCHAFT FUR BIOTECHNOLOGISCHE ENTWICKLUNG UND CONSULTING MBH 139478BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 140701BORIS GELMAN 163425BRIGHAM AND WOMEN'S HOSPITAL 165071BUMPADS, INC. 166759

CARDINAL HEALTH 303, INC. 158229CARMEL SYSTEMS LLC 152301CATHARON PRODUCTIONS, INC. 156075CELATOR PHARMACEUTICALS, CORP. 161214CELATOR PHARMACEUTICALS, INC. 161214CERATIZIT AUSTRIA GESELLSCHAFT M.B.H 165854CHAIM DAVIDIAN 163907CIBA SPECIALTY CHEMICALS HOLDING INC. 154220, 158925COMPUTER ASSOCIATES THINK, INC. 147824COMPUTER ASSOCIATES THINK, INC. 152132CPN SPOL S.R.O. 162801CREATIVE PLASTIC TECHNOLOGY, LLC 146498CROSSCARE RESEARCH & DEVELOPMENT LIMITED 153263CUBIC CORPORATION 156006CURIS, INC. 143403CV THERAPEUTICS, INC. 128652

DAIICHI SANKYO COMPANY LIMITED 140731, 148196

April 13, 2008 –התשס"ח ח' בניסן ii

DAINIPPON SUMITOMO PHARMA CO., LTD. 160924DAVID CHARLES ROBINSON 164475DAVIES INDUSTRIAL COMMUNICATIONS LIMITED 150172DESAL, LLC 164873DEUTSCHE POST AG 161238, 161239DEXCEL PHARMA TECHNOLOGIES LTD. 146708DEXXON LTD. 142929DIAMCAD N.V. 156034DRYKOR, LTD. 155042

EADS DEUTSCHLAND GMBH 156147ECI TELECOM LTD. 153941, 155449EGIS GYOGYSZERGYAR RT. 160486EISAI CO.,LTD. 155447EISAI R&D MANAGEMENT CO., LTD. 155447ELBION AG 155386EMIL KATZ 143810ENDOCARE, INC. 160692EURO-CELTIQUE S.A. 151417EXALENZ BIOSCIENCE LTD. 121793

F. HOFFMANN-LA ROCHE AG 153837FABBRICA D'ARMI PIETRO BERETTA S.P.A 149475FITEL U.S.A. CORPORATION 157502FORSVARETS MATERIELVERK 159447

GALDERMA RESEARCH & DEVELOPMENT, S.N.C. 142759GE MEDICAL SYSTEMS GLOBAL TECHNOLOGY COMPANY, LLC 155286GENENTECH, INC. 125939, 138488GENENTECH, INC. 149171GENETICO LTD. 119135GEOX S.P.A. 151834GILEAD SCIENCES, INC. 147872GLAXO GROUP LIMITED 156436GPT GLENDALE, INC. 159648

H. LUNDBECK A/S 150366H.C. STARCK GMBH 162969HARRIS CORPORATION 158840

HUSKY INJECTION MOLDING SYSTEMS LTD. 156886

ID BIOMEDICAL CORPORATION 117483, 137921IDALEX TECHNOLOGIES, INC. 166089IDLEAIRE TECHNOLOGIES CORP. 164553IMOVE INC. 155563INFINEON TECHNOLOGIES AG 153829INSCENTINEL LIMITED 162526INSTITUT FUR DIAGNOSTIKFORSCHUNG GMBH AN DER FREIEN UNIVERSITAT BERLIN 141384INSTITUTO BIOMAR, S.A. 153679INTERDIGITAL TECHNOLOGY CORPORATION 158259INTERNATIONAL BUSINESS MACHINES CORPORATION 160070IPSEN MANUFACTURING IRELAND LIMITED 156258IRRIMON, S.A.U. 167816ISCAR LTD. 127192, 129665ISCAR LTD. 127192, 129665, 165621ISCAR LTD. 165621ISHIHARA SANGYO KAISHA LTD. 150965ISOGENICA LIMITED 131435ISOTRON, INC. 148634ISRAEL AEROSPACE INDUSTRIES LTD. 167721ISRAEL AEROSPACE INDUSTRIES LTD. 167905

JACOB HALEVY-POLITCH 159653JOSEF BEKERMAN 151592JOZE JELENC 158535

KABUSHIKI KAISHA UENO SEIYAKU OYO KENKYUJO 153496KENNAMETAL INC. 161077KENT STATE UNIVERSITY 139911KLAYMAN METEOR LTD. 148526KODAK IL LTD. 140299KOSAN BIOSCIENCES, INC. 143069

April 13, 2008 –התשס"ח ח' בניסן iii

LABORATOIRE THERAMEX 149141LAM RESEARCH CORPORATION 157827LDR MEDICAL 158740LEO PHARMA A/S 180248LEONID GERBER 163427LITTON SYSTEMS, INC. 158515LOCKHEED MARTIN CORPORATION 158722LOYOLA UNIVERSITY OF CHICAGO 135528

MAGNOLIA MEDICAL TECHNOLOGIES LTD. 149523MARS, INCORPORATED 164095MATTHIAS RATH 140947MATTHIAS RATH 185384MAYTRONICS LTD. 150848MEDA PHARMA GMBH & CO. KG 151106MEDIGUS LTD. 138632MEDINOL LTD. 152107, 152109MOR RESEARCH APPLICATIONS, LTD. 145535MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY 140265

NIPPON SODA COMPANY LTD. 157724NIR PADAN 157401NOVELIS, INC. 156732

OBTECH MEDICAL AG 151134ORBOTECH LTD. 142354, 147565ORIDION BREATHID LTD. 121793

PALOMAR MEDICAL TECHNOLOGIES, INC. 158982PANACEA BIOTEC LIMITED 148864PANTHERIX LIMITED 154593PEPSCAN SYSTEMS B.V. 140381PFIZER PRODUCTS, INC. 149226PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. 141764POLYHEAL LTD. 167226

PURADYN FILTER TECHNOLOGIES INCORPORATED 152238

Q MED AB 154062QLT INC. 132066QUALCOMM INCORPORATED 146267, 151350, 151706, 151708, 152712QUALCOMM INCORPORATED 146363

RADIANCY, INC. 159910, 159971RAFAEL ADVANCED DEFENSE SYSTEMS LTD. 109014, 151672RAFAEL ADVANCED DEFENSE SYSTEMS LTD. 163785RAFAEL ARMAMENT DEVELOPMENT AUTHORITY LTD. 152966, 154894RAFAEL-ARMAMENT DEVELOPMENT AUTHORITY LTD. 158870RAYTHEON COMPANY 157424RECKITT BENCKISER HEALTHCARE (UK) LIMITED 150030RECKITT BENCKISER HEALTHCARE INTERNATIONAL LIMITED 150030REEFEDGE, INC. 154132, 154719REGA STICHTING V.Z.W. 159494ROBERT G. JAMES 144998ROLLING RAZOR, INC. 153208

SANCTUM LTD. 149322SANDOZ AG 154220SANGAMO BIOSCIENCES, INC. 150069SANOFI-AVENTIS DEUTSCHLAND GMBH 151518SCOTT INTERNATIONAL LIMITED 159660SELA SEMICONDUCTOR ENGINEERING LABORATORIES LTD. 140712SELEX COMMUNICATIONS LIMITED 150172SEQUELLA, INC. 140731, 148196SERGUEI BORISOVISH SIVOVOLENKO 156034SHIRE BIOCHEM INC. 117483

April 13, 2008 –התשס"ח ח' בניסן iv

SHIRE BIOCHEM INC. 137921SHIRE HUMAN GENETIC THERAPIES, INC. 149029SHUICHI HIRONO 161736SHUNICHI SHIOZAWA 161736SIEMENS COMPUTER AIDED DIAGNOSIS LTD. 153162SIG ALLCAP AG 161922SILVERBROOK RESEARCH PTY. LTD. 146608, 146671, 163493, 168706, 168707, 169629SILVERBROOK RESEARCH PTY. LTD. 149954, 168177SMITHKLINE BEECHAM P.L.C. 153231SOCIETE DES PRODUITS NESTLE S.A. 154594SUDIMPLANT COMPANY 160154SUMITOMO CHEMICAL COMPANY, LIMITED 160924SWITCH BIOTECH AG 143699SYMANTEC CORPORATION 154132, 154719SYMANTEC INTERNATIONAL LIMITED 154132, 154719

TADIRAN SPECTRALINK LTD. 164747TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. 158870TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) 159316THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 153324THE BOOTS COMPANY PLC 150030THE INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC 159494THE REGENTS OF THE UNIVERSITY OF MICHIGAN 146222THE TEXAS A&M UNIVERSITY SYSTEM 154684THE TRUSTEES OF PRINCETON UNIVERSITY 146242THE UNIVERSITY OF BRITISH

COLUMBIA 132066THE UNIVERSITY OF SOUTHERN CALIFORNIA 146242TORAY INDUSTRIES, INC. 162552TOYAMA CHEMICAL CO., LTD. 161736TOYAMA CHEMICAL CO., LTD. 161736TREFIMETAUX S.A. 162942TYCO ELECTRONICS CORPORATION 152323

UCB, S.A. 150842UNIVERSITAT STUTTGART (INST. FUR CHEMISCHE VERFAHRENSTECHNIK) 141972UNIVERSITY OF BRITISH COLUMBIA 173240UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. 135604URIEL FISCHER 159653

VERENIUM CORPORATION 124794VERIFONE ISRAEL LTD. 159163VERISITY LTD. 158481VLADIMIR GUREVICH 130032

WALDEMAR LINK GMBH & CO. KG 158220, 158221, 159411WATCHFIRE CORPORATION 149322WESTERN CLINICAL ENGINEERING LTD. 160337WISCONSIN ALUMNI RESEARCH FOUNDATION 141203WYETH 163574WYETH HOLDINGS CORPORATION 151249

YEDA RESEARCH AND DEVELOPMENT CO. LTD. 143019, 145842YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM 161632

April 13, 2008 –התשס"ח ח' בניסן v

April 13, 2008 –התשס"ח ח' בניסן vi

ענייני מפתחSUBJECT MATTER INDEX

A01G – 153435, 161632

A01K – 135604, 148526, 162526, 167092

A01N – 155319, 157998, 158475, 159149

A21D – 154594

A41D – 151834

A42B – 159660 A47G – 161238, 161239

A61B – 138632, 149523, 151134 , 158982 ,160337 ,160592

A61C – 160154

A61F – 143810, 152107, 152109, 153324 ,158220 ,158221, 158535 ,158740 ,159411, 159648 ,167226 ,173240

A61K– 132066, 135528, 139478,

140701 ,140947 ,141384, 141764 ,141914 ,142929, 143403 ,146222 ,146708, 148864 ,150030 ,150965, 151106 ,152248 ,153231, 153263 ,158678 ,160924, 161214 ,164095 ,180248,

185384

A61L– 144998, 162801

A61M – 146948, 154062, 158229

A61N– 141203, 148634

A62B – 163425

B01J – 164475, 166089B01J – 164475, 166089

B22D – 156732, 156886

B23B– 161077, 165854

B23C – 129665

B23D – 165621

B24B – 157827

B25J – 158870

B26B – 153208, 159910, 159971

B26D – 127192 B41J – 163493, 168177, 168706,

168707

B41M – 140299

B60H– 164553

B60K – 159447

B60R –160887

B64D – 157401 B64G – 167905 B65D– 161922

C02F– 164873 C06B – 163785

C07C –142759, 153496, 154220

C07D – 143019, 150126, 150201, 150366 ,150842 ,151249,

151417 ,151518 ,151626, 153679 ,155386 ,155447, 156436 ,157724 ,160486 ,

161736

C07F – 159494, 163574

C07H – 128652, 149226

C07J – 149141

C07K – 139102, 156258, 165701

C08F – 155120

C08G – 162969

C08J – 158925

C08K – 152238

C08L – 141972

C12N – 119135, 125939, 137921, 138488 ,140265 ,140381, 143069 ,149029 ,150736,

166505

C12P – 135517, 140731, 145842, 147823 ,148196

C12Q –124794, 147872, 153797

C40B – 131435, 150069

D04H – 155922

E01F – 154684

E03C – 163133

F61C– 163427

F04D – 150848

F24F – 155042

F28F – 162942

F41A – 149475F41G – 152966, 156006

F41H – 151672, 163907

F42B – 109014, 164747

G01N – 121793, 139911, 140712, 143699 ,145535 ,149171,

156034

G01R – 147565

G01S – 158722

G01T – 155286

G02B – 154894, 157502

G02C – 151592

G03F – 142354

G03H – 159653

G06F – 147824, 152132, 152301, 156075 ,158481 ,158840 ,

158880 ,169629

G06K – 146608, 146671, 149322, 153162

H01H – 130032

H01L – 146242, 159163, 160070

H01P – 156147

H02G – 152323

H02M – 154808

H03M – 158259

H04B – 150172, 151708, 153941

H04L – 151350, 153829, 154132,

154719 ,155449 ,159316

H04M – 149954H04N – 155563, 157424, 158515

H04Q – 146267, 146363, 151706, 152712

המשפטים, ירושלים הפטנטים, משרד רשות ע"י נערךהממשלתי, ירושלים במדפיס והודפס הופק

EDITED BY THE PATENT OFFICE, MINISTRY OF JUSTICE, JERUSALEMPRINTED AND PUBLISHED BY THE GOVERNMENT PRINTER

ידיעות כלליות - נבו - המאגר המשפטי - 05-06-2008... · web viewc07d 189429...

Documents